0001453687-21-000069.txt : 20210513 0001453687-21-000069.hdr.sgml : 20210513 20210513080337 ACCESSION NUMBER: 0001453687-21-000069 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 92 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210513 DATE AS OF CHANGE: 20210513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SELECTA BIOSCIENCES INC CENTRAL INDEX KEY: 0001453687 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37798 FILM NUMBER: 21917279 BUSINESS ADDRESS: STREET 1: 65 GROVE STREET CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-923-1400 MAIL ADDRESS: STREET 1: 65 GROVE STREET CITY: WATERTOWN STATE: MA ZIP: 02472 10-Q 1 selb-20210331.htm 10-Q selb-20210331
false2021Q10001453687--12-3100014536872021-01-012021-03-31xbrli:shares00014536872021-05-07iso4217:USD00014536872021-03-3100014536872020-12-31iso4217:USDxbrli:shares00014536872020-01-012020-03-310001453687us-gaap:CommonStockMember2020-12-310001453687us-gaap:AdditionalPaidInCapitalMember2020-12-310001453687us-gaap:RetainedEarningsMember2020-12-310001453687us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001453687us-gaap:CommonStockMember2021-01-012021-03-310001453687us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001453687us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001453687us-gaap:RetainedEarningsMember2021-01-012021-03-310001453687us-gaap:CommonStockMember2021-03-310001453687us-gaap:AdditionalPaidInCapitalMember2021-03-310001453687us-gaap:RetainedEarningsMember2021-03-310001453687us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001453687us-gaap:CommonStockMember2019-12-310001453687us-gaap:AdditionalPaidInCapitalMember2019-12-310001453687us-gaap:RetainedEarningsMember2019-12-310001453687us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-3100014536872019-12-310001453687us-gaap:CommonStockMember2020-01-012020-03-310001453687us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-310001453687us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-03-310001453687us-gaap:RetainedEarningsMember2020-01-012020-03-310001453687us-gaap:CommonStockMember2020-03-310001453687us-gaap:AdditionalPaidInCapitalMember2020-03-310001453687us-gaap:RetainedEarningsMember2020-03-310001453687us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-03-3100014536872020-03-310001453687country:RU2021-03-310001453687us-gaap:CorporateBondSecuritiesMember2021-03-310001453687us-gaap:CommercialPaperMember2021-03-310001453687us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001453687us-gaap:EmployeeStockOptionMember2020-01-012020-03-310001453687us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310001453687us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-03-310001453687us-gaap:WarrantMember2021-01-012021-03-310001453687us-gaap:WarrantMember2020-01-012020-03-310001453687us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-03-310001453687us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2021-03-310001453687us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2021-03-310001453687us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2021-03-310001453687us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001453687us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-03-310001453687us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-03-310001453687us-gaap:CorporateBondSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001453687us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2021-03-310001453687us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Member2021-03-310001453687us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member2021-03-310001453687us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2021-03-310001453687us-gaap:FairValueMeasurementsRecurringMember2021-03-310001453687us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2021-03-310001453687us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2021-03-310001453687us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-03-310001453687us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-12-310001453687us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2020-12-310001453687us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2020-12-310001453687us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MoneyMarketFundsMember2020-12-310001453687us-gaap:FairValueMeasurementsRecurringMember2020-12-310001453687us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-12-310001453687us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-12-310001453687us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2020-12-3100014536872020-01-012020-12-31xbrli:pure0001453687us-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2021-03-310001453687us-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:MeasurementInputExpectedDividendRateMember2021-03-310001453687us-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:MeasurementInputExpectedTermMember2021-03-310001453687us-gaap:ValuationTechniqueOptionPricingModelMemberus-gaap:MeasurementInputPriceVolatilityMember2021-03-310001453687us-gaap:WarrantMember2020-12-310001453687us-gaap:WarrantMember2021-01-012021-03-310001453687us-gaap:WarrantMember2021-03-310001453687selb:LaboratoryEquipmentMember2021-03-310001453687selb:LaboratoryEquipmentMember2020-12-310001453687us-gaap:ComputerEquipmentMember2021-03-310001453687us-gaap:ComputerEquipmentMember2020-12-310001453687us-gaap:LeaseholdImprovementsMember2021-03-310001453687us-gaap:LeaseholdImprovementsMember2020-12-310001453687us-gaap:FurnitureAndFixturesMember2021-03-310001453687us-gaap:FurnitureAndFixturesMember2020-12-310001453687us-gaap:OfficeEquipmentMember2021-03-310001453687us-gaap:OfficeEquipmentMember2020-12-310001453687us-gaap:ConstructionInProgressMember2021-03-310001453687us-gaap:ConstructionInProgressMember2020-12-31utr:sqft0001453687selb:A65GroveStreetWatertownMAMember2019-07-310001453687selb:A65GroveStreetWatertownMAMember2019-07-012019-07-310001453687us-gaap:LetterOfCreditMember2020-12-310001453687us-gaap:LetterOfCreditMember2021-03-310001453687selb:A2020TermLoansMember2020-08-310001453687selb:TermALoansMember2020-08-310001453687selb:TermBLoansMember2020-08-310001453687us-gaap:DebtInstrumentRedemptionPeriodOneMemberselb:A2020TermLoansMember2021-01-012021-03-310001453687selb:A2020TermLoansMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2021-01-012021-03-310001453687us-gaap:DebtInstrumentRedemptionPeriodThreeMemberselb:A2020TermLoansMember2021-01-012021-03-310001453687srt:MaximumMemberselb:A2020TermLoansMember2021-01-012021-03-310001453687selb:A2020TermLoansMembersrt:MinimumMember2021-01-012021-03-310001453687selb:A2020TermLoansMember2021-01-012021-03-310001453687selb:A2020TermLoansMember2020-08-312020-08-3100014536872020-08-3100014536872020-08-312020-08-310001453687selb:TermBLoansMemberus-gaap:WarrantMember2020-08-312020-08-310001453687selb:A2017TermLoansMember2020-08-312020-08-310001453687selb:A2017TermLoansMember2020-07-012020-09-300001453687selb:A2020TermLoansMember2021-03-310001453687selb:A2020TermLoansMember2020-12-310001453687selb:A2017TermLoansMember2021-03-310001453687selb:August2020ShelfRegistrationStatementMember2020-08-062020-08-060001453687selb:AtTheMarketOfferingMember2017-08-012017-08-310001453687selb:A2020SaleAgreementAtTheMarketOfferingMember2017-08-012017-08-310001453687selb:AtTheMarketOfferingMember2020-01-012020-12-310001453687selb:AtTheMarketOfferingMember2020-12-310001453687selb:AtTheMarketOfferingMember2021-01-012021-03-310001453687selb:AtTheMarketOfferingMember2021-03-310001453687selb:SOBIPurchaseAgreementMember2020-06-112020-06-110001453687selb:SOBIPurchaseAgreementMember2020-06-110001453687selb:SOBIPurchaseAgreementMember2021-01-012021-03-310001453687selb:SOBIPurchaseAgreementMember2020-07-282020-07-280001453687selb:DecemberTwoThousandNineteenFinancingMember2019-12-182019-12-180001453687selb:DecemberTwoThousandNineteenFinancingMember2019-12-180001453687selb:DecemberTwoThousandNineteenFinancingMemberselb:CommonWarrantMember2019-12-180001453687selb:DecemberTwoThousandNineteenFinancingMemberselb:PreFundedWarrantMember2019-12-182019-12-180001453687selb:DecemberTwoThousandNineteenFinancingMemberselb:PreFundedWarrantMember2019-12-180001453687selb:DecemberTwoThousandNineteenFinancingMember2020-01-012020-03-310001453687selb:DecemberTwoThousandNineteenFinancingMember2021-03-310001453687selb:DecemberTwoThousandNineteenFinancingMember2021-01-012021-03-310001453687us-gaap:WarrantMember2021-03-310001453687selb:A2017PIPEMember2021-03-31selb:vote0001453687us-gaap:WarrantMember2020-12-310001453687us-gaap:StockCompensationPlanMember2021-03-310001453687us-gaap:StockCompensationPlanMember2020-12-310001453687selb:RestrictedStockUnitsRSUsReservedForIssuanceMember2021-03-310001453687selb:RestrictedStockUnitsRSUsReservedForIssuanceMember2020-12-310001453687selb:RestrictedStockUnitsUnvestedMember2021-03-310001453687selb:RestrictedStockUnitsUnvestedMember2020-12-310001453687us-gaap:EmployeeStockOptionMember2021-03-310001453687us-gaap:EmployeeStockOptionMember2020-12-310001453687selb:StockIncentivePlan2016Member2016-06-210001453687selb:StockIncentivePlan2016Member2021-01-012021-03-310001453687selb:StockIncentivePlan2016Member2020-01-012020-03-310001453687selb:StockIncentivePlan2016Member2021-03-310001453687selb:EmploymentInducementIncentiveAwardPlanMember2018-09-250001453687selb:EmploymentInducementIncentiveAwardPlanMember2019-03-250001453687selb:EmploymentInducementIncentiveAwardPlanMember2021-03-310001453687selb:ResearchAndDevelopmentMember2021-01-012021-03-310001453687selb:ResearchAndDevelopmentMember2020-01-012020-03-310001453687us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-03-310001453687us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-03-310001453687us-gaap:StockCompensationPlanMember2021-01-012021-03-310001453687us-gaap:StockCompensationPlanMember2020-01-012020-03-310001453687us-gaap:StockCompensationPlanMemberselb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember2020-12-310001453687us-gaap:StockCompensationPlanMemberselb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember2020-01-012020-12-310001453687us-gaap:StockCompensationPlanMemberselb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember2021-01-012021-03-310001453687us-gaap:StockCompensationPlanMemberselb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember2021-03-310001453687selb:NonEmployeeStockOptionMemberselb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember2020-12-310001453687selb:NonEmployeeStockOptionMemberselb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember2020-01-012020-12-310001453687selb:NonEmployeeStockOptionMemberselb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember2021-01-012021-03-310001453687selb:NonEmployeeStockOptionMemberselb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember2021-03-310001453687selb:StockIncentivePlan2016Memberus-gaap:RestrictedStockUnitsRSUMember2021-01-012021-01-310001453687selb:StockIncentivePlan2016Memberus-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310001453687us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310001453687selb:EmploymentInducementIncentiveAwardPlanMemberus-gaap:RestrictedStockUnitsRSUMember2021-03-310001453687selb:EmploymentInducementIncentiveAwardPlanMemberus-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310001453687us-gaap:RestrictedStockUnitsRSUMember2020-12-310001453687us-gaap:RestrictedStockUnitsRSUMember2021-03-310001453687selb:EmployeeStockPurchasePlan2016Member2016-06-210001453687selb:EmployeeStockPurchasePlan2016Member2021-01-012021-03-310001453687selb:EmployeeStockPurchasePlan2016Member2020-01-012020-03-310001453687selb:EmployeeStockPurchasePlan2016Member2021-03-310001453687us-gaap:CollaborativeArrangementMember2020-06-112020-06-11selb:obligation0001453687us-gaap:CollaborativeArrangementMember2020-06-110001453687selb:SOBIPurchaseAgreementMember2021-03-310001453687selb:SOBIPurchaseAgreementMember2020-12-310001453687us-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberselb:SOBIPurchaseAgreementMember2021-03-310001453687us-gaap:OtherCurrentAssetsMemberselb:SOBIPurchaseAgreementMember2021-03-310001453687selb:SareptaTherapeuticsInc.Member2020-06-132020-06-130001453687selb:SareptaTherapeuticsInc.Member2020-12-310001453687selb:SareptaTherapeuticsInc.Member2021-03-310001453687selb:SareptaTherapeuticsInc.Member2021-01-012021-03-310001453687selb:SareptaTherapeuticsInc.Member2020-01-012020-03-310001453687selb:LicenseAgreementForPompeDiseaseMember2019-12-172019-12-170001453687selb:LicenseAgreementForPompeDiseaseMember2021-03-310001453687selb:LicenseAgreementForPompeDiseaseMember2020-12-310001453687selb:LicenseAgreementForPompeDiseaseMember2021-01-012021-03-310001453687selb:LicenseAgreementForPompeDiseaseMember2020-01-012020-03-310001453687selb:FounderMember2021-01-012021-03-310001453687selb:FounderMember2020-01-012020-03-310001453687selb:AskBioLicenseMember2020-01-012020-03-310001453687selb:AskBioLicenseMember2021-01-012021-03-310001453687selb:ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMemberus-gaap:LicenseAgreementTermsMember2021-01-012021-03-310001453687us-gaap:LicenseAgreementTermsMember2021-01-012021-03-310001453687selb:LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember2021-03-310001453687selb:LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember2021-01-012021-03-310001453687selb:A2020SaleAgreementAtTheMarketOfferingMemberus-gaap:SubsequentEventMember2021-04-012021-05-130001453687selb:A2020SaleAgreementAtTheMarketOfferingMemberus-gaap:SubsequentEventMember2021-05-130001453687srt:ScenarioForecastMemberselb:SareptaTherapeuticsInc.Member2021-04-132021-04-13

  
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
ýQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2021
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
Commission File Number: 001-37798
Selecta Biosciences, Inc.
(Exact name of registrant as specified in its charter)
Delaware
26-1622110
(State or other jurisdiction
of incorporation or organization)
(I.R.S. Employer Identification No.)
65 Grove Street, Watertown, MA
02472
(Address of principal executive offices)
(Zip Code)

(617) 923-1400
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.0001 par value per shareSELBThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ý No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ý No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filerAccelerated filer
Non-accelerated filerýSmaller reporting companyý
Emerging growth companyý
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ý
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No ý
As of May 7, 2021, the registrant had 113,193,597 shares of common stock, par value $0.0001 per share, outstanding.



TABLE OF CONTENTS
Item 2.
Item 3.
Item 4.
Item 1. 
Item 1A. 
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.

2


FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q, or the Quarterly Report, contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this Quarterly Report, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, the plans and objectives of management for future operations and future results of anticipated products, the impact of the COVID-19 pandemic on our business and operations and our future financial results, and the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our future operating expenses and capital expenditure requirements are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential”, or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this Quarterly Report are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of important factors that could cause actual results to differ materially from those in the forward-looking statements, including the factors described under the sections in this Quarterly Report titled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” as well as the following:
our status as a development-stage company and our expectation to incur losses in the future;
our future capital needs and our need to raise additional funds;
our ability to build a pipeline of product candidates and develop and commercialize such pipeline;
our unproven approach to therapeutic intervention;
our ability to enroll patients in clinical trials, timely and successfully complete those trials and receive necessary regulatory approvals;
our ability to access manufacturing facilities and to receive or manufacture sufficient quantities of our product candidates;
our ability to maintain our existing or future collaborations or licenses;
the continuing impact of the COVID-19 pandemic on our operations, the continuity of our business, including our preclinical studies and clinical trials, and general economic conditions;
our ability to protect and enforce our intellectual property rights;
federal, state, and foreign regulatory requirements, including FDA regulation of our product candidates;
our ability to obtain and retain key executives and attract and retain qualified personnel;
developments relating to our competitors and our industry, including the impact of government regulation; and
our ability to successfully manage our growth.
Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties.
You should read this Quarterly Report and the documents that we reference in this Quarterly Report completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
3

PART I. FINANCIAL INFORMATION
Item 1. Financial Statements

Selecta Biosciences, Inc. and Subsidiaries
Consolidated Balance Sheets
(Amounts in thousands, except share data and par value)
 March 31,December 31,
 20212020
 (Unaudited) 
Assets  
Current assets:  
Cash and cash equivalents$125,407 $138,685 
Marketable securities22,405  
Accounts receivable8,342 7,224 
Prepaid expenses and other current assets6,971 5,434 
Total current assets163,125 151,343 
Property and equipment, net1,301 1,395 
Right-of-use asset, net10,676 10,948 
Long-term restricted cash1,379 1,379 
Other assets265 370 
Total assets$176,746 $165,435 
Liabilities and stockholders’ (deficit) equity   
Current liabilities:  
Accounts payable$594 $443 
Accrued expenses6,847 8,146 
Loan payable460  
Lease liability942 908 
Deferred revenue75,764 72,050 
Total current liabilities84,607 81,547 
Non-current liabilities:
Loan payable, net of current portion24,551 24,793 
Lease liability9,403 9,647 
Deferred revenue32,301 38,746 
Warrant liabilities45,455 28,708 
Total liabilities196,317 183,441 
Commitments and contingencies (Note 17)
Stockholders’ (deficit) equity:  
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2021 and December 31, 2020
  
Common stock, $0.0001 par value; 200,000,000 shares authorized; 112,977,004 and 108,071,249 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively
11 11 
Additional paid-in capital414,214 391,175 
Accumulated deficit(429,226)(404,629)
Accumulated other comprehensive loss(4,570)(4,563)
Total stockholders’ (deficit) equity (19,571)(18,006)
Total liabilities and stockholders’ (deficit) equity $176,746 $165,435 

The accompanying notes are an integral part of these unaudited consolidated financial statements.
4


Selecta Biosciences, Inc. and Subsidiaries
Consolidated Statements of Operations and Comprehensive Loss
(Amounts in thousands, except share and per share data)

 Three Months Ended March 31,
 20212020
(Unaudited)
Grant and collaboration revenue$11,050 $ 
Operating expenses:
Research and development13,004 14,724 
General and administrative5,204 4,098 
Total operating expenses18,208 18,822 
Loss from operations(7,158)(18,822)
Investment income12 240 
Foreign currency transaction gain, net7 82 
Interest expense(711)(273)
Change in fair value of warrant liabilities(16,747)(846)
Other income (expense), net (1)
Net loss(24,597)(19,620)
Other comprehensive loss:
Foreign currency translation adjustment(6)(60)
Unrealized (losses) on marketable securities(1) 
Total comprehensive loss$(24,604)$(19,680)
Net loss per share:
Basic and diluted$(0.22)$(0.21)
Weighted average common shares outstanding:
Basic and diluted110,742,150 94,723,513 

The accompanying notes are an integral part of these unaudited consolidated financial statements.
5


Selecta Biosciences, Inc. and Subsidiaries
Consolidated Statements of Changes in Stockholders’ (Deficit) Equity
(Amounts in thousands, except share data)
(Unaudited)
     Accumulated
   Additional otherStockholders’
 Common stockpaid-inAccumulatedcomprehensive(Deficit)
 SharesAmountcapitaldeficitlossEquity
Balance at December 31, 2020108,071,249 $11 $391,175 $(404,629)$(4,563)$(18,006)
Issuance of common stock under Employee Stock Purchase Plan34,696 — 72 — — 72 
Issuance of common stock upon exercise of options153,278 — 244 — — 244 
Issuance of vested restricted stock units10,937 — — — —  
Issuance of common stock through at-the-market offering, net4,706,844 — 20,943 — — 20,943 
Stock-based compensation expense— — 1,780 — — 1,780 
Currency translation adjustment— — — — (6)(6)
Unrealized (losses) on marketable securities— — — — (1)(1)
Net loss— — — (24,597)— (24,597)
Balance at March 31, 2021
112,977,004 $11 $414,214 $(429,226)$(4,570)$(19,571)

The accompanying notes are an integral part of these unaudited consolidated financial statements.
6


Selecta Biosciences, Inc. and Subsidiaries
Consolidated Statements of Changes in Stockholders’ (Deficit) Equity
(Amounts in thousands, except share data)
(Unaudited)
     Accumulated 
   Additional otherStockholders’
 Common stockpaid-inAccumulatedcomprehensive(Deficit)
 SharesAmountcapitaldeficitlossEquity
Balance at December 31, 201986,325,547 $9 $348,664 $(335,753)$(4,523)$8,397 
Issuance of common stock under Employee Stock Purchase Plan78,583 — 114 — — 114 
Issuance of common stock upon exercise of options5,128 — 3 — — 3 
Issuance of vested restricted stock units10,937 — — — —  
Issuance of common stock through at-the-market offering, net598,977 — 1,141 — — 1,141 
Other financing fees— — (147)— — (147)
Stock-based compensation expense— — 1,409 — — 1,409 
Currency translation adjustment— — — — (60)(60)
Net loss— — — (19,620)— (19,620)
Balance at March 31, 202087,019,172 $9 $351,184 $(355,373)$(4,583)$(8,763)

The accompanying notes are an integral part of these unaudited consolidated financial statements.
7


Selecta Biosciences, Inc. and Subsidiaries 
Consolidated Statements of Cash Flows
(Amounts in thousands)
 Three Months Ended March 31,
20212020
(Unaudited)
Cash flows from operating activities
Net loss$(24,597)$(19,620)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization207 231 
Amortization of premiums and discounts on marketable securities14  
Non-cash lease expense272 366 
Loss on disposal of property and equipment
 1 
Stock-based compensation expense1,780 1,409 
Non-cash interest expense387 123 
Warrant liabilities revaluation16,747 846 
Changes in operating assets and liabilities:
Accounts receivable(1,118)5,000 
Prepaid expenses, deposits and other assets(1,512)(61)
Accounts payable151 836 
Deferred revenue(2,728) 
Accrued expenses and other liabilities(1,736)(829)
                    Net cash (used in) operating activities(12,133)(11,698)
Cash flows from investing activities
Purchases of marketable securities(22,420) 
Purchases of property and equipment(25)(135)
                    Net cash (used in) investing activities(22,445)(135)
Cash flows from financing activities
Repayments of principal on outstanding debt (2,100)
Net proceeds from issuance of common stock- at-the-market offering20,991 1,141 
Issuance costs paid for December 2019 financing (4,381)
Other financing fees (147)
Proceeds from exercise of stock options244 3 
Proceeds from issuance of common stock under Employee Stock Purchase Plan72 114 
                    Net cash provided by (used in) financing activities21,307 (5,370)
Effect of exchange rate changes on cash(7)(84)
Net change in cash, cash equivalents, and restricted cash(13,278)(17,287)
Cash, cash equivalents, and restricted cash at beginning of period140,064 91,551 
Cash, cash equivalents, and restricted cash at end of period$126,786 $74,264 
Supplement cash flow information
Cash paid for interest$494 $232 
Noncash investing and financing activities
Purchase of property and equipment not yet paid$10 $10 
Equity offering costs in accrued liabilities$48 $42 
Unrealized (losses) on marketable securities$(1)$ 

The accompanying notes are an integral part of these unaudited consolidated financial statements.
8

Selecta Biosciences, Inc. and Subsidiaries
Notes to Consolidated Financial Statements (Unaudited)

1. Nature of the Business and Basis of Presentation
Selecta Biosciences, Inc., or the Company was incorporated in Delaware on December 10, 2007, and is based in Watertown, Massachusetts. The Company is a clinical-stage biopharmaceutical company leveraging its ImmTOR™ immune tolerance platform with the goals of amplifying the efficacy of biologics, including enabling the re-dosing of life-saving gene therapies, and restoring self-tolerance in autoimmune diseases. The Company’s ImmTOR platform encapsulates rapamycin, also known as sirolimus, an immunomodulator, in biodegradable nanoparticles and is designed to induce antigen-specific immune tolerance. The Company believes ImmTOR has the potential to enhance the efficacy without compromising the safety of biologic therapies, improve product candidates under development, and enable novel therapeutic modalities. Since inception, the Company has devoted its efforts principally to research and development of its technology and product candidates, recruiting management and technical staff, acquiring operating assets, and raising capital.
The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities.
The Company’s product candidates are in development. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants.
Unaudited Interim Financial Information
The accompanying unaudited consolidated financial statements for the three months ended March 31, 2021 and 2020 have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC, for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K that was filed with the SEC on March 12, 2021. The unaudited interim financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments that are necessary for a fair statement of the Company’s financial position as of March 31, 2021 and consolidated results of operations and cash flows for the three months ended March 31, 2021. Such adjustments are of a normal and recurring nature. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2021.
Liquidity and Management’s Plan
The future success of the Company is dependent on its ability to develop its product candidates and ultimately upon its ability to attain profitable operations. The Company is subject to a number of risks similar to other early-stage life science companies, including, but not limited to, successful development of its product candidates, raising additional capital with favorable terms, protection of proprietary technology and market acceptance of any approved future products. The successful development of product candidates requires substantial working capital which may not be available to the Company on favorable terms or at all.
To date, the Company has financed its operations primarily through the initial public offering of its common stock, private placements of its common stock, issuances of common and preferred stock, debt, research grants and research collaborations. The Company currently has no source of product revenue, and it does not expect to generate product revenue for the foreseeable future. To date, all of the Company’s revenue has been collaboration and grant revenue. The Company has devoted substantially all of its financial resources and efforts to developing its ImmTOR platform, identifying potential product candidates and conducting preclinical studies and its clinical trials. The Company is in the early stages of development of its product candidates, and it has not completed development of any ImmTOR-enabled therapies.
9

As of March 31, 2021, the Company’s cash, cash equivalents, restricted cash and marketable securities were $149.2 million, of which $1.4 million was restricted cash related to lease commitments and $0.3 million was held by its Russian subsidiary designated solely for use in its operations. The Company believes the cash, cash equivalents, restricted cash and marketable securities as of March 31, 2021 will enable it to fund its operating expenses and capital expenditure requirements into the second quarter of 2023. The Company has incurred losses and negative cash flows from operating activities since inception. As of March 31, 2021, the Company had an accumulated deficit of $429.2 million. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research, development of its product candidates, conducting preclinical studies and clinical trials, and its administrative organization. The Company will require substantial additional financing to fund its operations and to continue to execute its strategy, and the Company will pursue a range of options to secure additional capital.
At this time, there is significant uncertainty relating to the trajectory of the COVID-19 pandemic and the impact of related responses. Any impact of COVID-19 on the Company’s business, revenues, results of operations and financial condition will largely depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, supply chain disruptions, the ultimate impact on financial markets and the global economy, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.
Guarantees and Indemnifications
As permitted under Delaware law, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. Through March 31, 2021, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.

2. Summary of Significant Accounting Policies
There have been no material changes to the Company’s significant accounting policies during the three months ended March 31, 2021, as compared to the significant accounting policies disclosed in Note 2 – Summary of Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.
Recent Accounting Pronouncements
Recently Adopted
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The Company adopted the new standard effective January 1, 2021, and there was no impact on its consolidated financial statements.
In October 2020, the FASB issued ASU 2020-10, Codification Improvements, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC’s regulations. The Company adopted the new standard effective January 1, 2021, and there was no impact on its consolidated financial statements.
Not Yet Adopted
In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2023, with early adoption permitted no earlier than January 1, 2021. The Company is assessing the impact this standard will have on its consolidated financial statements and disclosures.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. Subsequently, in November 2018, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments-Credit Losses. ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company is assessing the impact this standard will have on its consolidated financial statements and disclosures.

10

3. Marketable Securities
The following table summarizes the marketable securities held as of March 31, 2021 (in thousands):
Amortized costUnrealized gainsUnrealized lossesFair value
March 31, 2021
Corporate bonds$2,032 $ $(1)$2,031 
Commercial paper20,374   20,374 
Total$22,406 $ $(1)$22,405 
All marketable securities held at March 31, 2021 had maturities of less than 12 months when purchased and are classified as short-term marketable securities on the accompanying consolidated balance sheet. During the three months ended March 31, 2021, there were no marketable securities adjusted for other than temporary declines in fair value.
As of December 31, 2020, the Company held no marketable securities.

4. Net Loss Per Share
The Company has reported a net loss for the three months ended March 31, 2021 and 2020. For this reason basic and diluted net loss per share are the same for all periods presented. The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per-share data):
 Three Months Ended March 31,
 20212020
Numerator:
Net loss attributable to common stockholders$(24,597)$(19,620)
Denominator:
Weighted-average common shares and pre-funded warrants outstanding—basic and diluted110,742,150 94,723,513 
Net loss per share attributable to common stockholders —basic and diluted$(0.22)$(0.21)

All potential dilutive common shares have been excluded from the computation of the diluted net loss per share for all periods presented, as the effect would have been anti-dilutive. Potential dilutive common share equivalents consist of the following:
 March 31,
 20212020
Stock options to purchase common stock10,187,394 7,745,936 
Unvested restricted stock units544,313 170,313 
Warrants to purchase common stock12,378,016 23,084,120 
Total23,109,723 31,000,369 
 
5. Fair Value Measurements
The following tables present the Company’s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in thousands):
March 31, 2021
Total(Level 1)(Level 2)(Level 3)
Assets:
     Money market funds$58,158 $58,158 $ $ 
Marketable securities:
     Corporate bonds2,031  2,031  
     Commercial paper20,374  20,374  
Total assets$80,563 $58,158 $22,405 $ 
Liabilities:
     Warrant liabilities$45,455 $ $ $45,455 
Total liabilities$45,455 $ $ $45,455 
11

 
December 31, 2020
Total(Level 1)(Level 2)(Level 3)
Assets:
     Money market funds$80,576 $80,576 $ $ 
Total assets$80,576 $80,576 $ $ 
Liabilities:
     Warrant liabilities$28,708 $ $ $28,708 
Total liabilities$28,708 $ $ $28,708 

There were no transfers within the fair value hierarchy during the three months ended March 31, 2021 or the year ended December 31, 2020.

Cash and Cash Equivalents
As of March 31, 2021 and December 31, 2020, the money market funds were classified as cash and cash equivalents on the accompanying consolidated balance sheets as they mature within 90 days from the date of purchase.
As of March 31, 2021, the Company had restricted cash balances relating to a secured letter of credit in connection with its lease for the Company’s headquarters (see Note 8 included elsewhere in this Quarterly Report). The Company’s consolidated statement of cash flows includes the following as of March 31, 2021 and 2020 (in thousands):
March 31,
20212020
Cash and cash equivalents$125,407 $72,606 
Short-term restricted cash 279 
Long-term restricted cash1,379 1,379 
Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows$126,786 $74,264 

Marketable Securities
As of March 31, 2021, marketable securities classified as Level 2 within the valuation hierarchy consist of corporate bonds and commercial paper. Marketable securities represent holdings of available-for-sale marketable debt securities in accordance with the Company’s investment policy. The Company estimates the fair values of these marketable securities by taking into consideration valuations that include market pricing based on real-time trade data for the same or similar securities, and other observable inputs. The amortized cost of available-for-sale debt securities is adjusted for amortization of premiums and accretion of discounts to the earliest call date for premiums or to maturity for discounts.
Loans Payable
At March 31, 2021, given the recent issuance of the Term A Loan under the 2020 Term Loan, the Company believes the carrying value approximates the fair value of the loan.
Common Warrants
In December 2019, the Company issued common warrants in connection with a private placement of common shares. Pursuant to the terms of the common warrants, the Company could be required to settle the common warrants in cash in the event of certain acquisitions of the Company and, as a result, the common warrants are required to be measured at fair value and reported as a liability on the balance sheet. The Company recorded the fair value of the common warrants upon issuance using the Black-Scholes valuation model and is required to revalue the common warrants at each reporting date with any changes in fair value recorded in the statement of operations. The valuation of the common warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The significant unobservable inputs used in the fair value measurement of the warrant liabilities were the volatility rate and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value measurement. The change in
12

the fair value of the Level 3 warrant liability is reflected in the statement of operations for the three months ended March 31, 2021 and 2020.
The estimated fair value of warrants is determined using Level 3 inputs inherent in the Black-Scholes simulation valuation.
Estimated fair value of the underlying stock. The Company estimates the fair value of the common stock based on the closing stock price at the end of each reporting period.
Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury at the valuation date commensurate with the expected remaining life assumption.
Dividend rate. The dividend rate is based on the historical rate, which the Company anticipates will remain at zero.
Expected life. The expected life of the warrants is assumed to be equivalent to their remaining contractual term which expires on December 23, 2024.
Volatility. The Company estimates stock price volatility based on the Company’s historical volatility and the historical volatility of peer companies for a period of time commensurate with the expected remaining life of the warrants.
A summary of the Black-Scholes pricing model assumptions used to record the fair value of the warrant liability is as follows:
March 31,
 2021
Risk-free interest rate0.35 %
Dividend yield 
Expected life (in years)3.73
Expected volatility101.13 %
Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis
The following table reflects a roll-forward of fair value for the Company’s Level 3 warrant liabilities (see Note 10), for the three months ended March 31, 2021 (in thousands):
Warrant liabilities
Fair value as of December 31, 2020
$28,708 
     Change in fair value16,747 
Fair value as of March 31, 2021
$45,455 

6. Property and Equipment
Property and equipment consists of the following (in thousands):
 March 31,December 31,
 20212020
Laboratory equipment$4,429 $4,427 
Computer equipment and software694 532 
Leasehold improvements38 38 
Furniture and fixtures327 327 
Office equipment163 163 
Construction in process30 163 
Total property and equipment5,681 5,650 
Less accumulated depreciation(4,380)(4,255)
Property and equipment, net$1,301 $1,395 

Depreciation expense was $0.1 million and $0.2 million for the three months ended March 31, 2021 and 2020, respectively.

13

7. Accrued Expenses
Accrued expenses consist of the following (in thousands):
 March 31,December 31,
 20212020
Payroll and employee related expenses$1,840 $3,049 
Collaboration and licensing1,350 1,350 
Accrued patent fees471 534 
Accrued external research and development costs2,010 2,029 
Accrued professional and consulting services802 798 
Accrued interest170 170 
Other204 216 
     Accrued expenses$6,847 $8,146 

8. Leases
65 Grove Street Lease
In July 2019, the Company entered into a lease for 25,078 square feet of laboratory and office space located at 65 Grove Street, Watertown, Massachusetts, or the Headquarters Lease. As part of the Headquarters Lease, the Company incurred $0.8 million in non-reimbursable construction costs. The lease began in March 2020, consistent with when the Company took control of the office space, and the lease term is 8 years. The discount rate of 8.9% was determined based on the Company’s incremental borrowing rate adjusted for the lease term including any reasonably certain renewal periods. In connection with the Headquarters Lease, the Company secured a letter of credit from Silicon Valley Bank, or SVB, for $1.4 million, recognized as long-term restricted cash, as of March 31, 2021 and December 31, 2020, respectively, which automatically renews each year.
Moscow, Russia Lease
The Company has a month-to-month facility agreement for its Moscow, Russia office. Rent expense is recognized as incurred.
As of March 31, 2021 and December 31, 2020, the components of the operating leases were as follows (in thousands):
March 31,December 31,
20212020
Assets:
   Right-of-use asset, net$10,676 $10,948 
Liabilities:
   Current operating lease liabilities$942 $908 
   Non-current operating lease liabilities9,403 9,647 
Total operating lease liabilities$10,345 $10,555 

For the three months ended March 31, 2021 and 2020 the components of lease costs were as follows (in thousands):
March 31,
20212020
Operating lease cost$444 $472 
Variable lease cost288 199 
Short-term lease cost3 2 
Total lease cost$735 $673 

14

The maturity of the Company’s operating lease liabilities as of March 31, 2021 were as follows (in thousands):
March 31,
2021
2021 (remainder)$1,368 
20221,866 
20231,922 
20241,980 
20252,039 
Thereafter4,945 
     Total future minimum lease payments14,120 
Less imputed interest3,775 
     Total operating lease liabilities$10,345 

The supplemental disclosure for the statement of cash flows related to operating leases were as follows (in thousands):
March 31,
20212020
Cash paid for amounts included in the measurement of lease liabilities:$444 $487 

Other than the initial recording of the right-of-use asset and lease liability for the Headquarters Lease, which is non-cash, the changes in the Company’s right-of-use asset and lease liability for the three months ended March 31, 2021 and 2020 are reflected in the non-cash lease expense and accrued expenses and other liabilities, respectively, in the consolidated statements of cash flows.
The following summarizes additional information related to operating leases:
March 31,
20212020
Weighted-average remaining lease term7.1 years8.0 years
Weighted-average discount rate8.9 %8.9 %

9. Debt
2020 Term Loan
On August 31, 2020, the Company entered into a term loan of up to $35.0 million, or the 2020 Term Loan, consisting of term loans in an aggregate amount of $25.0 million, or the Term A Loan, and term loans in an aggregate amount of $10.0 million, or the Term B Loan, governed by a loan and security agreement, or the Loan Agreement, between the Company and Oxford Finance LLC, or Oxford, as Collateral Agent and a Lender, and SVB, as a Lender. The Term A Loan was funded in full on August 31, 2020, or the Funding Date.
The Term B Loan will be available, subject to Collateral Agent’s discretion and customary terms and conditions, during the period commencing on the date the Company has delivered to the Collateral Agent and the Lenders evidence: (i) the Company or one of the Company’s collaboration partners has enrolled its first patient for a Phase 1 clinical trial evaluating the treatment of methylmalonic acidemia, or MMA, and (ii) the Company has enrolled the first patient in each of two Phase 3 pivotal trials evaluating SEL-212, or the Second Draw Period Milestone, and ending on the earliest of (i) the date which is 30 days following the date the Second Draw Period Milestone is achieved, (ii) September 30, 2021 (iii) and the occurrence of an event of default, other than an event of default that has been waived in writing by Collateral Agent and the Lenders in their sole discretion, with such period referred to as the Second Draw Period.
The 2020 Term Loan will mature on August 1, 2025. Each advance under the Term Loan accrues interest at a floating per annum rate equal to the greater of (a) 7.90%, and (b) the lesser of (x) the sum of (i) the prime rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue, and (ii) 4.65% and (y) 10.00%. The Term Loan provides for interest-only payments on a monthly basis until April 1, 2022; provided however, if the Company has delivered to the Collateral Agent and the Lenders prior to September 30, 2021 evidence that Borrower has achieved the Second Draw Period Milestone, the Term Loan provides for interest-only payments on a monthly basis until October 1, 2022. Thereafter, amortization payments will be payable monthly in equal installments of principal and interest to fully amortize the outstanding principal over the remaining term of the loan, subject to recalculation upon a change in the prime rate. The Company may prepay the Term Loan in full but not in part provided that the Company (i) provides ten days’ prior written notice to Collateral Agent, (ii) pays on the date of such prepayment (A) all outstanding principal plus
15

accrued and unpaid interest, and (B) a prepayment fee of between 3.0% and 1.0% of the aggregate original principal amount advanced by the lender depending on the timing of the prepayment. Amounts outstanding during an event of default are payable upon SVB’s demand and shall accrue interest at an additional rate of 5.0% per annum of the past due amount outstanding. At the end of the loan term (whether at maturity, by prepayment in full or otherwise), the Company shall make a final payment to the lender in the amount of 9.0% of the aggregate original principal amount advanced by the lender. The final payment fee totaling $2.3 million is recorded as a loan discount.
The Term Loan is secured by a lien on substantially all of the assets of the Company, other than intellectual property, provided that such lien on substantially all assets includes any rights to payments and proceeds from the sale, licensing or disposition of intellectual property. The Company has also granted the Collateral Agent a negative pledge with respect to its intellectual property.
The Loan Agreement contains customary covenants and representations, including but not limited to financial reporting obligations and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. The Loan Agreement also contains other customary provisions, such as expense reimbursement, non-disclosure obligations as well as indemnification rights for the benefit of the Collateral Agent.
The events of default under the Loan Agreement include, but are not limited to, the Company’s failure to make any payments of principal or interest under the Loan Agreement or other transaction documents, the Company’s breach or default in the performance of any covenant under the Loan Agreement or other transaction documents, the occurrence of a material adverse change, the Company making a false or misleading representation or warranty in any material respect under the Loan Agreement, the Company’s insolvency or bankruptcy, any attachment or judgment on the Company’s assets of at least $0.5 million, or the occurrence of any default under any agreement or obligation of the Company involving indebtedness in excess of $0.5 million. If an event of default occurs, the Collateral Agent is entitled to take enforcement action, including acceleration of amounts due under the Loan Agreement.
The Company incurred $0.4 million in debt issuance costs in connection with the closing of the 2020 Term Loan. Debt issuance costs are presented in the consolidated balance sheet as a direct deduction from the associated liability and amortized to interest expense over the term of the related debt.
The Company assessed all terms and features of the 2020 Term Loan to identify any potential embedded features that would require bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the 2020 Term Loan, including any put, call, and contingent features. The Company determined that the interest rate collar and prepayment call option did not require bifurcation; whereas the contingent put option and default (contingent) interest rate feature met bifurcation criteria resulting in immaterial amounts.
Warrants
On August 31, 2020, in connection with the 2020 Term A Loan, the Company issued warrants to the Lenders to purchase an aggregate of 196,850 shares of its common stock at an exercise price equal to $2.54 per share. In accordance with ASC 815-40, these warrants are classified as permanent equity in the accompanying consolidated balance sheets and will expire ten years from the date of issuance. The initial grant date fair value of the warrants was $0.4 million as determined by the Black-Scholes valuation model and recorded to shareholders' equity, with the SVB portion allocated to the reacquisition price of the 2017 Term Loan and the Oxford fair value portion as a loan discount to the Term A Loan.
Additionally, on August 31, 2020, pursuant to the terms of a Warrant Side Letter agreement among the Company and the Lenders, the Company agreed to issue to the Lenders, on the date the Company draws the Term B Loan and in accordance with each party’s respective pro rata share with respect to the Term B Loan, one or more warrants to purchase an aggregate number of shares of its common stock that is equal to $200,000 divided by the average closing price of the Company’s common stock on The Nasdaq Stock Market LLC for the ten consecutive trading days ending the day before such issuance, rounded down to the nearest whole number of shares, and having an exercise price equal to the Term B Warrant Price.
Payoff
On the Funding Date, the Company entered into a payoff letter with SVB, pursuant to which the Company utilized $13.7 million of the 2020 Term Loan to pay off all outstanding obligations under the previous term loan, consisting of the principal payment, final prepayment and accrued interest. During the three months ended September 30, 2020, the Company recognized a loss on extinguishment of debt in the amount of $0.5 million determined as the difference between the reacquisition price and carrying value at August 31, 2020.
As of March 31, 2021 and December 31, 2020, the outstanding principal balance under the 2020 Term Loan was $25.0 million.
16

Future minimum principal and interest payments on the 2020 Term Loan as of March 31, 2021 are as follows (in thousands):
2021 (remainder)$1,509 
20227,343 
20238,611 
20248,027 
20257,274 
Total minimum debt payments32,764 
Less: Amount representing interest(5,514)
Less: Debt discount and deferred charges(2,239)
Less: Current portion of loan payable(460)
Loan payable, net of current portion$24,551 

10. Equity
Equity Financings
August 2020 Shelf Registration Statement
On August 6, 2020, the Company filed an updated universal shelf registration statement on Form S-3 (Reg. No. 333-241692) with the SEC to sell an aggregate amount of up to $200.0 million of certain of its securities. The shelf registration statement was declared effective by the SEC on August 14, 2020.
“At-the-Market” Offerings
In August 2017, the Company entered into a sales agreement, or the 2017 Sales Agreement, with Jefferies LLC, as sales agent, to sell shares of its common stock with an aggregate value of up to $50.0 million in an “at the market offering.” On August 6, 2020, concurrent with the filing of the updated shelf registration statement, the Company entered into a sales agreement, or the 2020 Sales Agreement with Jefferies LLC, as sales agent, pursuant to which the Company may, from time to time, issue and sell common stock with an aggregate value of up to $50.0 million in an “at the market offering.” The 2017 Sales Agreement terminated pursuant to its terms in August 2020.
Sales of common stock, if any, pursuant to the 2020 Sales Agreement, may be made in sales deemed to be an “at the market offering” as defined in Rule 415(a) of the Securities Act, including sales made directly through the Nasdaq Stock Market or on any other existing trading market for the Company’s common stock. The Company intends to use the proceeds from the offering for working capital and other general corporate purposes. The Company may suspend or terminate the 2020 Sales Agreement at any time.
During the year ended December 31, 2020, the Company sold 1,069,486 shares of its common stock pursuant to the 2020 and 2017 Sales Agreements at an average price of approximately $2.16 per share for aggregate net proceeds of $2.1 million, after deducting commissions and other transaction costs.
During the three months ended March 31, 2021, the Company sold 4,706,844 shares of its common stock pursuant to the 2020 Sales Agreement at an average price of approximately $4.59 per share for aggregate net proceeds of $20.9 million, after deducting commissions and other transaction costs.
June 2020 Sobi Stock Purchase
On June 11, 2020, the Company entered into a stock purchase agreement with Sobi, pursuant to which the Company sold an aggregate of 5,416,390 shares of its common stock at a purchase price equal to $4.6156 per share, which represented 120% of the 10-day volume-weighted average price of the Company’s common stock prior to signing, for aggregate gross proceeds of $25.0 million, or the Sobi Private Placement. The closing of the Sobi Private Placement occurred on July 31, 2020. The shares of common stock acquired in the Sobi Private Placement are subject to a one-year lock-up from closing, during which time Sobi is prohibited from selling or otherwise disposing of such shares.
In accordance with ASC 815, this forward sale treatment qualified as equity classification as the shares are not within the scope of ASC 480. The gross proceeds of $25.0 million were determined to include a premium to the fair value of the Company’s shares as of July 28, 2020 of approximately $14.5 million. As a result, such amount was included in the transaction price for revenue recognition of the Sobi License. See Note 12 for details.
Also on June 11, 2020, the Company entered into a registration rights agreement (as amended by that certain letter agreement, dated as of November 4, 2020) with Sobi, pursuant to which the Company agreed to prepare and file a registration statement with respect to the resale of the shares of common stock acquired in the Sobi Private Placement. The Company will be required to file this resale registration statement within 30 days following receipt by the Company of a written request from
17

Sobi to file such resale registration statement, and to have the registration statement declared effective within 10 business days after the SEC informs the Company that no review of such resale registration statement will be made or that the SEC has no further comments on such resale registration statement.
December 2019 Financing
On December 18, 2019, the Company entered into a securities purchase agreement, or the 2019 Purchase Agreement, with a group of institutional investors and certain members of the board of directors. Pursuant to the 2019 Purchase Agreement, the Company sold an aggregate of 37,634,883 shares of its common stock at a purchase price of $1.46 per share, warrants to purchase an aggregate of 22,988,501 shares of common stock at a purchase price of $0.125 per share underlying each common warrant, and pre-funded warrants to purchase an aggregate of 8,342,128 shares of common stock at a purchase price of $1.46 per share, all with five year terms, or the 2019 PIPE. The closing of the 2019 PIPE occurred on December 23, 2019. The exercise price of the pre-funded warrants is $0.0001 per share and the exercise price for the common warrants is $1.46 per share. In the event of a certain sale of the Company, the terms of the common warrants require us to make a payment to such common warrant holders based on a Black-Scholes valuation (using variables as specified in the warrants). This provision does not apply to the pre-funded warrants. Therefore, the Company is required to account for the common warrants as liabilities and record them at fair value, while the pre-funded warrants met the criteria to be classified as permanent equity.
The Company recorded the fair value of the common warrants of $40.7 million upon issuance using the Black-Scholes valuation model. Issuance costs were allocated between the equity component with an offset to additional paid-in capital and the liability component recorded as expense on a relative fair value basis. Total net proceeds from the equity offering was $65.6 million, after deducting transaction costs and commissions of $4.4 million which was paid in the three months ended March 31, 2020.
The common warrants were revalued as of March 31, 2021 at $45.5 million. During the three months ended March 31, 2021 and 2020, the Company recorded losses on the increases in the fair value of the warrants of $(16.7) million and $(0.8) million, respectively, in the unaudited consolidated statements of operations.

Warrants
During the three months ended March 31, 2021 and 2020, there were no warrants issued, exercised, or canceled.
Number of Warrants
Equity
 classified
Liability classifiedTotalWeighted average
exercise price
Outstanding at March 31, 2021292,469 12,085,547 12,378,016 $1.60 

Common Stock
As of March 31, 2021, the Company had 200,000,000 shares of common stock authorized for issuance, $0.0001 par value per share, with 112,977,004 shares issued and outstanding. The voting, dividend and liquidation rights of the common stockholders are subject to and qualified by the rights, powers and preferences of the preferred stock. The common stock has the following characteristics:
Voting
The common stockholders are entitled to one vote for each share of common stock held with respect to all matters voted on by the stockholders of the Company.
Dividends
The common stockholders are entitled to receive dividends, if and when declared by the Board of Directors. Through March 31, 2021, no dividends have been declared or paid on common stock.
Liquidation
Upon liquidation of the Company, the common stockholders are entitled to receive all assets of the Company available for distribution to such stockholders.

18

Reserved Shares
The Company has authorized shares of common stock for future issuance as follows:
 Period ended
 March 31, 2021December 31, 2020
Exercise of common warrants12,378,016 12,378,016 
Shares available for future stock incentive awards7,719,817 4,916,374 
RSUs reserved for issuance98,750  
Unvested restricted stock units544,313 87,500 
Outstanding common stock options10,187,394 7,775,249 
Total30,928,290 25,157,139 
 
11. Stock Incentive Plans
The Company maintains the 2008 Stock Incentive Plan, or the 2008 Plan, for employees, consultants, advisors, and directors. The 2008 Plan provided for the granting of incentive and non-qualified stock option and restricted stock awards as determined by the Board.
In June 2016, the Company’s stockholders approved the 2016 Incentive Award Plan, or the 2016 Plan, which authorized 1,210,256 shares of common stock for future issuance under the 2016 Plan and ceased granting awards under the 2008 Plan. Upon the effective date of the 2016 Plan, awards issued under the 2008 Plan remain subject to the terms of the 2008 Plan. Awards granted under the 2008 Plan that expire, lapse or terminate become available under the 2016 Plan as shares available for future grants.
Additionally, pursuant to the terms of the 2016 Plan, the Board is authorized to grant awards with respect to common stock, and may delegate to a committee of one or more members of the Board or executive officers of the Company the authority to grant options and restricted stock units. On December 9, 2020, the Board established a Stock Option Committee authorized to grant awards to certain employees and consultants subject to conditions and limitations within the 2016 Plan. In January 2021 and 2020, the number of shares of common stock that may be issued under the 2016 Plan was increased by 4,322,850 and 3,453,022 shares, respectively. As of March 31, 2021, 3,248,520 shares remain available for future issuance under the 2016 Plan.
In September 2018, the Company’s 2018 Employment Inducement Incentive Award Plan, or the 2018 Inducement Incentive Award Plan was adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules, which authorized 1,175,000 shares of its common stock for issuance. In March 2019, the Board approved the amendment and restatement of the 2018 Inducement Incentive Award Plan to reserve an additional 2,000,000 shares of the Company’s common stock for issuance thereunder. As of March 31, 2021, there are 1,358,333 shares available for future grant under the 2018 Inducement Incentive Award Plan.
Stock-based Compensation Expense
Stock-based compensation expense by classification included within the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):
 Three Months Ended March 31,
 20212020
Research and development$754 $623 
General and administrative1,026 786 
     Total stock-based compensation expense$1,780 $1,409 

Stock Options
Employees
The estimated grant date fair values of employee stock option awards granted under the 2016 Plan and the 2018 Inducement Incentive Award Plan were calculated using the Black-Scholes option pricing model, based on the following weighted-average assumptions:
19

Three Months Ended March 31,
 20212020
Risk-free interest rate0.44 %1.73 %
Dividend yield  
Expected term5.286.08
Expected volatility83.26 %87.96 %
Weighted-average fair value of common stock$3.13 $2.30 

The weighted average grant date fair value of stock options granted to employees during the three months ended March 31, 2021 and 2020 was $1.99 and $1.69, respectively.
As of March 31, 2021 total unrecognized compensation expense related to unvested employee stock options was $11.8 million, which is expected to be recognized over a weighted average period of 2.7 years.

Non-employee consultants
As of March 31, 2021, there was no unrecognized compensation expense related to non-employee consultants stock options.
The following table summarizes the stock option activity under the 2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan:
   Weighted-average 
  remainingAggregate
 Number ofWeighted-averagecontractual termintrinsic value
 optionsexercise price ($)(in years)(in thousands)
Employees    
Outstanding at December 31, 20207,302,176 $3.98 8.43$4,456 
Granted2,628,000 $3.13   
Exercised(153,278)$1.47   
Forfeited(62,577)$5.19   
Outstanding at March 31, 20219,714,321 $3.78 8.65$15,665 
Vested at March 31, 20213,064,130 $5.46 7.63$4,313 
Vested and expected to vest at March 31, 20218,920,548 $3.88 8.59$14,231 
Non-employee consultants    
Outstanding at December 31, 2020473,073 $5.89 5.23$86 
Granted $ 
Exercised $ 
Forfeited $ 
Outstanding at March 31, 2021473,073 $5.89 4.98$366 
Vested at March 31, 2021462,186 $5.82 4.92$366 
Vested and expected to vest at March 31, 2021473,073 $5.89 4.98$366 

Restricted Stock Units
In January 2021, the Company granted 369,800 restricted stock awards to employees under the 2016 Plan which will vest over a four year term.
In addition, during the first quarter of 2021, the Company awarded 197,500 restricted stock units to executives under the 2016 Plan, of which 98,750 were determined to be granted as of the award date consistent with ASC 718. The remaining 98,750 restricted stock units do not have a defined performance metric as of the award date, resulting in the restricted stock units being reserved for future issuance as of March 31, 2021. These restricted stock units will vest in two equal installments on the dates
20

an applicable performance condition is achieved, on or prior to December 31, 2021. If the performance conditions are not satisfied on or prior to December 31, 2021, the restricted stock units will be forfeited for no consideration.
The restricted stock units granted had a weighted average fair value of $2.99 per share based on the closing price of the Company’s common stock on the date of grant. The restricted stock units were valued at approximately $1.4 million on their grant date. Forfeitures are estimated at the time of grant and are adjusted, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has estimated a forfeiture rate of 10% for restricted stock awards to employees based on historical attrition trends.
Unrecognized compensation expense for all restricted stock units was $1.5 million as of March 31, 2021, which is expected to be recognized over a weighted average period of 3.1 years.
The following table summarizes the Company’s restricted stock units under the 2016 Plan and 2018 Inducement Incentive Award Plan:
 Number of sharesWeighted average
grant date
fair value ($)
Unvested at December 31, 2020
87,500 $6.03 
Granted468,550 2.99 
Vested(10,937)6.03 
Reserved for issuance98,750 2.99 
Forfeited(800)2.99 
Unvested at March 31, 2021
643,063 $3.35 

Employee Stock Purchase Plan
In June 2016, the Company approved the 2016 Employee Stock Purchase Plan, or the ESPP, which authorized 173,076 shares of common stock for future issuance under the ESPP to participating employees. In January 2021 and 2020, the number of shares of common stock authorized for issuance under the ESPP was increased by 1,080,711 shares and 863,254 shares, respectively. During the three months ended March 31, 2021, the Company issued 34,696 shares of common stock under the ESPP. As of March 31, 2021, 2,546,464 shares remain available for future issuance under the ESPP.
For each of the three months ended March 31, 2021 and 2020, the Company recognized less than $0.1 million of stock-based compensation expense under the ESPP.

12. Revenue Arrangements
Swedish Orphan Biovitrum
License and Development Agreement
On June 11, 2020, the Company and Sobi entered into the Sobi License. Pursuant to the Sobi License, the Company has agreed to grant Sobi an exclusive, worldwide (except as to Greater China) license to develop, manufacture and commercialize the Company’s SEL-212 drug candidate, which is currently in development for the treatment of chronic refractory gout. The SEL-212 drug candidate is a pharmaceutical composition containing a combination of SEL-037, or the Compound, and ImmTOR. Pursuant to the Sobi License, in consideration of the license, Sobi agreed to pay the Company a one-time, up-front payment of $75.0 million. Sobi has also agreed to make milestone payments totaling up to $630.0 million to the Company upon the achievement of various development and regulatory milestones and, if commercialized, sales thresholds for annual net sales of SEL-212, and tiered royalty payments ranging from the low double digits on the lowest sales tier to the high teens on the highest sales tier.
Pursuant to the Sobi License, the Company has agreed to supply (at cost) quantities of the Compound and ImmTOR as necessary for completion of the two Phase 3 clinical trials of SEL-212 (DISSOLVE I and DISSOLVE II) and a 6-month placebo extension. The Company is required to supply quantities of the Compound until all rights to the Compound and any materials needed to manufacture the Compound are transferred to Sobi. Sobi has agreed to reimburse the Company for all budgeted costs incurred to complete development of SEL-212, including but not limited to costs incurred while conducting and completing the Phase 3 DISSOLVE trials, except for any costs of additional development activities required that are related to ImmTOR and that are unrelated to SEL-212. Sobi will have control and responsibility over all regulatory filings, including any investigational drug applications (IND), biologics license applications (BLA), and marketing authorization applications (MAA) relating to the licensed product.
21

The transactions contemplated by the Sobi License were consummated on July 28, 2020 following the expiration or termination of the required waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Sobi may terminate the Sobi License for any reason upon 180 days’ written notice to the Company, whereby all rights granted under the Sobi License would revert back to the Company. In addition, if Sobi were to terminate the Sobi License, the Company has the option to obtain a license to all patents and know-how necessary to exploit SEL-212 in existence as of the termination date from Sobi in return for making an equitable royalty payment to Sobi.
Additionally, on June 11, 2020, the Company entered into the Sobi Purchase Agreement in connection with the Sobi License. The closing of the Sobi Private Placement occurred on July 31, 2020, following the closing of the transactions contemplated under the Sobi License. See Note 10 for details.
The Company determined that the Sobi License represents a service arrangement under the scope of ASC 606. In addition, given the Sobi License and Sobi Purchase Agreement were executed contemporaneously and negotiated as a package with a single commercial objective, the Company will account for the two agreements as a single contract. The term of the Sobi License commenced upon the effective date of July 28, 2020 and will continue on a product-by-product basis until the royalty terms for each country have expired. The royalty term for a given product begins upon the first commercial sale of the product in a country and ends at the later of ten years from the first commercial sale, expiration of the last valid patent claim covering the product and expiration of all regulatory exclusivity periods for the product in a country. Given the reversion of the rights under the Sobi License represents a penalty in substance for a termination by Sobi, the contract term would remain the stated term of the Sobi License.
The Company determined that the Sobi License contains three distinct performance obligations due to the nature of the promises in the contract, which includes conducting the Phase 3 DISSOLVE trials, Sobi’s option to set-up a second source supplier, and a combined obligation comprised of the delivery of the license to SEL-212, transfer of the know-how and the manufacturing and delivery of SEL-212 supply for development, or the Combined License Obligation. As the set-up of a second source supplier is optional for Sobi and the Company will be reimbursed at cost for its efforts in the subsequent set-up and technology transfer, the option for this future service was determined to be at a significant and incremental discount to its standalone selling price and treated as a material right in the arrangement, namely a distinct performance obligation.
In determining the transaction price, the Company concluded the upfront payment of $75.0 million and the $5.0 million development milestone associated with the dosing of the first patient in the Phase 3 DISSOLVE trials will be included in the transaction price. All other development milestones will be fully constrained and only be included in the transaction price when the respective milestone is deemed probable of achievement. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of the evaluation of the constraint, the Company considered numerous factors, including that receipt of such milestones is outside the control of the Company and probability of success criteria is estimated. The Company will re-evaluate the transaction price in each reporting period, as uncertain events are resolved. In accordance with ASC 606, the Company will only recognize revenue associated with sales-based milestones and royalties when the subsequent sales thresholds are reached and underlying sales occur, respectively. In connection with the Sobi Purchase Agreement, the Company determined that the gross proceeds of $25.0 million from the Sobi Private Placement included a premium to the fair value of the Company’s shares as of July 28, 2020 equal to approximately $14.5 million. The premium amount will be included in the transaction price for revenue recognition. The Company will estimate and include in the transaction price the total reimbursements to be received from Sobi for both the manufacturing and delivery of the Compound and ImmTOR as well as conducting the Phase 3 DISSOLVE trials. The Company determined that a significant financing component does not exist in its arrangement with Sobi.
The Company allocated the transaction price based on the relative standalone selling prices of the three distinct performance obligations. The Company estimated the standalone selling price of conducting the Phase 3 DISSOLVE trials by forecasting its anticipated costs and applying a margin reflective of the industry. The Company must determine the standalone selling price of the second source supplier option by determining the discount given to Sobi multiplied by the likelihood that Sobi will exercise the option in the future. Similar to the Phase 3 program estimate, the Company estimated the discount of the option by forecasting the set-up costs and applying a margin that is reflective of the industry. As the Company will be providing the set-up and technology transfer services and the future supply at cost, the discount of the option is equal to the margin amount. The Company considered discussions with Sobi as well as probability of regulatory success of SEL-212 in determining the likelihood of exercise. The Company estimated the standalone selling price of the Combined License Obligation by utilizing a discounted cash flow model.
The Company determined that the delivery of the supply to Sobi best represents the pattern of delivery of the Combined License Obligation as the supply is essential to the utility of the license and know-how. The Company will recognize the revenue allocated to the Combined License Obligation by utilizing the output method. The Company estimated the total supply of the Compound and ImmTOR to be required during the clinical trial period and will recognize revenue as this supply is shipped for use in the clinical trials. The Company will recognize the revenue allocated to the conducting of the Phase 3 DISSOLVE trials obligation by utilizing the input method. The Company estimated the total budgeted costs to be incurred over
22

the Phase 3 DISSOLVE trials and will recognize revenue as these costs are incurred. The Company’s costs best represent the pattern of transfer as these will capture all performance of the trials completed to date and can be readily measured. The Company will recognize the revenue allocated to the second source supplier option when the future services and goods are transferred.
As of March 31, 2021 and December 31, 2020, the Company recorded $72.0 million and $68.3 million, respectively, as a short-term contract liability and $17.8 million and $24.2 million, respectively, as a long-term contract liability, representing deferred revenue associated with this agreement.
In addition, as of March 31, 2021 the Company has recorded $1.3 million of contract assets related to incremental costs that would not have been incurred if the Sobi License had not been obtained, of which $1.0 million is presented in prepaid expenses and other current assets and $0.3 million is presented in other assets in the accompanying unaudited consolidated balance sheets. Amortization of contract assets was less than $0.1 million for the three months ended March 31, 2021.
As of March 31, 2021 and December 31, 2020, the Company recorded a total outstanding receivable of $8.3 million and $6.9 million, respectively, representing billings for the Phase 3 DISSOLVE program that are subject to reimbursement by Sobi. Revenue of $11.1 million related to the Sobi License was recognized during the three months ended March 31, 2021.
Sarepta Therapeutics, Inc.
Research License and Option Agreement
On June 13, 2020, the Company and Sarepta entered into a Research License and Option Agreement, or the Sarepta Agreement. Pursuant to the Sarepta Agreement, the Company agreed to grant Sarepta a license under the Company’s intellectual property rights covering the Company’s antigen-specific biodegradable nanoparticle encapsulating ImmTOR to research and evaluate ImmTOR in combination with Sarepta’s adeno-associated virus gene therapy technology, or gene editing technology, using viral or non-viral delivery, to treat Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophy subtypes, or the Indications. Sarepta will have an option term of 24 months during which it can opt-in to obtain an exclusive license to further develop and commercialize the Product to treat at least one Indication, with a potential to extend the option term for an additional fee. The Company will supply ImmTOR to Sarepta for clinical supply on a cost-plus basis.
Sarepta paid a $2.0 million up-front payment to the Company upon signing of the Sarepta Agreement, and the Company is eligible to receive additional preclinical payments during the option term. If Sarepta opts-in to an exclusive license agreement, the Company could receive option exercise payments per Indication upon execution of the exclusive license, and the Company would be entitled to significant development and commercial milestone payments and tiered royalties ranging from the mid-to-high single digits based on net sales.
Pursuant to the Sarepta Agreement, the Company determined the Sarepta Agreement represents a service arrangement under the scope of ASC 606, with a 24 month contract duration. Given the reversion of the rights under the Sarepta Agreement represents a penalty in substance for a termination by Sarepta, the contract term would remain the stated term of the Sarepta Agreement.
The Company determined that the Sarepta Agreement and supply obligation including the delivery of the research license, the licensed know-how, the manufactured supply and delivery of materials represent a single promise and performance obligation to be transferred to Sarepta over time due to the nature of the promises in the contract. The delivery of the manufactured supply is the predominant promise within the arrangement, as it is essential to the utility of the licensed intellectual property. As such, consideration in the initial transaction price will be allocated to the single performance obligation based on the contractual price.
In determining the transaction price, the Company concluded the payment associated with all the performance milestones will be fully constrained and only be included in the transaction price when the respective milestone is deemed probable of achievement. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of such study milestones is outside the control of the Company and probability of success criteria is estimated. As of March 31, 2021 and December 31, 2020, all milestones were constrained. The Company will re-evaluate the transaction price in each reporting period, as uncertain events are resolved. The Company will recognize the revenue associated with the upfront payment and combined single performance obligation utilizing the output method, over the 24 month term as the manufactured supply is delivered to Sarepta.
The Company also determined the option to enter into a future commercial license agreement and extend the term of the option does not represent a material right since it was not priced at an incremental discount. Sarepta may terminate the Sarepta Agreement for any reason upon 30 days’ written notice to the Company. The Sarepta Agreement contains other customary terms and conditions, including representations and warranties, covenants, termination, and indemnification obligations in favor of each party. During the year ended December 31, 2020, the Company and Sarepta entered into two amendments relating to an
23

additional feasibility study. During the three months ended March 31, 2021, the Company and Sarepta entered into a third amendment relating to feasibility study research plan. None of the amendments executed through March 31, 2021 had a material impact on deferred revenue or revenue recognition.
At each of March 31, 2021 and December 31, 2020, the Company recorded $2.0 million as a short-term contract liability representing deferred revenue associated with this agreement. No revenue related to the Sarepta Agreement was recognized during the three months ended March 31, 2021 and 2020.
Asklepios Biopharmaceutical, Inc.
License Agreement for Pompe Disease
On December 17, 2019, the Company and AskBio entered into a license agreement, or the AskBio License Agreement. Pursuant to the AskBio License Agreement, AskBio has exercised its option to exclusively license the Company’s intellectual property rights covering the Company’s ImmTOR platform to research, develop, and commercialize certain AAV gene therapy products utilizing ImmTOR, and targeting the GAA gene, or derivatives thereof, to treat Pompe Disease.
Pursuant to the AskBio License Agreement and ancillary documents, AskBio agreed to pay to the Company upfront fees of an aggregate of $7.0 million. Assuming successful development and commercialization, the Company could receive up to an additional $237.0 million in development, regulatory, and sales milestone payments. If commercialized, the Company would be eligible to receive tiered royalties on global net sales at percentages ranging from mid-to-high single digits. Under the terms of the agreement, the Company will be eligible to receive these royalties commencing on the first commercial sale of the licensed product until the expiration of the later of (i) ten years after the first commercial sale and (ii) expiration of the last to expire valid claim on patents covering the licensed product.
Pursuant to the AskBio License Agreement, the Company will supply AskBio with its ImmTOR platform, or the Supply Obligation, and AskBio will be responsible for all preclinical, clinical and commercial manufacture and supply of licensed products (other than ImmTOR) and carry out all other activities related to the research, development, and commercialization of licensed products at its sole expense, including all regulatory activities related thereto.
The Company determined that the AskBio License Agreement and Supply Obligation represent a single promise and performance obligation. This is because AskBio cannot derive benefit from the license without the simultaneous transfer of the patent protected ImmTOR supply. Therefore, the License Obligation and Supply Obligation represent the only promise in the arrangement and are combined as a single performance obligation.
In determining the transaction price, the Company concluded that the future development milestones, regulatory milestones, sales milestones, and sales royalties all represent variable consideration. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of such milestones is outside the control of the Company. Consideration related to sales-based milestones as well as royalties on net sales upon commercialization by AskBio, will be recognized when the related sales occur, as they were determined to relate predominantly to the intellectual property granted to AskBio and, therefore, have also been excluded from the transaction price in accordance with the royalty recognition constraint. As of March 31, 2021 and December 31, 2020, all milestones were constrained. The Company will re-evaluate the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur.
The total initial transaction price of the contract on the effective date was $7.0 million, comprised of a $2.0 million initial up-front payment upon agreement of terms, and a $5.0 million initial up-front execution fee.
At each of March 31, 2021 and December 31, 2020, the Company recorded $1.7 million as short-term and $5.3 million as a long-term, representing deferred revenue associated with this agreement. Revenue will be recognized over the period in which the particles are delivered. No revenue related to the AskBio License Agreement was recognized during the three months ended March 31, 2021 and 2020 as no deliveries were made during the periods.
Spark Therapeutics, Inc.
Spark License Agreement
The disclosures relating to the Company’s license and option agreement, or the Spark License Agreement, with Spark pursuant to which the Company and Spark agreed to collaborate on the development of gene therapies for certain targets utilizing the ImmTOR platform reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 which was filed with the SEC on March 12, 2021 have not materially changed since the Company filed such report.
24

Transaction Price Allocated to Future Performance Obligations
Remaining performance obligations represent the transaction price of contracts for which work has not been performed (or has been partially performed). As of March 31, 2021, the aggregate amount of the transaction price allocated to remaining performance obligations was $108.1 million.
Contract Balances from Contracts with Customers (Sobi, Sarepta, AskBio, and Spark)
The following table presents changes in the Company’s contract liabilities during the three months ended March 31, 2021 (in thousands):
Balance atBalance at
beginning of periodAdditionsDeductionsend of period
Three Months Ended March 31, 2021
Contract liabilities:
     Deferred revenue$110,796 $ $(2,730)$108,066 
Total contract liabilities$110,796 $ $(2,730)$108,066 

13. Related-Party Transactions
Consulting Services
The Company incurred expenses for consulting services provided by its founders totaling less than $0.1 million during each of the three months ended March 31, 2021 and 2020. The Company entered into consulting agreements with its founders to serve on its Scientific Advisory Board, effective January 1, 2020 to December 31, 2021, under which they will be paid quarterly for their services.

14. Collaboration Agreements
Asklepios Biopharmaceutical, Inc.
Feasibility Study and License Agreement
In August 2019, the Company entered into a feasibility study and license agreement with AskBio, or the AskBio Collaboration Agreement. Pursuant to the AskBio Collaboration Agreement, the Company and AskBio agreed to license intellectual property rights to each other as part of a collaboration to research, develop, and commercialize certain AAV gene therapy products utilizing the Company’s ImmTOR platform to enable re-dosing of such AAV gene therapy products to treat serious rare and orphan genetic diseases for which there is a significant unmet medical need.
Pursuant to the AskBio Collaboration Agreement, the Company and AskBio agreed to conduct proof of concept studies to potentially validate the use of ImmTOR in conjunction with AskBio’s AAV gene therapy, or MMA-101, for the treatment of MMA, to mitigate the formation of neutralizing anti-AAV capsid antibodies, or the POC Studies. If the POC Studies are successful, or the parties otherwise elect to do so, the parties will proceed with a collaboration to pursue the development and commercialization of AAV gene therapy product candidates utilizing ImmTOR for the treatment of certain agreed serious rare and orphan genetic diseases. If the POC Studies fail to demonstrate a proof-of-concept, and the parties do not mutually agree in writing to proceed with the collaboration, the AskBio Collaboration Agreement will expire.
The SEL-399 program combines an empty AAV capsid (EMC-101), which is an AAV capsid containing no transgene, with ImmTOR and is being conducted in partnership with AskBio. Building on the preclinical data the Company has generated showing ImmTOR’s effect on mitigating or reducing the formation of neutralizing antibodies to AAV gene therapies, the Company has commenced a clinical trial of SEL-399 in healthy adult volunteers in Belgium. The goal of the SEL-399 clinical trial is to demonstrate the appropriate dose of ImmTOR in humans to mitigate the formation of antibodies to AAV capsids used in gene therapies.
The Company and AskBio will share responsibility for the research, development and commercialization of products developed under this collaboration. The parties will also share research, development, and commercialization costs equally for all collaboration products, but with a right of either party to opt out of certain products, and thereby no longer be required to share costs for such products. Each party will receive a percentage of net profits for each product sold under the collaboration equal to the percentage of shared costs borne by such party in the development of such product. Pursuant to the AskBio Collaboration Agreement, AskBio is responsible for manufacturing the AAV capsids and AAV vectors and the Company is responsible for manufacturing ImmTOR.
The AskBio Collaboration Agreement is considered to be within the scope of ASC 808, as both parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company evaluated the terms of the AskBio
25

Collaboration Agreement and have identified the following promises in the arrangement (1) conducting research and development activities to develop and commercialize products under the collaboration, or the R&D Services, (2) granting a non-exclusive, non-transferable, royalty-free, fully paid up, worldwide license to certain intellectual property of the Company, or the IP Rights, for the purpose of performing the POC Studies, or the Research License, (3) granting an exclusive, nontransferable, worldwide license to the IP Rights for use in certain indications, or the Collaboration License, (4) providing manufactured supply of preclinical and clinical ImmTOR, or the Manufactured Supply, (5) participation on identified steering committees responsible for the oversight of the collaboration, or the JSC Participation, and (6) granting an exclusive option to obtain a license under the IP Rights to research, develop and commercialize Licensed Products. The Company determined that the R&D Services, Research License, Collaboration License, Manufactured Supply, and JSC Participation were not capable of being distinct, and therefore must be combined into a single performance obligation. Therefore, promises (1) through (5) identified above were combined into a single performance obligation. Furthermore, the Company evaluated the Option Agreement and determined that it does not provide AskBio with a material right under ASC 606 as the option was not priced at a discount (see discussion of the option exercise in Note 12). The Company noted that AskBio did not meet the definition of a customer within the scope of ASC 606 for any distinct performance obligations as the Company concluded that such items were not an output of the Company’s ordinary activities. As such, the Company determined that the entire arrangement would be accounted for within the scope of ASC 808.
In accordance with ASC 808, collaboration expenses are recognized within R&D expense and selling, general and administrative expense on the Company’s condensed consolidated statements of operations. For each of the three months ended March 31, 2021 and 2020, the Company recognized $1.2 million of collaboration expense under the AskBio Collaboration Agreement in which actual costs incurred by both parties approximate a 50% cost share.
Under certain collaborative arrangements, the Company is entitled to reimbursement of certain R&D expense. Activities under collaborative arrangements for which the Company is entitled to reimbursement are considered to be collaborative activities under the scope of ASC 808. For these units of account, the Company does not analogize to ASC 606 or recognize revenue. Rather, the Company analogizes to the guidance in ASC 730, which requires that reimbursements from counterparties be recognized as an offset to the related costs. In accordance with ASC 730, the Company records reimbursement payments received from collaborators as reductions to R&D expense.
Massachusetts Institute of Technology
In November 2008, the Company entered into an exclusive patent license agreement, or the MIT License, with the Massachusetts Institute of Technology, or MIT, under which the Company received an exclusive royalty-bearing license to utilize patents held by MIT in exchange for upfront consideration and annual license maintenance fees. Such fees are expensed as incurred and have not been material to any period presented.
In June 2020, the Company entered into a Fifth Amendment, or the MIT Amendment, to the MIT License, which is effective as of May 15, 2020. Pursuant to the MIT Amendment, certain of the Company’s diligence obligations were extended, including a diligence obligation to commence a Phase 3 trial for a licensed product by a specific date in the second quarter of 2021. Additionally, certain of the Company’s development and regulatory milestones and payments upon achievement of such milestones were adjusted.
As of March 31, 2021, and in connection with the execution of the Spark License Agreement, the Company has made contractual payments pursuant to the MIT License totaling $2.2 million for the sublicense granted to Spark, and $0.4 million relative to the calculated premium paid by Spark for the equity investments made under the Spark Purchase Agreement. The Company made no additional payments during the three months ended March 31, 2021.
Shenyang Sunshine Pharmaceutical Co., Ltd
In May 2014, the Company entered into a license agreement, or the 3SBio License, with Shenyang Sunshine Pharmaceutical Co., Ltd., or 3SBio. The Company has paid to 3SBio an aggregate of $7.0 million in upfront and milestone-based payments under the 3SBio License as of March 31, 2021. The Company is required to make future payments to 3SBio contingent upon the occurrence of events related to the achievement of clinical and regulatory approval milestones of up to an aggregate of $15.0 million for products containing the Company’s ImmTOR platform.

15. Income Taxes
The Company provides for income taxes under ASC 740. Under ASC 740, the Company provides deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company’s financial statement carrying amounts and the tax bases of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse.
For the three months ended March 31, 2021 and 2020, the Company did not record a current or deferred income tax expense or benefit.
26

The Company has provided a full valuation allowance against its net deferred tax assets, as the Company believes that it is more likely than not that the deferred tax assets will not be realized.
Utilization of the net operating loss and research and development credit carryforwards may be subject to a substantial annual limitation under Section 382 and 383 of the Internal Revenue Code due to ownership change limitations that have occurred previously, or that could occur in the future. These ownership changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. As of December 31, 2020, the Company completed a Section 382 study. The Company has determined that all of the $234.5 million of net operating losses are available in the future, with approximately $36.5 million of that total limited under Section 382 and therefore available for future use through 2028.
The Company applies ASC 740, Income Taxes to uncertain tax positions. As of March 31, 2021 and December 31, 2020, the Company had no unrecognized tax benefits or related interest and penalties accrued.
The Company has not, as of yet, conducted a study of its research and development credit carryforwards. This study may result in an adjustment to the Company’s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position.
The statute of limitations for assessment by the United States Internal Revenue Service and Massachusetts tax authorities is open for tax years since inception. The Company files income tax returns in the United States and Massachusetts. There are currently no federal, state or foreign audits in progress.

16. Defined Contribution Plan
The Company maintains a defined contribution plan, or the 401(k) Plan, under Section 401(k) of the Internal Revenue Code. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. The 401(k) Plan provides for matching contributions on a portion of participant contributions pursuant to the 401(k) Plan’s matching formula. All matching contributions vest ratably over 4 years and participant contributions vest immediately. Contributions by the Company totaled less than $0.1 million during each of the three months ended March 31, 2021 and 2020.

17. Commitments and Contingencies
As of March 31, 2021, the Company was not a party to any litigation that could have a material adverse effect on the Company’s business, financial position, results of operations or cash flows.
On August 4, 2020, a putative stockholder of Selecta filed a stockholder derivative action, purportedly on behalf of Selecta and against certain current and former members of the Company’s Board of Directors, as well as one affiliated company owned by a current board member, in the Court of Chancery of the State of Delaware, namely Franchi v. Barabe, et al. The complaint alleges that the individual defendants breached their fiduciary duties and committed corporate waste when they authorized a private placement transaction, announced on December 19, 2019, at a price allegedly below fair value. The complaint further alleges that the four defendant directors who participated in the private placement were unjustly enriched in connection with the transaction. On September 25, 2020, the defendants filed a motion to dismiss the lawsuit. On November 6, 2020, the plaintiff filed an amended complaint, and the defendants filed a second motion to dismiss on January 8, 2021. On December 31, 2020, the Company received a litigation demand letter from two other putative stockholders relating to the same private placement transaction. On April 12, 2021, the Court of Chancery in the State of Delaware granted a motion to stay the litigation pending a review by a Special Committee appointed by the Company’s Board of Directors. At this time, the Company has not accrued a liability for this matter, as any liability has been determined to be either not estimable or not probable.
Other
As permitted under Delaware law, the Company indemnifies its directors for certain events or occurrences while the director is, or was, serving at the Company’s request in such capacity. The term of the indemnification is for the director’s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ insurance coverage that limits its exposure and enables it to recover a portion of any future amounts paid. The Company also has indemnification arrangements under certain of its facility leases that require it to indemnify the landlord against certain costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from certain breaches, violations, or non-performance of any covenant or condition of the Company’s lease. The term of the indemnification is for the term of the related lease agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. To date, the Company had not experienced any material losses related to any of its indemnification obligations, and no material claims with respect thereto were outstanding.
27

The Company is a party in various other contractual disputes and potential claims arising in the ordinary course of business. The Company does not believe that the resolution of these matters will have a material adverse effect the Company’s business, financial position, results of operations or cash flows.

18. Subsequent Events
“At-the-Market” Offerings
Subsequent to March 31, 2021 through May 13, 2021, the Company sold 206,593 shares of its common stock pursuant to the 2020 Sales Agreement, at an average price of approximately $4.51 per share for aggregate net proceeds of $0.9 million, after deducting commissions and other transaction costs.
Milestone Event
On April 13, 2021, the Company was notified by Sarepta of the achievement of the milestone event related to the completion of a non-clinical study for Duchenne muscular dystrophy and certain limb-girdle muscular dystrophies under the Company’s Research License and Option Agreement. Under the terms of the Agreement, Sarepta is obligated to pay a non-refundable, non-creditable milestone payment of $3.0 million to the Company within 60 days of Sarepta’s receipt of the related invoice from the Company.
The AskBio Collaboration Agreement
On April 29, 2021, the Company was notified by AskBio that it intended to opt-out of development of the MMA indication. Consequently, the Company will assume all rights to the MMA program and intends to continue to progress the MMA-101 and ImmTOR combination through clinical development.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and related notes appearing elsewhere in this Quarterly Report and with our audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020, which we filed with the SEC on March 12, 2021. In addition, you should read the “Risk Factors” and “Information Regarding Forward-Looking Statements” sections of this Quarterly Report and our Annual Report on Form 10-K for the year ended December 31, 2020 for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

Overview
We are a clinical-stage biopharmaceutical company leveraging our ImmTOR immune tolerance platform with the goals of amplifying the efficacy of biologics, including enabling the re-dosing of life-saving gene therapies, and restoring self-tolerance in autoimmune diseases. Our ImmTOR platform encapsulates rapamycin, also known as sirolimus, an immunomodulator, in biodegradable nanoparticles and is designed to induce antigen-specific immune tolerance.
We believe ImmTOR has the potential to enhance the efficacy without compromising the safety of biologic therapies, improve product candidates under development, and enable novel therapeutic modalities. We have developed a portfolio of proprietary and collaboration-driven applications of ImmTOR, and we plan to continue to develop proprietary compounds and pursue collaboration-driven development in certain disease areas, which could include strategic collaborations, out-licensing, and in-licensing transactions.
We believe our ImmTOR platform has a broad range of potential applications.
Enzyme therapies. Enzyme therapies are a class of biologic drugs frequently used to treat rare diseases. Through our analysis of biologic drugs, including in our preclinical studies, we have observed that enzymes are especially prone to causing undesired immune responses. Our product candidate, SEL-212, which is currently in Phase 3 clinical development, includes pegadricase, a pegylated uricase enzyme, which is an example of an immunogenic enzyme for which we are applying ImmTOR with the intention of improving the enzyme’s efficacy and safety. We are also combining ImmTOR with an immunoglobulin A, or IgA, protease for the treatment of IgA nephropathy. We intend to seek, if appropriate, licenses to other enzymes that we would evaluate in combination with ImmTOR.
Gene therapies. We believe gene therapies have the potential to address key unmet medical needs for many rare genetic diseases, but undesired immune responses to the viral vectors used for gene replacement, augmentation and editing may be restricting their broader use. Through our analysis of genetic diseases, we have identified applications and patient segments that we believe would benefit from our ImmTOR platform. We intend to develop ImmTOR-
28

enabled non-immunogenic gene therapy candidates which are designed to be utilized with adeno-associated virus, or AAV, vectors. We believe our product candidates have the potential to increase transgene expression and to prevent undesired immune responses to the vector and transgene product that can occur with the first dose of gene therapy by using our ImmTOR platform. Our initial area of focus is on genetic metabolic diseases but may also include lysosomal storage diseases and genetic muscular diseases. We believe we are the first company to systematically pursue the development of AAV gene therapy product candidates with the goal of enabling repeat administration. We have engaged third parties with experience in gene therapy and rare diseases to support the development of our products. We also have licensed our ImmTOR platform to AskBio, Sarepta, and Spark for certain pre-specified targets.
Restoring self-tolerance to auto-antigens. We believe that ImmTOR has the potential to restore self-tolerance in autoimmune diseases. Our first program in autoimmune diseases is in primary biliary cholangitis, or PBC. PBC has a significant unmet medical need and a well-defined target antigen, known as PDC-E2.
Other products and product candidates affected by undesired immune responses. We have generated preclinical data which we believe suggests a broad potential benefit of ImmTOR for immune tolerance. For many biologic drugs, undesired immune responses limit efficacy and cause safety concerns. We intend to strategically out-license ImmTOR for use with other products that are outside our focus to larger biopharmaceutical companies. We believe our ImmTOR platform may also be of interest to biopharmaceutical companies with novel biologic development concepts or product candidates in clinical development that have demonstrated initial efficacy but are experiencing issues with safety or sustained efficacy due to inhibitory ADAs.
Our Current Programs
Amplifying the Efficacy of Biologics: Enzyme therapy – Chronic Refractory Gout
SEL-212 is designed to be a monthly treatment for chronic refractory gout, a debilitating rare disease with an unmet medical need. SEL-212 consists of a combination of our ImmTOR platform co-administered with pegadricase. Pegadricase is an investigational recombinant pegylated uricase (urate oxidase), an enzyme not naturally found in humans, and is therefore highly immunogenic. This enzyme is designed to treat patients with symptomatic gout, refractory to standard uric acid lowering treatment, by breaking down the excess uric acid to the more soluble allantoin. In preclinical studies, we observed that ImmTOR, when co-administered with pegadricase, induced antigen-specific immune tolerance to pegadricase and substantially reduced the formation of associated ADAs. Based on our clinical data, we believe that SEL-212 has the potential to control serum uric acid, or SUA levels and mitigate the formation of ADAs in response to the therapeutic enzyme. Additionally, we believe that SEL-212 serves as proof of concept for the ImmTOR platform in ameliorating the unwanted immune response to an immunogenic biologic. SEL-212 has been licensed (except as to Greater China) to Sobi, pursuant to our license and development agreement dated June 11, 2020 with Sobi, or the Sobi License.
We and Sobi commenced the Phase 3 DISSOLVE clinical program of SEL-212 in September 2020. The Phase 3 clinical program consists of two double blinded, placebo-controlled trials of SEL-212, DISSOLVE I and DISSOLVE II. Each trial is expected to enroll 105 patients, with 35 patients receiving 0.1 mg/kg of ImmTOR and 0.2 mg/kg of pegadricase, 35 patients receiving 0.15 mg/kg of ImmTOR and 0.2 mg/kg of pegadricase, and 35 patients receiving placebo. DISSOLVE I and DISSOLVE II both have a six-month primary endpoint with a six-month safety extension for DISSOLVE I. The primary endpoint of the DISSOLVE program is the maintenance of SUA levels below 6 mg/dL at six months. Secondary endpoints include tender and swollen joint counts, tophus burden, patient reported outcomes of activity limitation and quality of life and gout flare incidence. Topline data from the Phase 3 DISSOLVE clinical program is expected in the second half of 2022. The Phase 3 DISSOLVE clinical program is being conducted by Selecta and funded by Sobi.
Amplifying the Efficacy of Biologics: Enzyme therapy – IgA Nephropathy
The second indication in our enzyme therapy program is IgA nephropathy, an autoimmune kidney disease that occurs when immune complexes of a subclass of antibodies called immunoglobulin A1 (IgA1) accumulates in the kidneys.
In October 2020, we entered into an Option and License Agreement, or the IGAN Agreement, with IGAN Biosciences, Inc., or IGAN. Pursuant to the IGAN Agreement, IGAN has granted us an exclusive license to research, evaluate, and conduct pre-clinical development activities on IGAN’s proprietary IgA proteases. Previous studies in animal models conducted at independent laboratories demonstrated that IgA protease removed injurious IgA immune complexes from kidneys and reduced inflammation, fibrosis, and hematuria. These results suggest that it is an excellent candidate to potentially decrease the rate of disease progression and possibly even reverse the disease. The barrier to IgA protease commercialization is the bacterial origin of the protease, which makes it immunogenic. Our ImmTOR platform has shown in clinical studies the ability to mitigate the formation of ADAs to immunogenic enzymes, which has been observed with SEL-212. We intend to combine IgA protease with our ImmTOR platform to develop a novel combination product candidate for the treatment of IgA nephropathy and IgA-mediated diseases. We will have an option term of 24 months, during which we can elect to obtain an exclusive license to further develop and commercialize the product candidate to treat all IgA-mediated diseases, including IgA nephropathy, Linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura (also known as IgA vasculitis).
29

We plan to file an Investigational New Drug, or IND, application, for this program by the end of 2021.
Amplifying the Efficacy of Biologics: Gene Therapies
When used in combination with AAV gene therapy vectors, ImmTOR has been observed to inhibit the immune response to the vector and enable successful redosing in mice and non-human primates, or NHPs. Currently, the ability to re-administer systemic AAV gene therapy is limited by the development of neutralizing antibodies. The ability to safely re-dose AAV may help achieve therapeutic benefit in patients who are under-dosed; it may also help restore transgene expression in patients, particularly pediatric patients, who may lose gene expression over time as they grow. In addition, a study conducted in NHPs showed that co-administration of AAV vector and ImmTOR in NHPs enabled higher and more durable transgene expression after the first dose of gene therapy as well as robust inhibition of anti-AAV8 immunoglobulin G, or IgG, and neutralizing antibodies. The observation that co-administration of AAV vector and ImmTOR leads to higher transgene expression demonstrates the potential for dosing lower levels of AAV gene therapies when combined with ImmTOR. Thus, integrating ImmTOR into a gene therapy protocol has the potential to provide a first dose benefit by enhancing liver-directed transgene expression and durability, as well as the potential for enabling re-dosing.
Our lead therapeutic gene therapy program is in methylmalonic acidemia, or MMA, an inherited disorder in which the body is unable to process certain proteins and fats (lipids) properly. This program was previously being conducted under our collaboration with AskBio. In April 2021, we were notified by AskBio that it intended to opt-out of development of the MMA indication. The feasibility study and license agreement with AskBio, or AskBio Collaboration Agreement, otherwise remains in effect. Due to a manufacturing issue with the AAV vector we believe is related to a component sourced from a third party, our plans to file an IND for this product candidate, MMA-101, have been delayed to the end of 2021. ImmTOR manufacturing, controlled by us, continues to proceed in accordance with our expectations, and we have not observed any impact to any of our ImmTOR programs. In October and November 2020, we and AskBio received rare pediatric disease designation and orphan drug designation, respectively, from the FDA for MMA-101, for the treatment of MMA due to methylmalonyl-CoA mutase, or MMUT gene mutations.
Our proprietary gene therapy product candidate, SEL-313, is being developed to treat ornithine transcarbamylase, or OTC deficiency, and is currently in preclinical development. OTC deficiency is a rare genetic disorder that causes ammonia to accumulate in the blood due to mutations in the OTC gene, which is critical for proper function of the urea cycle. The most severe form of the disorder presents within the first few days of life. Severe symptoms include inability to control body temperature and breathing rate, seizures, coma, developmental delays and intellectual disability. Less severe forms of the disorder are characterized by delirium, erratic behavior, aversion to high protein foods, vomiting and seizures. We expect to file an IND and/or Clinical Trial Application for SEL-313 in 2022.
SEL-399 combines an empty AAV capsid (EMC-101), which is an AAV capsid containing no transgene, with ImmTOR and is being conducted in partnership with AskBio. Building on the preclinical data we have generated showing ImmTOR’s effect on mitigating or reducing the formation of neutralizing antibodies to AAV gene therapies, we have commenced a clinical trial of SEL-399 in healthy adult volunteers in Belgium. The goal of the SEL-399 clinical trial is to demonstrate the appropriate dose of ImmTOR in humans to mitigate the formation of antibodies to AAV capsids used in gene therapies. An initial control cohort of healthy volunteers received a single dose of EMC-101 in December 2020 and dose escalating cohorts of EMC-101 plus ImmTOR were initiated in February 2021. Topline results are expected in the fourth quarter of 2021.
Restoring Self-tolerance in Autoimmune Diseases
Our lead autoimmune diseases indication is PBC, a T-cell driven autoimmune disease that causes progressive destruction of the bile ducts. Patients with PBC are in need of a highly targeted, liver-directed approach to treating the root cause of the disorder. We believe PBC has a well-defined target antigen, significant unmet medical need, and is well suited to the application of our ImmTOR immune tolerance platform, as preclinical data suggest that ImmTOR has the potential to enhance the tolerogenic environment in the liver and provide a hepatoprotective benefit. We expect to file an IND for our PBC program in the second half of 2022.
Licenses and Collaborations
Swedish Orphan Biovitrum
In June 2020, we announced that we had entered into the Sobi License, pursuant to which we agreed to grant Sobi an exclusive, worldwide (except as to Greater China) license to develop, manufacture and commercialize SEL-212, which is currently in development for the treatment of chronic refractory gout. In September 2020, pursuant to the Sobi License, Sobi paid us a one-time, up-front payment of $75 million. Sobi has also agreed to make milestone payments totaling up to $630 million to us upon the achievement of various development and regulatory milestones and sales thresholds for annual net sales of SEL-212, and tiered royalty payments ranging from the low double digits on the lowest sales tier to the high teens on the highest sales tier.
30

Additionally, Sobi purchased an aggregate of 5,416,390 shares of our common stock at $4.6156 for aggregate gross proceeds of $25 million, which we refer to as the Sobi Private Placement. The closing of the Sobi Private Placement occurred on July 31, 2020.
Under the Sobi License, we will have operational oversight of the Phase 3 DISSOLVE clinical program of SEL-212 (DISSOLVE I and DISSOLVE II) that commenced in September 2020, at Sobi’s expense.
IGAN Biosciences
In October 2020, we entered into the IGAN Agreement. Pursuant to the IGAN Agreement, IGAN granted us an exclusive license to research, evaluate, and conduct pre-clinical development activities on IGAN’s proprietary IgA proteases. We have an option term of 24 months, during which we can elect to obtain an exclusive license to further develop and commercialize the product to treat all IgA-mediated diseases, including IgA nephropathy, Linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura (also known as IgA vasculitis).
Sarepta Therapeutics
In June 2020, we entered into a research license and option agreement with Sarepta, or the Sarepta Agreement. Pursuant to the agreement, we granted Sarepta a license to research and evaluate ImmTOR in combination with Sarepta’s AAV gene therapy or gene editing technology, using viral or non-viral delivery, or the Sarepta Product, to treat Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophy subtypes, or the Sarepta Indications. Sarepta will have an option term of 24 months during which it can opt-in to obtain an exclusive license to further develop and commercialize the Sarepta Product to treat at least one Sarepta Indication, with a potential to extend the option term if Sarepta pays an additional fee to us. Sarepta made an up-front payment to us upon signing of the agreement, and we are eligible to receive additional payments under the option term. If Sarepta opts-in to an exclusive license agreement, we could receive option exercise payments per indication, we would be entitled to significant development and commercial milestone payments and tiered royalties ranging from the mid-to-high single digits based on net sales.
AskBio
In August 2019, we entered into the AskBio Collaboration Agreement. The initial proof-of-concept study being conducted under this collaboration is in SEL-399, which combines an empty AAV capsid (EMC-101), an AAV capsid containing no transgene, with ImmTOR, and is being conducted in partnership with AskBio. Building on the preclinical data we have generated showing ImmTOR’s effect on mitigating or reducing the formation of neutralizing antibodies to AAV gene therapies, we have commenced a clinical trial of SEL-399 in healthy adult volunteers in Belgium. The goal of the SEL-399 clinical trial is to demonstrate the appropriate dose of ImmTOR in humans to mitigate the formation of antibodies to AAV capsids used in gene therapies, which currently precludes re-dosing. An initial control cohort of healthy volunteers received a single dose of EMC-101 in December 2020 and dose escalating cohorts of EMC-101 plus ImmTOR were initiated in February 2021. Topline results are expected in the fourth quarter of 2021.
Previously, we and AskBio were developing a gene therapy for MMA, which can cause severe developmental defects and premature death as a result of an accumulation of toxic metabolites. We conducted preclinical studies for this product candidate and will leverage that work within the collaboration. In April 2021, we were notified by AskBio that it intended to opt-out of development of the MMA indication. The AskBio Collaboration Agreement otherwise remains in effect and we intend to continue to develop MMA-101 combined with ImmTOR through clinical development.
Additionally, in December 2019, we entered into a License Agreement with AskBio, or the AskBio License Agreement, which provides AskBio with exclusive worldwide rights to our ImmTOR platform to research, develop and commercialize certain AAV-gene therapy products targeting the GAA gene, or derivatives thereof, to treat Pompe Disease.
Spark Therapeutics
In December 2016, we entered into a license and option agreement with Spark Therapeutics, or the Spark License Agreement, which provides Spark with exclusive worldwide rights to our ImmTOR platform to research, develop and commercialize gene therapies for Factor VIII, an essential blood clotting protein relevant to the treatment of hemophilia A.
Impact of COVID-19
We are closely monitoring how COVID-19 is affecting our employees, business, preclinical studies and clinical trials. In response to the spread of COVID-19, we have continued to have our administrative employees work outside of our offices and limited the number of staff in any given research and development laboratory. Disruptions caused by the COVID-19 pandemic may result in difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials, and the incurrence of unforeseen costs as a result of preclinical study or clinical trial delays.
While the COVID-19 pandemic has not had a material impact on our clinical programs as of the date of this Quarterly Report, it could have an impact on our ability to complete the Phase 3 DISSOLVE clinical program of SEL-212, our ability to commence preclinical and clinical studies of our IgA nephropathy, gene therapy, and autoimmune disease programs, and our
31

ability to obtain supply of both active drug substances and finished drug product as well as efficient execution of the overall supply chain for SEL-212 and our other programs. We have been proactively working with our CRO, clinical sites, and principal investigators to provide patients with more convenient locations to have their SUA measured for the primary endpoint of the study, such as at local laboratories or their homes, as well as alternative sites to receive infusions of study drug. We are also working with our primary and back-up suppliers for SEL-037 (pegadricase) and SEL-110 (ImmTOR) to ensure that we have adequate supply of our materials for both our clinical and preclinical programs. We believe we will have adequate supply of all material necessary to conduct our Phase 3 DISSOLVE clinical program of SEL-212 in chronic refractory gout and to complete our clinical trial for SEL-399 in gene therapy under our collaboration with AskBio.
At this time, there is significant uncertainty relating to the trajectory of the COVID-19 pandemic and the impact of related responses. Any impact of COVID-19 on the Company’s business, revenues, results of operations and financial condition will largely depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, supply chain disruptions, the ultimate impact on financial markets and the global economy, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.

Financial Operations
To date, we have financed our operations primarily through public offerings and private placements of our securities, funding received from research grants and collaboration arrangements and our credit facility. We do not have any products approved for sale and have not generated any product sales. All of our revenue to date has been collaboration and grant revenue.
Since inception, we have incurred significant operating losses. We incurred net losses of $24.6 million and $19.6 million for the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021, we had an accumulated deficit of $429.2 million. We expect to continue to incur significant expenses and operating losses for at least the next several years as we:
continue the research and development of our other product candidates as well as product candidates that we may be developing jointly with collaboration partners;
seek to enhance our ImmTOR platform and discover and develop additional product candidates;
seek to enter into collaboration, licensing and other agreements, including, but not limited to research and development, and/or commercialization agreements;
seek regulatory approvals for any product candidates that successfully complete clinical trials;
potentially establish a sales, marketing and distribution infrastructure and scales-up external manufacturing capabilities to commercialize any products for which we may obtain regulatory approval;
maintain, expand and protect our intellectual property portfolio, including through licensing arrangements; and
add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our product development and potential future commercialization efforts and to support our operations as a public company.
Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, license and collaboration agreements, and research grants. We may be unable to raise capital when needed or on reasonable terms, if at all, which would force us to delay, limit, reduce or terminate our product development or future commercialization efforts. We will need to generate significant revenues to achieve profitability, and we may never do so.
We believe that our existing cash, cash equivalents, marketable securities, and restricted cash as of March 31, 2021 will enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2023. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect.
The consolidated financial information presented below includes the accounts of Selecta Biosciences, Inc. and our wholly owned subsidiaries, Selecta (RUS) LLC, a Russian limited liability company, or Selecta (RUS), and Selecta Biosciences Security Corporation, a Massachusetts securities corporation. All intercompany accounts and transactions have been eliminated.
Collaboration and grant revenue
To date, we have not generated any product sales. Our revenue consists of collaboration and grant revenue, which includes amounts recognized related to upfront and milestone payments for research and development funding under collaboration and license agreements. In addition, we earn revenue under the terms of government contracts or grants, which require the
32

performance of certain research and development activities. We expect that any revenue we generate will fluctuate from quarter to quarter because of the timing and amount of fees, research and development reimbursements and other payments from collaborators. We do not expect to generate revenue from product sales for at least the next several years. If we or our collaborators fail to complete the development of our product candidates in a timely manner or fail to obtain regulatory approval as needed, our ability to generate future revenue will be harmed, and will affect the results of our operations and financial position. For a further description of the agreements underlying our collaboration and grant-based revenue, see Notes 2 and 12 to our unaudited consolidated financial statements included elsewhere in this Quarterly Report.
Research and development
Our research and development expenses consist of external research and development costs, which we track on a program-by-program basis and primarily include CMO-related costs, fees paid to CROs and internal research and development costs, which are primarily compensation expenses for our research and development employees, lab supplies, analytical testing, allocated overhead costs and other related expenses. Our internal research and development costs are often devoted to expanding our programs and are not necessarily allocable to a specific target.
We have incurred a total of $308.3 million in research and development expenses from inception through March 31, 2021, with a majority of the expenses being spent on the development of SEL-212 and a prior nicotine vaccine candidate, and the remainder being spent on our various discovery and preclinical stage product candidate programs and the general expansion of our technology.
We expense research and development costs as incurred. Conducting a significant amount of research and development is central to our business model. Product candidates in clinical development generally have higher development costs than those in earlier stages of development, primarily due to the size, duration and cost of clinical trials. The successful development of our clinical and preclinical product candidates is highly uncertain. Clinical development timelines, the probability of success and development costs can differ materially from our expectations. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those which we currently expect will be required for the completion of clinical development of a product candidate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time to complete any clinical development.
The following table sets forth the components of our research and development expenses during the periods indicated (in thousands):
 Three Months Ended March 31,
 20212020
Research and development expenses (key projects and initiatives):
SEL-212$6,724 $8,648 
AskBio collaboration813 976 
Discovery and preclinical stage product candidate programs, collectively571 166 
Other internal research and development expenses4,896 4,934 
     Total research and development expenses$13,004 $14,724 
On June 11, 2020, we and Sobi entered into the Sobi License. Pursuant to the Sobi License, clinical trial costs incurred to complete development of SEL-212, including but not limited to costs incurred while conducting and completing the Phase 3 DISSOLVE trials, will be reimbursed by Sobi. These costs, when reimbursed, will be recognized as revenue consistent with the revenue recognition methodology disclosed in Note 12 to our unaudited consolidated financial statements included elsewhere in this Quarterly Report. The reimbursable costs exclude any costs of additional development activities required that are related to ImmTOR and that are unrelated to SEL-212.
General and administrative
General and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation, related to our executive, finance, business development and support functions. Other general and administrative expenses include facility-related costs not otherwise allocated to research and development expenses, travel expenses for our general and administrative personnel and professional fees for auditing, tax and corporate legal services, including intellectual property-related legal services.
Investment income
Investment income consists primarily of interest income earned on our cash, cash equivalents and marketable securities.
Interest expense
Interest expense consists of interest expense on amounts borrowed under our credit facilities.
33

Other income (expense)
Other income (expense) was de minimis during the three months ended March 31, 2021 and 2020.
Change in fair value of warrant liabilities
Common warrants classified as liabilities are remeasured at fair value, utilizing a Black-Scholes valuation methodology, quarterly with the change in fair value recognized as a component of earnings.
Foreign currency transaction gain (loss)
The functional currency of our Russian subsidiary is the Russian ruble. In addition to holding cash denominated in Russian rubles, our Russian bank accounts also hold cash balances denominated in U.S. dollars to facilitate payments to be settled in U.S. dollars or other currencies. As of March 31, 2021 and December 31, 2020, we maintained cash of $0.3 million in Russian banks, all of which was denominated in U.S. dollars. The amounts denominated in U.S. dollars and used in transacting the day-to-day operations of our Russian subsidiary are subject to transaction gains and losses, which are reported as incurred.

Results of Operations
Comparison of the Three Months Ended March 31, 2021 and 2020
Revenue
The following is a comparison of revenue for the three months ended March 31, 2021 and 2020 (in thousands, except percentages):
 Three Months Ended March 31,Increase
 20212020(decrease)
Collaboration revenue$11,050 $— $11,050 — 
During the three months ended March 31, 2021, collaboration revenue was $11.1 million, compared to no revenue recognition in 2020. During the three months ended March 31, 2021 we recognized $11.1 million under the license agreement with Sobi which began in July 2020 resulting from the shipment of clinical supply and the reimbursement of costs incurred for the Phase 3 DISSOLVE clinical program.

Research and development
The following is a comparison of research and development expenses for the three months ended March 31, 2021 and 2020 (in thousands, except percentages):
 Three Months Ended March 31,Increase
 20212020(decrease)
Research and development$13,004 $14,724 $(1,720)(12)%
During the three months ended March 31, 2021, our research and development expenses decreased by $1.7 million, or 12%, as compared to 2020. The decrease in cost was primarily the result of less expense incurred for the SEL-212 clinical programs and for the AskBio Collaboration, offset by an increase of expense for discovery and preclinical programs.

General and administrative
The following is a comparison of general and administrative expenses for the three months ended March 31, 2021 and 2020 (in thousands, except percentages):
 Three Months Ended March 31,Increase
 20212020(decrease)
General and administrative$5,204 $4,098 $1,106 27 %
During the three months ended March 31, 2021, our general and administrative expenses increased by $1.1 million, or 27%, as compared to 2020. The increase in costs was the result of expenses for consulting and professional fees and salaries offset by reduced travel expenses.

34

Investment income
Investment income was less than $0.1 million and $0.2 million for the three months ended March 31, 2021 and 2020, respectively. The decrease reflects reduced interest rates.
Foreign currency transaction gain (loss)
We recognized minimal foreign currency gains of less than $0.1 million for each of the three months ended March 31, 2021 and 2020, respectively.
Interest expense
Interest expense was $0.7 million and $0.3 million for the three ended March 31, 2021 and 2020, respectively, representing interest expense and amortization of the carrying costs of our credit facilities.
Change in fair value of warrant liabilities
For the three months ended March 31, 2021, we recognized a $16.7 million charge for the increase in the fair value of warrant liabilities utilizing the Black-Scholes valuation methodology. The increase in value was primarily driven by an increase in the Company’s share price (see Note 5). For the three months ended March 31, 2020, we recognized $0.8 million as a change in the fair value of warrant liabilities primarily driven by an increase in the Company’s share price and volatility, offset by a decreased discount rate this quarter.
Other income (expense)
Other income (expense) was de minimis for each of the three months ended March 31, 2021 and 2020.
Net Loss
Net loss for the three months ended March 31, 2021 was $24.6 million compared to $19.6 million for the three months ended March 31, 2020.

Liquidity and Capital Resources
Since our inception, we have incurred recurring net losses. We expect that we will continue to incur losses and that such losses will increase for the foreseeable future. We expect that our research and development and general and administrative expenses will continue to increase and, as a result, we will need additional capital to fund our operations, which we may raise through a combination of equity offerings, debt financings, third-party funding and other collaborations and strategic alliances.
From our inception through March 31, 2021, we have raised an aggregate of $576.9 million to fund our operations, which includes $118.5 million from the sale of preferred stock, $11.1 million in government grant funding, $36.7 million from borrowings under our credit facility, $172.8 million from our collaborations and license agreements, $64.5 million in combined net proceeds from our initial public offering, $149.3 million in combined net proceeds from private placements and follow-on offerings of our common stock, and $24.0 million in aggregate net proceeds from “at-the-market” offerings of our common stock.
As of March 31, 2021, our cash, cash equivalents, restricted cash, and marketable securities were $149.2 million, of which $1.4 million was restricted cash related to lease commitments and $0.3 million was held by our Russian subsidiary designated solely for use in its operations. Our Russian subsidiary cash is consolidated for financial reporting purposes.
In addition to our existing cash equivalents, we receive research and development funding pursuant to our collaboration agreements. Currently, funding from payments under our collaboration agreements represent our only source of committed external funds.
Indebtedness
On August 31, 2020, we entered into a term loan of up to $35.0 million, consisting of term loans in an aggregate amount of $25.0 million, or the Term A Loan, and term loans in an aggregate amount of $10.0 million, or the Term B Loan, governed by a loan and security agreement among us and Oxford Finance LLC, or Oxford, as collateral agent and a lender, and Silicon Valley Bank, or SVB, as a lender. The Term A Loan was funded in full on August 31, 2020, the proceeds of which were used to repay our previously existing 2017 Term Loan and for general corporate and working capital purposes. The Term B Loan will be available, subject to the collateral agent’s discretion and customary terms and conditions, during the period commencing on the date we have delivered to Oxford and SVB evidence: (i) we or one of the our collaboration partners has enrolled its first patient for a Phase 1 clinical trial evaluating the treatment of MMA, and (ii) we have enrolled the first patient in each of two Phase 3 pivotal trials evaluating SEL-212, or the Second Draw Period Milestone, and ending on the earliest of (i) the date which is 30 days following the date the Second Draw Period Milestone is achieved, (ii) September 30, 2021 (iii) and the occurrence of an event of default, other than an event of default that has been waived in writing by Oxford and SVB in their sole discretion.
35

The 2020 Term Loan is secured by a lien on substantially all of our assets, other than intellectual property, provided that such lien on substantially all assets includes any rights to payments and proceeds from the sale, licensing or disposition of intellectual property. We also granted Oxford a negative pledge with respect to our intellectual property.
The 2020 Term Loan contains customary covenants and representations, including but not limited to financial reporting obligations and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. The 2020 Term Loan also contains other customary provisions, such as expense reimbursement, non-disclosure obligations as well as indemnification rights.
The events of default under the 2020 Term Loan include, but are not limited to, our failure to make any payments of principal or interest under the 2020 Term Loan or other transaction documents, our breach or default in the performance of any covenant under the 2020 Term Loan or other transaction documents, the occurrence of a material adverse event, making a false or misleading representation or warranty in any material respect under the 2020 Term Loan, our insolvency or bankruptcy, any attachment or judgment on our assets of at least approximately $0.5 million, or the occurrence of any default under any of our agreements or obligations involving indebtedness in excess of approximately $0.5 million. If an event of default occurs, Oxford and SVB are entitled to take enforcement action, including acceleration of amounts due under the 2020 Term Loan. If we raise any additional debt financing, the terms of such additional debt could further restrict our operating and financial flexibility.
For a further description of the 2020 Term Loan, see Note 9 to our unaudited consolidated financial statements included elsewhere in this Quarterly Report.
Plan of operations and future funding requirements
As of the date of this Quarterly Report, we have not generated any product sales. We do not know when, or if, we will generate revenue from product sales. We will not generate significant revenue from product sales unless and until we obtain regulatory approval and commercialize one of our current or future product candidates. Our primary uses of capital are, and we expect will continue to be, compensation and related expenses, third-party clinical research and development services, laboratory and related supplies, clinical costs, legal and other regulatory expenses, and general overhead costs. We expect that we will continue to generate losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates, and begin to commercialize any approved products. We are subject to risks in the development of our products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. We expect that we will need substantial additional funding to support our continuing operations.
As of March 31, 2021, we had an accumulated deficit of $429.2 million. We anticipate operating losses to continue for the foreseeable future due to, among other things, costs related to research, development of our product candidates, conducting preclinical studies and clinical trials, and our administrative organization. We will require substantial additional financing to fund our operations and to continue to execute our strategy, and we will pursue a range of options to secure additional capital.
We are exploring various sources of funding such as strategic collaborations and the issuance of equity to fund our operations. If we raise additional funds through strategic collaborations and alliances, which may include existing collaboration partners, we may have to relinquish valuable rights to our technologies or product candidates, or grant licenses on terms that are not favorable to us. To the extent that we raise additional capital through the sale of equity, the ownership interest of our existing shareholders will be diluted and other preferences may be necessary that adversely affect the rights of existing shareholders.
We believe that our existing cash, cash equivalents, marketable securities and restricted cash as of March 31, 2021 will enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2023. Additionally, while the potential economic impact brought by and the duration of the COVID-19 pandemic may be difficult to assess or predict, the widespread pandemic has resulted in, and may continue to result in, significant disruption of global financial markets, reducing our ability to access capital as and when needed. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect.
Our future capital requirements will depend on many factors, including:
the number of product candidates that we pursue;
our collaboration agreements remaining in effect, our entering into additional collaboration agreements and our ability to achieve milestones under these agreements;
the cost of manufacturing clinical supplies of our product candidates;
our headcount growth and associated costs;
the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our other product candidates;
36

the costs, timing and outcome of regulatory review of our product candidates;
the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval;
the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval;
the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims;
the effect of competing technological and market developments; and
the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or collaboration arrangements for product candidates.
As noted above, the magnitude and duration of the COVID-19 pandemic and its impact on our liquidity future funding requirements is uncertain as of the filing date of this Quarterly Report as this continues to evolve globally.

Summary of Cash Flows
 Three Months Ended March 31,
(In thousands)20212020
Cash (used in) and provided by:
Operating activities$(12,133)$(11,698)
Investing activities(22,445)(135)
Financing activities21,307 (5,370)
Effect of exchange rate changes on cash(7)(84)
Net change in cash, cash equivalents, and restricted cash$(13,278)$(17,287)

Operating activities
Cash used in operations of $12.1 million for the three months ended March 31, 2021 included approximately $5.2 million of net losses, adjusted for non-cash items, and uses of cash of approximately $6.9 million for changes in operating assets and liabilities.
Cash used in operations of $11.7 million for the three months ended March 31, 2020 included $16.6 million of net losses, adjusted for non-cash items, partially offset by cash generated from changes in operating assets and liabilities of $5.0 million, principally related to changes in accounts receivable.
Investing activities
Net cash used in investing activities for the three months ended March 31, 2021 was $22.4 million compared to net cash used in investing activities of $0.1 million in the same period in 2020. The net cash used in investing activities in 2021 was to purchase marketable securities. The net cash used in investing activities in 2020 was to purchase property and equipment.
Financing activities
Net cash provided by financing activities for the three months ended March 31, 2021 was $21.3 million compared to net cash used in financing activities of $5.4 million in the same period in 2020. The net cash provided by financing activities in 2021 was primarily the result of net proceeds from at-the-marketofferings.
The net cash used in financing activities in 2020 was the result of $4.4 million of issuance costs paid for December 2019 financing, $2.1 million principal payment on outstanding debt, offset by $1.1 million net proceeds from at-the-marketofferings.
Recent Accounting Pronouncements
For a discussion of recently adopted or issued accounting pronouncements please see Note 2 to our unaudited consolidated financial statements included elsewhere in this Quarterly Report.
Off-Balance Sheet Arrangements
As of March 31, 2021, we did not have any off-balance sheet arrangements as defined in the rules and regulations of the
Securities and Exchange Commission.

37

Critical Accounting Policies and Use of Estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported revenues and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. During the three months ended March 31, 2021, there were no material changes to our critical accounting policies from those described in our Annual Report on Form 10-K for the year ended December 31, 2020.
Emerging Growth Company Status
The Jumpstart Our Business Startups Act of 2012, or the JOBS Act, permits an ‘‘emerging growth company’’ such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. We will remain an emerging growth company until December 31, 2021, the last day of the fiscal year following the fifth anniversary of the closing of the initial public offering of our common stock. However, if certain events occur prior to December 31, 2021, including if we become a “large accelerated filer,” our annual gross revenues exceed $1.07 billion or we issue more than $1.07 billion of non-convertible debt in any three-year period, we will cease to be an emerging growth company prior to December 31, 2021.
Smaller Reporting Company
We qualify as a “smaller reporting company” under the rules of the Securities Act and the Exchange Act. As a result, in addition to the exemptions available to us as an “emerging growth company,” we may choose to take advantage of certain scaled disclosure requirements available specifically to smaller reporting companies. Additionally, even if we cease to be an emerging growth company as noted above, as long as we continue to be a smaller reporting company, we may continue to rely on the reduced executive compensation disclosure obligations available to emerging growth companies. We will remain a smaller reporting company until the last day of the fiscal year in which the aggregate market value of our common stock held by non-affiliated persons and entities, or our public float, was less than $250 million as of the last business day of our most recently completed second fiscal quarter, or the last day of the fiscal year in which we have at least $100 million in revenue and at least $700 million in public float as of the last business day of our most recently completed second fiscal quarter.

Item 3. Quantitative and Qualitative Disclosures About Market Risk
The market risk inherent in our financial instruments and in our financial position represents the potential loss arising from adverse changes in interest rates. As of March 31, 2021 and December 31, 2020, we had cash, cash equivalents, restricted cash and marketable securities of $149.2 million and $140.1 million, respectively, consisting of non-interest and interest-bearing money market accounts. Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the short-term and the low risk profile of our money market accounts and marketable securities, and our current plan to hold marketable securities to maturity, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents or short-term marketable securities.
In addition, we are subject to currency risk for balances held in Russian rubles in our foreign subsidiary. We hold portions of our funds in both U.S. dollars and Russian rubles. The exchange rate between the U.S. dollar and Russian ruble changes from period to period. As of March 31, 2021, we held cash and cash equivalents totaling $0.3 million in Russian banks to support our Russian subsidiary, all of which were denominated in U.S. dollars. We do not hedge against foreign currency risks. We do not believe that inflation and changing prices had a significant impact on our results of operations for any periods presented herein.

Item 4. Controls and Procedures
Limitations on effectiveness of controls and procedures
In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.
38

Evaluation of disclosure controls and procedures
Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated, as of the end of the period covered by this Quarterly Report, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2021.
Changes in internal control over financial reporting
There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended March 31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
39

PART II. OTHER INFORMATION
Item 1. Legal Proceedings
On August 4, 2020, a putative stockholder of Selecta filed a stockholder derivative action, purportedly on behalf of Selecta and against certain current and former members of the Company’s Board of Directors, as well as one affiliated company owned by a current board member, in the Court of Chancery of the State of Delaware, namely Franchi v. Barabe, et al. The complaint alleges that the individual defendants breached their fiduciary duties and committed corporate waste when they authorized a private placement transaction, announced on December 19, 2019, at a price allegedly below fair value. The complaint further alleges that the four defendant directors who participated in the private placement were unjustly enriched in connection with the transaction. On September 25, 2020, the defendants filed a motion to dismiss the lawsuit. On November 6, 2020, the plaintiff filed an amended complaint, and the defendants filed a second motion to dismiss on January 8, 2021. On December 31, 2020, we received a litigation demand letter from two other putative stockholders relating to the same private placement transaction. On April 12, 2021, the Court of Chancery in the State of Delaware granted a motion to stay the litigation pending a review by a Special Committee appointed by the Company’s Board of Directors.

Item 1A. Risk Factors
Our risk factors are disclosed in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2020. There have been no material changes from the risk factors previously disclosed in such filing.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.

Item 3. Defaults Upon Senior Securities
None.

Item 4. Mine Safety Disclosures
None.

Item 5. Other Information
None.

40


Item 6.  Exhibits
EXHIBIT INDEX
  Incorporated by Reference
Exhibit
Number
Exhibit DescriptionFormFile No.ExhibitFiling
Date
Filed
Herewith
8-K001-377983.16/29/2016 
8-K001-377983.26/29/2016 
*
    *
    *
    **
    **
101.INSInline XBRL Instance Document - the Instance Document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.    ***
101.SCHInline XBRL Taxonomy Extension Schema Document    ***
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document   ***
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document    ***
101.LABInline XBRL Taxonomy Extension Label Linkbase Document    ***
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document    ***
104Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)    ***
*
Filed herewith.
**Furnished herewith.
***Submitted electronically herewith.
41

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant in the capacities and on the dates indicated.
 SELECTA BIOSCIENCES, INC.
  
Date: May 13, 2021
By:/s/ Carsten Brunn, Ph.D.
 Carsten Brunn, Ph.D.
 President and Chief Executive Officer, and Director
(Principal Executive Officer)
  
Date: May 13, 2021By:/s/ Bradford D. Dahms
 Bradford D. Dahms
 Chief Financial Officer
(Principal Financial Officer)
42
EX-10.1 2 exhibit101_dircompprogram.htm EX-10.1 Document

Exhibit 10.1
SELECTA BIOSCIENCES, INC.

NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM

Non-employee members of the board of directors (the “Board”) of Selecta Biosciences, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”), as amended by the Board effective March 30, 2021 (the “Effective Date”). The cash and equity compensation described in this Program shall be paid or be made, as applicable, automatically and without further action of the Board, to each member of the Board who is not an employee of the Company or any parent or subsidiary of the Company (each, a “Non-Employee Director”) who is entitled to receive such cash or equity compensation, unless such Non-Employee Director declines the receipt of such cash or equity compensation by written notice to the Company. This Program shall remain in effect until it is revised or rescinded by further action of the Board. This Program may be amended, modified or terminated by the Board at any time in its sole discretion. The terms and conditions of this Program shall supersede any prior cash and/or equity compensation arrangements for service as a member of the Board between the Company and any of its Non-Employee Directors. No Non-Employee Director shall have any rights hereunder, except with respect to stock options granted pursuant to the Program. This Program shall become effective on the Effective Date.
I.CASH COMPENSATION
A.Annual Retainers. Each Non-Employee Director shall receive an annual retainer of $40,000 for service on the Board.
B.Additional Annual Retainers. In addition, each Non-Employee Director shall receive the following annual retainers:
1.Chairperson of the Board or Lead Independent Director. A Non-Employee Director serving as Chairperson of the Board shall receive an additional annual retainer of $30,000 for such service, and a Non-Employee Director serving as Lead Independent Director shall receive an additional annual retainer of $20,000 for such service.
2.Audit Committee. A Non-Employee Director serving as Chairperson of the Audit Committee shall receive an additional annual retainer of $15,000 for such service. A Non-Employee Director serving as a member other than the Chairperson of the Audit Committee shall receive an additional annual retainer of $7,500 for such service.
3.Compensation Committee. A Non-Employee Director serving as Chairperson of the Compensation Committee shall receive an additional annual retainer of $12,000 for such service. A Non-Employee Director serving as a member other than the Chairperson of the Compensation Committee shall receive an additional annual retainer of $6,000 for such service.



4.Nominating and Corporate Governance Committee. A Non-Employee Director serving as Chairperson of the Nominating and Corporate Governance Committee shall receive an additional annual retainer of $8,000 for such service. A Non-Employee Director serving as a member other than the Chairperson of the Nominating and Corporate Governance Committee shall receive an additional annual retainer of $4,000 for such service.
5.Science Committee. A Non-Employee Director serving as Chairperson of the Science Committee shall receive an additional annual retainer of $8,000 for such service. A Non-Employee Director serving as a member other than the Chairperson of the Science Committee shall receive an additional annual retainer of $4,000 for such service.
C.Payment of Retainers. The annual retainers described in Sections I(A) and I(B) shall be earned on a quarterly basis based on a calendar quarter and shall be paid in cash by the Company in arrears not later than the fifteenth day following the end of each calendar quarter. In the event a Non-Employee Director does not serve as a Non-Employee Director, or in the applicable positions described in Section I(B), for an entire calendar quarter, the retainer paid to such Non-Employee Director shall be prorated for the portion of such calendar quarter actually served as a Non-Employee Director, or in such position, as applicable.

II.EQUITY COMPENSATION
Non-Employee Directors shall be granted the equity awards described below. The awards described below shall be granted under and shall be subject to the terms and provisions of the Company’s 2016 Incentive Award Plan or any other applicable Company equity incentive plan then-maintained by the Company (the “Equity Plan”) and shall be granted subject to award agreements, including attached exhibits, in substantially the form previously approved by the Board. All applicable terms of the Equity Plan apply to this Program as if fully set forth herein, and all grants of stock options hereby are subject in all respects to the terms of the Equity Plan and the applicable award agreement. For the avoidance of doubt, the share numbers in Sections II(A) and II(B) shall be subject to adjustment as provided in the Equity Plan, including without limitation with respect to any stock dividend, stock split, reverse stock split or other similar event affecting the Company’s common stock that is effected prior to the Effective Date.
A.Initial Awards. Each Non-Employee Director who is initially elected or appointed to the Board after the Effective Date shall receive an option to purchase 80,000 shares of the Company’s common stock on the date of such initial election or appointment. The awards described in this Section II(A) shall be referred to as “Initial Awards.” No Non-Employee Director shall be granted more than one Initial Award.
B.Subsequent Awards. A Non-Employee Director who (i) has been serving as a Non-Employee Director on the Board for at least six months as of the first business day of any calendar year after the Effective Date (each, a “Subsequent Award Grant Date”) and (ii) will continue to serve as a Non-Employee Director immediately following such Subsequent Award Grant Date, shall be automatically granted an option to purchase 40,000 shares of the Company’s common stock on such Subsequent Award Grant Date,



provided, however that if such Non-Employee Director will serve as Chairperson of the Board as of immediately following such Subsequent Award Grant Date, such Non-Employee Director shall receive an option to purchase 60,000 shares of the Company’s common stock on such the Subsequent Award Grant Date. The awards described in this Section II(B) shall be referred to as “Subsequent Awards.” Notwithstanding anything to the contrary in this paragraph, for the calendar year 2021, each Non-Employee Director, including the Chairperson of the Board, as of the Effective Date shall receive a Subsequent Award grant on the Effective Date.
C.Termination of Employment of Employee Directors. Members of the Board who are employees of the Company or any parent or subsidiary of the Company who subsequently terminate their employment with the Company and any parent or subsidiary of the Company and remain on the Board will not receive an Initial Award pursuant to Section II(A) above, but to the extent that they are otherwise entitled, will receive, after termination from employment with the Company and any parent or subsidiary of the Company, Subsequent Awards as described in Section II(B) above.
D.Terms of Awards Granted to Non-Employee Directors
1.Exercise Price. The per share exercise price of each option granted to a Non-Employee Director shall equal the Fair Market Value (as defined in the Equity Plan) of a share of common stock on the date the option is granted.
2.Vesting. Each Initial Award shall vest and become exercisable in thirty-six (36) substantially equal monthly installments following the date of grant, such that the Initial Award shall be fully vested on the third anniversary of the date of grant, subject to the Non-Employee Director continuing in service as a Non-Employee Director through each such vesting date. Each Subsequent Award shall vest and become exercisable on the first anniversary of the date of grant, subject to the Non-Employee Director continuing in service on the Board as a Non-Employee Director through each such vesting date. Unless the Board otherwise determines, any portion of an Initial Award or Subsequent Award which is unvested or unexercisable at the time of a Non-Employee Director’s termination of service on the Board as a Non-Employee Director shall be immediately forfeited upon such termination of service and shall not thereafter become vested and exercisable. All of a Non-Employee Director’s Initial Awards and Subsequent Awards shall vest in full immediately prior to the occurrence of a Change in Control (as defined in the Equity Plan), to the extent outstanding at such time.
3.Term. The maximum term of each stock option granted to a Non-Employee Director hereunder shall be ten (10) years from the date the option is granted.
III. COMPENSATION LIMITS
Notwithstanding anything to the contrary in this Program, all compensation payable under this Program will be subject to any limits on the maximum amount of Non-Employee Director compensation set forth in the Equity Plan, as in effect from time to time.
* * * * *

EX-31.1 3 exhibit311_03312021.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATIONS
I, Carsten Brunn, Ph.D. certify that:
1.    I have reviewed this Quarterly Report on Form 10-Q of Selecta Biosciences, Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
   
May 13, 2021    /s/ Carsten Brunn, Ph.D.
  Carsten Brunn, Ph.D.
  President and Chief Executive Officer, and Director
(Principal Executive Officer)

EX-31.2 4 exhibit312_03312021.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATIONS
I, Bradford D. Dahms, certify that:
1.    I have reviewed this Quarterly Report on Form 10-Q of Selecta Biosciences, Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
   
May 13, 2021    /s/ Bradford D. Dahms
  Bradford D. Dahms
Chief Financial Officer
  (Principal Financial and Accounting Officer)

EX-32.1 5 exhibit321_03312021.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO 
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Carsten Brunn, Ph.D., President and Chief Executive Officer of Selecta Biosciences, Inc. (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
1.    The Quarterly Report on Form 10-Q of the Company for the period ended March 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
   
May 13, 2021    /s/ Carsten Brunn, Ph.D.
  Carsten Brunn, Ph.D.
  President and Chief Executive Officer, and Director
(Principal Executive Officer)


EX-32.2 6 exhibit322_03312021.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO 
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Bradford D. Dahms, Chief Financial Officer of Selecta Biosciences, Inc. (the “Company”), hereby certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge:
1.    The Quarterly Report on Form 10-Q of the Company for the period ended March 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
2.    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
   
May 13, 2021    /s/ Bradford D. Dahms
  Bradford D. Dahms
  Chief Financial Officer
(Principal Financial and Accounting Officer)


EX-101.SCH 7 selb-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - Consolidated Statements of Changes in Stockholders’ (Deficit) Equity link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Nature of the Business and Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2402401 - Disclosure - Nature of the Business and Basis of Presentation - Liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2105103 - Disclosure - Marketable Securities link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Marketable Securities - Summary of Available-for-Sale Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2408403 - Disclosure - Marketable Securities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2109104 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 2310302 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2411404 - Disclosure - Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2412405 - Disclosure - Net Loss Per Share - Schedule of Potential Common Shares Issuable Upon Conversion of Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 2113105 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2314303 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2415406 - Disclosure - Fair Value Measurements - Summary of Assets Measured at Fair Value on a Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2416407 - Disclosure - Fair Value Measurements - Assumptions used to record the fair value of the warrants (Details) link:presentationLink link:calculationLink link:definitionLink 2417408 - Disclosure - Fair Value Measurements - Change in the warrant liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2418409 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2419410 - Disclosure - Fair Value Measurements - Schedule of Cash and Cash Equivalents (Details) link:presentationLink link:calculationLink link:definitionLink 2120106 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 2321304 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 2422411 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 2423412 - Disclosure - Property and Equipment - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2124107 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 2325305 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 2426413 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 2127108 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 2328306 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 2429414 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2430415 - Disclosure - Leases - Components of Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 2431416 - Disclosure - Leases - Components of lease costs (Details) link:presentationLink link:calculationLink link:definitionLink 2432417 - Disclosure - Leases - Operating Lease, Liability, Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 2432417 - Disclosure - Leases - Operating Lease, Liability, Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 2433418 - Disclosure - Leases - Other Information (Details) link:presentationLink link:calculationLink link:definitionLink 2434419 - Disclosure - Leases - Lease Term and Discount Rate (Details) link:presentationLink link:calculationLink link:definitionLink 2135109 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 2336307 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 2437420 - Disclosure - Debt - Term Loans (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2438421 - Disclosure - Debt - Schedule of Future Minimum Payments on the Term Loans (Details) link:presentationLink link:calculationLink link:definitionLink 2139110 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 2340308 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2441422 - Disclosure - Equity - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2442423 - Disclosure - Equity - Warranty Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2443424 - Disclosure - Equity - Schedule of Authorized Shares of Common Stock for Future Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 2144111 - Disclosure - Stock Incentive Plans link:presentationLink link:calculationLink link:definitionLink 2345309 - Disclosure - Stock Incentive Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 2446425 - Disclosure - Stock Incentive Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2447426 - Disclosure - Stock Incentive Plans - Schedule of Stock-Based Compensation Expense Related to Stock Options and Restricted Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 2448427 - Disclosure - Stock Incentive Plans - Schedule of Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2449428 - Disclosure - Stock Incentive Plans - Summary of Options Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2450429 - Disclosure - Stock Incentive Plans - Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 2451430 - Disclosure - Stock Incentive Plans - Employee Stock Purchase Plan (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2152112 - Disclosure - Revenue Arrangements link:presentationLink link:calculationLink link:definitionLink 2353310 - Disclosure - Revenue Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 2454431 - Disclosure - Revenue Arrangements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2455432 - Disclosure - Revenue Arrangements - Schedule of Changes in Contract Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 2156113 - Disclosure - Related-Party Transactions link:presentationLink link:calculationLink link:definitionLink 2457433 - Disclosure - Related-Party Transactions - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2158114 - Disclosure - Collaboration Agreements link:presentationLink link:calculationLink link:definitionLink 2459434 - Disclosure - Collaboration Agreements - AskBio (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2460435 - Disclosure - Collaboration Agreements - MIT (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2461436 - Disclosure - Collaboration Agreements - Shenyang Sunshine Pharmaceutical Co., Ltd (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2162115 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 2463437 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2164116 - Disclosure - Defined Contribution Plan link:presentationLink link:calculationLink link:definitionLink 2465438 - Disclosure - Defined Contribution Plan - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2166117 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 2167118 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 2468439 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 selb-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 9 selb-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 10 selb-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Area of additional office space leased Area of Real Estate Property Grants in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Document Type Document Type Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Other income (expense), net Other Nonoperating Income (Expense) Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Related Party [Axis] Related Party [Axis] Payables and Accruals [Abstract] Payables and Accruals [Abstract] Class of warrant or right, number of warrants exercised (in shares) Class Of Warrant Or Right, Number Of Warrants Exercised Class of Warrant or Right, Number Of Warrants Exercised Marketable Securities Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Weighted-average remaining contractual term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract] n/a Defined Contribution Plan Retirement Benefits [Text Block] Vested in period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Contract liabilities, additions Contract with Customer, Liability, Increase From Cash Receipts Contract with Customer, Liability, Increase From Cash Receipts (Level 3) Fair Value, Inputs, Level 3 [Member] Consulting services expenses (less than) Related Party Transaction, Expenses from Transactions with Related Party Other Current Assets Other Current Assets [Member] Schedule of Stockholders' Equity Note, Warrants or Rights Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Statistical Measurement [Domain] Statistical Measurement [Domain] Liabilities and stockholders’ (deficit) equity Liabilities and Equity [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Non-cash lease expense Finance Lease, Right-of-Use Asset, Amortization Security Exchange Name Security Exchange Name Loss from operations Operating Income (Loss) Total current liabilities Liabilities, Current Accrued external research and development costs Accrued Research And Development Costs Current Carrying value as of the balance sheet date of research and development costs. Schedule of Changes in Contract Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Unvested at beginning of period (in dollars per share) Unvested at end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Number of votes per share that common stockholders are entitled to Votes Per Share of Common Stock Votes Per Share of Common Stock Awarded in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Awarded in Period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Awarded in Period Variable Rate [Domain] Variable Rate [Domain] Variable Rate [Axis] Variable Rate [Axis] Commitments and contingencies (Note 17) Commitments and Contingencies Assets Assets: Assets [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Award vesting term Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Accounting Policies [Abstract] Accounting Policies [Abstract] Furniture and fixtures Furniture and Fixtures [Member] Entity Address, State or Province Entity Address, State or Province Vested in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Proceeds from issuance of common stock under Employee Stock Purchase Plan Proceeds from Stock Plans Cash paid for amounts included in the measurement of lease liabilities: Operating Lease, Payments Accounts payable Accounts Payable, Current August 2020 Shelf Registration Statement August 2020 Shelf Registration Statement [Member] August 2020 Shelf Registration Statement 2024 Long-Term Debt, Maturity, Year Three Schedule of Cash and Cash Equivalents [Table] Schedule of Cash and Cash Equivalents [Table] Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Repayments of lines of credit Repayments of Lines of Credit Right-of-use asset, net Operating Lease, Right-of-Use Asset Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt 2022 Lessee, Operating Lease, Liability, to be Paid, Year One Beginning balance (in shares) Ending balance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number 2025 Lessee, Operating Lease, Liability, to be Paid, Year Four Summary of Assets Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Employment Inducement Incentive Award Plan Employment Inducement Incentive Award Plan [Member] Employment Inducement Incentive Award Plan [Member] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2021 and December 31, 2020 Preferred Stock, Value, Issued Lessee-paid construction costs Total lease cost Lease, Cost Vesting period Defined Contribution Plan Employers Matching Contribution Vesting Period Period which an employee's right to exercise a plan is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Total operating expenses Operating expenses Operating Expenses Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Issuance costs paid for December 2019 financing Payments of Financing Costs Operating expenses: Cost of Revenue [Abstract] Liability Class [Axis] Liability Class [Axis] Lease Arrangement [Axis] Lease Arrangement [Axis] Lease Arrangement [Axis] Stock-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Grant and collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax Measurement Frequency [Domain] Measurement Frequency [Domain] Accrued interest Accrued Interest, Current Accrued Interest, Current 65 Grove Street, Watertown,MA 65 Grove Street, Watertown,MA [Member] 65 Grove Street, Watertown,MA [Member] Contract assets amortization (less than) Capitalized Contract Cost, Amortization Geographical [Domain] Geographical [Domain] Valuation Technique, Option Pricing Model Valuation Technique, Option Pricing Model [Member] Statement [Line Items] Statement [Line Items] Schedule of Potential Common Shares Issuable Upon Conversion of Warrants Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Forecast Forecast [Member] Net loss per share: Earnings Per Share, Basic and Diluted [Abstract] Less: Amount representing interest Debt Instrument Interest Portion The interest portion of gross outstanding debt. Computer equipment and software Computer Equipment [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares Measurement Input Type [Domain] Measurement Input Type [Domain] 2020 Sale Agreement - At-the-Market Offering 2020 Sale Agreement - At-The-Market Offering [Member] 2020 Sale Agreement - At-The-Market Offering Statement [Table] Statement [Table] Statistical Measurement [Axis] Statistical Measurement [Axis] Credit Facility [Axis] Credit Facility [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Preferred stock, shares issued Preferred Stock, Shares Issued Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Basic and diluted (in dollars per share) Net loss per share attributable to common stockholders—basic and diluted (in dollars per share) Earnings Per Share, Basic and Diluted Entity Smaller Reporting Company Entity Small Business Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] RSUs reserved for issuance Restricted Stock Units (RSUs) Reserved For Issuance [Member] Restricted Stock Units (RSUs) Reserved For Issuance Sale of stock, number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Debt Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Collaborative Arrangement Collaborative Arrangement [Member] Net proceeds from issuance of common stock Shares issued, value Proceeds from Issuance of Common Stock Schedule of Operating Lease, Lease Income Operating Lease, Lease Income [Table Text Block] Debt Instrument, Redemption, Period One Debt Instrument, Redemption, Period One [Member] Amendment Flag Amendment Flag Computation of Basic and Diluted Net Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] December 2019 Financing December Two Thousand Nineteen Financing [Member] December Two Thousand Nineteen Financing [Member] Disclosure of Share-based Compensation Arrangements by Share-based Payment Award Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] Weighted average common shares outstanding: Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Fair value as of December 31, 2020 Fair value as of March 31, 2021 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Aggregate amount of upfront and milestone-based payments Aggregate Amount Of Upfront And Milestone Based Payments Paid Aggregate Amount Of Upfront And Milestone Based Payments Paid Laboratory equipment Laboratory Equipment [Member] Represents information pertaining to laboratory equipment. Number of shares authorized for grants (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Other Other Accrued Liabilities, Current Term loan facility Long-term Line of Credit Aggregate amount for future payments upon achievement of clinical and regulatory approval milestones for products containing ImmTOR platform Aggregate Amount For Future Payments Upon Achievement Of Clinical And Regulatory Approval Milestones For Products Containing ImmTOR Platform Aggregate Amount For Future Payments Upon Achievement Of Clinical And Regulatory Approval Milestones For Products Containing ImmTOR Platform Net cash (used in) operating activities Net Cash Provided by (Used in) Operating Activities Non-current liabilities: Other Liabilities, Noncurrent [Abstract] Pre-Funded Warrant Pre-Funded Warrant [Member] Pre-Funded Warrant [Member] Entity Central Index Key Entity Central Index Key Related Party [Domain] Related Party [Domain] Measurement Frequency [Axis] Measurement Frequency [Axis] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Marketable securities Debt Securities, Available-for-sale, Current Financial Instruments [Domain] Financial Instruments [Domain] Debt Instrument, Redemption, Period Three Debt Instrument, Redemption, Period Three [Member] Purchase of property and equipment not yet paid Capital Expenditures Incurred but Not yet Paid Geographical [Axis] Geographical [Axis] Subsequent Events Subsequent Events [Text Block] Shares of common stock issued to employees under the ESPP (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period Change in fair value of warrant liabilities Warrant liabilities revaluation Fair Value Adjustment of Warrants Amortized cost Debt Securities, Available-for-sale, Amortized Cost Unrecognized compensation expense related to unvested employee stock options Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Unrealized gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Number of obligations Revenue, Number Of Performance Obligations Revenue, Number Of Performance Obligations 2025 Long-Term Debt, Maturity, Year Four Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Effect of exchange rate changes on cash Effect of Exchange Rate on Cash and Cash Equivalents Income Statement Location [Axis] Income Statement Location [Axis] Dividend yield Measurement Input, Expected Dividend Rate [Member] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Income Statement Location [Domain] Income Statement Location [Domain] Lock-up from closing, term Lock-up From Closing, Term Lock-up From Closing, Term 2023 Lessee, Operating Lease, Liability, to be Paid, Year Two MIT Exclusive Patent License Agreement With Massachusetts Institute Of Technology [Member] Represents information pertaining to Exclusive patent license agreement with Massachusetts Institute of Technology. " Line of Credit Facility [Table] Line of Credit Facility [Table] Schedule of Lease, Cost Lease, Cost [Table Text Block] Reserved for issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reserved For Issuance Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reserved For Issuance 2024 Lessee, Operating Lease, Liability, to be Paid, Year Three Plan Name [Axis] Plan Name [Axis] Money market funds Cash and Cash Equivalents, Fair Value Disclosure Total assets Assets Related-Party Transactions Related Party Transactions Disclosure [Text Block] Scenario [Axis] Scenario [Axis] Non-employee stock options Non-employee consultants Non Employee Stock Option [Member] An arrangement whereby a non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Unvested at beginning of period (in shares) Unvested at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Title of 12(b) Security Title of 12(b) Security Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Weighted average grant date fair value of stock options (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Subsequent Event Type [Axis] Subsequent Event Type [Axis] Unrealized (losses) on marketable securities OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Antidilutive Securities [Axis] Antidilutive Securities [Axis] Period after first commercial sale when the Company is eligible to receive royalties Eligible Period To Receive Royalties Eligible Period To Receive Royalties Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Estimated forfeitures rate Share-based Compensation Arrangement By Share-based Payment Award Forfeitures Rate Represents the percentage of forfeitures rate of the stock options based on the historical trends. ESPP Employee Stock Purchase Plan2016 [Member] Represent information pertaining to the 2016 Employee Stock Purchase Plan. Interest expense Interest Expense Sale common stock Sale of Stock, Consideration Received on Transaction Debt instrument, prepayment fee, percentage Debt Instrument, Prepayment Fee, Percentage Debt Instrument, Prepayment Fee, Percentage Total liabilities Liabilities 2016 Plan Stock Incentive Plan2016 [Member] Represents the information pertaining to the 2016 stock incentive plan, which provides for the granting of stock based awards to employees, directors, and consultants under terms and provisions established by the board of directors. Weighted average period for recognition Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Vested and expected to vest, term Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term 2023 Long-Term Debt, Maturity, Year Two Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Authorized Shares of Common Stock for Future Issuance Schedule of Stock by Class [Table Text Block] Revenue recognized Contract liabilities, deductions Contract with Customer, Liability, Revenue Recognized Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Net loss attributable to common stockholders Net Income (Loss) Available to Common Stockholders, Basic Equity offering costs in accrued liabilities Equity Offering Costs In Accrued Liabilities Equity Offering Costs In Accrued Liabilities (Level 1) Fair Value, Inputs, Level 1 [Member] Vested, term Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Remaining Contractual Term Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Remaining Contractual Term Loan payable Loans Payable, Current Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Long-term restricted cash Restricted Cash and Cash Equivalents, Noncurrent Accounts payable Increase (Decrease) in Accounts Payable Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Contract liabilities: Change In Contract With Customer, Liability [Roll Forward] Change In Contract With Customer, Liability [Roll Forward] Additional paid-in capital Additional Paid-in Capital [Member] Other assets Other Assets Expected life (in years) Measurement Input, Expected Term [Member] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Class of Stock [Line Items] Class of Stock [Line Items] Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Cash and Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] Common stock, shares outstanding Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Term A Loans Term A Loans [Member] Term A Loans Variable lease cost Variable Lease, Cost Spark License Agreement License Agreement Terms [Member] Research and development Research and Development Expense Subsequent Event Subsequent Event [Member] Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Common stock, shares authorized (in shares) Common Stock, Shares Authorized Total property and equipment Property, Plant and Equipment, Gross Proceeds from exercise of stock options Proceeds from Stock Options Exercised Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Warrant, increase (decrease) in equity, amount Warrant, Down Round Feature, (Increase) Decrease in Equity, Amount Lease liability Non-current operating lease liabilities Operating Lease, Liability, Noncurrent Prepaid expenses, deposits and other assets Increase (Decrease) in Prepaid Expense and Other Assets Less: Debt discount and deferred charges Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Current assets: Assets, Current [Abstract] Cash flows from investing activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Vested Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Intrinsic Value Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Intrinsic Value Total comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Weighted-average fair value of common stock (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Fair Value Weighed-average fair value relating to the share-based payment award. Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share 2022 Long-Term Debt, Maturity, Year One Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Scenario [Domain] Scenario [Domain] Deferred revenue, additions Contract with Customer, Liability, Deferred Revenue, Increase From Cash Receipts Contract with Customer, Liability, Deferred Revenue, Increase From Cash Receipts Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment City Area Code City Area Code Contractual payments defined in the Exclusive Patent License agreement License And Option Agreement, Contractual Payments Made License And Option Agreement, Contractual Payments Made Document Period End Date Document Period End Date Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Total (in shares) Common stock authorized and reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Term of contract Lessee, Operating Lease, Term of Contract Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Schedule of Stock-Based Compensation Share-based Payment Arrangement, Cost by Plan [Table Text Block] Stock-based compensation expense Share-based Payment Arrangement, Noncash Expense 2021 (remainder) Long-Term Debt, Maturity, Remainder of Fiscal Year Other financing fees Proceeds from (Payments for) Other Financing Activities Issuance of vested restricted stock units (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross Cover [Abstract] Cover [Abstract] Measurement Input Type [Axis] Measurement Input Type [Axis] Summary of Available-for-Sale Marketable Securities Debt Securities, Available-for-sale [Table Text Block] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Total minimum debt payments Long-term Debt Deferred revenue Increase (Decrease) in Contract with Customer, Liability Leases Lessee, Operating Leases [Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Restricted cash and cash equivalents Restricted Cash and Cash Equivalents Amortization of premiums and discounts on marketable securities Accretion (Amortization) of Discounts and Premiums, Investments SOBI Purchase Agreement SOBI Purchase Agreement [Member] SOBI Purchase Agreement [Member] Cost share percentage Collaborative Arrangement, Cost Share Percentage Collaborative Arrangement, Cost Share Percentage Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Fair value Marketable securities: Debt Securities, Available-for-sale Equity Components [Axis] Equity Components [Axis] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Minimum Minimum [Member] 2017 Term Loans 2017 Term Loans [Member] 2017 Term Loans [Member] Final payment fee Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid Lease liability Current operating lease liabilities Operating Lease, Liability, Current Unrecognized compensation expense Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Forfeited in period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Schedule of Weighted Average Assumptions Used Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Entity Interactive Data Current Entity Interactive Data Current Corporate bonds Corporate Bond Securities [Member] Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Schedule of Restricted Cash and Cash Equivalents Restrictions on Cash and Cash Equivalents [Table Text Block] Fair Value Measurements Fair Value Disclosures [Text Block] Equity Stockholders' Equity Note Disclosure [Text Block] Summary of Options Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Cash, cash equivalents, restricted cash and marketable securities Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Debt Securities, Available-For-Sale Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Debt Securities, Available-For-Sale Unrecognized compensation expense related to unvested non-employee stock options Share-Based Goods And Non Employee Services Transaction, Compensation Not Yet Recognized, Stock Options Share-Based Goods And Non Employee Services Transaction, Compensation Not Yet Recognized, Stock Options Entity Registrant Name Entity Registrant Name Subsequent Event Type [Domain] Subsequent Event Type [Domain] Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Exercise Price Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Operating lease, weighted average discount rate, percent Operating Lease, Weighted Average Discount Rate, Percent Assets: Assets, Fair Value Disclosure [Abstract] Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers, net Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net Accrued professional and consulting services Accrued Audit Fees, Current Accrued Audit Fees, Current Weighted-average exercise price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Russian subsidiary RUSSIAN FEDERATION Non-cash interest expense Paid-in-Kind Interest Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Total future minimum lease payments Lessee, Operating Lease, Liability, to be Paid Marketable securities adjusted for other than temporary declines in fair value Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale Other financing fees Adjustments to Additional Paid in Capital, Other Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Debt Instrument, Redemption, Period [Domain] Debt Instrument, Redemption, Period [Domain] Long-term restricted cash Restricted Cash, Noncurrent Unrealized losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Sale of Stock [Axis] Sale of Stock [Axis] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Basic and diluted (in shares) Weighted‑average common shares outstanding—basic and diluted (in shares) Weighted Average Number of Shares Outstanding, Basic and Diluted Debt Instrument, Redemption, Period Two Debt Instrument, Redemption, Period Two [Member] Accrued Expenses Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block] Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Cash maintained in Russian bank accounts Cash Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Schedule of Fair Value Measurement Inputs and Valuation Techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] License and option agreement, written day notice period before cancellation License And Option Agreement, Written Day Notice Period Before Cancellation License And Option Agreement, Written Day Notice Period Before Cancellation Document Transition Report Document Transition Report Development milestone License And Option Agreement, Development Milestone License And Option Agreement, Development Milestone Debt Instrument, Redemption, Period [Axis] Debt Instrument, Redemption, Period [Axis] Sarepta Therapeutics, Inc. Sarepta Therapeutics, Inc. [Member] Sarepta Therapeutics, Inc. [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Class of warrant or right, outstanding (in shares) Class of Warrant or Right, Outstanding Warrants to purchase common stock Warrant liabilities Exercise of common warrants Warrant [Member] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Short-term restricted cash Restricted Cash and Cash Equivalents, Current Debt issuance costs, line of credit arrangements (less than) Debt Issuance Costs, Line of Credit Arrangements, Net (Level 2) Fair Value, Inputs, Level 2 [Member] Document Quarterly Report Document Quarterly Report Founders Founder [Member] Represents information pertaining to founder member. Liabilities: Liabilities, Fair Value Disclosure [Abstract] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Number of shares authorized, increase (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant, Increase (Decrease) Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant, Increase (Decrease) Deferred revenue, beginning of period Deferred revenue, end of period Contract with Customer, Liability, Deferred Revenue Contract with Customer, Liability, Deferred Revenue General and administrative General and Administrative Expense [Member] Equity [Abstract] Equity [Abstract] Total assets Assets, Fair Value Disclosure Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Deferred revenue Short-term contract liability Contract with Customer, Liability, Current Subsequent Event [Line Items] Subsequent Event [Line Items] Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Vested and expected to vest (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Credit Facility [Domain] Credit Facility [Domain] Letter of credit Letter of Credit [Member] Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net Aggregate intrinsic value Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value [Abstract] n/a Expected term Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Entity File Number Entity File Number Forfeited in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Debt Disclosure [Abstract] Debt Disclosure [Abstract] Operating lease, weighted average remaining lease term Operating Lease, Weighted Average Remaining Lease Term Cash flows from operating activities Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Repayments of principal on outstanding debt Repayments of Long-term Debt Dividends declared or paid on common stock Dividends, Common Stock Adjustments to additional paid in capital, warrant issued Adjustments to Additional Paid in Capital, Warrant Issued Remaining performance obligation Revenue, Remaining Performance Obligation, Amount Stock‑based compensation expense Total stock-based compensation expense Stock-based compensation expense Share-based Payment Arrangement, Expense Depreciation and amortization Other Depreciation and Amortization Unrecognized tax benefits Unrecognized Tax Benefits Issuance of common stock under Employee Stock Purchase Plan Stock Issued During Period, Value, Employee Stock Purchase Plan Common stock, $0.0001 par value; 200,000,000 shares authorized; 112,977,004 and 108,071,249 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively Common Stock, Value, Issued Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Commercial paper Commercial Paper [Member] Debt instrument, default, bankruptcy, or insolvency value of triggering accelerated redemption Debt Instrument, Default, Bankruptcy, Or Insolvency Value Of Triggering Accelerated Redemption Debt Instrument, Default, Bankruptcy, Or Insolvency Value Of Triggering Accelerated Redemption Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Less: Current portion of loan payable Long-term Debt, Current Maturities Entity Current Reporting Status Entity Current Reporting Status Share price (in dollars per share) Sale of Stock, Price Per Share Change in fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Expected volatility Measurement Input, Price Volatility [Member] Retirement Benefits [Abstract] Retirement Benefits [Abstract] Subsequent Event [Table] Subsequent Event [Table] Purchases of marketable securities Payments to Acquire Debt Securities, Available-for-sale Common Warrant Common Warrant [Member] Common Warrant [Member] Grants in period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Common stock, shares issued Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Risk-free interest rate Measurement Input, Risk Free Interest Rate [Member] Total operating lease liabilities Lease liabilities Operating Lease, Liability Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Reserved for issuance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reserved For Issuance, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reserved For Issuance, Weighted Average Grant Date Fair Value Loan payable, net of current portion Long-term Debt, Excluding Current Maturities Debt instrument, redemption price, percentage of principal amount redeemed Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed Accounts receivable Increase (Decrease) in Accounts Receivable Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Total stockholders’ (deficit) equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Issuance costs Payments of Stock Issuance Costs Total liabilities and stockholders’ (deficit) equity Liabilities and Equity Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Income Taxes Income Tax Disclosure [Text Block] Entity Address, City or Town Entity Address, City or Town Payroll and employee related expenses Employee-related Liabilities, Current AskBio License AskBio License [Member] AskBio License [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Unvested restricted stock units Restricted Stock Units (RSUs) [Member] Operating lease cost Operating Lease, Cost General and administrative General and Administrative Expense Financial Instrument [Axis] Financial Instrument [Axis] 2017 PIPE 2017 PIPE [Member] 2017 PIPE [Member] Total (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Entity Extended Transition Period Entity Ex Transition Period Short-term lease cost Short-term Lease, Cost Loss on disposal of property and equipment Gain (Loss) on Disposition of Property Plant Equipment Equity Component [Domain] Equity Component [Domain] Loan payable, net of current portion Loans Payable, Noncurrent Liabilities: Liabilities [Abstract] Debt instrument, additional accrued interest in the event of default Debt Instrument, Additional Accrued Interest In the Event Of Default Debt Instrument, Additional Accrued Interest In the Event Of Default Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Construction in process Construction in Progress [Member] Entity Tax Identification Number Entity Tax Identification Number Warrants and rights outstanding, term Warrants and Rights Outstanding, Term Unrealized (losses) on marketable securities Marketable Securities, Unrealized Gain (Loss) Stock Incentive Plans Share-based Payment Arrangement [Text Block] Net loss Net loss Net Income (Loss) Attributable to Parent Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] 2021 (remainder) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Lease Arrangement [Domain] Lease Arrangement [Domain] [Domain] for Lease Arrangement [Axis] Collaboration and licensing Accrued Collaboration and Licensing Accrued Collaboration and Licensing Leases [Abstract] Leases [Abstract] At-The-Market Offering At-The-Market Offering [Member] At-The-Market Offering [Member] Total current assets Assets, Current Current Fiscal Year End Date Current Fiscal Year End Date License Agreement For Pompe Disease License Agreement For Pompe Disease [Member] License Agreement For Pompe Disease [Member] Earnings Per Share [Abstract] Earnings Per Share [Abstract] 2020 Term Loans 2020 Term Loans [Member] 2020 Term Loans Warrant Issued Warrant Issued Warrant Issued Class of warrant or right, expiration period Class Of Warrant Or Right, Expiration Period Class Of Warrant Or Right, Expiration Period Potential common shares Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] License and option agreement, payments made relative to calculated premium paid for initial equity investment made under the purchase agreement License And Option Agreement, Calculated Premium Paid For Equity Investment Under Purchase Agreement License And Option Agreement, Calculated Premium Paid For Equity Investment Under Purchase Agreement Stockholders’ (deficit) equity: Stockholders' Equity Attributable to Parent [Abstract] Class of warrant or right, number of securities called by warrants or rights (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Number of Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Document Fiscal Period Focus Document Fiscal Period Focus Issuance of vested restricted stock units Stock Issued During Period, Value, Restricted Stock Award, Gross Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Redemption premium Redemption Premium 3SBio License License Agreement With Shenyang Sunshine Pharmaceutical Company Limited [Member] Represents information pertaining to License agreement with Shenyang Sunshine Pharmaceutical co., ltd. Deferred revenue Long-term contract liability Contract with Customer, Liability, Noncurrent Supplement cash flow information Supplemental Cash Flow Information [Abstract] Issuance of common stock under Employee Stock Purchase Plan (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans Term B Loans Term B Loans [Member] Term B Loans Entity Filer Category Entity Filer Category Common stock Common Stock [Member] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Sales milestone payments License And Option Agreement, Sales Milestone Payments That May Be Received License And Option Agreement, Sales Milestone Payments That May Be Received Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Employer contribution made Defined Contribution Plan, Cost Option term License And Option Agreement, Option Term License And Option Agreement, Option Term Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Sale of stock, percentage of ten-day volume weighted average price of common stock Sale of Stock, Percentage Of Ten-Day Volume Weighted Average Price Of Common Stock Sale of Stock, Percentage Of Ten-Day Volume Weighted Average Price Of Common Stock Leasehold improvements Leasehold Improvements [Member] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Money market funds Money Market Funds [Member] Shares available for future stock incentive awards Employee stock option grants Employees Share-based Payment Arrangement [Member] Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Contract assets Contract with Customer, Asset, after Allowance for Credit Loss, Current Vested and expected to vest Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value Noncash investing and financing activities Noncash Investing and Financing Items [Abstract] Issuance of common stock upon exercise of options (in shares) Exercised (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Related Party Transactions [Abstract] Related Party Transactions [Abstract] Net change in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Schedule of Lessee, Operating Lease, Liability, Maturity Lessee, Operating Lease, Liability, Maturity [Table Text Block] Stock options to purchase common stock Outstanding common stock options Share-based Payment Arrangement, Option [Member] Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Subsequent Events [Abstract] Subsequent Events [Abstract] Forfeited (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Foreign currency translation adjustment Currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Sale of Stock [Domain] Sale of Stock [Domain] 2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan 2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan [Member] 2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan Research and development Research And Development [Member] Represents the information pertaining to research and development expenses included in the income statement. Plan Name [Domain] Plan Name [Domain] Revenue Arrangements Revenue from Contract with Customer [Text Block] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Operating loss carryforwards, carried forward indefinitely Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration Issuance of common stock through at-the-market offering, net (in shares) Stock Issued During Period, Shares, Other Long-term Debt, Fiscal Year Maturity [Abstract] Long-term Debt, Fiscal Year Maturity [Abstract] Nature of the Business and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Additional paid-in capital Additional Paid in Capital Accrued patent fees Accrued Patent Fees Current Carrying value as of the balance sheet date of patent fees. Foreign currency transaction gain, net Foreign Currency Transaction Gain (Loss), before Tax Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Unvested restricted stock units Restricted Stock Units, Unvested [Member] Restricted Stock Units, Unvested Schedule of Future Minimum Payments on the Term Loans Schedule of Maturities of Long-term Debt [Table Text Block] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Total liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure Accrued expenses Accrued expenses Accrued Liabilities, Current Local Phone Number Local Phone Number Net operating losses available for use through 2028 Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Warrants and rights outstanding, measurement input Warrants and Rights Outstanding, Measurement Input Schedule Of Changes In The Warrant Liabilities Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Investment income Investment Income, Net Depreciation expense Depreciation Entity Address, Address Line One Entity Address, Address Line One Thereafter Lessee, Operating Lease, Liability, To Be Paid, After Year Four Lessee, Operating Lease, Liability, To Be Paid, After Year Four Contract liabilities, beginning of period Contract liabilities, end of period Contract with Customer, Liability Entity Emerging Growth Company Entity Emerging Growth Company Issuance of common stock upon exercise of options Stock Issued During Period, Value, Stock Options Exercised Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Award Type [Axis] Award Type [Axis] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Prepaid Expenses and Other Current Assets Prepaid Expenses and Other Current Assets [Member] Vested in period Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Maximum Maximum [Member] Initial upfront execution fee payment License And Option Agreement, Execution Fee Payment License And Option Agreement, Execution Fee Payment Preferred stock, shares authorized Preferred Stock, Shares Authorized Schedule of Lessee, Components Of Operating Lease Lessee, Components Of Operating Lease [Table Text Block] Lessee, Components Of Operating Lease Other comprehensive loss: Other Comprehensive Income (Loss), Tax [Abstract] Accumulated deficit Retained Earnings [Member] Preferred stock, shares outstanding Preferred Stock, Shares Outstanding Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Net cash (used in) investing activities Net Cash Provided by (Used in) Investing Activities Outstanding, term Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Collaboration Agreements Collaboration And License Agreements [Text Block] Collaboration And License Agreements Warrant liabilities Warrant liabilities Warrants and Rights Outstanding Award Type [Domain] Award Type [Domain] Trading Symbol Trading Symbol Property and Equipment Property, Plant and Equipment Disclosure [Text Block] Upfront cash payment License And Option Agreement, Upfront Cash Payment License And Option Agreement, Upfront Cash Payment Initial up-front cash payment License And Option Agreement, Initial Up-Front Cash Payment License And Option Agreement, Initial Up-Front Cash Payment Office equipment Office Equipment [Member] Net Loss Per Share Earnings Per Share [Text Block] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Current liabilities: Liabilities, Current [Abstract] Cash flows from financing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Entity Shell Company Entity Shell Company Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Recurring Fair Value, Recurring [Member] Vested and expected to vest (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Issuance of common stock through at-the-market offering, net Stock Issued During Period, Value, Other Milestone payment License And Option Agreement, Milestone Payments License And Option Agreement, Milestone Payments Deferred revenue, deductions Contract with Customer, Liability, Deferred Revenue, Revenue Recognized Contract with Customer, Liability, Deferred Revenue, Revenue Recognized Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] EX-101.PRE 11 selb-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 12 selb-20210331_htm.xml IDEA: XBRL DOCUMENT 0001453687 2021-01-01 2021-03-31 0001453687 2021-05-07 0001453687 2021-03-31 0001453687 2020-12-31 0001453687 2020-01-01 2020-03-31 0001453687 us-gaap:CommonStockMember 2020-12-31 0001453687 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001453687 us-gaap:RetainedEarningsMember 2020-12-31 0001453687 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001453687 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001453687 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001453687 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001453687 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001453687 us-gaap:CommonStockMember 2021-03-31 0001453687 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001453687 us-gaap:RetainedEarningsMember 2021-03-31 0001453687 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001453687 us-gaap:CommonStockMember 2019-12-31 0001453687 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001453687 us-gaap:RetainedEarningsMember 2019-12-31 0001453687 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001453687 2019-12-31 0001453687 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001453687 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001453687 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001453687 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001453687 us-gaap:CommonStockMember 2020-03-31 0001453687 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001453687 us-gaap:RetainedEarningsMember 2020-03-31 0001453687 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001453687 2020-03-31 0001453687 country:RU 2021-03-31 0001453687 us-gaap:CorporateBondSecuritiesMember 2021-03-31 0001453687 us-gaap:CommercialPaperMember 2021-03-31 0001453687 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001453687 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-03-31 0001453687 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001453687 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-03-31 0001453687 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001453687 us-gaap:WarrantMember 2020-01-01 2020-03-31 0001453687 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001453687 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001453687 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001453687 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001453687 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2021-03-31 0001453687 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2021-03-31 0001453687 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2021-03-31 0001453687 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateBondSecuritiesMember 2021-03-31 0001453687 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-03-31 0001453687 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-03-31 0001453687 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-03-31 0001453687 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2021-03-31 0001453687 us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001453687 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001453687 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001453687 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001453687 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001453687 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001453687 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001453687 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001453687 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001453687 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001453687 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001453687 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001453687 2020-01-01 2020-12-31 0001453687 us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ValuationTechniqueOptionPricingModelMember 2021-03-31 0001453687 us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:ValuationTechniqueOptionPricingModelMember 2021-03-31 0001453687 us-gaap:MeasurementInputExpectedTermMember us-gaap:ValuationTechniqueOptionPricingModelMember 2021-03-31 0001453687 us-gaap:MeasurementInputPriceVolatilityMember us-gaap:ValuationTechniqueOptionPricingModelMember 2021-03-31 0001453687 us-gaap:WarrantMember 2020-12-31 0001453687 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001453687 us-gaap:WarrantMember 2021-03-31 0001453687 selb:LaboratoryEquipmentMember 2021-03-31 0001453687 selb:LaboratoryEquipmentMember 2020-12-31 0001453687 us-gaap:ComputerEquipmentMember 2021-03-31 0001453687 us-gaap:ComputerEquipmentMember 2020-12-31 0001453687 us-gaap:LeaseholdImprovementsMember 2021-03-31 0001453687 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001453687 us-gaap:FurnitureAndFixturesMember 2021-03-31 0001453687 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001453687 us-gaap:OfficeEquipmentMember 2021-03-31 0001453687 us-gaap:OfficeEquipmentMember 2020-12-31 0001453687 us-gaap:ConstructionInProgressMember 2021-03-31 0001453687 us-gaap:ConstructionInProgressMember 2020-12-31 0001453687 selb:A65GroveStreetWatertownMAMember 2019-07-31 0001453687 selb:A65GroveStreetWatertownMAMember 2019-07-01 2019-07-31 0001453687 us-gaap:LetterOfCreditMember 2020-12-31 0001453687 us-gaap:LetterOfCreditMember 2021-03-31 0001453687 selb:A2020TermLoansMember 2020-08-31 0001453687 selb:TermALoansMember 2020-08-31 0001453687 selb:TermBLoansMember 2020-08-31 0001453687 selb:A2020TermLoansMember us-gaap:DebtInstrumentRedemptionPeriodOneMember 2021-01-01 2021-03-31 0001453687 selb:A2020TermLoansMember us-gaap:DebtInstrumentRedemptionPeriodTwoMember 2021-01-01 2021-03-31 0001453687 selb:A2020TermLoansMember us-gaap:DebtInstrumentRedemptionPeriodThreeMember 2021-01-01 2021-03-31 0001453687 srt:MaximumMember selb:A2020TermLoansMember 2021-01-01 2021-03-31 0001453687 srt:MinimumMember selb:A2020TermLoansMember 2021-01-01 2021-03-31 0001453687 selb:A2020TermLoansMember 2021-01-01 2021-03-31 0001453687 selb:A2020TermLoansMember 2020-08-31 2020-08-31 0001453687 2020-08-31 0001453687 2020-08-31 2020-08-31 0001453687 selb:TermBLoansMember us-gaap:WarrantMember 2020-08-31 2020-08-31 0001453687 selb:A2017TermLoansMember 2020-08-31 2020-08-31 0001453687 selb:A2017TermLoansMember 2020-07-01 2020-09-30 0001453687 selb:A2020TermLoansMember 2021-03-31 0001453687 selb:A2020TermLoansMember 2020-12-31 0001453687 selb:A2017TermLoansMember 2021-03-31 0001453687 selb:August2020ShelfRegistrationStatementMember 2020-08-06 2020-08-06 0001453687 selb:AtTheMarketOfferingMember 2017-08-01 2017-08-31 0001453687 selb:A2020SaleAgreementAtTheMarketOfferingMember 2017-08-01 2017-08-31 0001453687 selb:AtTheMarketOfferingMember 2020-01-01 2020-12-31 0001453687 selb:AtTheMarketOfferingMember 2020-12-31 0001453687 selb:AtTheMarketOfferingMember 2021-01-01 2021-03-31 0001453687 selb:AtTheMarketOfferingMember 2021-03-31 0001453687 selb:SOBIPurchaseAgreementMember 2020-06-11 2020-06-11 0001453687 selb:SOBIPurchaseAgreementMember 2020-06-11 0001453687 selb:SOBIPurchaseAgreementMember 2021-01-01 2021-03-31 0001453687 selb:SOBIPurchaseAgreementMember 2020-07-28 2020-07-28 0001453687 selb:DecemberTwoThousandNineteenFinancingMember 2019-12-18 2019-12-18 0001453687 selb:DecemberTwoThousandNineteenFinancingMember 2019-12-18 0001453687 selb:CommonWarrantMember selb:DecemberTwoThousandNineteenFinancingMember 2019-12-18 0001453687 selb:PreFundedWarrantMember selb:DecemberTwoThousandNineteenFinancingMember 2019-12-18 2019-12-18 0001453687 selb:PreFundedWarrantMember selb:DecemberTwoThousandNineteenFinancingMember 2019-12-18 0001453687 selb:DecemberTwoThousandNineteenFinancingMember 2020-01-01 2020-03-31 0001453687 selb:DecemberTwoThousandNineteenFinancingMember 2021-03-31 0001453687 selb:DecemberTwoThousandNineteenFinancingMember 2021-01-01 2021-03-31 0001453687 us-gaap:WarrantMember 2021-03-31 0001453687 selb:A2017PIPEMember 2021-03-31 0001453687 us-gaap:WarrantMember 2020-12-31 0001453687 us-gaap:StockCompensationPlanMember 2021-03-31 0001453687 us-gaap:StockCompensationPlanMember 2020-12-31 0001453687 selb:RestrictedStockUnitsRSUsReservedForIssuanceMember 2021-03-31 0001453687 selb:RestrictedStockUnitsRSUsReservedForIssuanceMember 2020-12-31 0001453687 selb:RestrictedStockUnitsUnvestedMember 2021-03-31 0001453687 selb:RestrictedStockUnitsUnvestedMember 2020-12-31 0001453687 us-gaap:EmployeeStockOptionMember 2021-03-31 0001453687 us-gaap:EmployeeStockOptionMember 2020-12-31 0001453687 selb:StockIncentivePlan2016Member 2016-06-21 0001453687 selb:StockIncentivePlan2016Member 2021-01-01 2021-03-31 0001453687 selb:StockIncentivePlan2016Member 2020-01-01 2020-03-31 0001453687 selb:StockIncentivePlan2016Member 2021-03-31 0001453687 selb:EmploymentInducementIncentiveAwardPlanMember 2018-09-25 0001453687 selb:EmploymentInducementIncentiveAwardPlanMember 2019-03-25 0001453687 selb:EmploymentInducementIncentiveAwardPlanMember 2021-03-31 0001453687 selb:ResearchAndDevelopmentMember 2021-01-01 2021-03-31 0001453687 selb:ResearchAndDevelopmentMember 2020-01-01 2020-03-31 0001453687 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001453687 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001453687 us-gaap:StockCompensationPlanMember 2021-01-01 2021-03-31 0001453687 us-gaap:StockCompensationPlanMember 2020-01-01 2020-03-31 0001453687 us-gaap:StockCompensationPlanMember selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember 2020-12-31 0001453687 us-gaap:StockCompensationPlanMember selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember 2020-01-01 2020-12-31 0001453687 us-gaap:StockCompensationPlanMember selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember 2021-01-01 2021-03-31 0001453687 us-gaap:StockCompensationPlanMember selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember 2021-03-31 0001453687 selb:NonEmployeeStockOptionMember selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember 2020-12-31 0001453687 selb:NonEmployeeStockOptionMember selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember 2020-01-01 2020-12-31 0001453687 selb:NonEmployeeStockOptionMember selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember 2021-01-01 2021-03-31 0001453687 selb:NonEmployeeStockOptionMember selb:A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember 2021-03-31 0001453687 us-gaap:RestrictedStockUnitsRSUMember selb:StockIncentivePlan2016Member 2021-01-01 2021-01-31 0001453687 us-gaap:RestrictedStockUnitsRSUMember selb:StockIncentivePlan2016Member 2021-01-01 2021-03-31 0001453687 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-03-31 0001453687 us-gaap:RestrictedStockUnitsRSUMember selb:EmploymentInducementIncentiveAwardPlanMember 2021-03-31 0001453687 us-gaap:RestrictedStockUnitsRSUMember selb:EmploymentInducementIncentiveAwardPlanMember 2021-01-01 2021-03-31 0001453687 us-gaap:RestrictedStockUnitsRSUMember 2020-12-31 0001453687 us-gaap:RestrictedStockUnitsRSUMember 2021-03-31 0001453687 selb:EmployeeStockPurchasePlan2016Member 2016-06-21 0001453687 selb:EmployeeStockPurchasePlan2016Member 2021-01-01 2021-03-31 0001453687 selb:EmployeeStockPurchasePlan2016Member 2020-01-01 2020-03-31 0001453687 selb:EmployeeStockPurchasePlan2016Member 2021-03-31 0001453687 us-gaap:CollaborativeArrangementMember 2020-06-11 2020-06-11 0001453687 us-gaap:CollaborativeArrangementMember 2020-06-11 0001453687 selb:SOBIPurchaseAgreementMember 2021-03-31 0001453687 selb:SOBIPurchaseAgreementMember 2020-12-31 0001453687 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember selb:SOBIPurchaseAgreementMember 2021-03-31 0001453687 us-gaap:OtherCurrentAssetsMember selb:SOBIPurchaseAgreementMember 2021-03-31 0001453687 selb:SareptaTherapeuticsInc.Member 2020-06-13 2020-06-13 0001453687 selb:SareptaTherapeuticsInc.Member 2020-12-31 0001453687 selb:SareptaTherapeuticsInc.Member 2021-03-31 0001453687 selb:SareptaTherapeuticsInc.Member 2021-01-01 2021-03-31 0001453687 selb:SareptaTherapeuticsInc.Member 2020-01-01 2020-03-31 0001453687 selb:LicenseAgreementForPompeDiseaseMember 2019-12-17 2019-12-17 0001453687 selb:LicenseAgreementForPompeDiseaseMember 2021-03-31 0001453687 selb:LicenseAgreementForPompeDiseaseMember 2020-12-31 0001453687 selb:LicenseAgreementForPompeDiseaseMember 2021-01-01 2021-03-31 0001453687 selb:LicenseAgreementForPompeDiseaseMember 2020-01-01 2020-03-31 0001453687 selb:FounderMember 2021-01-01 2021-03-31 0001453687 selb:FounderMember 2020-01-01 2020-03-31 0001453687 selb:AskBioLicenseMember 2020-01-01 2020-03-31 0001453687 selb:AskBioLicenseMember 2021-01-01 2021-03-31 0001453687 us-gaap:LicenseAgreementTermsMember selb:ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember 2021-01-01 2021-03-31 0001453687 us-gaap:LicenseAgreementTermsMember 2021-01-01 2021-03-31 0001453687 selb:LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember 2021-03-31 0001453687 selb:LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember 2021-01-01 2021-03-31 0001453687 us-gaap:SubsequentEventMember selb:A2020SaleAgreementAtTheMarketOfferingMember 2021-04-01 2021-05-13 0001453687 us-gaap:SubsequentEventMember selb:A2020SaleAgreementAtTheMarketOfferingMember 2021-05-13 0001453687 srt:ScenarioForecastMember selb:SareptaTherapeuticsInc.Member 2021-04-13 2021-04-13 shares iso4217:USD iso4217:USD shares pure utr:sqft selb:vote selb:obligation false 2021 Q1 0001453687 --12-31 10-Q true 2021-03-31 false 001-37798 Selecta Biosciences, Inc DE 26-1622110 65 Grove Street, Watertown, MA 02472 617 923-1400 Common Stock, $0.0001 par value per share SELB NASDAQ Yes Yes Non-accelerated Filer true true true false 113193597 125407000 138685000 22405000 0 8342000 7224000 6971000 5434000 163125000 151343000 1301000 1395000 10676000 10948000 1379000 1379000 265000 370000 176746000 165435000 594000 443000 6847000 8146000 460000 0 942000 908000 75764000 72050000 84607000 81547000 24551000 24793000 9403000 9647000 32301000 38746000 45455000 28708000 196317000 183441000 0.0001 0.0001 10000000 10000000 0 0 0 0 0 0 0.0001 0.0001 200000000 200000000 112977004 112977004 108071249 108071249 11000 11000 414214000 391175000 -429226000 -404629000 -4570000 -4563000 -19571000 -18006000 176746000 165435000 11050000 0 13004000 14724000 5204000 4098000 18208000 18822000 -7158000 -18822000 12000 240000 7000 82000 711000 273000 16747000 846000 0 -1000 -24597000 -19620000 -6000 -60000 -1000 0 -24604000 -19680000 -0.22 -0.21 110742150 94723513 108071249 11000 391175000 -404629000 -4563000 -18006000 34696 72000 72000 153278 244000 244000 10937 0 4706844 20943000 20943000 1780000 1780000 -6000 -6000 -1000 -1000 -24597000 -24597000 112977004 11000 414214000 -429226000 -4570000 -19571000 86325547 9000 348664000 -335753000 -4523000 8397000 78583 114000 114000 5128 3000 3000 10937 0 598977 1141000 1141000 -147000 -147000 1409000 1409000 -60000 -60000 -19620000 -19620000 87019172 9000 351184000 -355373000 -4583000 -8763000 -24597000 -19620000 207000 231000 -14000 0 272000 366000 0 -1000 1780000 1409000 387000 123000 16747000 846000 1118000 -5000000 1512000 61000 151000 836000 -2728000 0 -1736000 -829000 -12133000 -11698000 22420000 0 25000 135000 -22445000 -135000 0 2100000 20991000 1141000 0 4381000 0 -147000 244000 3000 72000 114000 21307000 -5370000 -7000 -84000 -13278000 -17287000 140064000 91551000 126786000 74264000 494000 232000 10000 10000 48000 42000 -1000 0 Nature of the Business and Basis of Presentation<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selecta Biosciences, Inc., or the Company was incorporated in Delaware on December 10, 2007, and is based in Watertown, Massachusetts. The Company is a clinical-stage biopharmaceutical company leveraging its ImmTOR™ immune tolerance platform with the goals of amplifying the efficacy of biologics, including enabling the re-dosing of life-saving gene therapies, and restoring self-tolerance in autoimmune diseases. The Company’s ImmTOR platform encapsulates rapamycin, also known as sirolimus, an immunomodulator, in biodegradable nanoparticles and is designed to induce antigen-specific immune tolerance. The Company believes ImmTOR has the potential to enhance the efficacy without compromising the safety of biologic therapies, improve product candidates under development, and enable novel therapeutic modalities. Since inception, the Company has devoted its efforts principally to research and development of its technology and product candidates, recruiting management and technical staff, acquiring operating assets, and raising capital.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s product candidates are in development. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited consolidated financial statements for the three months ended March 31, 2021 and 2020 have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC, for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K that was filed with the SEC on March 12, 2021. The unaudited interim financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments that are necessary for a fair statement of the Company’s financial position as of March 31, 2021 and consolidated results of operations and cash flows for the three months ended March 31, 2021. Such adjustments are of a normal and recurring nature. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Management’s Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The future success of the Company is dependent on its ability to develop its product candidates and ultimately upon its ability to attain profitable operations. The Company is subject to a number of risks similar to other early-stage life science companies, including, but not limited to, successful development of its product candidates, raising additional capital with favorable terms, protection of proprietary technology and market acceptance of any approved future products. The successful development of product candidates requires substantial working capital which may not be available to the Company on favorable terms or at all.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has financed its operations primarily through the initial public offering of its common stock, private placements of its common stock, issuances of common and preferred stock, debt, research grants and research collaborations. The Company currently has no source of product revenue, and it does not expect to generate product revenue for the foreseeable future. To date, all of the Company’s revenue has been collaboration and grant revenue. The Company has devoted substantially all of its financial resources and efforts to developing its ImmTOR platform, identifying potential product candidates and conducting preclinical studies and its clinical trials. The Company is in the early stages of development of its product candidates, and it has not completed development of any ImmTOR-enabled therapies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company’s cash, cash equivalents, restricted cash and marketable securities were $149.2 million, of which $1.4 million was restricted cash related to lease commitments and $0.3 million was held by its Russian subsidiary designated solely for use in its operations. The Company believes the cash, cash equivalents, restricted cash and marketable securities as of March 31, 2021 will enable it to fund its operating expenses and capital expenditure requirements into the second quarter of 2023. The Company has incurred losses and negative cash flows from operating activities since inception. As of March 31, 2021, the Company had an accumulated deficit of $429.2 million. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research, development of its product candidates, conducting preclinical studies and clinical trials, and its administrative organization. The Company will require substantial additional financing to fund its operations and to continue to execute its strategy, and the Company will pursue a range of options to secure additional capital.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At this time, there is significant uncertainty relating to the trajectory of the COVID-19 pandemic and the impact of related responses. Any impact of COVID-19 on the Company’s business, revenues, results of operations and financial condition will largely depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, supply chain disruptions, the ultimate impact on financial markets and the global economy, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Guarantees and Indemnifications</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. Through March 31, 2021, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.</span></div> 149200000 1400000 300000 -429200000 Summary of Significant Accounting Policies<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to the Company’s significant accounting policies during the three months ended March 31, 2021, as compared to the significant accounting policies disclosed in Note 2 – Summary of Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The Company adopted the new standard effective January 1, 2021, and there was no impact on its consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU 2020-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC’s regulations. The Company adopted the new standard effective January 1, 2021, and there was no impact on its consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2023, with early adoption permitted no earlier than January 1, 2021. The Company is assessing the impact this standard will have on its consolidated financial statements and disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subsequently, in November 2018, the FASB issued ASU 2018-19,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Codification Improvements to Topic 326, Financial Instruments-Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company is assessing the impact this standard will have on its consolidated financial statements and disclosures.</span></div> <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU 2019-12,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The Company adopted the new standard effective January 1, 2021, and there was no impact on its consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the FASB issued ASU 2020-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Codification Improvements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC’s regulations. The Company adopted the new standard effective January 1, 2021, and there was no impact on its consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Not Yet Adopted</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2023, with early adoption permitted no earlier than January 1, 2021. The Company is assessing the impact this standard will have on its consolidated financial statements and disclosures.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Subsequently, in November 2018, the FASB issued ASU 2018-19,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Codification Improvements to Topic 326, Financial Instruments-Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company is assessing the impact this standard will have on its consolidated financial statements and disclosures.</span></div> Marketable Securities<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the marketable securities held as of March 31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,032 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,406 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,405 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All marketable securities held at March 31, 2021 had maturities of less than 12 months when purchased and are classified as short-term marketable securities on the accompanying consolidated balance sheet. During the three months ended March 31, 2021, there were no marketable securities adjusted for other than temporary declines in fair value.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, the Company held no marketable securities.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the marketable securities held as of March 31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,032 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,406 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,405 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 2032000 0 1000 2031000 20374000 0 0 20374000 22406000 0 1000 22405000 0 0 Net Loss Per Share<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has reported a net loss for the three months ended March 31, 2021 and 2020. For this reason basic and diluted net loss per share are the same for all periods presented. The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per-share data):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,597)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,620)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares and pre-funded warrants outstanding—basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,742,150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94,723,513 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders —basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All potential dilutive common shares have been excluded from the computation of the diluted net loss per share for all periods presented, as the effect would have been anti-dilutive. Potential dilutive common share equivalents consist of the following:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,187,394 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,745,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544,313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170,313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,378,016 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,084,120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,109,723 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,000,369 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per-share data):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24,597)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19,620)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average common shares and pre-funded warrants outstanding—basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,742,150 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94,723,513 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders —basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> -24597000 -19620000 110742150 94723513 -0.22 -0.21 Potential dilutive common share equivalents consist of the following:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,187,394 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,745,936 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544,313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170,313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Warrants to purchase common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,378,016 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,084,120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23,109,723 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31,000,369 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 10187394 7745936 544313 170313 12378016 23084120 23109723 31000369 Fair Value Measurements<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Company’s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,563 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,158 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,405 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Warrant liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,455 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,455 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,576 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,576 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Warrant liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,708 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,708 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,708 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,708 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers within the fair value hierarchy during the three months ended March 31, 2021 or the year ended December 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the money market funds were classified as cash and cash equivalents on the accompanying consolidated balance sheets as they mature within 90 days from the date of purchase.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company had restricted cash balances relating to a secured letter of credit in connection with its lease for the Company’s headquarters (see Note 8 included elsewhere in this Quarterly Report). The Company’s consolidated statement of cash flows includes the following as of March 31, 2021 and 2020 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,407 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,606 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126,786 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,264 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketable Securities</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, marketable securities classified as Level 2 within the valuation hierarchy consist of corporate bonds and commercial paper. Marketable securities represent holdings of available-for-sale marketable debt securities in accordance with the Company’s investment policy. The Company estimates the fair values of these marketable securities by taking into consideration valuations that include market pricing based on real-time trade data for the same or similar securities, and other observable inputs. The amortized cost of available-for-sale debt securities is adjusted for amortization of premiums and accretion of discounts to the earliest call date for premiums or to maturity for discounts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loans Payable</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At March 31, 2021, given the recent issuance of the Term A Loan under the 2020 Term Loan, the Company believes the carrying value approximates the fair value of the loan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Warrants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company issued common warrants in connection with a private placement of common shares. Pursuant to the terms of the common warrants, the Company could be required to settle the common warrants in cash in the event of certain acquisitions of the Company and, as a result, the common warrants are required to be measured at fair value and reported as a liability on the balance sheet. The Company recorded the fair value of the common warrants upon issuance using the Black-Scholes valuation model and is required to revalue the common warrants at each reporting date with any changes in fair value recorded in the statement of operations. The valuation of the common warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The significant unobservable inputs used in the fair value measurement of the warrant liabilities were the volatility rate and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value measurement. The change in </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the fair value of the Level 3 warrant liability is reflected in the statement of operations for the three months ended March 31, 2021 and 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of warrants is determined using Level 3 inputs inherent in the Black-Scholes simulation valuation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated fair value of the underlying stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of the common stock based on the closing stock price at the end of each reporting period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The risk-free interest rate is based on the U.S. Treasury at the valuation date commensurate with the expected remaining life assumption.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The dividend rate is based on the historical rate, which the Company anticipates will remain at zero.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The expected life of the warrants is assumed to be equivalent to their remaining contractual term which expires on December 23, 2024.</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company estimates stock price volatility based on the Company’s historical volatility and the historical volatility of peer companies for a period of time commensurate with the expected remaining life of the warrants.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Black-Scholes pricing model assumptions used to record the fair value of the warrant liability is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.35 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.73</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects a roll-forward of fair value for the Company’s Level 3 warrant liabilities (see Note 10), for the three months ended March 31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrant liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of December 31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,708 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,747 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of March 31, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,455 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Company’s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,031 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20,374 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,563 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58,158 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22,405 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Warrant liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,455 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,455 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,455 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,576 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,576 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80,576 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Warrant liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,708 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,708 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,708 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,708 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 58158000 58158000 0 0 2031000 0 2031000 0 20374000 0 20374000 0 80563000 58158000 22405000 0 45455000 0 0 45455000 45455000 0 0 45455000 80576000 80576000 0 0 80576000 80576000 0 0 28708000 0 0 28708000 28708000 0 0 28708000 0 0 0 0 The Company’s consolidated statement of cash flows includes the following as of March 31, 2021 and 2020 (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,407 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,606 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126,786 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,264 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> The Company’s consolidated statement of cash flows includes the following as of March 31, 2021 and 2020 (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">125,407 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72,606 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">279 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-term restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,379 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126,786 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74,264 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 125407000 72606000 0 279000 1379000 1379000 126786000 74264000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Black-Scholes pricing model assumptions used to record the fair value of the warrant liability is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.35 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.73</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.0035 0 P3Y8M23D 1.0113 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects a roll-forward of fair value for the Company’s Level 3 warrant liabilities (see Note 10), for the three months ended March 31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Warrant liabilities</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of December 31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28,708 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16,747 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value as of March 31, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,455 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 28708000 16747000 45455000 Property and Equipment<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,429 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,427 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">694 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,681 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,380)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,301 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,395 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense was $0.1 million and $0.2 million for the three months ended March 31, 2021 and 2020, respectively.</span></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment consists of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,429 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,427 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">694 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">327 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Construction in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,681 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,380)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,255)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,301 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,395 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 4429000 4427000 694000 532000 38000 38000 327000 327000 163000 163000 30000 163000 5681000 5650000 4380000 4255000 1301000 1395000 100000 200000 Accrued Expenses<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payroll and employee related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,840 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,049 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration and licensing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued patent fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">471 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued external research and development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,010 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,029 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued professional and consulting services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">798 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,847 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,146 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payroll and employee related expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,840 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,049 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration and licensing</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,350 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued patent fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">471 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">534 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued external research and development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,010 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,029 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued professional and consulting services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">798 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Accrued expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,847 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,146 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1840000 3049000 1350000 1350000 471000 534000 2010000 2029000 802000 798000 170000 170000 204000 216000 6847000 8146000 Leases <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">65 Grove Street Lease</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company entered into a lease for 25,078 square feet of laboratory and office space located at 65 Grove Street, Watertown, Massachusetts, or the Headquarters Lease. As part of the Headquarters Lease, the Company incurred $0.8 million in non-reimbursable construction costs. The lease began in March 2020, consistent with when the Company took control of the office space, and the lease term is 8 years. The discount rate of 8.9% was determined based on the Company’s incremental borrowing rate adjusted for the lease term including any reasonably certain renewal periods. In connection with the Headquarters Lease, the Company secured a letter of credit from Silicon Valley Bank, or SVB, for $1.4 million, recognized as long-term restricted cash, as of March 31, 2021 and December 31, 2020, respectively, which automatically renews each year.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Moscow, Russia Lease</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a month-to-month facility agreement for its Moscow, Russia office. Rent expense is recognized as incurred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the components of the operating leases were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">   Right-of-use asset, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,948 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">   Current operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">942 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">   Non-current operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,345 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,555 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 and 2020 the components of lease costs were as follows (in thousands): </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">735 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">673 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity of the Company’s operating lease liabilities as of March 31, 2021 were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remainder)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,368 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,922 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,945 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,775 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,345 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supplemental disclosure for the statement of cash flows related to operating leases were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.451%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the initial recording of the right-of-use asset and lease liability for the Headquarters Lease, which is non-cash, the changes in the Company’s right-of-use asset and lease liability for the three months ended March 31, 2021 and 2020 are reflected in the non-cash lease expense and accrued expenses and other liabilities, respectively, in the consolidated statements of cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes additional information related to operating leases:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 25078 800000 P8Y 0.089 1400000 1400000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the components of the operating leases were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">   Right-of-use asset, net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,948 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">   Current operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">942 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">908 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">   Non-current operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,647 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,345 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,555 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 10676000 10948000 942000 908000 9403000 9647000 10345000 10555000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 and 2020 the components of lease costs were as follows (in thousands): </span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">472 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">735 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">673 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes additional information related to operating leases:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.484%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 444000 472000 288000 199000 3000 2000 735000 673000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maturity of the Company’s operating lease liabilities as of March 31, 2021 were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remainder)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,368 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,866 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,922 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,980 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,039 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,945 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Total future minimum lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,120 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,775 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,345 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 1368000 1866000 1922000 1980000 2039000 4945000 14120000 3775000 10345000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The supplemental disclosure for the statement of cash flows related to operating leases were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.451%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 444000 487000 P7Y1M6D P8Y 0.089 0.089 Debt<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Term Loan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 31, 2020, the Company entered into a term loan of up to $35.0 million, or the 2020 Term Loan, consisting of term loans in an aggregate amount of $25.0 million, or the Term A Loan, and term loans in an aggregate amount of $10.0 million, or the Term B Loan, governed by a loan and security agreement, or the Loan Agreement, between the Company and Oxford Finance LLC, or Oxford, as Collateral Agent and a Lender, and SVB, as a Lender. The Term A Loan was funded in full on August 31, 2020, or the Funding Date.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term B Loan will be available, subject to Collateral Agent’s discretion and customary terms and conditions, during the period commencing on the date the Company has delivered to the Collateral Agent and the Lenders evidence: (i) the Company or one of the Company’s collaboration partners has enrolled its first patient for a Phase 1 clinical trial evaluating the treatment of methylmalonic acidemia, or MMA, and (ii) the Company has enrolled the first patient in each of two Phase 3 pivotal trials evaluating SEL-212, or the Second Draw Period Milestone, and ending on the earliest of (i) the date which is 30 days following the date the Second Draw Period Milestone is achieved, (ii) September 30, 2021 (iii) and the occurrence of an event of default, other than an event of default that has been waived in writing by Collateral Agent and the Lenders in their sole discretion, with such period referred to as the Second Draw Period.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Term Loan will mature on August 1, 2025. Each advance under the Term Loan accrues interest at a floating per annum rate equal to the greater of (a) 7.90%, and (b) the lesser of (x) the sum of (i) the prime rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue, and (ii) 4.65% and (y) 10.00%. The Term Loan provides for interest-only payments on a monthly basis until April 1, 2022; provided however, if the Company has delivered to the Collateral Agent and the Lenders prior to September 30, 2021 evidence that Borrower has achieved the Second Draw Period Milestone, the Term Loan provides for interest-only payments on a monthly basis until October 1, 2022. Thereafter, amortization payments will be payable monthly in equal installments of principal and interest to fully amortize the outstanding principal over the remaining term of the loan, subject to recalculation upon a change in the prime rate. The Company may prepay the Term Loan in full but not in part provided that the Company (i) provides ten days’ prior written notice to Collateral Agent, (ii) pays on the date of such prepayment (A) all outstanding principal plus </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accrued and unpaid interest, and (B) a prepayment fee of between 3.0% and 1.0% of the aggregate original principal amount advanced by the lender depending on the timing of the prepayment. Amounts outstanding during an event of default are payable upon SVB’s demand and shall accrue interest at an additional rate of 5.0% per annum of the past due amount outstanding. At the end of the loan term (whether at maturity, by prepayment in full or otherwise), the Company shall make a final payment to the lender in the amount of 9.0% of the aggregate original principal amount advanced by the lender. The final payment fee totaling $2.3 million is recorded as a loan discount.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Term Loan is secured by a lien on substantially all of the assets of the Company, other than intellectual property, provided that such lien on substantially all assets includes any rights to payments and proceeds from the sale, licensing or disposition of intellectual property. The Company has also granted the Collateral Agent a negative pledge with respect to its intellectual property.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Loan Agreement contains customary covenants and representations, including but not limited to financial reporting obligations and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. The Loan Agreement also contains other customary provisions, such as expense reimbursement, non-disclosure obligations as well as indemnification rights for the benefit of the Collateral Agent.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The events of default under the Loan Agreement include, but are not limited to, the Company’s failure to make any payments of principal or interest under the Loan Agreement or other transaction documents, the Company’s breach or default in the performance of any covenant under the Loan Agreement or other transaction documents, the occurrence of a material adverse change, the Company making a false or misleading representation or warranty in any material respect under the Loan Agreement, the Company’s insolvency or bankruptcy, any attachment or judgment on the Company’s assets of at least $0.5 million, or the occurrence of any default under any agreement or obligation of the Company involving indebtedness in excess of $0.5 million. If an event of default occurs, the Collateral Agent is entitled to take enforcement action, including acceleration of amounts due under the Loan Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred $0.4 million in debt issuance costs in connection with the closing of the 2020 Term Loan. Debt issuance costs are presented in the consolidated balance sheet as a direct deduction from the associated liability and amortized to interest expense over the term of the related debt.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed all terms and features of the 2020 Term Loan to identify any potential embedded features that would require bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the 2020 Term Loan, including any put, call, and contingent features. The Company determined that the interest rate collar and prepayment call option did not require bifurcation; whereas the contingent put option and default (contingent) interest rate feature met bifurcation criteria resulting in immaterial amounts.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 31, 2020, in connection with the 2020 Term A Loan, the Company issued warrants to the Lenders to purchase an aggregate of 196,850 shares of its common stock at an exercise price equal to $2.54 per share. In accordance with ASC 815-40, these warrants are classified as permanent equity in the accompanying consolidated balance sheets and will expire ten years from the date of issuance. The initial grant date fair value of the warrants was $0.4 million as determined by the Black-Scholes valuation model and recorded to shareholders' equity, with the SVB portion allocated to the reacquisition price of the 2017 Term Loan and the Oxford fair value portion as a loan discount to the Term A Loan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on August 31, 2020, pursuant to the terms of a Warrant Side Letter agreement among the Company and the Lenders, the Company agreed to issue to the Lenders, on the date the Company draws the Term B Loan and in accordance with each party’s respective pro rata share with respect to the Term B Loan, one or more warrants to purchase an aggregate number of shares of its common stock that is equal to $200,000 divided by the average closing price of the Company’s common stock on The Nasdaq Stock Market LLC for the ten consecutive trading days ending the day before such issuance, rounded down to the nearest whole number of shares, and having an exercise price equal to the Term B Warrant Price.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payoff</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the Funding Date, the Company entered into a payoff letter with SVB, pursuant to which the Company utilized $13.7 million of the 2020 Term Loan to pay off all outstanding obligations under the previous term loan, consisting of the principal payment, final prepayment and accrued interest. During the three months ended September 30, 2020, the Company recognized a loss on extinguishment of debt in the amount of $0.5 million determined as the difference between the reacquisition price and carrying value at August 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the outstanding principal balance under the 2020 Term Loan was $25.0 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum principal and interest payments on the 2020 Term Loan as of March 31, 2021 are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remainder)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,509 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,611 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,274 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum debt payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,764 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Amount representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,514)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Debt discount and deferred charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,239)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Current portion of loan payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loan payable, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,551 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div> 35000000.0 25000000.0 10000000.0 0.0790 0.0465 0.1000 0.030 0.010 0.050 0.090 2300000 500000 500000 400000 196850 2.54 P10Y 400000 200000000 13700000 -500000 25000000.0 25000000.0 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum principal and interest payments on the 2020 Term Loan as of March 31, 2021 are as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.596%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021 (remainder)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,509 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,611 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,274 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total minimum debt payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32,764 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Amount representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,514)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Debt discount and deferred charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,239)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Current portion of loan payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(460)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loan payable, net of current portion</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24,551 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div> 1509000 7343000 8611000 8027000 7274000 32764000 5514000 2239000 460000 24551000 Equity<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Financings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">August 2020 Shelf Registration Statement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 6, 2020, the Company filed an updated universal shelf registration statement on Form S-3 (Reg. No. 333-241692) with the SEC to sell an aggregate amount of up to $200.0 million of certain of its securities. The shelf registration statement was declared effective by the SEC on August 14, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">“At-the-Market” Offerings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2017, the Company entered into a sales agreement, or the 2017 Sales Agreement, with Jefferies LLC, as sales agent, to sell shares of its common stock with an aggregate value of up to $50.0 million in an “at the market offering.” On August 6, 2020, concurrent with the filing of the updated shelf registration statement, the Company entered into a sales agreement, or the 2020 Sales Agreement with Jefferies LLC, as sales agent, pursuant to which the Company may, from time to time, issue and sell common stock with an aggregate value of up to $50.0 million in an “at the market offering.” The 2017 Sales Agreement terminated pursuant to its terms in August 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of common stock, if any, pursuant to the 2020 Sales Agreement, may be made in sales deemed to be an “at the market offering” as defined in Rule 415(a) of the Securities Act, including sales made directly through the Nasdaq Stock Market or on any other existing trading market for the Company’s common stock. The Company intends to use the proceeds from the offering for working capital and other general corporate purposes. The Company may suspend or terminate the 2020 Sales Agreement at any time.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2020, the Company sold 1,069,486 shares of its common stock pursuant to the 2020 and 2017 Sales Agreements at an average price of approximately $2.16 per share for aggregate net proceeds of $2.1 million, after deducting commissions and other transaction costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021, the Company sold 4,706,844 shares of its common stock pursuant to the 2020 Sales Agreement at an average price of approximately $4.59 per share for aggregate net proceeds of $20.9 million, after deducting commissions and other transaction costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">June 2020 Sobi Stock Purchase</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2020, the Company entered into a stock purchase agreement with Sobi, pursuant to which the Company sold an aggregate of 5,416,390 shares of its common stock at a purchase price equal to $4.6156 per share, which represented 120% of the 10-day volume-weighted average price of the Company’s common stock prior to signing, for aggregate gross proceeds of $25.0 million, or the Sobi Private Placement. The closing of the Sobi Private Placement occurred on July 31, 2020. The shares of common stock acquired in the Sobi Private Placement are subject to a one-year lock-up from closing, during which time Sobi is prohibited from selling or otherwise disposing of such shares.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 815, this forward sale treatment qualified as equity classification as the shares are not within the scope of ASC 480. The gross proceeds of $25.0 million were determined to include a premium to the fair value of the Company’s shares as of July 28, 2020 of approximately $14.5 million. As a result, such amount was included in the transaction price for revenue recognition of the Sobi License. See Note 12 for details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also on June 11, 2020, the Company entered into a registration rights agreement (as amended by that certain letter agreement, dated as of November 4, 2020) with Sobi, pursuant to which the Company agreed to prepare and file a registration statement with respect to the resale of the shares of common stock acquired in the Sobi Private Placement. The Company will be required to file this resale registration statement within 30 days following receipt by the Company of a written request from </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sobi to file such resale registration statement, and to have the registration statement declared effective within 10 business days after the SEC informs the Company that no review of such resale registration statement will be made or that the SEC has no further comments on such resale registration statement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">December 2019 Financing</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On December 18, 2019, the Company entered into a securities purchase agreement, or the 2019 Purchase Agreement, with a group of institutional investors and certain members of the board of directors. Pursuant to the 2019 Purchase Agreement, the Company sold an aggregate of 37,634,883 shares of its common stock at a purchase price of $1.46 per share, warrants to purchase an aggregate of 22,988,501 shares of common stock at a purchase price of $0.125 per share underlying each common warrant, and pre-funded warrants to purchase an aggregate of 8,342,128 shares of common stock at a purchase price of $1.46 per share, all with five year terms, or the 2019 PIPE. The closing of the 2019 PIPE occurred on December 23, 2019. The exercise price of the pre-funded warrants is $0.0001 per share and the exercise price for the common warrants is $1.46 per share. In the event of a certain sale of the Company, the terms of the common warrants require us to make a payment to such common warrant holders based on a Black-Scholes valuation (using variables as specified in the warrants). This provision does not apply to the pre-funded warrants. Therefore, the Company is required to account for the common warrants as liabilities and record them at fair value, while the pre-funded warrants met the criteria to be classified as permanent equity. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded the fair value of the common warrants of $40.7 million upon issuance using the Black-Scholes valuation model. Issuance costs were allocated between the equity component with an offset to additional paid-in capital and the liability component recorded as expense on a relative fair value basis. Total net proceeds from the equity offering was $65.6 million, after deducting transaction costs and commissions of $4.4 million which was paid in the three months ended March 31, 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The common warrants were revalued as of March 31, 2021 at $45.5 million. During the three months ended March 31, 2021 and 2020, the Company recorded losses on the increases in the fair value of the warrants of $(16.7) million and $(0.8) million, respectively, in the unaudited consolidated statements of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2021 and 2020, there were no warrants issued, exercised, or canceled.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity<br/> classified</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability classified</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average<br/>exercise price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292,469 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,085,547 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,378,016 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.60 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company had 200,000,000 shares of common stock authorized for issuance, $0.0001 par value per share, with 112,977,004 shares issued and outstanding. The voting, dividend and liquidation rights of the common stockholders are subject to and qualified by the rights, powers and preferences of the preferred stock. The common stock has the following characteristics:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Voting</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The common stockholders are entitled to one vote for each share of common stock held with respect to all matters voted on by the stockholders of the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The common stockholders are entitled to receive dividends, if and when declared by the Board of Directors. Through March 31, 2021, no dividends have been declared or paid on common stock.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidation</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon liquidation of the Company, the common stockholders are entitled to receive all assets of the Company available for distribution to such stockholders.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reserved Shares</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has authorized shares of common stock for future issuance as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of common warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,378,016 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,378,016 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares available for future stock incentive awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,719,817 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,916,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RSUs reserved for issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544,313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding common stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,187,394 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,775,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,928,290 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,157,139 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 200000000.0 50000000.0 50000000.0 1069486 2.16 2100000 4706844 4.59 20900000 5416390 4.6156 1.20 25000000.0 P1Y 25000000.0 14500000 37634883 1.46 22988501 0.125 8342128 1.46 0.0001 1.46 40700000 65600000 4400000 45500000 -16700000 -800000 <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Equity<br/> classified</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liability classified</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average<br/>exercise price</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292,469 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,085,547 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,378,016 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.60 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 292469000 12085547000 12378016000 1.60 200000000 0.0001 112977004 112977004 1 0 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has authorized shares of common stock for future issuance as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:68.929%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.522%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period ended</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of common warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,378,016 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,378,016 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares available for future stock incentive awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,719,817 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,916,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RSUs reserved for issuance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,750 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544,313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,500 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding common stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,187,394 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,775,249 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,928,290 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25,157,139 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 12378016 12378016 7719817 4916374 98750 0 544313 87500 10187394 7775249 30928290 25157139 Stock Incentive Plans<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains the 2008 Stock Incentive Plan, or the 2008 Plan, for employees, consultants, advisors, and directors. The 2008 Plan provided for the granting of incentive and non-qualified stock option and restricted stock awards as determined by the Board. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company’s stockholders approved the 2016 Incentive Award Plan, or the 2016 Plan, which authorized 1,210,256 shares of common stock for future issuance under the 2016 Plan and ceased granting awards under the 2008 Plan. Upon the effective date of the 2016 Plan, awards issued under the 2008 Plan remain subject to the terms of the 2008 Plan. Awards granted under the 2008 Plan that expire, lapse or terminate become available under the 2016 Plan as shares available for future grants.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, pursuant to the terms of the 2016 Plan, the Board is authorized to grant awards with respect to common stock, and may delegate to a committee of one or more members of the Board or executive officers of the Company the authority to grant options and restricted stock units. On December 9, 2020, the Board established a Stock Option Committee authorized to grant awards to certain employees and consultants subject to conditions and limitations within the 2016 Plan. In January 2021 and 2020, the number of shares of common stock that may be issued under the 2016 Plan was increased by 4,322,850 and 3,453,022 shares, respectively. As of March 31, 2021, 3,248,520 shares remain available for future issuance under the 2016 Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company’s 2018 Employment Inducement Incentive Award Plan, or the 2018 Inducement Incentive Award Plan was adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules, which authorized 1,175,000 shares of its common stock for issuance. In March 2019, the Board approved the amendment and restatement of the 2018 Inducement Incentive Award Plan to reserve an additional 2,000,000 shares of the Company’s common stock for issuance thereunder. As of March 31, 2021, there are 1,358,333 shares available for future grant under the 2018 Inducement Incentive Award Plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation Expense</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by classification included within the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">754 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">623 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,026 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">786 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,780 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,409 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employees</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated grant date fair values of employee stock option awards granted under the 2016 Plan and the 2018 Inducement Incentive Award Plan were calculated using the Black-Scholes option pricing model, based on the following weighted-average assumptions:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.73 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average fair value of common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of stock options granted to employees during the three months ended March 31, 2021 and 2020 was $1.99 and $1.69, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 total unrecognized compensation expense related to unvested employee stock options was $11.8 million, which is expected to be recognized over a weighted average period of 2.7 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-employee consultants</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, there was no unrecognized compensation expense related to non-employee consultants stock options.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the 2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">remaining</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">contractual term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">intrinsic value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise price ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,302,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.43</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,456 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,628,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153,278)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(62,577)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,714,321 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.65</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,064,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.63</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,920,548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-employee consultants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473,073 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.23</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473,073 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.98</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">462,186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.92</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473,073 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.98</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">366 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company granted 369,800 restricted stock awards to employees under the 2016 Plan which will vest over a four year term.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, during the first quarter of 2021, the Company awarded 197,500 restricted stock units to executives under the 2016 Plan, of which 98,750 were determined to be granted as of the award date consistent with ASC 718. The remaining 98,750 restricted stock units do not have a defined performance metric as of the award date, resulting in the restricted stock units being reserved for future issuance as of March 31, 2021. These restricted stock units will vest in two equal installments on the dates </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an applicable performance condition is achieved, on or prior to December 31, 2021. If the performance conditions are not satisfied on or prior to December 31, 2021, the restricted stock units will be forfeited for no consideration.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The restricted stock units granted had a weighted average fair value of $2.99 per share based on the closing price of the Company’s common stock on the date of grant. The restricted stock units were valued at approximately $1.4 million on their grant date. Forfeitures are estimated at the time of grant and are adjusted, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has estimated a forfeiture rate of 10% for restricted stock awards to employees based on historical attrition trends.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized compensation expense for all restricted stock units was $1.5 million as of March 31, 2021, which is expected to be recognized over a weighted average period of 3.1 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s restricted stock units under the 2016 Plan and 2018 Inducement Incentive Award Plan:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:69.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average<br/>grant date<br/>fair value ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.03 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">468,550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,937)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.03 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reserved for issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at March 31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">643,063 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.35 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company approved the 2016 Employee Stock Purchase Plan, or the ESPP, which authorized 173,076 shares of common stock for future issuance under the ESPP to participating employees. In January 2021 and 2020, the number of shares of common stock authorized for issuance under the ESPP was increased by 1,080,711 shares and 863,254 shares, respectively. During the three months ended March 31, 2021, the Company issued 34,696 shares of common stock under the ESPP. As of March 31, 2021, 2,546,464 shares remain available for future issuance under the ESPP.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each of the three months ended March 31, 2021 and 2020, the Company recognized less than $0.1 million of stock-based compensation expense under the ESPP.</span></div> 1210256 4322850 3453022 3248520 1175000 2000000 1358333 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense by classification included within the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">754 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">623 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,026 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">786 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,780 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,409 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 754000 623000 1026000 786000 1780000 1409000 The estimated grant date fair values of employee stock option awards granted under the 2016 Plan and the 2018 Inducement Incentive Award Plan were calculated using the Black-Scholes option pricing model, based on the following weighted-average assumptions:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.598%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.44 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.73 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.08</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted-average fair value of common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table> 0.0044 0.0173 0 0 P5Y3M10D P6Y29D 0.8326 0.8796 3.13 2.30 1.99 1.69 11800000 P2Y8M12D 0 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the stock option activity under the 2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">remaining</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-average</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">contractual term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">intrinsic value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">exercise price ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,302,176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.43</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,456 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,628,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153,278)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(62,577)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,714,321 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.65</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,665 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,064,130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.63</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,920,548 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,231 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-employee consultants</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473,073 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.23</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Outstanding at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473,073 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.98</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested at March 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">462,186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.92</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">366 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested and expected to vest at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">473,073 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.98</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">366 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 7302176 3.98 P8Y5M4D 4456000 2628000 3.13 153278 1.47 62577 5.19 9714321 3.78 P8Y7M24D 15665000 3064130 5.46 P7Y7M17D 4313000 8920548 3.88 P8Y7M2D 14231000 473073 5.89 P5Y2M23D 86000 0 0 0 0 0 0 473073 5.89 P4Y11M23D 366000 462186 5.82 P4Y11M1D 366000 473073 5.89 P4Y11M23D 366000 369800 P4Y 197500 98750 98750 2.99 1400000 0.10 1500000 P3Y1M6D <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company’s restricted stock units under the 2016 Plan and 2018 Inducement Incentive Award Plan:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:69.721%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.124%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted average<br/>grant date<br/>fair value ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at December 31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87,500 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.03 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">468,550 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10,937)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.03 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reserved for issuance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98,750 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(800)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.99 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unvested at March 31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">643,063 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.35 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 87500 6.03 468550 2.99 10937 6.03 98750 2.99 800 2.99 643063 3.35 173076 1080711 863254 34696 2546464 100000 100000 Revenue Arrangements<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Swedish Orphan Biovitrum</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License and Development Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2020, the Company and Sobi entered into the Sobi License. Pursuant to the Sobi License, the Company has agreed to grant Sobi an exclusive, worldwide (except as to Greater China) license to develop, manufacture and commercialize the Company’s SEL-212 drug candidate, which is currently in development for the treatment of chronic refractory gout. The SEL-212 drug candidate is a pharmaceutical composition containing a combination of SEL-037, or the Compound, and ImmTOR. Pursuant to the Sobi License, in consideration of the license, Sobi agreed to pay the Company a one-time, up-front payment of $75.0 million. Sobi has also agreed to make milestone payments totaling up to $630.0 million to the Company upon the achievement of various development and regulatory milestones and, if commercialized, sales thresholds for annual net sales of SEL-212, and tiered royalty payments ranging from the low double digits on the lowest sales tier to the high teens on the highest sales tier.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Sobi License, the Company has agreed to supply (at cost) quantities of the Compound and ImmTOR as necessary for completion of the two Phase 3 clinical trials of SEL-212 (DISSOLVE I and DISSOLVE II) and a 6-month placebo extension. The Company is required to supply quantities of the Compound until all rights to the Compound and any materials needed to manufacture the Compound are transferred to Sobi. Sobi has agreed to reimburse the Company for all budgeted costs incurred to complete development of SEL-212, including but not limited to costs incurred while conducting and completing the Phase 3 DISSOLVE trials, except for any costs of additional development activities required that are related to ImmTOR and that are unrelated to SEL-212. Sobi will have control and responsibility over all regulatory filings, including any investigational drug applications (IND), biologics license applications (BLA), and marketing authorization applications (MAA) relating to the licensed product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transactions contemplated by the Sobi License were consummated on July 28, 2020 following the expiration or termination of the required waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Sobi may terminate the Sobi License for any reason upon 180 days’ written notice to the Company, whereby all rights granted under the Sobi License would revert back to the Company. In addition, if Sobi were to terminate the Sobi License, the Company has the option to obtain a license to all patents and know-how necessary to exploit SEL-212 in existence as of the termination date from Sobi in return for making an equitable royalty payment to Sobi.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, on June 11, 2020, the Company entered into the Sobi Purchase Agreement in connection with the Sobi License. The closing of the Sobi Private Placement occurred on July 31, 2020, following the closing of the transactions contemplated under the Sobi License. See Note 10 for details.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Sobi License represents a service arrangement under the scope of ASC 606. In addition, given the Sobi License and Sobi Purchase Agreement were executed contemporaneously and negotiated as a package with a single commercial objective, the Company will account for the two agreements as a single contract. The term of the Sobi License commenced upon the effective date of July 28, 2020 and will continue on a product-by-product basis until the royalty terms for each country have expired. The royalty term for a given product begins upon the first commercial sale of the product in a country and ends at the later of ten years from the first commercial sale, expiration of the last valid patent claim covering the product and expiration of all regulatory exclusivity periods for the product in a country. Given the reversion of the rights under the Sobi License represents a penalty in substance for a termination by Sobi, the contract term would remain the stated term of the Sobi License.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Sobi License contains three distinct performance obligations due to the nature of the promises in the contract, which includes conducting the Phase 3 DISSOLVE trials, Sobi’s option to set-up a second source supplier, and a combined obligation comprised of the delivery of the license to SEL-212, transfer of the know-how and the manufacturing and delivery of SEL-212 supply for development, or the Combined License Obligation. As the set-up of a second source supplier is optional for Sobi and the Company will be reimbursed at cost for its efforts in the subsequent set-up and technology transfer, the option for this future service was determined to be at a significant and incremental discount to its standalone selling price and treated as a material right in the arrangement, namely a distinct performance obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company concluded the upfront payment of $75.0 million and the $5.0 million development milestone associated with the dosing of the first patient in the Phase 3 DISSOLVE trials will be included in the transaction price. All other development milestones will be fully constrained and only be included in the transaction price when the respective milestone is deemed probable of achievement. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of the evaluation of the constraint, the Company considered numerous factors, including that receipt of such milestones is outside the control of the Company and probability of success criteria is estimated. The Company will re-evaluate the transaction price in each reporting period, as uncertain events are resolved. In accordance with ASC 606, the Company will only recognize revenue associated with sales-based milestones and royalties when the subsequent sales thresholds are reached and underlying sales occur, respectively. In connection with the Sobi Purchase Agreement, the Company determined that the gross proceeds of $25.0 million from the Sobi Private Placement included a premium to the fair value of the Company’s shares as of July 28, 2020 equal to approximately $14.5 million. The premium amount will be included in the transaction price for revenue recognition. The Company will estimate and include in the transaction price the total reimbursements to be received from Sobi for both the manufacturing and delivery of the Compound and ImmTOR as well as conducting the Phase 3 DISSOLVE trials. The Company determined that a significant financing component does not exist in its arrangement with Sobi.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocated the transaction price based on the relative standalone selling prices of the three distinct performance obligations. The Company estimated the standalone selling price of conducting the Phase 3 DISSOLVE trials by forecasting its anticipated costs and applying a margin reflective of the industry. The Company must determine the standalone selling price of the second source supplier option by determining the discount given to Sobi multiplied by the likelihood that Sobi will exercise the option in the future. Similar to the Phase 3 program estimate, the Company estimated the discount of the option by forecasting the set-up costs and applying a margin that is reflective of the industry. As the Company will be providing the set-up and technology transfer services and the future supply at cost, the discount of the option is equal to the margin amount. The Company considered discussions with Sobi as well as probability of regulatory success of SEL-212 in determining the likelihood of exercise. The Company estimated the standalone selling price of the Combined License Obligation by utilizing a discounted cash flow model.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the delivery of the supply to Sobi best represents the pattern of delivery of the Combined License Obligation as the supply is essential to the utility of the license and know-how. The Company will recognize the revenue allocated to the Combined License Obligation by utilizing the output method. The Company estimated the total supply of the Compound and ImmTOR to be required during the clinical trial period and will recognize revenue as this supply is shipped for use in the clinical trials. The Company will recognize the revenue allocated to the conducting of the Phase 3 DISSOLVE trials obligation by utilizing the input method. The Company estimated the total budgeted costs to be incurred over </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Phase 3 DISSOLVE trials and will recognize revenue as these costs are incurred. The Company’s costs best represent the pattern of transfer as these will capture all performance of the trials completed to date and can be readily measured. The Company will recognize the revenue allocated to the second source supplier option when the future services and goods are transferred.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the Company recorded $72.0 million and $68.3 million, respectively, as a short-term contract liability and $17.8 million and $24.2 million, respectively, as a long-term contract liability, representing deferred revenue associated with this agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of March 31, 2021 the Company has recorded $1.3 million of contract assets related to incremental costs that would not have been incurred if the Sobi License had not been obtained, of which $1.0 million is presented in prepaid expenses and other current assets and $0.3 million is presented in other assets in the accompanying unaudited consolidated balance sheets. Amortization of contract assets was less than $0.1 million for the three months ended March 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021 and December 31, 2020, the Company recorded a total outstanding receivable of $8.3 million and $6.9 million, respectively, representing billings for the Phase 3 DISSOLVE program that are subject to reimbursement by Sobi. Revenue of $11.1 million related to the Sobi License was recognized during the three months ended March 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sarepta Therapeutics, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research License and Option Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 13, 2020, the Company and Sarepta entered into a Research License and Option Agreement, or the Sarepta Agreement. Pursuant to the Sarepta Agreement, the Company agreed to grant Sarepta a license under the Company’s intellectual property rights covering the Company’s antigen-specific biodegradable nanoparticle encapsulating ImmTOR to research and evaluate ImmTOR in combination with Sarepta’s adeno-associated virus gene therapy technology, or gene editing technology, using viral or non-viral delivery, to treat Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophy subtypes, or the Indications. Sarepta will have an option term of 24 months during which it can opt-in to obtain an exclusive license to further develop and commercialize the Product to treat at least one Indication, with a potential to extend the option term for an additional fee. The Company will supply ImmTOR to Sarepta for clinical supply on a cost-plus basis.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sarepta paid a $2.0 million up-front payment to the Company upon signing of the Sarepta Agreement, and the Company is eligible to receive additional preclinical payments during the option term. If Sarepta opts-in to an exclusive license agreement, the Company could receive option exercise payments per Indication upon execution of the exclusive license, and the Company would be entitled to significant development and commercial milestone payments and tiered royalties ranging from the mid-to-high single digits based on net sales.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Sarepta Agreement, the Company determined the Sarepta Agreement represents a service arrangement under the scope of ASC 606, with a 24 month contract duration. Given the reversion of the rights under the Sarepta Agreement represents a penalty in substance for a termination by Sarepta, the contract term would remain the stated term of the Sarepta Agreement.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Sarepta Agreement and supply obligation including the delivery of the research license, the licensed know-how, the manufactured supply and delivery of materials represent a single promise and performance obligation to be transferred to Sarepta over time due to the nature of the promises in the contract. The delivery of the manufactured supply is the predominant promise within the arrangement, as it is essential to the utility of the licensed intellectual property. As such, consideration in the initial transaction price will be allocated to the single performance obligation based on the contractual price.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company concluded the payment associated with all the performance milestones will be fully constrained and only be included in the transaction price when the respective milestone is deemed probable of achievement. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of such study milestones is outside the control of the Company and probability of success criteria is estimated. As of March 31, 2021 and December 31, 2020, all milestones were constrained. The Company will re-evaluate the transaction price in each reporting period, as uncertain events are resolved. The Company will recognize the revenue associated with the upfront payment and combined single performance obligation utilizing the output method, over the 24 month term as the manufactured supply is delivered to Sarepta.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also determined the option to enter into a future commercial license agreement and extend the term of the option does not represent a material right since it was not priced at an incremental discount. Sarepta may terminate the Sarepta Agreement for any reason upon 30 days’ written notice to the Company. The Sarepta Agreement contains other customary terms and conditions, including representations and warranties, covenants, termination, and indemnification obligations in favor of each party. During the year ended December 31, 2020, the Company and Sarepta entered into two amendments relating to an </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional feasibility study. During the three months ended March 31, 2021, the Company and Sarepta entered into a third amendment relating to feasibility study research plan. None of the amendments executed through March 31, 2021 had a material impact on deferred revenue or revenue recognition.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each of March 31, 2021 and December 31, 2020, the Company recorded $2.0 million as a short-term contract liability representing deferred revenue associated with this agreement. No revenue related to the Sarepta Agreement was recognized during the three months ended March 31, 2021 and 2020.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asklepios Biopharmaceutical, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement for Pompe Disease</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 17, 2019, the Company and AskBio entered into a license agreement, or the AskBio License Agreement. Pursuant to the AskBio License Agreement, AskBio has exercised its option to exclusively license the Company’s intellectual property rights covering the Company’s ImmTOR platform to research, develop, and commercialize certain AAV gene therapy products utilizing ImmTOR, and targeting the GAA gene, or derivatives thereof, to treat Pompe Disease.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the AskBio License Agreement and ancillary documents, AskBio agreed to pay to the Company upfront fees of an aggregate of $7.0 million. Assuming successful development and commercialization, the Company could receive up to an additional $237.0 million in development, regulatory, and sales milestone payments. If commercialized, the Company would be eligible to receive tiered royalties on global net sales at percentages ranging from mid-to-high single digits. Under the terms of the agreement, the Company will be eligible to receive these royalties commencing on the first commercial sale of the licensed product until the expiration of the later of (i) ten years after the first commercial sale and (ii) expiration of the last to expire valid claim on patents covering the licensed product.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the AskBio License Agreement, the Company will supply AskBio with its ImmTOR platform, or the Supply Obligation, and AskBio will be responsible for all preclinical, clinical and commercial manufacture and supply of licensed products (other than ImmTOR) and carry out all other activities related to the research, development, and commercialization of licensed products at its sole expense, including all regulatory activities related thereto.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the AskBio License Agreement and Supply Obligation represent a single promise and performance obligation. This is because AskBio cannot derive benefit from the license without the simultaneous transfer of the patent protected ImmTOR supply. Therefore, the License Obligation and Supply Obligation represent the only promise in the arrangement and are combined as a single performance obligation.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the transaction price, the Company concluded that the future development milestones, regulatory milestones, sales milestones, and sales royalties all represent variable consideration. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of such milestones is outside the control of the Company. Consideration related to sales-based milestones as well as royalties on net sales upon commercialization by AskBio, will be recognized when the related sales occur, as they were determined to relate predominantly to the intellectual property granted to AskBio and, therefore, have also been excluded from the transaction price in accordance with the royalty recognition constraint. As of March 31, 2021 and December 31, 2020, all milestones were constrained. The Company will re-evaluate the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total initial transaction price of the contract on the effective date was $7.0 million, comprised of a $2.0 million initial up-front payment upon agreement of terms, and a $5.0 million initial up-front execution fee.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each of March 31, 2021 and December 31, 2020, the Company recorded $1.7 million as short-term and $5.3 million as a long-term, representing deferred revenue associated with this agreement. Revenue will be recognized over the period in which the particles are delivered. No revenue related to the AskBio License Agreement was recognized during the three months ended March 31, 2021 and 2020 as no deliveries were made during the periods.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Spark Therapeutics, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Spark License Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The disclosures relating to the Company’s license and option agreement, or the Spark License Agreement, with Spark pursuant to which the Company and Spark agreed to collaborate on the development of gene therapies for certain targets utilizing the ImmTOR platform reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 which was filed with the SEC on March 12, 2021 have not materially changed since the Company filed such report.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transaction Price Allocated to Future Performance Obligations</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Remaining performance obligations represent the transaction price of contracts for which work has not been performed (or has been partially performed). As of March 31, 2021, the aggregate amount of the transaction price allocated to remaining performance obligations was $108.1 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Balances from Contracts with Customers (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sobi, Sarepta, AskBio, and Spark</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the Company’s contract liabilities during the three months ended March 31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:29.488%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">beginning of period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">end of period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108,066 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,796 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,730)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108,066 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 75000000.0 630000000.0 P180D P10Y 3 75000000.0 5000000.0 25000000.0 14500000 3 72000000.0 68300000 17800000 24200000 1300000 1000000.0 300000 100000 8300000 6900000 11100000 P24M 2000000.0 P24M P24M P30D 2000000.0 2000000.0 0 0 7000000.0 237000000.0 P10Y 7000000.0 2000000.0 5000000.0 1700000 1700000 5300000 5300000 0 0 108100000 <div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents changes in the Company’s contract liabilities during the three months ended March 31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:29.488%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.521%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">beginning of period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Deductions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">end of period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">     Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,796 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,730)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108,066 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110,796 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,730)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">108,066 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div> 110796000 0 2730000 108066000 110796000 0 2730000 108066000 Related-Party Transactions<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consulting Services</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company incurred expenses for consulting services provided by its founders totaling less than $0.1 million during each of the three months ended March 31, 2021 and 2020. The Company entered into consulting agreements with its founders to serve on its Scientific Advisory Board, effective January 1, 2020 to December 31, 2021, under which they will be paid quarterly for their services.</span></div> 100000 100000 Collaboration Agreements<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Asklepios Biopharmaceutical, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Feasibility Study and License Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company entered into a feasibility study and license agreement with AskBio, or the AskBio Collaboration Agreement. Pursuant to the AskBio Collaboration Agreement, the Company and AskBio agreed to license intellectual property rights to each other as part of a collaboration to research, develop, and commercialize certain AAV gene therapy products utilizing the Company’s ImmTOR platform to enable re-dosing of such AAV gene therapy products to treat serious rare and orphan genetic diseases for which there is a significant unmet medical need.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the AskBio Collaboration Agreement, the Company and AskBio agreed to conduct proof of concept studies to potentially validate the use of ImmTOR in conjunction with AskBio’s AAV gene therapy, or MMA-101, for the treatment of MMA, to mitigate the formation of neutralizing anti-AAV capsid antibodies, or the POC Studies. If the POC Studies are successful, or the parties otherwise elect to do so, the parties will proceed with a collaboration to pursue the development and commercialization of AAV gene therapy product candidates utilizing ImmTOR for the treatment of certain agreed serious rare and orphan genetic diseases. If the POC Studies fail to demonstrate a proof-of-concept, and the parties do not mutually agree in writing to proceed with the collaboration, the AskBio Collaboration Agreement will expire.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEL-399 program combines an empty AAV capsid (EMC-101), which is an AAV capsid containing no transgene, with ImmTOR and is being conducted in partnership with AskBio. Building on the preclinical data the Company has generated showing ImmTOR’s effect on mitigating or reducing the formation of neutralizing antibodies to AAV gene therapies, the Company has commenced a clinical trial of SEL-399 in healthy adult volunteers in Belgium. The goal of the SEL-399 clinical trial is to demonstrate the appropriate dose of ImmTOR in humans to mitigate the formation of antibodies to AAV capsids used in gene therapies.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and AskBio will share responsibility for the research, development and commercialization of products developed under this collaboration. The parties will also share research, development, and commercialization costs equally for all collaboration products, but with a right of either party to opt out of certain products, and thereby no longer be required to share costs for such products. Each party will receive a percentage of net profits for each product sold under the collaboration equal to the percentage of shared costs borne by such party in the development of such product. Pursuant to the AskBio Collaboration Agreement, AskBio is responsible for manufacturing the AAV capsids and AAV vectors and the Company is responsible for manufacturing ImmTOR.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The AskBio Collaboration Agreement is considered to be within the scope of ASC 808, as both parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company evaluated the terms of the AskBio </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement and have identified the following promises in the arrangement (1) conducting research and development activities to develop and commercialize products under the collaboration, or the R&amp;D Services, (2) granting a non-exclusive, non-transferable, royalty-free, fully paid up, worldwide license to certain intellectual property of the Company, or the IP Rights, for the purpose of performing the POC Studies, or the Research License, (3) granting an exclusive, nontransferable, worldwide license to the IP Rights for use in certain indications, or the Collaboration License, (4) providing manufactured supply of preclinical and clinical ImmTOR, or the Manufactured Supply, (5) participation on identified steering committees responsible for the oversight of the collaboration, or the JSC Participation, and (6) granting an exclusive option to obtain a license under the IP Rights to research, develop and commercialize Licensed Products. The Company determined that the R&amp;D Services, Research License, Collaboration License, Manufactured Supply, and JSC Participation were not capable of being distinct, and therefore must be combined into a single performance obligation. Therefore, promises (1) through (5) identified above were combined into a single performance obligation. Furthermore, the Company evaluated the Option Agreement and determined that it does not provide AskBio with a material right under ASC 606 as the option was not priced at a discount (see discussion of the option exercise in Note 12). The Company noted that AskBio did not meet the definition of a customer within the scope of ASC 606 for any distinct performance obligations as the Company concluded that such items were not an output of the Company’s ordinary activities. As such, the Company determined that the entire arrangement would be accounted for within the scope of ASC 808.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 808, collaboration expenses are recognized within R&amp;D expense and selling, general and administrative expense on the Company’s condensed consolidated statements of operations. For each of the three months ended March 31, 2021 and 2020, the Company recognized $1.2 million of collaboration expense under the AskBio Collaboration Agreement in which actual costs incurred by both parties approximate a 50% cost share.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain collaborative arrangements, the Company is entitled to reimbursement of certain R&amp;D expense. Activities under collaborative arrangements for which the Company is entitled to reimbursement are considered to be collaborative activities under the scope of ASC 808. For these units of account, the Company does not analogize to ASC 606 or recognize revenue. Rather, the Company analogizes to the guidance in ASC 730, which requires that reimbursements from counterparties be recognized as an offset to the related costs. In accordance with ASC 730, the Company records reimbursement payments received from collaborators as reductions to R&amp;D expense.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Massachusetts Institute of Technology</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2008, the Company entered into an exclusive patent license agreement, or the MIT License, with the Massachusetts Institute of Technology, or MIT, under which the Company received an exclusive royalty-bearing license to utilize patents held by MIT in exchange for upfront consideration and annual license maintenance fees. Such fees are expensed as incurred and have not been material to any period presented.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company entered into a Fifth Amendment, or the MIT Amendment, to the MIT License, which is effective as of May 15, 2020. Pursuant to the MIT Amendment, certain of the Company’s diligence obligations were extended, including a diligence obligation to commence a Phase 3 trial for a licensed product by a specific date in the second quarter of 2021. Additionally, certain of the Company’s development and regulatory milestones and payments upon achievement of such milestones were adjusted.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, and in connection with the execution of the Spark License Agreement, the Company has made contractual payments pursuant to the MIT License totaling $2.2 million for the sublicense granted to Spark, and $0.4 million relative to the calculated premium paid by Spark for the equity investments made under the Spark Purchase Agreement. The Company made no additional payments during the three months ended March 31, 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shenyang Sunshine Pharmaceutical Co., Ltd</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2014, the Company entered into a license agreement, or the 3SBio License, with Shenyang Sunshine Pharmaceutical Co., Ltd., or 3SBio. The Company has paid to 3SBio an aggregate of $7.0 million in upfront and milestone-based payments under the 3SBio License as of March 31, 2021. The Company is required to make future payments to 3SBio contingent upon the occurrence of events related to the achievement of clinical and regulatory approval milestones of up to an aggregate of $15.0 million for products containing the Company’s ImmTOR platform.</span></div> 1200000 0.50 2200000 400000 0 7000000.0 15000000.0 Income Taxes<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for income taxes under ASC 740. Under ASC 740, the Company provides deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company’s financial statement carrying amounts and the tax bases of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2021 and 2020, the Company did not record a current or deferred income tax expense or benefit.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has provided a full valuation allowance against its net deferred tax assets, as the Company believes that it is more likely than not that the deferred tax assets will not be realized.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Utilization of the net operating loss and research and development credit carryforwards may be subject to a substantial annual limitation under Section 382 and 383 of the Internal Revenue Code due to ownership change limitations that have occurred previously, or that could occur in the future. These ownership changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. As of December 31, 2020, the Company completed a Section 382 study. The Company has determined that all of the $234.5 million of net operating losses are available in the future, with approximately $36.5 million of that total limited under Section 382 and therefore available for future use through 2028.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company applies ASC 740,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to uncertain tax positions. As of March 31, 2021 and December 31, 2020, the Company had no unrecognized tax benefits or related interest and penalties accrued.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not, as of yet, conducted a study of its research and development credit carryforwards. This study may result in an adjustment to the Company’s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The statute of limitations for assessment by the United States Internal Revenue Service and Massachusetts tax authorities is open for tax years since inception. The Company files income tax returns in the United States and Massachusetts. There are currently no federal, state or foreign audits in progress.</span></div> 234500000 36500000 0 0 Defined Contribution PlanThe Company maintains a defined contribution plan, or the 401(k) Plan, under Section 401(k) of the Internal Revenue Code. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. The 401(k) Plan provides for matching contributions on a portion of participant contributions pursuant to the 401(k) Plan’s matching formula. All matching contributions vest ratably over 4 years and participant contributions vest immediately. Contributions by the Company totaled less than $0.1 million during each of the three months ended March 31, 2021 and 2020. P4Y 100000 100000 Commitments and Contingencies<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2021, the Company was not a party to any litigation that could have a material adverse effect on the Company’s business, financial position, results of operations or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2020, a putative stockholder of Selecta filed a stockholder derivative action, purportedly on behalf of Selecta and against certain current and former members of the Company’s Board of Directors, as well as one affiliated company owned by a current board member, in the Court of Chancery of the State of Delaware, namely Franchi v. Barabe, et al. The complaint alleges that the individual defendants breached their fiduciary duties and committed corporate waste when they authorized a private placement transaction, announced on December 19, 2019, at a price allegedly below fair value. The complaint further alleges that the four defendant directors who participated in the private placement were unjustly enriched in connection with the transaction. On September 25, 2020, the defendants filed a motion to dismiss the lawsuit. On November 6, 2020, the plaintiff filed an amended complaint, and the defendants filed a second motion to dismiss on January 8, 2021. On December 31, 2020, the Company received a litigation demand letter from two other putative stockholders relating to the same private placement transaction. On April 12, 2021, the Court of Chancery in the State of Delaware granted a motion to stay the litigation pending a review by a Special Committee appointed by the Company’s Board of Directors. At this time, the Company has not accrued a liability for this matter, as any liability has been determined to be either not estimable or not probable.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Delaware law, the Company indemnifies its directors for certain events or occurrences while the director is, or was, serving at the Company’s request in such capacity. The term of the indemnification is for the director’s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ insurance coverage that limits its exposure and enables it to recover a portion of any future amounts paid. The Company also has indemnification arrangements under certain of its facility leases that require it to indemnify the landlord against certain costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from certain breaches, violations, or non-performance of any covenant or condition of the Company’s lease. The term of the indemnification is for the term of the related lease agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. To date, the Company had not experienced any material losses related to any of its indemnification obligations, and no material claims with respect thereto were outstanding.</span></div>The Company is a party in various other contractual disputes and potential claims arising in the ordinary course of business. The Company does not believe that the resolution of these matters will have a material adverse effect the Company’s business, financial position, results of operations or cash flows. Subsequent Events<div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">“At-the-Market” Offerings</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to March 31, 2021 through May 13, 2021, the Company sold 206,593 shares of its common stock pursuant to the 2020 Sales Agreement, at an average price of approximately $4.51 per share for aggregate net proceeds of $0.9 million, after deducting commissions and other transaction costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestone Event</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 13, 2021, the Company was notified by Sarepta of the achievement of the milestone event related to the completion of a non-clinical study for Duchenne muscular dystrophy and certain limb-girdle muscular dystrophies under the Company’s Research License and Option Agreement. Under the terms of the Agreement, Sarepta is obligated to pay a non-refundable, non-creditable milestone payment of $3.0 million to the Company within 60 days of Sarepta’s receipt of the related invoice from the Company.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The AskBio Collaboration Agreement</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 29, 2021, the Company was notified by AskBio that it intended to opt-out of development of the MMA indication. Consequently, the Company will assume all rights to the MMA program and intends to continue to progress the MMA-101 and ImmTOR combination through clinical development.</span></div> 206593 4.51 900000 3000000.0 XML 13 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Cover page - shares
3 Months Ended
Mar. 31, 2021
May 07, 2021
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2021  
Document Transition Report false  
Entity File Number 001-37798  
Entity Registrant Name Selecta Biosciences, Inc  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 26-1622110  
Entity Address, Address Line One 65 Grove Street,  
Entity Address, City or Town Watertown,  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02472  
City Area Code 617  
Local Phone Number 923-1400  
Title of 12(b) Security Common Stock, $0.0001 par value per share  
Trading Symbol SELB  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Smaller Reporting Company true  
Entity Emerging Growth Company true  
Entity Extended Transition Period true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   113,193,597
Amendment Flag false  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q1  
Current Fiscal Year End Date --12-31  
Entity Central Index Key 0001453687  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 125,407 $ 138,685
Marketable securities 22,405 0
Accounts receivable 8,342 7,224
Prepaid expenses and other current assets 6,971 5,434
Total current assets 163,125 151,343
Property and equipment, net 1,301 1,395
Right-of-use asset, net 10,676 10,948
Long-term restricted cash 1,379 1,379
Other assets 265 370
Total assets 176,746 165,435
Current liabilities:    
Accounts payable 594 443
Accrued expenses 6,847 8,146
Loan payable 460 0
Lease liability 942 908
Deferred revenue 75,764 72,050
Total current liabilities 84,607 81,547
Non-current liabilities:    
Loan payable, net of current portion 24,551 24,793
Lease liability 9,403 9,647
Deferred revenue 32,301 38,746
Warrant liabilities 45,455 28,708
Total liabilities 196,317 183,441
Commitments and contingencies (Note 17)
Stockholders’ (deficit) equity:    
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2021 and December 31, 2020 0 0
Common stock, $0.0001 par value; 200,000,000 shares authorized; 112,977,004 and 108,071,249 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively 11 11
Additional paid-in capital 414,214 391,175
Accumulated deficit (429,226) (404,629)
Accumulated other comprehensive loss (4,570) (4,563)
Total stockholders’ (deficit) equity (19,571) (18,006)
Total liabilities and stockholders’ (deficit) equity $ 176,746 $ 165,435
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2021
Dec. 31, 2020
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 200,000,000 200,000,000
Common stock, shares issued 112,977,004 108,071,249
Common stock, shares outstanding 112,977,004 108,071,249
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Operations and Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Statement of Comprehensive Income [Abstract]    
Grant and collaboration revenue $ 11,050 $ 0
Operating expenses:    
Research and development 13,004 14,724
General and administrative 5,204 4,098
Total operating expenses 18,208 18,822
Loss from operations (7,158) (18,822)
Investment income 12 240
Foreign currency transaction gain, net 7 82
Interest expense (711) (273)
Change in fair value of warrant liabilities (16,747) (846)
Other income (expense), net 0 (1)
Net loss (24,597) (19,620)
Other comprehensive loss:    
Foreign currency translation adjustment (6) (60)
Unrealized (losses) on marketable securities (1) 0
Total comprehensive loss $ (24,604) $ (19,680)
Net loss per share:    
Basic and diluted (in dollars per share) $ (0.22) $ (0.21)
Weighted average common shares outstanding:    
Basic and diluted (in shares) 110,742,150 94,723,513
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Changes in Stockholders’ (Deficit) Equity - USD ($)
$ in Thousands
Total
Common stock
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive loss
Beginning balance (in shares) at Dec. 31, 2019   86,325,547      
Beginning balance at Dec. 31, 2019 $ 8,397 $ 9 $ 348,664 $ (335,753) $ (4,523)
Increase (Decrease) in Stockholders' Equity          
Issuance of common stock under Employee Stock Purchase Plan (in shares)   78,583      
Issuance of common stock under Employee Stock Purchase Plan 114   114    
Issuance of common stock upon exercise of options (in shares)   5,128      
Issuance of common stock upon exercise of options 3   3    
Issuance of vested restricted stock units (in shares)   10,937      
Issuance of vested restricted stock units 0        
Issuance of common stock through at-the-market offering, net (in shares)   598,977      
Issuance of common stock through at-the-market offering, net 1,141   1,141    
Other financing fees (147)   (147)    
Stock-based compensation expense 1,409   1,409    
Currency translation adjustment (60)       (60)
Unrealized (losses) on marketable securities 0        
Net loss (19,620)     (19,620)  
Ending balance (in shares) at Mar. 31, 2020   87,019,172      
Ending balance at Mar. 31, 2020 $ (8,763) $ 9 351,184 (355,373) (4,583)
Beginning balance (in shares) at Dec. 31, 2020 108,071,249 108,071,249      
Beginning balance at Dec. 31, 2020 $ (18,006) $ 11 391,175 (404,629) (4,563)
Increase (Decrease) in Stockholders' Equity          
Issuance of common stock under Employee Stock Purchase Plan (in shares)   34,696      
Issuance of common stock under Employee Stock Purchase Plan 72   72    
Issuance of common stock upon exercise of options (in shares)   153,278      
Issuance of common stock upon exercise of options 244   244    
Issuance of vested restricted stock units (in shares)   10,937      
Issuance of vested restricted stock units 0        
Issuance of common stock through at-the-market offering, net (in shares)   4,706,844      
Issuance of common stock through at-the-market offering, net 20,943   20,943    
Stock-based compensation expense 1,780   1,780    
Currency translation adjustment (6)       (6)
Unrealized (losses) on marketable securities (1)       (1)
Net loss $ (24,597)     (24,597)  
Ending balance (in shares) at Mar. 31, 2021 112,977,004 112,977,004      
Ending balance at Mar. 31, 2021 $ (19,571) $ 11 $ 414,214 $ (429,226) $ (4,570)
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Cash flows from operating activities    
Net loss $ (24,597) $ (19,620)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 207 231
Amortization of premiums and discounts on marketable securities 14 0
Non-cash lease expense 272 366
Loss on disposal of property and equipment 0 1
Stock-based compensation expense 1,780 1,409
Non-cash interest expense 387 123
Warrant liabilities revaluation 16,747 846
Changes in operating assets and liabilities:    
Accounts receivable (1,118) 5,000
Prepaid expenses, deposits and other assets (1,512) (61)
Accounts payable 151 836
Deferred revenue (2,728) 0
Accrued expenses and other liabilities (1,736) (829)
Net cash (used in) operating activities (12,133) (11,698)
Cash flows from investing activities    
Purchases of marketable securities (22,420) 0
Purchases of property and equipment (25) (135)
Net cash (used in) investing activities (22,445) (135)
Cash flows from financing activities    
Repayments of principal on outstanding debt 0 (2,100)
Net proceeds from issuance of common stock 20,991 1,141
Issuance costs paid for December 2019 financing 0 (4,381)
Other financing fees 0 (147)
Proceeds from exercise of stock options 244 3
Proceeds from issuance of common stock under Employee Stock Purchase Plan 72 114
Net cash provided by (used in) financing activities 21,307 (5,370)
Effect of exchange rate changes on cash (7) (84)
Net change in cash, cash equivalents, and restricted cash (13,278) (17,287)
Cash, cash equivalents, and restricted cash at beginning of period 140,064 91,551
Cash, cash equivalents, and restricted cash at end of period 126,786 74,264
Supplement cash flow information    
Cash paid for interest 494 232
Noncash investing and financing activities    
Purchase of property and equipment not yet paid 10 10
Equity offering costs in accrued liabilities 48 42
Unrealized (losses) on marketable securities $ (1) $ 0
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.21.1
Nature of the Business and Basis of Presentation
3 Months Ended
Mar. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Nature of the Business and Basis of Presentation Nature of the Business and Basis of Presentation
Selecta Biosciences, Inc., or the Company was incorporated in Delaware on December 10, 2007, and is based in Watertown, Massachusetts. The Company is a clinical-stage biopharmaceutical company leveraging its ImmTOR™ immune tolerance platform with the goals of amplifying the efficacy of biologics, including enabling the re-dosing of life-saving gene therapies, and restoring self-tolerance in autoimmune diseases. The Company’s ImmTOR platform encapsulates rapamycin, also known as sirolimus, an immunomodulator, in biodegradable nanoparticles and is designed to induce antigen-specific immune tolerance. The Company believes ImmTOR has the potential to enhance the efficacy without compromising the safety of biologic therapies, improve product candidates under development, and enable novel therapeutic modalities. Since inception, the Company has devoted its efforts principally to research and development of its technology and product candidates, recruiting management and technical staff, acquiring operating assets, and raising capital.
The Company is subject to risks common to companies in the biotechnology industry including, but not limited to, new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance-reporting capabilities.
The Company’s product candidates are in development. There can be no assurance that the Company’s research and development will be successfully completed, that adequate protection for the Company’s intellectual property will be obtained, or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company’s product development efforts are successful, it is uncertain when, if ever, the Company will generate significant revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from pharmaceutical and biotechnology companies. In addition, the Company is dependent upon the services of its employees and consultants.
Unaudited Interim Financial Information
The accompanying unaudited consolidated financial statements for the three months ended March 31, 2021 and 2020 have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission, or the SEC, for interim financial statements. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP, have been condensed or omitted pursuant to such rules and regulations. These consolidated financial statements should be read in conjunction with the Company’s audited consolidated financial statements and the notes thereto for the year ended December 31, 2020 included in the Company’s Annual Report on Form 10-K that was filed with the SEC on March 12, 2021. The unaudited interim financial statements have been prepared on the same basis as the audited consolidated financial statements. In the opinion of management, the accompanying unaudited interim consolidated financial statements contain all adjustments that are necessary for a fair statement of the Company’s financial position as of March 31, 2021 and consolidated results of operations and cash flows for the three months ended March 31, 2021. Such adjustments are of a normal and recurring nature. The results of operations for the three months ended March 31, 2021 are not necessarily indicative of the results of operations that may be expected for the year ending December 31, 2021.
Liquidity and Management’s Plan
The future success of the Company is dependent on its ability to develop its product candidates and ultimately upon its ability to attain profitable operations. The Company is subject to a number of risks similar to other early-stage life science companies, including, but not limited to, successful development of its product candidates, raising additional capital with favorable terms, protection of proprietary technology and market acceptance of any approved future products. The successful development of product candidates requires substantial working capital which may not be available to the Company on favorable terms or at all.
To date, the Company has financed its operations primarily through the initial public offering of its common stock, private placements of its common stock, issuances of common and preferred stock, debt, research grants and research collaborations. The Company currently has no source of product revenue, and it does not expect to generate product revenue for the foreseeable future. To date, all of the Company’s revenue has been collaboration and grant revenue. The Company has devoted substantially all of its financial resources and efforts to developing its ImmTOR platform, identifying potential product candidates and conducting preclinical studies and its clinical trials. The Company is in the early stages of development of its product candidates, and it has not completed development of any ImmTOR-enabled therapies.
As of March 31, 2021, the Company’s cash, cash equivalents, restricted cash and marketable securities were $149.2 million, of which $1.4 million was restricted cash related to lease commitments and $0.3 million was held by its Russian subsidiary designated solely for use in its operations. The Company believes the cash, cash equivalents, restricted cash and marketable securities as of March 31, 2021 will enable it to fund its operating expenses and capital expenditure requirements into the second quarter of 2023. The Company has incurred losses and negative cash flows from operating activities since inception. As of March 31, 2021, the Company had an accumulated deficit of $429.2 million. The Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research, development of its product candidates, conducting preclinical studies and clinical trials, and its administrative organization. The Company will require substantial additional financing to fund its operations and to continue to execute its strategy, and the Company will pursue a range of options to secure additional capital.
At this time, there is significant uncertainty relating to the trajectory of the COVID-19 pandemic and the impact of related responses. Any impact of COVID-19 on the Company’s business, revenues, results of operations and financial condition will largely depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions, supply chain disruptions, the ultimate impact on financial markets and the global economy, and the effectiveness of actions taken in the United States and other countries to contain and treat the disease.
Guarantees and Indemnifications
As permitted under Delaware law, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences that happen by reason of the relationship with, or position held at, the Company. Through March 31, 2021, the Company had not experienced any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies
3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
There have been no material changes to the Company’s significant accounting policies during the three months ended March 31, 2021, as compared to the significant accounting policies disclosed in Note 2 – Summary of Significant Accounting Policies included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.
Recent Accounting Pronouncements
Recently Adopted
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The Company adopted the new standard effective January 1, 2021, and there was no impact on its consolidated financial statements.
In October 2020, the FASB issued ASU 2020-10, Codification Improvements, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC’s regulations. The Company adopted the new standard effective January 1, 2021, and there was no impact on its consolidated financial statements.
Not Yet Adopted
In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2023, with early adoption permitted no earlier than January 1, 2021. The Company is assessing the impact this standard will have on its consolidated financial statements and disclosures.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. Subsequently, in November 2018, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments-Credit Losses. ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company is assessing the impact this standard will have on its consolidated financial statements and disclosures.
XML 21 R9.htm IDEA: XBRL DOCUMENT v3.21.1
Marketable Securities
3 Months Ended
Mar. 31, 2021
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities Marketable Securities
The following table summarizes the marketable securities held as of March 31, 2021 (in thousands):
Amortized costUnrealized gainsUnrealized lossesFair value
March 31, 2021
Corporate bonds$2,032 $— $(1)$2,031 
Commercial paper20,374 — — 20,374 
Total$22,406 $— $(1)$22,405 
All marketable securities held at March 31, 2021 had maturities of less than 12 months when purchased and are classified as short-term marketable securities on the accompanying consolidated balance sheet. During the three months ended March 31, 2021, there were no marketable securities adjusted for other than temporary declines in fair value.
As of December 31, 2020, the Company held no marketable securities.
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss Per Share
3 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
Net Loss Per Share Net Loss Per Share
The Company has reported a net loss for the three months ended March 31, 2021 and 2020. For this reason basic and diluted net loss per share are the same for all periods presented. The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per-share data):
 Three Months Ended March 31,
 20212020
Numerator:
Net loss attributable to common stockholders$(24,597)$(19,620)
Denominator:
Weighted-average common shares and pre-funded warrants outstanding—basic and diluted110,742,150 94,723,513 
Net loss per share attributable to common stockholders —basic and diluted$(0.22)$(0.21)

All potential dilutive common shares have been excluded from the computation of the diluted net loss per share for all periods presented, as the effect would have been anti-dilutive. Potential dilutive common share equivalents consist of the following:
 March 31,
 20212020
Stock options to purchase common stock10,187,394 7,745,936 
Unvested restricted stock units544,313 170,313 
Warrants to purchase common stock12,378,016 23,084,120 
Total23,109,723 31,000,369 
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements
3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The following tables present the Company’s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in thousands):
March 31, 2021
Total(Level 1)(Level 2)(Level 3)
Assets:
     Money market funds$58,158 $58,158 $— $— 
Marketable securities:
     Corporate bonds2,031 — 2,031 — 
     Commercial paper20,374 — 20,374 — 
Total assets$80,563 $58,158 $22,405 $— 
Liabilities:
     Warrant liabilities$45,455 $— $— $45,455 
Total liabilities$45,455 $— $— $45,455 
 
December 31, 2020
Total(Level 1)(Level 2)(Level 3)
Assets:
     Money market funds$80,576 $80,576 $— $— 
Total assets$80,576 $80,576 $— $— 
Liabilities:
     Warrant liabilities$28,708 $— $— $28,708 
Total liabilities$28,708 $— $— $28,708 

There were no transfers within the fair value hierarchy during the three months ended March 31, 2021 or the year ended December 31, 2020.

Cash and Cash Equivalents
As of March 31, 2021 and December 31, 2020, the money market funds were classified as cash and cash equivalents on the accompanying consolidated balance sheets as they mature within 90 days from the date of purchase.
As of March 31, 2021, the Company had restricted cash balances relating to a secured letter of credit in connection with its lease for the Company’s headquarters (see Note 8 included elsewhere in this Quarterly Report). The Company’s consolidated statement of cash flows includes the following as of March 31, 2021 and 2020 (in thousands):
March 31,
20212020
Cash and cash equivalents$125,407 $72,606 
Short-term restricted cash— 279 
Long-term restricted cash1,379 1,379 
Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows$126,786 $74,264 

Marketable Securities
As of March 31, 2021, marketable securities classified as Level 2 within the valuation hierarchy consist of corporate bonds and commercial paper. Marketable securities represent holdings of available-for-sale marketable debt securities in accordance with the Company’s investment policy. The Company estimates the fair values of these marketable securities by taking into consideration valuations that include market pricing based on real-time trade data for the same or similar securities, and other observable inputs. The amortized cost of available-for-sale debt securities is adjusted for amortization of premiums and accretion of discounts to the earliest call date for premiums or to maturity for discounts.
Loans Payable
At March 31, 2021, given the recent issuance of the Term A Loan under the 2020 Term Loan, the Company believes the carrying value approximates the fair value of the loan.
Common Warrants
In December 2019, the Company issued common warrants in connection with a private placement of common shares. Pursuant to the terms of the common warrants, the Company could be required to settle the common warrants in cash in the event of certain acquisitions of the Company and, as a result, the common warrants are required to be measured at fair value and reported as a liability on the balance sheet. The Company recorded the fair value of the common warrants upon issuance using the Black-Scholes valuation model and is required to revalue the common warrants at each reporting date with any changes in fair value recorded in the statement of operations. The valuation of the common warrants is considered under Level 3 of the fair value hierarchy due to the need to use assumptions in the valuation that are both significant to the fair value measurement and unobservable. The significant unobservable inputs used in the fair value measurement of the warrant liabilities were the volatility rate and the estimated term of the warrants. Generally, increases (decreases) in the fair value of the underlying stock and estimated term would result in a directionally similar impact to the fair value measurement. The change in
the fair value of the Level 3 warrant liability is reflected in the statement of operations for the three months ended March 31, 2021 and 2020.
The estimated fair value of warrants is determined using Level 3 inputs inherent in the Black-Scholes simulation valuation.
Estimated fair value of the underlying stock. The Company estimates the fair value of the common stock based on the closing stock price at the end of each reporting period.
Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury at the valuation date commensurate with the expected remaining life assumption.
Dividend rate. The dividend rate is based on the historical rate, which the Company anticipates will remain at zero.
Expected life. The expected life of the warrants is assumed to be equivalent to their remaining contractual term which expires on December 23, 2024.
Volatility. The Company estimates stock price volatility based on the Company’s historical volatility and the historical volatility of peer companies for a period of time commensurate with the expected remaining life of the warrants.
A summary of the Black-Scholes pricing model assumptions used to record the fair value of the warrant liability is as follows:
March 31,
 2021
Risk-free interest rate0.35 %
Dividend yield— 
Expected life (in years)3.73
Expected volatility101.13 %
Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis
The following table reflects a roll-forward of fair value for the Company’s Level 3 warrant liabilities (see Note 10), for the three months ended March 31, 2021 (in thousands):
Warrant liabilities
Fair value as of December 31, 2020
$28,708 
     Change in fair value16,747 
Fair value as of March 31, 2021
$45,455 
XML 24 R12.htm IDEA: XBRL DOCUMENT v3.21.1
Property and Equipment
3 Months Ended
Mar. 31, 2021
Property, Plant and Equipment [Abstract]  
Property and Equipment Property and Equipment
Property and equipment consists of the following (in thousands):
 March 31,December 31,
 20212020
Laboratory equipment$4,429 $4,427 
Computer equipment and software694 532 
Leasehold improvements38 38 
Furniture and fixtures327 327 
Office equipment163 163 
Construction in process30 163 
Total property and equipment5,681 5,650 
Less accumulated depreciation(4,380)(4,255)
Property and equipment, net$1,301 $1,395 

Depreciation expense was $0.1 million and $0.2 million for the three months ended March 31, 2021 and 2020, respectively.
XML 25 R13.htm IDEA: XBRL DOCUMENT v3.21.1
Accrued Expenses
3 Months Ended
Mar. 31, 2021
Payables and Accruals [Abstract]  
Accrued Expenses Accrued Expenses
Accrued expenses consist of the following (in thousands):
 March 31,December 31,
 20212020
Payroll and employee related expenses$1,840 $3,049 
Collaboration and licensing1,350 1,350 
Accrued patent fees471 534 
Accrued external research and development costs2,010 2,029 
Accrued professional and consulting services802 798 
Accrued interest170 170 
Other204 216 
     Accrued expenses$6,847 $8,146 
XML 26 R14.htm IDEA: XBRL DOCUMENT v3.21.1
Leases
3 Months Ended
Mar. 31, 2021
Leases [Abstract]  
Leases Leases
65 Grove Street Lease
In July 2019, the Company entered into a lease for 25,078 square feet of laboratory and office space located at 65 Grove Street, Watertown, Massachusetts, or the Headquarters Lease. As part of the Headquarters Lease, the Company incurred $0.8 million in non-reimbursable construction costs. The lease began in March 2020, consistent with when the Company took control of the office space, and the lease term is 8 years. The discount rate of 8.9% was determined based on the Company’s incremental borrowing rate adjusted for the lease term including any reasonably certain renewal periods. In connection with the Headquarters Lease, the Company secured a letter of credit from Silicon Valley Bank, or SVB, for $1.4 million, recognized as long-term restricted cash, as of March 31, 2021 and December 31, 2020, respectively, which automatically renews each year.
Moscow, Russia Lease
The Company has a month-to-month facility agreement for its Moscow, Russia office. Rent expense is recognized as incurred.
As of March 31, 2021 and December 31, 2020, the components of the operating leases were as follows (in thousands):
March 31,December 31,
20212020
Assets:
   Right-of-use asset, net$10,676 $10,948 
Liabilities:
   Current operating lease liabilities$942 $908 
   Non-current operating lease liabilities9,403 9,647 
Total operating lease liabilities$10,345 $10,555 

For the three months ended March 31, 2021 and 2020 the components of lease costs were as follows (in thousands):
March 31,
20212020
Operating lease cost$444 $472 
Variable lease cost288 199 
Short-term lease cost
Total lease cost$735 $673 
The maturity of the Company’s operating lease liabilities as of March 31, 2021 were as follows (in thousands):
March 31,
2021
2021 (remainder)$1,368 
20221,866 
20231,922 
20241,980 
20252,039 
Thereafter4,945 
     Total future minimum lease payments14,120 
Less imputed interest3,775 
     Total operating lease liabilities$10,345 

The supplemental disclosure for the statement of cash flows related to operating leases were as follows (in thousands):
March 31,
20212020
Cash paid for amounts included in the measurement of lease liabilities:$444 $487 

Other than the initial recording of the right-of-use asset and lease liability for the Headquarters Lease, which is non-cash, the changes in the Company’s right-of-use asset and lease liability for the three months ended March 31, 2021 and 2020 are reflected in the non-cash lease expense and accrued expenses and other liabilities, respectively, in the consolidated statements of cash flows.
The following summarizes additional information related to operating leases:
March 31,
20212020
Weighted-average remaining lease term7.1 years8.0 years
Weighted-average discount rate8.9 %8.9 %
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Debt
3 Months Ended
Mar. 31, 2021
Debt Disclosure [Abstract]  
Debt Debt
2020 Term Loan
On August 31, 2020, the Company entered into a term loan of up to $35.0 million, or the 2020 Term Loan, consisting of term loans in an aggregate amount of $25.0 million, or the Term A Loan, and term loans in an aggregate amount of $10.0 million, or the Term B Loan, governed by a loan and security agreement, or the Loan Agreement, between the Company and Oxford Finance LLC, or Oxford, as Collateral Agent and a Lender, and SVB, as a Lender. The Term A Loan was funded in full on August 31, 2020, or the Funding Date.
The Term B Loan will be available, subject to Collateral Agent’s discretion and customary terms and conditions, during the period commencing on the date the Company has delivered to the Collateral Agent and the Lenders evidence: (i) the Company or one of the Company’s collaboration partners has enrolled its first patient for a Phase 1 clinical trial evaluating the treatment of methylmalonic acidemia, or MMA, and (ii) the Company has enrolled the first patient in each of two Phase 3 pivotal trials evaluating SEL-212, or the Second Draw Period Milestone, and ending on the earliest of (i) the date which is 30 days following the date the Second Draw Period Milestone is achieved, (ii) September 30, 2021 (iii) and the occurrence of an event of default, other than an event of default that has been waived in writing by Collateral Agent and the Lenders in their sole discretion, with such period referred to as the Second Draw Period.
The 2020 Term Loan will mature on August 1, 2025. Each advance under the Term Loan accrues interest at a floating per annum rate equal to the greater of (a) 7.90%, and (b) the lesser of (x) the sum of (i) the prime rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue, and (ii) 4.65% and (y) 10.00%. The Term Loan provides for interest-only payments on a monthly basis until April 1, 2022; provided however, if the Company has delivered to the Collateral Agent and the Lenders prior to September 30, 2021 evidence that Borrower has achieved the Second Draw Period Milestone, the Term Loan provides for interest-only payments on a monthly basis until October 1, 2022. Thereafter, amortization payments will be payable monthly in equal installments of principal and interest to fully amortize the outstanding principal over the remaining term of the loan, subject to recalculation upon a change in the prime rate. The Company may prepay the Term Loan in full but not in part provided that the Company (i) provides ten days’ prior written notice to Collateral Agent, (ii) pays on the date of such prepayment (A) all outstanding principal plus
accrued and unpaid interest, and (B) a prepayment fee of between 3.0% and 1.0% of the aggregate original principal amount advanced by the lender depending on the timing of the prepayment. Amounts outstanding during an event of default are payable upon SVB’s demand and shall accrue interest at an additional rate of 5.0% per annum of the past due amount outstanding. At the end of the loan term (whether at maturity, by prepayment in full or otherwise), the Company shall make a final payment to the lender in the amount of 9.0% of the aggregate original principal amount advanced by the lender. The final payment fee totaling $2.3 million is recorded as a loan discount.
The Term Loan is secured by a lien on substantially all of the assets of the Company, other than intellectual property, provided that such lien on substantially all assets includes any rights to payments and proceeds from the sale, licensing or disposition of intellectual property. The Company has also granted the Collateral Agent a negative pledge with respect to its intellectual property.
The Loan Agreement contains customary covenants and representations, including but not limited to financial reporting obligations and limitations on dividends, indebtedness, collateral, investments, distributions, transfers, mergers or acquisitions, taxes, corporate changes, deposit accounts, and subsidiaries. The Loan Agreement also contains other customary provisions, such as expense reimbursement, non-disclosure obligations as well as indemnification rights for the benefit of the Collateral Agent.
The events of default under the Loan Agreement include, but are not limited to, the Company’s failure to make any payments of principal or interest under the Loan Agreement or other transaction documents, the Company’s breach or default in the performance of any covenant under the Loan Agreement or other transaction documents, the occurrence of a material adverse change, the Company making a false or misleading representation or warranty in any material respect under the Loan Agreement, the Company’s insolvency or bankruptcy, any attachment or judgment on the Company’s assets of at least $0.5 million, or the occurrence of any default under any agreement or obligation of the Company involving indebtedness in excess of $0.5 million. If an event of default occurs, the Collateral Agent is entitled to take enforcement action, including acceleration of amounts due under the Loan Agreement.
The Company incurred $0.4 million in debt issuance costs in connection with the closing of the 2020 Term Loan. Debt issuance costs are presented in the consolidated balance sheet as a direct deduction from the associated liability and amortized to interest expense over the term of the related debt.
The Company assessed all terms and features of the 2020 Term Loan to identify any potential embedded features that would require bifurcation. As part of this analysis, the Company assessed the economic characteristics and risks of the 2020 Term Loan, including any put, call, and contingent features. The Company determined that the interest rate collar and prepayment call option did not require bifurcation; whereas the contingent put option and default (contingent) interest rate feature met bifurcation criteria resulting in immaterial amounts.
Warrants
On August 31, 2020, in connection with the 2020 Term A Loan, the Company issued warrants to the Lenders to purchase an aggregate of 196,850 shares of its common stock at an exercise price equal to $2.54 per share. In accordance with ASC 815-40, these warrants are classified as permanent equity in the accompanying consolidated balance sheets and will expire ten years from the date of issuance. The initial grant date fair value of the warrants was $0.4 million as determined by the Black-Scholes valuation model and recorded to shareholders' equity, with the SVB portion allocated to the reacquisition price of the 2017 Term Loan and the Oxford fair value portion as a loan discount to the Term A Loan.
Additionally, on August 31, 2020, pursuant to the terms of a Warrant Side Letter agreement among the Company and the Lenders, the Company agreed to issue to the Lenders, on the date the Company draws the Term B Loan and in accordance with each party’s respective pro rata share with respect to the Term B Loan, one or more warrants to purchase an aggregate number of shares of its common stock that is equal to $200,000 divided by the average closing price of the Company’s common stock on The Nasdaq Stock Market LLC for the ten consecutive trading days ending the day before such issuance, rounded down to the nearest whole number of shares, and having an exercise price equal to the Term B Warrant Price.
Payoff
On the Funding Date, the Company entered into a payoff letter with SVB, pursuant to which the Company utilized $13.7 million of the 2020 Term Loan to pay off all outstanding obligations under the previous term loan, consisting of the principal payment, final prepayment and accrued interest. During the three months ended September 30, 2020, the Company recognized a loss on extinguishment of debt in the amount of $0.5 million determined as the difference between the reacquisition price and carrying value at August 31, 2020.
As of March 31, 2021 and December 31, 2020, the outstanding principal balance under the 2020 Term Loan was $25.0 million.
Future minimum principal and interest payments on the 2020 Term Loan as of March 31, 2021 are as follows (in thousands):
2021 (remainder)$1,509 
20227,343 
20238,611 
20248,027 
20257,274 
Total minimum debt payments32,764 
Less: Amount representing interest(5,514)
Less: Debt discount and deferred charges(2,239)
Less: Current portion of loan payable(460)
Loan payable, net of current portion$24,551 
XML 28 R16.htm IDEA: XBRL DOCUMENT v3.21.1
Equity
3 Months Ended
Mar. 31, 2021
Equity [Abstract]  
Equity Equity
Equity Financings
August 2020 Shelf Registration Statement
On August 6, 2020, the Company filed an updated universal shelf registration statement on Form S-3 (Reg. No. 333-241692) with the SEC to sell an aggregate amount of up to $200.0 million of certain of its securities. The shelf registration statement was declared effective by the SEC on August 14, 2020.
“At-the-Market” Offerings
In August 2017, the Company entered into a sales agreement, or the 2017 Sales Agreement, with Jefferies LLC, as sales agent, to sell shares of its common stock with an aggregate value of up to $50.0 million in an “at the market offering.” On August 6, 2020, concurrent with the filing of the updated shelf registration statement, the Company entered into a sales agreement, or the 2020 Sales Agreement with Jefferies LLC, as sales agent, pursuant to which the Company may, from time to time, issue and sell common stock with an aggregate value of up to $50.0 million in an “at the market offering.” The 2017 Sales Agreement terminated pursuant to its terms in August 2020.
Sales of common stock, if any, pursuant to the 2020 Sales Agreement, may be made in sales deemed to be an “at the market offering” as defined in Rule 415(a) of the Securities Act, including sales made directly through the Nasdaq Stock Market or on any other existing trading market for the Company’s common stock. The Company intends to use the proceeds from the offering for working capital and other general corporate purposes. The Company may suspend or terminate the 2020 Sales Agreement at any time.
During the year ended December 31, 2020, the Company sold 1,069,486 shares of its common stock pursuant to the 2020 and 2017 Sales Agreements at an average price of approximately $2.16 per share for aggregate net proceeds of $2.1 million, after deducting commissions and other transaction costs.
During the three months ended March 31, 2021, the Company sold 4,706,844 shares of its common stock pursuant to the 2020 Sales Agreement at an average price of approximately $4.59 per share for aggregate net proceeds of $20.9 million, after deducting commissions and other transaction costs.
June 2020 Sobi Stock Purchase
On June 11, 2020, the Company entered into a stock purchase agreement with Sobi, pursuant to which the Company sold an aggregate of 5,416,390 shares of its common stock at a purchase price equal to $4.6156 per share, which represented 120% of the 10-day volume-weighted average price of the Company’s common stock prior to signing, for aggregate gross proceeds of $25.0 million, or the Sobi Private Placement. The closing of the Sobi Private Placement occurred on July 31, 2020. The shares of common stock acquired in the Sobi Private Placement are subject to a one-year lock-up from closing, during which time Sobi is prohibited from selling or otherwise disposing of such shares.
In accordance with ASC 815, this forward sale treatment qualified as equity classification as the shares are not within the scope of ASC 480. The gross proceeds of $25.0 million were determined to include a premium to the fair value of the Company’s shares as of July 28, 2020 of approximately $14.5 million. As a result, such amount was included in the transaction price for revenue recognition of the Sobi License. See Note 12 for details.
Also on June 11, 2020, the Company entered into a registration rights agreement (as amended by that certain letter agreement, dated as of November 4, 2020) with Sobi, pursuant to which the Company agreed to prepare and file a registration statement with respect to the resale of the shares of common stock acquired in the Sobi Private Placement. The Company will be required to file this resale registration statement within 30 days following receipt by the Company of a written request from
Sobi to file such resale registration statement, and to have the registration statement declared effective within 10 business days after the SEC informs the Company that no review of such resale registration statement will be made or that the SEC has no further comments on such resale registration statement.
December 2019 Financing
On December 18, 2019, the Company entered into a securities purchase agreement, or the 2019 Purchase Agreement, with a group of institutional investors and certain members of the board of directors. Pursuant to the 2019 Purchase Agreement, the Company sold an aggregate of 37,634,883 shares of its common stock at a purchase price of $1.46 per share, warrants to purchase an aggregate of 22,988,501 shares of common stock at a purchase price of $0.125 per share underlying each common warrant, and pre-funded warrants to purchase an aggregate of 8,342,128 shares of common stock at a purchase price of $1.46 per share, all with five year terms, or the 2019 PIPE. The closing of the 2019 PIPE occurred on December 23, 2019. The exercise price of the pre-funded warrants is $0.0001 per share and the exercise price for the common warrants is $1.46 per share. In the event of a certain sale of the Company, the terms of the common warrants require us to make a payment to such common warrant holders based on a Black-Scholes valuation (using variables as specified in the warrants). This provision does not apply to the pre-funded warrants. Therefore, the Company is required to account for the common warrants as liabilities and record them at fair value, while the pre-funded warrants met the criteria to be classified as permanent equity.
The Company recorded the fair value of the common warrants of $40.7 million upon issuance using the Black-Scholes valuation model. Issuance costs were allocated between the equity component with an offset to additional paid-in capital and the liability component recorded as expense on a relative fair value basis. Total net proceeds from the equity offering was $65.6 million, after deducting transaction costs and commissions of $4.4 million which was paid in the three months ended March 31, 2020.
The common warrants were revalued as of March 31, 2021 at $45.5 million. During the three months ended March 31, 2021 and 2020, the Company recorded losses on the increases in the fair value of the warrants of $(16.7) million and $(0.8) million, respectively, in the unaudited consolidated statements of operations.

Warrants
During the three months ended March 31, 2021 and 2020, there were no warrants issued, exercised, or canceled.
Number of Warrants
Equity
 classified
Liability classifiedTotalWeighted average
exercise price
Outstanding at March 31, 2021292,469 12,085,547 12,378,016 $1.60 

Common Stock
As of March 31, 2021, the Company had 200,000,000 shares of common stock authorized for issuance, $0.0001 par value per share, with 112,977,004 shares issued and outstanding. The voting, dividend and liquidation rights of the common stockholders are subject to and qualified by the rights, powers and preferences of the preferred stock. The common stock has the following characteristics:
Voting
The common stockholders are entitled to one vote for each share of common stock held with respect to all matters voted on by the stockholders of the Company.
Dividends
The common stockholders are entitled to receive dividends, if and when declared by the Board of Directors. Through March 31, 2021, no dividends have been declared or paid on common stock.
Liquidation
Upon liquidation of the Company, the common stockholders are entitled to receive all assets of the Company available for distribution to such stockholders.
Reserved Shares
The Company has authorized shares of common stock for future issuance as follows:
 Period ended
 March 31, 2021December 31, 2020
Exercise of common warrants12,378,016 12,378,016 
Shares available for future stock incentive awards7,719,817 4,916,374 
RSUs reserved for issuance98,750 — 
Unvested restricted stock units544,313 87,500 
Outstanding common stock options10,187,394 7,775,249 
Total30,928,290 25,157,139 
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.21.1
Stock Incentive Plans
3 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
Stock Incentive Plans Stock Incentive Plans
The Company maintains the 2008 Stock Incentive Plan, or the 2008 Plan, for employees, consultants, advisors, and directors. The 2008 Plan provided for the granting of incentive and non-qualified stock option and restricted stock awards as determined by the Board.
In June 2016, the Company’s stockholders approved the 2016 Incentive Award Plan, or the 2016 Plan, which authorized 1,210,256 shares of common stock for future issuance under the 2016 Plan and ceased granting awards under the 2008 Plan. Upon the effective date of the 2016 Plan, awards issued under the 2008 Plan remain subject to the terms of the 2008 Plan. Awards granted under the 2008 Plan that expire, lapse or terminate become available under the 2016 Plan as shares available for future grants.
Additionally, pursuant to the terms of the 2016 Plan, the Board is authorized to grant awards with respect to common stock, and may delegate to a committee of one or more members of the Board or executive officers of the Company the authority to grant options and restricted stock units. On December 9, 2020, the Board established a Stock Option Committee authorized to grant awards to certain employees and consultants subject to conditions and limitations within the 2016 Plan. In January 2021 and 2020, the number of shares of common stock that may be issued under the 2016 Plan was increased by 4,322,850 and 3,453,022 shares, respectively. As of March 31, 2021, 3,248,520 shares remain available for future issuance under the 2016 Plan.
In September 2018, the Company’s 2018 Employment Inducement Incentive Award Plan, or the 2018 Inducement Incentive Award Plan was adopted by the Board without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules, which authorized 1,175,000 shares of its common stock for issuance. In March 2019, the Board approved the amendment and restatement of the 2018 Inducement Incentive Award Plan to reserve an additional 2,000,000 shares of the Company’s common stock for issuance thereunder. As of March 31, 2021, there are 1,358,333 shares available for future grant under the 2018 Inducement Incentive Award Plan.
Stock-based Compensation Expense
Stock-based compensation expense by classification included within the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):
 Three Months Ended March 31,
 20212020
Research and development$754 $623 
General and administrative1,026 786 
     Total stock-based compensation expense$1,780 $1,409 

Stock Options
Employees
The estimated grant date fair values of employee stock option awards granted under the 2016 Plan and the 2018 Inducement Incentive Award Plan were calculated using the Black-Scholes option pricing model, based on the following weighted-average assumptions:
Three Months Ended March 31,
 20212020
Risk-free interest rate0.44 %1.73 %
Dividend yield— — 
Expected term5.286.08
Expected volatility83.26 %87.96 %
Weighted-average fair value of common stock$3.13 $2.30 

The weighted average grant date fair value of stock options granted to employees during the three months ended March 31, 2021 and 2020 was $1.99 and $1.69, respectively.
As of March 31, 2021 total unrecognized compensation expense related to unvested employee stock options was $11.8 million, which is expected to be recognized over a weighted average period of 2.7 years.

Non-employee consultants
As of March 31, 2021, there was no unrecognized compensation expense related to non-employee consultants stock options.
The following table summarizes the stock option activity under the 2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan:
   Weighted-average 
  remainingAggregate
 Number ofWeighted-averagecontractual termintrinsic value
 optionsexercise price ($)(in years)(in thousands)
Employees    
Outstanding at December 31, 20207,302,176 $3.98 8.43$4,456 
Granted2,628,000 $3.13   
Exercised(153,278)$1.47   
Forfeited(62,577)$5.19   
Outstanding at March 31, 20219,714,321 $3.78 8.65$15,665 
Vested at March 31, 20213,064,130 $5.46 7.63$4,313 
Vested and expected to vest at March 31, 20218,920,548 $3.88 8.59$14,231 
Non-employee consultants    
Outstanding at December 31, 2020473,073 $5.89 5.23$86 
Granted— $— 
Exercised— $— 
Forfeited— $— 
Outstanding at March 31, 2021473,073 $5.89 4.98$366 
Vested at March 31, 2021462,186 $5.82 4.92$366 
Vested and expected to vest at March 31, 2021473,073 $5.89 4.98$366 

Restricted Stock Units
In January 2021, the Company granted 369,800 restricted stock awards to employees under the 2016 Plan which will vest over a four year term.
In addition, during the first quarter of 2021, the Company awarded 197,500 restricted stock units to executives under the 2016 Plan, of which 98,750 were determined to be granted as of the award date consistent with ASC 718. The remaining 98,750 restricted stock units do not have a defined performance metric as of the award date, resulting in the restricted stock units being reserved for future issuance as of March 31, 2021. These restricted stock units will vest in two equal installments on the dates
an applicable performance condition is achieved, on or prior to December 31, 2021. If the performance conditions are not satisfied on or prior to December 31, 2021, the restricted stock units will be forfeited for no consideration.
The restricted stock units granted had a weighted average fair value of $2.99 per share based on the closing price of the Company’s common stock on the date of grant. The restricted stock units were valued at approximately $1.4 million on their grant date. Forfeitures are estimated at the time of grant and are adjusted, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has estimated a forfeiture rate of 10% for restricted stock awards to employees based on historical attrition trends.
Unrecognized compensation expense for all restricted stock units was $1.5 million as of March 31, 2021, which is expected to be recognized over a weighted average period of 3.1 years.
The following table summarizes the Company’s restricted stock units under the 2016 Plan and 2018 Inducement Incentive Award Plan:
 Number of sharesWeighted average
grant date
fair value ($)
Unvested at December 31, 2020
87,500 $6.03 
Granted468,550 2.99 
Vested(10,937)6.03 
Reserved for issuance98,750 2.99 
Forfeited(800)2.99 
Unvested at March 31, 2021
643,063 $3.35 

Employee Stock Purchase Plan
In June 2016, the Company approved the 2016 Employee Stock Purchase Plan, or the ESPP, which authorized 173,076 shares of common stock for future issuance under the ESPP to participating employees. In January 2021 and 2020, the number of shares of common stock authorized for issuance under the ESPP was increased by 1,080,711 shares and 863,254 shares, respectively. During the three months ended March 31, 2021, the Company issued 34,696 shares of common stock under the ESPP. As of March 31, 2021, 2,546,464 shares remain available for future issuance under the ESPP.
For each of the three months ended March 31, 2021 and 2020, the Company recognized less than $0.1 million of stock-based compensation expense under the ESPP.
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Arrangements
3 Months Ended
Mar. 31, 2021
Revenue from Contract with Customer [Abstract]  
Revenue Arrangements Revenue Arrangements
Swedish Orphan Biovitrum
License and Development Agreement
On June 11, 2020, the Company and Sobi entered into the Sobi License. Pursuant to the Sobi License, the Company has agreed to grant Sobi an exclusive, worldwide (except as to Greater China) license to develop, manufacture and commercialize the Company’s SEL-212 drug candidate, which is currently in development for the treatment of chronic refractory gout. The SEL-212 drug candidate is a pharmaceutical composition containing a combination of SEL-037, or the Compound, and ImmTOR. Pursuant to the Sobi License, in consideration of the license, Sobi agreed to pay the Company a one-time, up-front payment of $75.0 million. Sobi has also agreed to make milestone payments totaling up to $630.0 million to the Company upon the achievement of various development and regulatory milestones and, if commercialized, sales thresholds for annual net sales of SEL-212, and tiered royalty payments ranging from the low double digits on the lowest sales tier to the high teens on the highest sales tier.
Pursuant to the Sobi License, the Company has agreed to supply (at cost) quantities of the Compound and ImmTOR as necessary for completion of the two Phase 3 clinical trials of SEL-212 (DISSOLVE I and DISSOLVE II) and a 6-month placebo extension. The Company is required to supply quantities of the Compound until all rights to the Compound and any materials needed to manufacture the Compound are transferred to Sobi. Sobi has agreed to reimburse the Company for all budgeted costs incurred to complete development of SEL-212, including but not limited to costs incurred while conducting and completing the Phase 3 DISSOLVE trials, except for any costs of additional development activities required that are related to ImmTOR and that are unrelated to SEL-212. Sobi will have control and responsibility over all regulatory filings, including any investigational drug applications (IND), biologics license applications (BLA), and marketing authorization applications (MAA) relating to the licensed product.
The transactions contemplated by the Sobi License were consummated on July 28, 2020 following the expiration or termination of the required waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Sobi may terminate the Sobi License for any reason upon 180 days’ written notice to the Company, whereby all rights granted under the Sobi License would revert back to the Company. In addition, if Sobi were to terminate the Sobi License, the Company has the option to obtain a license to all patents and know-how necessary to exploit SEL-212 in existence as of the termination date from Sobi in return for making an equitable royalty payment to Sobi.
Additionally, on June 11, 2020, the Company entered into the Sobi Purchase Agreement in connection with the Sobi License. The closing of the Sobi Private Placement occurred on July 31, 2020, following the closing of the transactions contemplated under the Sobi License. See Note 10 for details.
The Company determined that the Sobi License represents a service arrangement under the scope of ASC 606. In addition, given the Sobi License and Sobi Purchase Agreement were executed contemporaneously and negotiated as a package with a single commercial objective, the Company will account for the two agreements as a single contract. The term of the Sobi License commenced upon the effective date of July 28, 2020 and will continue on a product-by-product basis until the royalty terms for each country have expired. The royalty term for a given product begins upon the first commercial sale of the product in a country and ends at the later of ten years from the first commercial sale, expiration of the last valid patent claim covering the product and expiration of all regulatory exclusivity periods for the product in a country. Given the reversion of the rights under the Sobi License represents a penalty in substance for a termination by Sobi, the contract term would remain the stated term of the Sobi License.
The Company determined that the Sobi License contains three distinct performance obligations due to the nature of the promises in the contract, which includes conducting the Phase 3 DISSOLVE trials, Sobi’s option to set-up a second source supplier, and a combined obligation comprised of the delivery of the license to SEL-212, transfer of the know-how and the manufacturing and delivery of SEL-212 supply for development, or the Combined License Obligation. As the set-up of a second source supplier is optional for Sobi and the Company will be reimbursed at cost for its efforts in the subsequent set-up and technology transfer, the option for this future service was determined to be at a significant and incremental discount to its standalone selling price and treated as a material right in the arrangement, namely a distinct performance obligation.
In determining the transaction price, the Company concluded the upfront payment of $75.0 million and the $5.0 million development milestone associated with the dosing of the first patient in the Phase 3 DISSOLVE trials will be included in the transaction price. All other development milestones will be fully constrained and only be included in the transaction price when the respective milestone is deemed probable of achievement. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of the evaluation of the constraint, the Company considered numerous factors, including that receipt of such milestones is outside the control of the Company and probability of success criteria is estimated. The Company will re-evaluate the transaction price in each reporting period, as uncertain events are resolved. In accordance with ASC 606, the Company will only recognize revenue associated with sales-based milestones and royalties when the subsequent sales thresholds are reached and underlying sales occur, respectively. In connection with the Sobi Purchase Agreement, the Company determined that the gross proceeds of $25.0 million from the Sobi Private Placement included a premium to the fair value of the Company’s shares as of July 28, 2020 equal to approximately $14.5 million. The premium amount will be included in the transaction price for revenue recognition. The Company will estimate and include in the transaction price the total reimbursements to be received from Sobi for both the manufacturing and delivery of the Compound and ImmTOR as well as conducting the Phase 3 DISSOLVE trials. The Company determined that a significant financing component does not exist in its arrangement with Sobi.
The Company allocated the transaction price based on the relative standalone selling prices of the three distinct performance obligations. The Company estimated the standalone selling price of conducting the Phase 3 DISSOLVE trials by forecasting its anticipated costs and applying a margin reflective of the industry. The Company must determine the standalone selling price of the second source supplier option by determining the discount given to Sobi multiplied by the likelihood that Sobi will exercise the option in the future. Similar to the Phase 3 program estimate, the Company estimated the discount of the option by forecasting the set-up costs and applying a margin that is reflective of the industry. As the Company will be providing the set-up and technology transfer services and the future supply at cost, the discount of the option is equal to the margin amount. The Company considered discussions with Sobi as well as probability of regulatory success of SEL-212 in determining the likelihood of exercise. The Company estimated the standalone selling price of the Combined License Obligation by utilizing a discounted cash flow model.
The Company determined that the delivery of the supply to Sobi best represents the pattern of delivery of the Combined License Obligation as the supply is essential to the utility of the license and know-how. The Company will recognize the revenue allocated to the Combined License Obligation by utilizing the output method. The Company estimated the total supply of the Compound and ImmTOR to be required during the clinical trial period and will recognize revenue as this supply is shipped for use in the clinical trials. The Company will recognize the revenue allocated to the conducting of the Phase 3 DISSOLVE trials obligation by utilizing the input method. The Company estimated the total budgeted costs to be incurred over
the Phase 3 DISSOLVE trials and will recognize revenue as these costs are incurred. The Company’s costs best represent the pattern of transfer as these will capture all performance of the trials completed to date and can be readily measured. The Company will recognize the revenue allocated to the second source supplier option when the future services and goods are transferred.
As of March 31, 2021 and December 31, 2020, the Company recorded $72.0 million and $68.3 million, respectively, as a short-term contract liability and $17.8 million and $24.2 million, respectively, as a long-term contract liability, representing deferred revenue associated with this agreement.
In addition, as of March 31, 2021 the Company has recorded $1.3 million of contract assets related to incremental costs that would not have been incurred if the Sobi License had not been obtained, of which $1.0 million is presented in prepaid expenses and other current assets and $0.3 million is presented in other assets in the accompanying unaudited consolidated balance sheets. Amortization of contract assets was less than $0.1 million for the three months ended March 31, 2021.
As of March 31, 2021 and December 31, 2020, the Company recorded a total outstanding receivable of $8.3 million and $6.9 million, respectively, representing billings for the Phase 3 DISSOLVE program that are subject to reimbursement by Sobi. Revenue of $11.1 million related to the Sobi License was recognized during the three months ended March 31, 2021.
Sarepta Therapeutics, Inc.
Research License and Option Agreement
On June 13, 2020, the Company and Sarepta entered into a Research License and Option Agreement, or the Sarepta Agreement. Pursuant to the Sarepta Agreement, the Company agreed to grant Sarepta a license under the Company’s intellectual property rights covering the Company’s antigen-specific biodegradable nanoparticle encapsulating ImmTOR to research and evaluate ImmTOR in combination with Sarepta’s adeno-associated virus gene therapy technology, or gene editing technology, using viral or non-viral delivery, to treat Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophy subtypes, or the Indications. Sarepta will have an option term of 24 months during which it can opt-in to obtain an exclusive license to further develop and commercialize the Product to treat at least one Indication, with a potential to extend the option term for an additional fee. The Company will supply ImmTOR to Sarepta for clinical supply on a cost-plus basis.
Sarepta paid a $2.0 million up-front payment to the Company upon signing of the Sarepta Agreement, and the Company is eligible to receive additional preclinical payments during the option term. If Sarepta opts-in to an exclusive license agreement, the Company could receive option exercise payments per Indication upon execution of the exclusive license, and the Company would be entitled to significant development and commercial milestone payments and tiered royalties ranging from the mid-to-high single digits based on net sales.
Pursuant to the Sarepta Agreement, the Company determined the Sarepta Agreement represents a service arrangement under the scope of ASC 606, with a 24 month contract duration. Given the reversion of the rights under the Sarepta Agreement represents a penalty in substance for a termination by Sarepta, the contract term would remain the stated term of the Sarepta Agreement.
The Company determined that the Sarepta Agreement and supply obligation including the delivery of the research license, the licensed know-how, the manufactured supply and delivery of materials represent a single promise and performance obligation to be transferred to Sarepta over time due to the nature of the promises in the contract. The delivery of the manufactured supply is the predominant promise within the arrangement, as it is essential to the utility of the licensed intellectual property. As such, consideration in the initial transaction price will be allocated to the single performance obligation based on the contractual price.
In determining the transaction price, the Company concluded the payment associated with all the performance milestones will be fully constrained and only be included in the transaction price when the respective milestone is deemed probable of achievement. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of such study milestones is outside the control of the Company and probability of success criteria is estimated. As of March 31, 2021 and December 31, 2020, all milestones were constrained. The Company will re-evaluate the transaction price in each reporting period, as uncertain events are resolved. The Company will recognize the revenue associated with the upfront payment and combined single performance obligation utilizing the output method, over the 24 month term as the manufactured supply is delivered to Sarepta.
The Company also determined the option to enter into a future commercial license agreement and extend the term of the option does not represent a material right since it was not priced at an incremental discount. Sarepta may terminate the Sarepta Agreement for any reason upon 30 days’ written notice to the Company. The Sarepta Agreement contains other customary terms and conditions, including representations and warranties, covenants, termination, and indemnification obligations in favor of each party. During the year ended December 31, 2020, the Company and Sarepta entered into two amendments relating to an
additional feasibility study. During the three months ended March 31, 2021, the Company and Sarepta entered into a third amendment relating to feasibility study research plan. None of the amendments executed through March 31, 2021 had a material impact on deferred revenue or revenue recognition.
At each of March 31, 2021 and December 31, 2020, the Company recorded $2.0 million as a short-term contract liability representing deferred revenue associated with this agreement. No revenue related to the Sarepta Agreement was recognized during the three months ended March 31, 2021 and 2020.
Asklepios Biopharmaceutical, Inc.
License Agreement for Pompe Disease
On December 17, 2019, the Company and AskBio entered into a license agreement, or the AskBio License Agreement. Pursuant to the AskBio License Agreement, AskBio has exercised its option to exclusively license the Company’s intellectual property rights covering the Company’s ImmTOR platform to research, develop, and commercialize certain AAV gene therapy products utilizing ImmTOR, and targeting the GAA gene, or derivatives thereof, to treat Pompe Disease.
Pursuant to the AskBio License Agreement and ancillary documents, AskBio agreed to pay to the Company upfront fees of an aggregate of $7.0 million. Assuming successful development and commercialization, the Company could receive up to an additional $237.0 million in development, regulatory, and sales milestone payments. If commercialized, the Company would be eligible to receive tiered royalties on global net sales at percentages ranging from mid-to-high single digits. Under the terms of the agreement, the Company will be eligible to receive these royalties commencing on the first commercial sale of the licensed product until the expiration of the later of (i) ten years after the first commercial sale and (ii) expiration of the last to expire valid claim on patents covering the licensed product.
Pursuant to the AskBio License Agreement, the Company will supply AskBio with its ImmTOR platform, or the Supply Obligation, and AskBio will be responsible for all preclinical, clinical and commercial manufacture and supply of licensed products (other than ImmTOR) and carry out all other activities related to the research, development, and commercialization of licensed products at its sole expense, including all regulatory activities related thereto.
The Company determined that the AskBio License Agreement and Supply Obligation represent a single promise and performance obligation. This is because AskBio cannot derive benefit from the license without the simultaneous transfer of the patent protected ImmTOR supply. Therefore, the License Obligation and Supply Obligation represent the only promise in the arrangement and are combined as a single performance obligation.
In determining the transaction price, the Company concluded that the future development milestones, regulatory milestones, sales milestones, and sales royalties all represent variable consideration. Each of these variable consideration items was evaluated under the most likely amount method to determine whether such amounts were probable of occurrence, or whether such amounts should be constrained until they become probable. As part of its evaluation of the constraint, the Company considered numerous factors, including that receipt of such milestones is outside the control of the Company. Consideration related to sales-based milestones as well as royalties on net sales upon commercialization by AskBio, will be recognized when the related sales occur, as they were determined to relate predominantly to the intellectual property granted to AskBio and, therefore, have also been excluded from the transaction price in accordance with the royalty recognition constraint. As of March 31, 2021 and December 31, 2020, all milestones were constrained. The Company will re-evaluate the transaction price in each reporting period, as uncertain events are resolved, or as other changes in circumstances occur.
The total initial transaction price of the contract on the effective date was $7.0 million, comprised of a $2.0 million initial up-front payment upon agreement of terms, and a $5.0 million initial up-front execution fee.
At each of March 31, 2021 and December 31, 2020, the Company recorded $1.7 million as short-term and $5.3 million as a long-term, representing deferred revenue associated with this agreement. Revenue will be recognized over the period in which the particles are delivered. No revenue related to the AskBio License Agreement was recognized during the three months ended March 31, 2021 and 2020 as no deliveries were made during the periods.
Spark Therapeutics, Inc.
Spark License Agreement
The disclosures relating to the Company’s license and option agreement, or the Spark License Agreement, with Spark pursuant to which the Company and Spark agreed to collaborate on the development of gene therapies for certain targets utilizing the ImmTOR platform reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020 which was filed with the SEC on March 12, 2021 have not materially changed since the Company filed such report.
Transaction Price Allocated to Future Performance Obligations
Remaining performance obligations represent the transaction price of contracts for which work has not been performed (or has been partially performed). As of March 31, 2021, the aggregate amount of the transaction price allocated to remaining performance obligations was $108.1 million.
Contract Balances from Contracts with Customers (Sobi, Sarepta, AskBio, and Spark)
The following table presents changes in the Company’s contract liabilities during the three months ended March 31, 2021 (in thousands):
Balance atBalance at
beginning of periodAdditionsDeductionsend of period
Three Months Ended March 31, 2021
Contract liabilities:
     Deferred revenue$110,796 $— $(2,730)$108,066 
Total contract liabilities$110,796 $— $(2,730)$108,066 
XML 31 R19.htm IDEA: XBRL DOCUMENT v3.21.1
Related-Party Transactions
3 Months Ended
Mar. 31, 2021
Related Party Transactions [Abstract]  
Related-Party Transactions Related-Party Transactions
Consulting Services
The Company incurred expenses for consulting services provided by its founders totaling less than $0.1 million during each of the three months ended March 31, 2021 and 2020. The Company entered into consulting agreements with its founders to serve on its Scientific Advisory Board, effective January 1, 2020 to December 31, 2021, under which they will be paid quarterly for their services.
XML 32 R20.htm IDEA: XBRL DOCUMENT v3.21.1
Collaboration Agreements
3 Months Ended
Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Collaboration Agreements Collaboration Agreements
Asklepios Biopharmaceutical, Inc.
Feasibility Study and License Agreement
In August 2019, the Company entered into a feasibility study and license agreement with AskBio, or the AskBio Collaboration Agreement. Pursuant to the AskBio Collaboration Agreement, the Company and AskBio agreed to license intellectual property rights to each other as part of a collaboration to research, develop, and commercialize certain AAV gene therapy products utilizing the Company’s ImmTOR platform to enable re-dosing of such AAV gene therapy products to treat serious rare and orphan genetic diseases for which there is a significant unmet medical need.
Pursuant to the AskBio Collaboration Agreement, the Company and AskBio agreed to conduct proof of concept studies to potentially validate the use of ImmTOR in conjunction with AskBio’s AAV gene therapy, or MMA-101, for the treatment of MMA, to mitigate the formation of neutralizing anti-AAV capsid antibodies, or the POC Studies. If the POC Studies are successful, or the parties otherwise elect to do so, the parties will proceed with a collaboration to pursue the development and commercialization of AAV gene therapy product candidates utilizing ImmTOR for the treatment of certain agreed serious rare and orphan genetic diseases. If the POC Studies fail to demonstrate a proof-of-concept, and the parties do not mutually agree in writing to proceed with the collaboration, the AskBio Collaboration Agreement will expire.
The SEL-399 program combines an empty AAV capsid (EMC-101), which is an AAV capsid containing no transgene, with ImmTOR and is being conducted in partnership with AskBio. Building on the preclinical data the Company has generated showing ImmTOR’s effect on mitigating or reducing the formation of neutralizing antibodies to AAV gene therapies, the Company has commenced a clinical trial of SEL-399 in healthy adult volunteers in Belgium. The goal of the SEL-399 clinical trial is to demonstrate the appropriate dose of ImmTOR in humans to mitigate the formation of antibodies to AAV capsids used in gene therapies.
The Company and AskBio will share responsibility for the research, development and commercialization of products developed under this collaboration. The parties will also share research, development, and commercialization costs equally for all collaboration products, but with a right of either party to opt out of certain products, and thereby no longer be required to share costs for such products. Each party will receive a percentage of net profits for each product sold under the collaboration equal to the percentage of shared costs borne by such party in the development of such product. Pursuant to the AskBio Collaboration Agreement, AskBio is responsible for manufacturing the AAV capsids and AAV vectors and the Company is responsible for manufacturing ImmTOR.
The AskBio Collaboration Agreement is considered to be within the scope of ASC 808, as both parties are active participants and exposed to the risks and rewards of the collaborative activity. The Company evaluated the terms of the AskBio
Collaboration Agreement and have identified the following promises in the arrangement (1) conducting research and development activities to develop and commercialize products under the collaboration, or the R&D Services, (2) granting a non-exclusive, non-transferable, royalty-free, fully paid up, worldwide license to certain intellectual property of the Company, or the IP Rights, for the purpose of performing the POC Studies, or the Research License, (3) granting an exclusive, nontransferable, worldwide license to the IP Rights for use in certain indications, or the Collaboration License, (4) providing manufactured supply of preclinical and clinical ImmTOR, or the Manufactured Supply, (5) participation on identified steering committees responsible for the oversight of the collaboration, or the JSC Participation, and (6) granting an exclusive option to obtain a license under the IP Rights to research, develop and commercialize Licensed Products. The Company determined that the R&D Services, Research License, Collaboration License, Manufactured Supply, and JSC Participation were not capable of being distinct, and therefore must be combined into a single performance obligation. Therefore, promises (1) through (5) identified above were combined into a single performance obligation. Furthermore, the Company evaluated the Option Agreement and determined that it does not provide AskBio with a material right under ASC 606 as the option was not priced at a discount (see discussion of the option exercise in Note 12). The Company noted that AskBio did not meet the definition of a customer within the scope of ASC 606 for any distinct performance obligations as the Company concluded that such items were not an output of the Company’s ordinary activities. As such, the Company determined that the entire arrangement would be accounted for within the scope of ASC 808.
In accordance with ASC 808, collaboration expenses are recognized within R&D expense and selling, general and administrative expense on the Company’s condensed consolidated statements of operations. For each of the three months ended March 31, 2021 and 2020, the Company recognized $1.2 million of collaboration expense under the AskBio Collaboration Agreement in which actual costs incurred by both parties approximate a 50% cost share.
Under certain collaborative arrangements, the Company is entitled to reimbursement of certain R&D expense. Activities under collaborative arrangements for which the Company is entitled to reimbursement are considered to be collaborative activities under the scope of ASC 808. For these units of account, the Company does not analogize to ASC 606 or recognize revenue. Rather, the Company analogizes to the guidance in ASC 730, which requires that reimbursements from counterparties be recognized as an offset to the related costs. In accordance with ASC 730, the Company records reimbursement payments received from collaborators as reductions to R&D expense.
Massachusetts Institute of Technology
In November 2008, the Company entered into an exclusive patent license agreement, or the MIT License, with the Massachusetts Institute of Technology, or MIT, under which the Company received an exclusive royalty-bearing license to utilize patents held by MIT in exchange for upfront consideration and annual license maintenance fees. Such fees are expensed as incurred and have not been material to any period presented.
In June 2020, the Company entered into a Fifth Amendment, or the MIT Amendment, to the MIT License, which is effective as of May 15, 2020. Pursuant to the MIT Amendment, certain of the Company’s diligence obligations were extended, including a diligence obligation to commence a Phase 3 trial for a licensed product by a specific date in the second quarter of 2021. Additionally, certain of the Company’s development and regulatory milestones and payments upon achievement of such milestones were adjusted.
As of March 31, 2021, and in connection with the execution of the Spark License Agreement, the Company has made contractual payments pursuant to the MIT License totaling $2.2 million for the sublicense granted to Spark, and $0.4 million relative to the calculated premium paid by Spark for the equity investments made under the Spark Purchase Agreement. The Company made no additional payments during the three months ended March 31, 2021.
Shenyang Sunshine Pharmaceutical Co., Ltd
In May 2014, the Company entered into a license agreement, or the 3SBio License, with Shenyang Sunshine Pharmaceutical Co., Ltd., or 3SBio. The Company has paid to 3SBio an aggregate of $7.0 million in upfront and milestone-based payments under the 3SBio License as of March 31, 2021. The Company is required to make future payments to 3SBio contingent upon the occurrence of events related to the achievement of clinical and regulatory approval milestones of up to an aggregate of $15.0 million for products containing the Company’s ImmTOR platform.
XML 33 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes
3 Months Ended
Mar. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The Company provides for income taxes under ASC 740. Under ASC 740, the Company provides deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the Company’s financial statement carrying amounts and the tax bases of assets and liabilities using enacted tax rates expected to be in effect in the years in which the differences are expected to reverse.
For the three months ended March 31, 2021 and 2020, the Company did not record a current or deferred income tax expense or benefit.
The Company has provided a full valuation allowance against its net deferred tax assets, as the Company believes that it is more likely than not that the deferred tax assets will not be realized.
Utilization of the net operating loss and research and development credit carryforwards may be subject to a substantial annual limitation under Section 382 and 383 of the Internal Revenue Code due to ownership change limitations that have occurred previously, or that could occur in the future. These ownership changes may limit the amount of net operating loss and research and development credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. As of December 31, 2020, the Company completed a Section 382 study. The Company has determined that all of the $234.5 million of net operating losses are available in the future, with approximately $36.5 million of that total limited under Section 382 and therefore available for future use through 2028.
The Company applies ASC 740, Income Taxes to uncertain tax positions. As of March 31, 2021 and December 31, 2020, the Company had no unrecognized tax benefits or related interest and penalties accrued.
The Company has not, as of yet, conducted a study of its research and development credit carryforwards. This study may result in an adjustment to the Company’s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax position.
The statute of limitations for assessment by the United States Internal Revenue Service and Massachusetts tax authorities is open for tax years since inception. The Company files income tax returns in the United States and Massachusetts. There are currently no federal, state or foreign audits in progress.
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.21.1
Defined Contribution Plan
3 Months Ended
Mar. 31, 2021
Retirement Benefits [Abstract]  
Defined Contribution Plan Defined Contribution PlanThe Company maintains a defined contribution plan, or the 401(k) Plan, under Section 401(k) of the Internal Revenue Code. The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. The 401(k) Plan provides for matching contributions on a portion of participant contributions pursuant to the 401(k) Plan’s matching formula. All matching contributions vest ratably over 4 years and participant contributions vest immediately. Contributions by the Company totaled less than $0.1 million during each of the three months ended March 31, 2021 and 2020.
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.21.1
Commitments and Contingencies
3 Months Ended
Mar. 31, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
As of March 31, 2021, the Company was not a party to any litigation that could have a material adverse effect on the Company’s business, financial position, results of operations or cash flows.
On August 4, 2020, a putative stockholder of Selecta filed a stockholder derivative action, purportedly on behalf of Selecta and against certain current and former members of the Company’s Board of Directors, as well as one affiliated company owned by a current board member, in the Court of Chancery of the State of Delaware, namely Franchi v. Barabe, et al. The complaint alleges that the individual defendants breached their fiduciary duties and committed corporate waste when they authorized a private placement transaction, announced on December 19, 2019, at a price allegedly below fair value. The complaint further alleges that the four defendant directors who participated in the private placement were unjustly enriched in connection with the transaction. On September 25, 2020, the defendants filed a motion to dismiss the lawsuit. On November 6, 2020, the plaintiff filed an amended complaint, and the defendants filed a second motion to dismiss on January 8, 2021. On December 31, 2020, the Company received a litigation demand letter from two other putative stockholders relating to the same private placement transaction. On April 12, 2021, the Court of Chancery in the State of Delaware granted a motion to stay the litigation pending a review by a Special Committee appointed by the Company’s Board of Directors. At this time, the Company has not accrued a liability for this matter, as any liability has been determined to be either not estimable or not probable.
Other
As permitted under Delaware law, the Company indemnifies its directors for certain events or occurrences while the director is, or was, serving at the Company’s request in such capacity. The term of the indemnification is for the director’s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ insurance coverage that limits its exposure and enables it to recover a portion of any future amounts paid. The Company also has indemnification arrangements under certain of its facility leases that require it to indemnify the landlord against certain costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from certain breaches, violations, or non-performance of any covenant or condition of the Company’s lease. The term of the indemnification is for the term of the related lease agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. To date, the Company had not experienced any material losses related to any of its indemnification obligations, and no material claims with respect thereto were outstanding.
The Company is a party in various other contractual disputes and potential claims arising in the ordinary course of business. The Company does not believe that the resolution of these matters will have a material adverse effect the Company’s business, financial position, results of operations or cash flows.
XML 36 R24.htm IDEA: XBRL DOCUMENT v3.21.1
Subsequent Events
3 Months Ended
Mar. 31, 2021
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
“At-the-Market” Offerings
Subsequent to March 31, 2021 through May 13, 2021, the Company sold 206,593 shares of its common stock pursuant to the 2020 Sales Agreement, at an average price of approximately $4.51 per share for aggregate net proceeds of $0.9 million, after deducting commissions and other transaction costs.
Milestone Event
On April 13, 2021, the Company was notified by Sarepta of the achievement of the milestone event related to the completion of a non-clinical study for Duchenne muscular dystrophy and certain limb-girdle muscular dystrophies under the Company’s Research License and Option Agreement. Under the terms of the Agreement, Sarepta is obligated to pay a non-refundable, non-creditable milestone payment of $3.0 million to the Company within 60 days of Sarepta’s receipt of the related invoice from the Company.
The AskBio Collaboration Agreement
On April 29, 2021, the Company was notified by AskBio that it intended to opt-out of development of the MMA indication. Consequently, the Company will assume all rights to the MMA program and intends to continue to progress the MMA-101 and ImmTOR combination through clinical development.
XML 37 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of Significant Accounting Policies (Policies)
3 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Recent Accounting Pronouncements
Recent Accounting Pronouncements
Recently Adopted
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) - Simplifying the Accounting for Income Taxes. ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The Company adopted the new standard effective January 1, 2021, and there was no impact on its consolidated financial statements.
In October 2020, the FASB issued ASU 2020-10, Codification Improvements, which updates various codification topics by clarifying or improving disclosure requirements to align with the SEC’s regulations. The Company adopted the new standard effective January 1, 2021, and there was no impact on its consolidated financial statements.
Not Yet Adopted
In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2023, with early adoption permitted no earlier than January 1, 2021. The Company is assessing the impact this standard will have on its consolidated financial statements and disclosures.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments. Subsequently, in November 2018, the FASB issued ASU 2018-19, Codification Improvements to Topic 326, Financial Instruments-Credit Losses. ASU 2016-13 requires entities to measure all expected credit losses for most financial assets held at the reporting date based on an expected loss model which includes historical experience, current conditions, and reasonable and supportable forecasts. ASU 2016-13 also requires enhanced disclosures to help financial statement users better understand significant estimates and judgments used in estimating credit losses. This ASU is effective for smaller reporting companies for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company is assessing the impact this standard will have on its consolidated financial statements and disclosures.
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.21.1
Marketable Securities (Tables)
3 Months Ended
Mar. 31, 2021
Investments, Debt and Equity Securities [Abstract]  
Summary of Available-for-Sale Marketable Securities
The following table summarizes the marketable securities held as of March 31, 2021 (in thousands):
Amortized costUnrealized gainsUnrealized lossesFair value
March 31, 2021
Corporate bonds$2,032 $— $(1)$2,031 
Commercial paper20,374 — — 20,374 
Total$22,406 $— $(1)$22,405 
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss Per Share (Tables)
3 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
Computation of Basic and Diluted Net Loss Per Share The following table sets forth the computation of basic and diluted net loss per share (in thousands, except share and per-share data):
 Three Months Ended March 31,
 20212020
Numerator:
Net loss attributable to common stockholders$(24,597)$(19,620)
Denominator:
Weighted-average common shares and pre-funded warrants outstanding—basic and diluted110,742,150 94,723,513 
Net loss per share attributable to common stockholders —basic and diluted$(0.22)$(0.21)
Schedule of Potential Common Shares Issuable Upon Conversion of Warrants Potential dilutive common share equivalents consist of the following:
 March 31,
 20212020
Stock options to purchase common stock10,187,394 7,745,936 
Unvested restricted stock units544,313 170,313 
Warrants to purchase common stock12,378,016 23,084,120 
Total23,109,723 31,000,369 
XML 40 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements (Tables)
3 Months Ended
Mar. 31, 2021
Fair Value Disclosures [Abstract]  
Summary of Assets Measured at Fair Value on a Recurring Basis
The following tables present the Company’s assets and liabilities that are measured at fair value on a recurring basis as of March 31, 2021 and December 31, 2020 (in thousands):
March 31, 2021
Total(Level 1)(Level 2)(Level 3)
Assets:
     Money market funds$58,158 $58,158 $— $— 
Marketable securities:
     Corporate bonds2,031 — 2,031 — 
     Commercial paper20,374 — 20,374 — 
Total assets$80,563 $58,158 $22,405 $— 
Liabilities:
     Warrant liabilities$45,455 $— $— $45,455 
Total liabilities$45,455 $— $— $45,455 
 
December 31, 2020
Total(Level 1)(Level 2)(Level 3)
Assets:
     Money market funds$80,576 $80,576 $— $— 
Total assets$80,576 $80,576 $— $— 
Liabilities:
     Warrant liabilities$28,708 $— $— $28,708 
Total liabilities$28,708 $— $— $28,708 
Schedule of Fair Value Measurement Inputs and Valuation Techniques
A summary of the Black-Scholes pricing model assumptions used to record the fair value of the warrant liability is as follows:
March 31,
 2021
Risk-free interest rate0.35 %
Dividend yield— 
Expected life (in years)3.73
Expected volatility101.13 %
Schedule Of Changes In The Warrant Liabilities
The following table reflects a roll-forward of fair value for the Company’s Level 3 warrant liabilities (see Note 10), for the three months ended March 31, 2021 (in thousands):
Warrant liabilities
Fair value as of December 31, 2020
$28,708 
     Change in fair value16,747 
Fair value as of March 31, 2021
$45,455 
Schedule of Cash and Cash Equivalents The Company’s consolidated statement of cash flows includes the following as of March 31, 2021 and 2020 (in thousands):
March 31,
20212020
Cash and cash equivalents$125,407 $72,606 
Short-term restricted cash— 279 
Long-term restricted cash1,379 1,379 
Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows$126,786 $74,264 
Schedule of Restricted Cash and Cash Equivalents The Company’s consolidated statement of cash flows includes the following as of March 31, 2021 and 2020 (in thousands):
March 31,
20212020
Cash and cash equivalents$125,407 $72,606 
Short-term restricted cash— 279 
Long-term restricted cash1,379 1,379 
Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows$126,786 $74,264 
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Property and Equipment (Tables)
3 Months Ended
Mar. 31, 2021
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
Property and equipment consists of the following (in thousands):
 March 31,December 31,
 20212020
Laboratory equipment$4,429 $4,427 
Computer equipment and software694 532 
Leasehold improvements38 38 
Furniture and fixtures327 327 
Office equipment163 163 
Construction in process30 163 
Total property and equipment5,681 5,650 
Less accumulated depreciation(4,380)(4,255)
Property and equipment, net$1,301 $1,395 
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Accrued Expenses (Tables)
3 Months Ended
Mar. 31, 2021
Payables and Accruals [Abstract]  
Schedule of Accrued Expenses
Accrued expenses consist of the following (in thousands):
 March 31,December 31,
 20212020
Payroll and employee related expenses$1,840 $3,049 
Collaboration and licensing1,350 1,350 
Accrued patent fees471 534 
Accrued external research and development costs2,010 2,029 
Accrued professional and consulting services802 798 
Accrued interest170 170 
Other204 216 
     Accrued expenses$6,847 $8,146 
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Leases (Tables)
3 Months Ended
Mar. 31, 2021
Leases [Abstract]  
Schedule of Lessee, Components Of Operating Lease
As of March 31, 2021 and December 31, 2020, the components of the operating leases were as follows (in thousands):
March 31,December 31,
20212020
Assets:
   Right-of-use asset, net$10,676 $10,948 
Liabilities:
   Current operating lease liabilities$942 $908 
   Non-current operating lease liabilities9,403 9,647 
Total operating lease liabilities$10,345 $10,555 
Schedule of Lease, Cost
For the three months ended March 31, 2021 and 2020 the components of lease costs were as follows (in thousands):
March 31,
20212020
Operating lease cost$444 $472 
Variable lease cost288 199 
Short-term lease cost
Total lease cost$735 $673 
The following summarizes additional information related to operating leases:
March 31,
20212020
Weighted-average remaining lease term7.1 years8.0 years
Weighted-average discount rate8.9 %8.9 %
Schedule of Lessee, Operating Lease, Liability, Maturity
The maturity of the Company’s operating lease liabilities as of March 31, 2021 were as follows (in thousands):
March 31,
2021
2021 (remainder)$1,368 
20221,866 
20231,922 
20241,980 
20252,039 
Thereafter4,945 
     Total future minimum lease payments14,120 
Less imputed interest3,775 
     Total operating lease liabilities$10,345 
Schedule of Operating Lease, Lease Income
The supplemental disclosure for the statement of cash flows related to operating leases were as follows (in thousands):
March 31,
20212020
Cash paid for amounts included in the measurement of lease liabilities:$444 $487 
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.21.1
Debt (Tables)
3 Months Ended
Mar. 31, 2021
Debt Disclosure [Abstract]  
Schedule of Future Minimum Payments on the Term Loans
Future minimum principal and interest payments on the 2020 Term Loan as of March 31, 2021 are as follows (in thousands):
2021 (remainder)$1,509 
20227,343 
20238,611 
20248,027 
20257,274 
Total minimum debt payments32,764 
Less: Amount representing interest(5,514)
Less: Debt discount and deferred charges(2,239)
Less: Current portion of loan payable(460)
Loan payable, net of current portion$24,551 
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Equity (Tables)
3 Months Ended
Mar. 31, 2021
Equity [Abstract]  
Schedule of Stockholders' Equity Note, Warrants or Rights
Number of Warrants
Equity
 classified
Liability classifiedTotalWeighted average
exercise price
Outstanding at March 31, 2021292,469 12,085,547 12,378,016 $1.60 
Schedule of Authorized Shares of Common Stock for Future Issuance
The Company has authorized shares of common stock for future issuance as follows:
 Period ended
 March 31, 2021December 31, 2020
Exercise of common warrants12,378,016 12,378,016 
Shares available for future stock incentive awards7,719,817 4,916,374 
RSUs reserved for issuance98,750 — 
Unvested restricted stock units544,313 87,500 
Outstanding common stock options10,187,394 7,775,249 
Total30,928,290 25,157,139 
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.21.1
Stock Incentive Plans (Tables)
3 Months Ended
Mar. 31, 2021
Share-based Payment Arrangement [Abstract]  
Schedule of Stock-Based Compensation
Stock-based compensation expense by classification included within the condensed consolidated statements of operations and comprehensive loss was as follows (in thousands):
 Three Months Ended March 31,
 20212020
Research and development$754 $623 
General and administrative1,026 786 
     Total stock-based compensation expense$1,780 $1,409 
Schedule of Weighted Average Assumptions Used The estimated grant date fair values of employee stock option awards granted under the 2016 Plan and the 2018 Inducement Incentive Award Plan were calculated using the Black-Scholes option pricing model, based on the following weighted-average assumptions:
Three Months Ended March 31,
 20212020
Risk-free interest rate0.44 %1.73 %
Dividend yield— — 
Expected term5.286.08
Expected volatility83.26 %87.96 %
Weighted-average fair value of common stock$3.13 $2.30 
Summary of Options Activity
The following table summarizes the stock option activity under the 2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan:
   Weighted-average 
  remainingAggregate
 Number ofWeighted-averagecontractual termintrinsic value
 optionsexercise price ($)(in years)(in thousands)
Employees    
Outstanding at December 31, 20207,302,176 $3.98 8.43$4,456 
Granted2,628,000 $3.13   
Exercised(153,278)$1.47   
Forfeited(62,577)$5.19   
Outstanding at March 31, 20219,714,321 $3.78 8.65$15,665 
Vested at March 31, 20213,064,130 $5.46 7.63$4,313 
Vested and expected to vest at March 31, 20218,920,548 $3.88 8.59$14,231 
Non-employee consultants    
Outstanding at December 31, 2020473,073 $5.89 5.23$86 
Granted— $— 
Exercised— $— 
Forfeited— $— 
Outstanding at March 31, 2021473,073 $5.89 4.98$366 
Vested at March 31, 2021462,186 $5.82 4.92$366 
Vested and expected to vest at March 31, 2021473,073 $5.89 4.98$366 
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award
The following table summarizes the Company’s restricted stock units under the 2016 Plan and 2018 Inducement Incentive Award Plan:
 Number of sharesWeighted average
grant date
fair value ($)
Unvested at December 31, 2020
87,500 $6.03 
Granted468,550 2.99 
Vested(10,937)6.03 
Reserved for issuance98,750 2.99 
Forfeited(800)2.99 
Unvested at March 31, 2021
643,063 $3.35 
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Arrangements (Tables)
3 Months Ended
Mar. 31, 2021
Revenue from Contract with Customer [Abstract]  
Schedule of Changes in Contract Liabilities
The following table presents changes in the Company’s contract liabilities during the three months ended March 31, 2021 (in thousands):
Balance atBalance at
beginning of periodAdditionsDeductionsend of period
Three Months Ended March 31, 2021
Contract liabilities:
     Deferred revenue$110,796 $— $(2,730)$108,066 
Total contract liabilities$110,796 $— $(2,730)$108,066 
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.21.1
Nature of the Business and Basis of Presentation - Liquidity (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Cash and Cash Equivalents [Line Items]    
Cash, cash equivalents, restricted cash and marketable securities $ 149,200  
Restricted cash and cash equivalents 1,400  
Accumulated deficit 429,226 $ 404,629
Russian subsidiary    
Cash and Cash Equivalents [Line Items]    
Cash maintained in Russian bank accounts $ 300  
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.21.1
Marketable Securities - Summary of Available-for-Sale Marketable Securities (Details) - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Debt Securities, Available-for-sale [Line Items]    
Amortized cost $ 22,406,000  
Unrealized gains 0  
Unrealized losses (1,000)  
Fair value 22,405,000 $ 0
Corporate bonds    
Debt Securities, Available-for-sale [Line Items]    
Amortized cost 2,032,000  
Unrealized gains 0  
Unrealized losses (1,000)  
Fair value 2,031,000  
Commercial paper    
Debt Securities, Available-for-sale [Line Items]    
Amortized cost 20,374,000  
Unrealized gains 0  
Unrealized losses 0  
Fair value $ 20,374,000  
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.21.1
Marketable Securities - Narrative (Details) - USD ($)
3 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Investments, Debt and Equity Securities [Abstract]    
Marketable securities adjusted for other than temporary declines in fair value $ 0  
Marketable securities: $ 22,405,000 $ 0
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Numerator:    
Net loss attributable to common stockholders $ (24,597) $ (19,620)
Denominator:    
Weighted‑average common shares outstanding—basic and diluted (in shares) 110,742,150 94,723,513
Net loss per share attributable to common stockholders—basic and diluted (in dollars per share) $ (0.22) $ (0.21)
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.21.1
Net Loss Per Share - Schedule of Potential Common Shares Issuable Upon Conversion of Warrants (Details) - shares
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Potential common shares    
Total (in shares) 23,109,723 31,000,369
Stock options to purchase common stock    
Potential common shares    
Total (in shares) 10,187,394 7,745,936
Unvested restricted stock units    
Potential common shares    
Total (in shares) 544,313 170,313
Warrants to purchase common stock    
Potential common shares    
Total (in shares) 12,378,016 23,084,120
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Summary of Assets Measured at Fair Value on a Recurring Basis (Details) - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Assets:    
Marketable securities: $ 22,405,000 $ 0
Liabilities:    
Warrant liabilities 45,455,000 28,708,000
Corporate bonds    
Assets:    
Marketable securities: 2,031,000  
Commercial paper    
Assets:    
Marketable securities: 20,374,000  
Recurring    
Assets:    
Total assets 80,563,000 80,576,000
Liabilities:    
Warrant liabilities 45,455,000 28,708,000
Total liabilities 45,455,000 28,708,000
Recurring | (Level 1)    
Assets:    
Total assets 58,158,000 80,576,000
Liabilities:    
Warrant liabilities 0 0
Total liabilities 0 0
Recurring | (Level 2)    
Assets:    
Total assets 22,405,000 0
Liabilities:    
Warrant liabilities 0 0
Total liabilities 0 0
Recurring | (Level 3)    
Assets:    
Total assets 0 0
Liabilities:    
Warrant liabilities 45,455,000 28,708,000
Total liabilities 45,455,000 28,708,000
Recurring | Corporate bonds    
Assets:    
Marketable securities: 2,031,000  
Recurring | Corporate bonds | (Level 1)    
Assets:    
Marketable securities: 0  
Recurring | Corporate bonds | (Level 2)    
Assets:    
Marketable securities: 2,031,000  
Recurring | Corporate bonds | (Level 3)    
Assets:    
Marketable securities: 0  
Recurring | Commercial paper    
Assets:    
Marketable securities: 20,374,000  
Recurring | Commercial paper | (Level 1)    
Assets:    
Marketable securities: 0  
Recurring | Commercial paper | (Level 2)    
Assets:    
Marketable securities: 20,374,000  
Recurring | Commercial paper | (Level 3)    
Assets:    
Marketable securities: 0  
Recurring | Money market funds    
Assets:    
Money market funds 58,158,000 80,576,000
Recurring | Money market funds | (Level 1)    
Assets:    
Money market funds 58,158,000 80,576,000
Recurring | Money market funds | (Level 2)    
Assets:    
Money market funds 0 0
Recurring | Money market funds | (Level 3)    
Assets:    
Money market funds $ 0 $ 0
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Assumptions used to record the fair value of the warrants (Details) - Valuation Technique, Option Pricing Model
Mar. 31, 2021
Risk-free interest rate  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Warrants and rights outstanding, measurement input 0.0035
Dividend yield  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Warrants and rights outstanding, measurement input 0
Expected life (in years)  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Warrants and rights outstanding, term 3 years 8 months 23 days
Expected volatility  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Warrants and rights outstanding, measurement input 1.0113
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Change in the warrant liabilities (Details) - Warrant liabilities
$ in Thousands
3 Months Ended
Mar. 31, 2021
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Fair value as of December 31, 2020 $ 28,708
Change in fair value 16,747
Fair value as of March 31, 2021 $ 45,455
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Narrative (Details) - USD ($)
3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Fair Value Disclosures [Abstract]    
Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers, net $ 0 $ 0
Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net $ 0 $ 0
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.21.1
Fair Value Measurements - Schedule of Cash and Cash Equivalents (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Mar. 31, 2020
Dec. 31, 2019
Fair Value Disclosures [Abstract]        
Cash and cash equivalents $ 125,407 $ 138,685 $ 72,606  
Short-term restricted cash 0   279  
Long-term restricted cash 1,379 1,379 1,379  
Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows $ 126,786 $ 140,064 $ 74,264 $ 91,551
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.21.1
Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 5,681 $ 5,650
Less accumulated depreciation (4,380) (4,255)
Property and equipment, net 1,301 1,395
Laboratory equipment    
Property, Plant and Equipment [Line Items]    
Total property and equipment 4,429 4,427
Computer equipment and software    
Property, Plant and Equipment [Line Items]    
Total property and equipment 694 532
Leasehold improvements    
Property, Plant and Equipment [Line Items]    
Total property and equipment 38 38
Furniture and fixtures    
Property, Plant and Equipment [Line Items]    
Total property and equipment 327 327
Office equipment    
Property, Plant and Equipment [Line Items]    
Total property and equipment 163 163
Construction in process    
Property, Plant and Equipment [Line Items]    
Total property and equipment $ 30 $ 163
XML 59 R47.htm IDEA: XBRL DOCUMENT v3.21.1
Property and Equipment - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Property, Plant and Equipment [Abstract]    
Depreciation expense $ 0.1 $ 0.2
XML 60 R48.htm IDEA: XBRL DOCUMENT v3.21.1
Accrued Expenses (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Payroll and employee related expenses $ 1,840 $ 3,049
Collaboration and licensing 1,350 1,350
Accrued patent fees 471 534
Accrued external research and development costs 2,010 2,029
Accrued professional and consulting services 802 798
Accrued interest 170 170
Other 204 216
Accrued expenses $ 6,847 $ 8,146
XML 61 R49.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Narrative (Details)
$ in Thousands
1 Months Ended 3 Months Ended
Jul. 31, 2019
USD ($)
ft²
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
Operating Leased Assets [Line Items]        
Lessee-paid construction costs   $ 735 $ 673  
Operating lease, weighted average discount rate, percent   8.90% 8.90%  
65 Grove Street, Watertown,MA        
Operating Leased Assets [Line Items]        
Area of additional office space leased | ft² 25,078      
Lessee-paid construction costs $ 800      
Term of contract 8 years      
Letter of credit        
Operating Leased Assets [Line Items]        
Long-term restricted cash   $ 1,400   $ 1,400
XML 62 R50.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Components of Operating Leases (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Assets:    
Right-of-use asset, net $ 10,676 $ 10,948
Liabilities:    
Current operating lease liabilities 942 908
Non-current operating lease liabilities 9,403 9,647
Total operating lease liabilities $ 10,345 $ 10,555
XML 63 R51.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Components of lease costs (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Leases [Abstract]    
Operating lease cost $ 444 $ 472
Variable lease cost 288 199
Short-term lease cost 3 2
Total lease cost $ 735 $ 673
XML 64 R52.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Operating Lease, Liability, Maturity (Details) - USD ($)
$ in Thousands
Mar. 31, 2021
Dec. 31, 2020
Leases [Abstract]    
2021 (remainder) $ 1,368  
2022 1,866  
2023 1,922  
2024 1,980  
2025 2,039  
Thereafter 4,945  
Total future minimum lease payments 14,120  
Less imputed interest 3,775  
Lease liabilities $ 10,345 $ 10,555
XML 65 R53.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Other Information (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Leases [Abstract]    
Cash paid for amounts included in the measurement of lease liabilities: $ 444 $ 487
XML 66 R54.htm IDEA: XBRL DOCUMENT v3.21.1
Leases - Lease Term and Discount Rate (Details)
Mar. 31, 2021
Mar. 31, 2020
Leases [Abstract]    
Operating lease, weighted average remaining lease term 7 years 1 month 6 days 8 years
Operating lease, weighted average discount rate, percent 8.90% 8.90%
XML 67 R55.htm IDEA: XBRL DOCUMENT v3.21.1
Debt - Term Loans (Narrative) (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended
Aug. 31, 2020
Mar. 31, 2021
Sep. 30, 2020
Dec. 31, 2020
Line of Credit Facility [Line Items]        
Final payment fee   $ 2,300    
Class of warrant or right, number of securities called by warrants or rights (in shares) 196,850      
Exercise price (in dollars per share) $ 2.54 $ 1.60    
Class of warrant or right, expiration period 10 years      
Adjustments to additional paid in capital, warrant issued $ 400      
2020 Term Loans        
Line of Credit Facility [Line Items]        
Maximum borrowing capacity 35,000      
Debt instrument, additional accrued interest in the event of default   0.050    
Debt instrument, redemption price, percentage of principal amount redeemed   9.00%    
Debt instrument, default, bankruptcy, or insolvency value of triggering accelerated redemption 500      
Debt issuance costs, line of credit arrangements (less than) 400      
Term loan facility   $ 25,000   $ 25,000
Term A Loans        
Line of Credit Facility [Line Items]        
Maximum borrowing capacity 25,000      
Term B Loans        
Line of Credit Facility [Line Items]        
Maximum borrowing capacity 10,000      
2017 Term Loans        
Line of Credit Facility [Line Items]        
Repayments of lines of credit 13,700      
Loss on extinguishment of debt     $ 500  
Warrants to purchase common stock | Term B Loans        
Line of Credit Facility [Line Items]        
Sale common stock $ 200,000      
Maximum | 2020 Term Loans        
Line of Credit Facility [Line Items]        
Debt instrument, prepayment fee, percentage   0.030    
Minimum | 2020 Term Loans        
Line of Credit Facility [Line Items]        
Debt instrument, prepayment fee, percentage   0.010    
Debt Instrument, Redemption, Period One | 2020 Term Loans        
Line of Credit Facility [Line Items]        
Basis spread on variable rate   7.90%    
Debt Instrument, Redemption, Period Two | 2020 Term Loans        
Line of Credit Facility [Line Items]        
Basis spread on variable rate   4.65%    
Debt Instrument, Redemption, Period Three | 2020 Term Loans        
Line of Credit Facility [Line Items]        
Basis spread on variable rate   10.00%    
XML 68 R56.htm IDEA: XBRL DOCUMENT v3.21.1
Debt - Schedule of Future Minimum Payments on the Term Loans (Details) - 2017 Term Loans
$ in Thousands
Mar. 31, 2021
USD ($)
Long-term Debt, Fiscal Year Maturity [Abstract]  
2021 (remainder) $ 1,509
2022 7,343
2023 8,611
2024 8,027
2025 7,274
Total minimum debt payments 32,764
Less: Amount representing interest (5,514)
Less: Debt discount and deferred charges (2,239)
Less: Current portion of loan payable (460)
Loan payable, net of current portion $ 24,551
XML 69 R57.htm IDEA: XBRL DOCUMENT v3.21.1
Equity - Narrative (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Aug. 06, 2020
USD ($)
Jul. 28, 2020
USD ($)
Jun. 11, 2020
USD ($)
$ / shares
shares
Dec. 18, 2019
USD ($)
$ / shares
shares
Aug. 31, 2017
USD ($)
Mar. 31, 2021
USD ($)
vote
$ / shares
shares
Mar. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
$ / shares
shares
Aug. 31, 2020
$ / shares
Subsidiary, Sale of Stock [Line Items]                  
Shares issued, value           $ 20,991,000 $ 1,141,000    
Class of warrant or right, outstanding (in shares) | shares           12,378,016,000      
Exercise price (in dollars per share) | $ / shares           $ 1.60     $ 2.54
Warrant liabilities           $ 45,455,000   $ 28,708,000  
Common stock, shares authorized (in shares) | shares           200,000,000   200,000,000  
Common stock, par value (in dollars per share) | $ / shares           $ 0.0001   $ 0.0001  
Common stock, shares issued | shares           112,977,004   108,071,249  
Common stock, shares outstanding | shares           112,977,004   108,071,249  
Number of votes per share that common stockholders are entitled to | vote           1      
Dividends declared or paid on common stock           $ 0      
Exercise of common warrants                  
Subsidiary, Sale of Stock [Line Items]                  
Class of warrant or right, outstanding (in shares) | shares           292,469,000      
August 2020 Shelf Registration Statement                  
Subsidiary, Sale of Stock [Line Items]                  
Sale common stock $ 200,000,000.0                
At-The-Market Offering                  
Subsidiary, Sale of Stock [Line Items]                  
Sale common stock         $ 50,000,000.0        
Sale of stock, number of shares issued in transaction (in shares) | shares           4,706,844   1,069,486  
Share price (in dollars per share) | $ / shares           $ 4.59   $ 2.16  
Shares issued, value           $ 20,900,000   $ 2,100,000  
2020 Sale Agreement - At-the-Market Offering                  
Subsidiary, Sale of Stock [Line Items]                  
Sale common stock         $ 50,000,000.0        
SOBI Purchase Agreement                  
Subsidiary, Sale of Stock [Line Items]                  
Sale common stock     $ 25,000,000.0            
Sale of stock, number of shares issued in transaction (in shares) | shares     5,416,390            
Share price (in dollars per share) | $ / shares     $ 4.6156            
Sale of stock, percentage of ten-day volume weighted average price of common stock     120.00%            
Lock-up from closing, term           1 year      
Redemption premium   $ 14,500,000              
December 2019 Financing                  
Subsidiary, Sale of Stock [Line Items]                  
Sale common stock       $ 65,600,000          
Sale of stock, number of shares issued in transaction (in shares) | shares       37,634,883          
Share price (in dollars per share) | $ / shares       $ 1.46          
Class of warrant or right, outstanding (in shares) | shares       22,988,501          
Warrant Issued       $ 40,700,000          
Issuance costs             4,400,000    
Warrant liabilities           $ 45,500,000      
Warrant, increase (decrease) in equity, amount           $ (16,700,000) $ (800,000)    
December 2019 Financing | Pre-Funded Warrant                  
Subsidiary, Sale of Stock [Line Items]                  
Class of warrant or right, number of warrants exercised (in shares) | shares       8,342,128          
Exercise price (in dollars per share) | $ / shares       $ 0.0001          
December 2019 Financing | Common Warrant                  
Subsidiary, Sale of Stock [Line Items]                  
Share price (in dollars per share) | $ / shares       0.125          
Exercise price (in dollars per share) | $ / shares       $ 1.46          
2017 PIPE                  
Subsidiary, Sale of Stock [Line Items]                  
Common stock, shares authorized (in shares) | shares           200,000,000      
Common stock, par value (in dollars per share) | $ / shares           $ 0.0001      
XML 70 R58.htm IDEA: XBRL DOCUMENT v3.21.1
Equity - Warranty Activity (Details) - $ / shares
shares in Thousands
Mar. 31, 2021
Aug. 31, 2020
Class of Warrant or Right [Line Items]    
Class of warrant or right, outstanding (in shares) 12,378,016  
Exercise price (in dollars per share) $ 1.60 $ 2.54
Exercise of common warrants    
Class of Warrant or Right [Line Items]    
Class of warrant or right, outstanding (in shares) 292,469  
Exercise of common warrants    
Class of Warrant or Right [Line Items]    
Class of warrant or right, outstanding (in shares) 12,085,547  
XML 71 R59.htm IDEA: XBRL DOCUMENT v3.21.1
Equity - Schedule of Authorized Shares of Common Stock for Future Issuance (Details) - shares
Mar. 31, 2021
Dec. 31, 2020
Class of Stock [Line Items]    
Total (in shares) 30,928,290 25,157,139
Shares available for future stock incentive awards    
Class of Stock [Line Items]    
Total (in shares) 7,719,817 4,916,374
RSUs reserved for issuance    
Class of Stock [Line Items]    
Total (in shares) 98,750 0
Unvested restricted stock units    
Class of Stock [Line Items]    
Total (in shares) 544,313 87,500
Outstanding common stock options    
Class of Stock [Line Items]    
Total (in shares) 10,187,394 7,775,249
Exercise of common warrants    
Class of Stock [Line Items]    
Total (in shares) 12,378,016 12,378,016
XML 72 R60.htm IDEA: XBRL DOCUMENT v3.21.1
Stock Incentive Plans - Narrative (Details) - USD ($)
1 Months Ended 3 Months Ended
Jan. 31, 2021
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Mar. 25, 2019
Sep. 25, 2018
Jun. 21, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Common stock authorized and reserved for future issuance (in shares)   30,928,290   25,157,139      
Stock‑based compensation expense   $ 1,780,000 $ 1,409,000        
Unrecognized compensation expense related to unvested non-employee stock options   $ 0          
Employee stock option grants              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Common stock authorized and reserved for future issuance (in shares)   7,719,817   4,916,374      
Estimated forfeitures rate   10.00%          
Weighted average grant date fair value of stock options (in dollars per share)   $ 1.99 $ 1.69        
Unrecognized compensation expense related to unvested employee stock options   $ 11,800,000          
Weighted average period for recognition   2 years 8 months 12 days          
Unvested restricted stock units              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Grants in period (in dollars per share)   $ 2.99          
Grants in period (in shares)   468,550          
Reserved for issuance (in shares)   98,750          
Reserved for issuance (in dollars per share)   $ 2.99          
2016 Plan              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of shares authorized for grants (in shares)             1,210,256
Number of shares authorized, increase (in shares)   4,322,850 3,453,022        
Common stock authorized and reserved for future issuance (in shares)   3,248,520          
2016 Plan | Unvested restricted stock units              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Vested in period   $ 1,400,000          
Grants in period (in shares) 369,800 98,750          
Awarded in period (in shares)   197,500          
Reserved for issuance (in shares)   98,750          
Award vesting term   4 years          
Employment Inducement Incentive Award Plan              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of shares authorized for grants (in shares)   1,358,333          
Common stock authorized and reserved for future issuance (in shares)         2,000,000 1,175,000  
Employment Inducement Incentive Award Plan | Unvested restricted stock units              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Weighted average period for recognition   3 years 1 month 6 days          
Unrecognized compensation expense   $ 1,500,000          
ESPP              
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]              
Number of shares authorized, increase (in shares)   1,080,711 863,254        
Common stock authorized and reserved for future issuance (in shares)   2,546,464         173,076
Stock‑based compensation expense   $ 100,000 $ 100,000        
XML 73 R61.htm IDEA: XBRL DOCUMENT v3.21.1
Stock Incentive Plans - Schedule of Stock-Based Compensation Expense Related to Stock Options and Restricted Common Stock (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense $ 1,780 $ 1,409
Research and development    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense 754 623
General and administrative    
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]    
Total stock-based compensation expense $ 1,026 $ 786
XML 74 R62.htm IDEA: XBRL DOCUMENT v3.21.1
Stock Incentive Plans - Schedule of Assumptions (Details) - Shares available for future stock incentive awards - $ / shares
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Risk-free interest rate 0.44% 1.73%
Dividend yield 0.00% 0.00%
Expected term 5 years 3 months 10 days 6 years 29 days
Expected volatility 83.26% 87.96%
Weighted-average fair value of common stock (in dollars per share) $ 3.13 $ 2.30
XML 75 R63.htm IDEA: XBRL DOCUMENT v3.21.1
Stock Incentive Plans - Summary of Options Activity (Details) - 2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Employees    
Number of Options    
Beginning balance (in shares) 7,302,176  
Granted (in shares) 2,628,000  
Exercised (in shares) (153,278)  
Forfeited (in shares) (62,577)  
Ending balance (in shares) 9,714,321 7,302,176
Vested (in shares) 3,064,130  
Vested and expected to vest (in shares) 8,920,548  
Weighted-average exercise price    
Beginning balance (in dollars per share) $ 3.98  
Granted (in dollars per share) 3.13  
Exercised (in dollars per share) 1.47  
Forfeited (in dollars per share) 5.19  
Ending balance (in dollars per share) 3.78 $ 3.98
Vested (in dollars per share) 5.46  
Vested and expected to vest (in dollars per share) $ 3.88  
Weighted-average remaining contractual term    
Outstanding, term 8 years 7 months 24 days 8 years 5 months 4 days
Vested, term 7 years 7 months 17 days  
Vested and expected to vest, term 8 years 7 months 2 days  
Aggregate intrinsic value    
Outstanding $ 15,665 $ 4,456
Vested 4,313  
Vested and expected to vest $ 14,231  
Non-employee consultants    
Number of Options    
Beginning balance (in shares) 473,073  
Granted (in shares) 0  
Exercised (in shares) 0  
Forfeited (in shares) 0  
Ending balance (in shares) 473,073 473,073
Vested (in shares) 462,186  
Vested and expected to vest (in shares) 473,073  
Weighted-average exercise price    
Beginning balance (in dollars per share) $ 5.89  
Granted (in dollars per share) 0  
Exercised (in dollars per share) 0  
Forfeited (in dollars per share) 0  
Ending balance (in dollars per share) 5.89 $ 5.89
Vested (in dollars per share) 5.82  
Vested and expected to vest (in dollars per share) $ 5.89  
Weighted-average remaining contractual term    
Outstanding, term 4 years 11 months 23 days 5 years 2 months 23 days
Vested, term 4 years 11 months 1 day  
Vested and expected to vest, term 4 years 11 months 23 days  
Aggregate intrinsic value    
Outstanding $ 366 $ 86
Vested 366  
Vested and expected to vest $ 366  
XML 76 R64.htm IDEA: XBRL DOCUMENT v3.21.1
Stock Incentive Plans - Restricted Stock Units (Details) - Unvested restricted stock units
3 Months Ended
Mar. 31, 2021
$ / shares
shares
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Unvested at beginning of period (in shares) | shares 87,500
Grants in period (in shares) | shares 468,550
Vested in period (in shares) | shares (10,937)
Reserved for issuance (in shares) | shares 98,750
Forfeited in period (in shares) | shares (800)
Unvested at end of period (in shares) | shares 643,063
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Unvested at beginning of period (in dollars per share) | $ / shares $ 6.03
Grants in period (in dollars per share) | $ / shares 2.99
Vested in period (in dollars per share) | $ / shares 6.03
Reserved for issuance (in dollars per share) | $ / shares 2.99
Forfeited in period (in dollars per share) | $ / shares 2.99
Unvested at end of period (in dollars per share) | $ / shares $ 3.35
XML 77 R65.htm IDEA: XBRL DOCUMENT v3.21.1
Stock Incentive Plans - Employee Stock Purchase Plan (Narrative) (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Dec. 31, 2020
Jun. 21, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Common stock authorized and reserved for future issuance (in shares) 30,928,290   25,157,139  
Stock-based compensation expense $ 1,780 $ 1,409    
ESPP        
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]        
Common stock authorized and reserved for future issuance (in shares) 2,546,464     173,076
Number of shares authorized, increase (in shares) 1,080,711 863,254    
Shares of common stock issued to employees under the ESPP (in shares) 34,696      
Stock-based compensation expense $ 100 $ 100    
XML 78 R66.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Arrangements - Narrative (Details)
3 Months Ended
Jul. 28, 2020
USD ($)
Jun. 13, 2020
USD ($)
Jun. 11, 2020
USD ($)
obligation
Dec. 17, 2019
USD ($)
Mar. 31, 2021
USD ($)
Mar. 31, 2020
USD ($)
Dec. 31, 2020
USD ($)
Disaggregation of Revenue [Line Items]              
Short-term contract liability         $ 75,764,000   $ 72,050,000
Long-term contract liability         32,301,000   38,746,000
Contract assets amortization (less than)         100,000    
Accounts receivable         8,342,000   7,224,000
Revenue recognized         2,730,000    
Remaining performance obligation         108,100,000    
SOBI Purchase Agreement              
Disaggregation of Revenue [Line Items]              
Sale common stock     $ 25,000,000.0        
Redemption premium $ 14,500,000            
Short-term contract liability         72,000,000.0   68,300,000
Long-term contract liability         17,800,000   24,200,000
Contract assets         1,300,000    
Accounts receivable         8,300,000   6,900,000
Revenue recognized         11,100,000    
SOBI Purchase Agreement | Prepaid Expenses and Other Current Assets              
Disaggregation of Revenue [Line Items]              
Contract assets         1,000,000.0    
SOBI Purchase Agreement | Other Current Assets              
Disaggregation of Revenue [Line Items]              
Contract assets         300,000    
Collaborative Arrangement              
Disaggregation of Revenue [Line Items]              
Upfront cash payment     75,000,000.0        
Sales milestone payments     $ 630,000,000.0        
License and option agreement, written day notice period before cancellation     180 days        
Period after first commercial sale when the Company is eligible to receive royalties     10 years        
Number of obligations | obligation     3        
Development milestone     $ 5,000,000.0        
Sarepta Therapeutics, Inc.              
Disaggregation of Revenue [Line Items]              
Upfront cash payment   $ 2,000,000.0          
License and option agreement, written day notice period before cancellation   30 days          
Short-term contract liability         2,000,000.0   2,000,000.0
Revenue recognized         0 $ 0  
Option term   24 months          
License Agreement For Pompe Disease              
Disaggregation of Revenue [Line Items]              
Upfront cash payment       $ 7,000,000.0      
Sales milestone payments       $ 237,000,000.0      
Period after first commercial sale when the Company is eligible to receive royalties       10 years      
Short-term contract liability         1,700,000   1,700,000
Long-term contract liability         5,300,000   $ 5,300,000
Revenue recognized         $ 0 $ 0  
Initial up-front cash payment       $ 2,000,000.0      
Initial upfront execution fee payment       $ 5,000,000.0      
XML 79 R67.htm IDEA: XBRL DOCUMENT v3.21.1
Revenue Arrangements - Schedule of Changes in Contract Liabilities (Details)
$ in Thousands
3 Months Ended
Mar. 31, 2021
USD ($)
Contract liabilities:  
Deferred revenue, beginning of period $ 110,796
Contract liabilities, beginning of period 110,796
Deferred revenue, additions 0
Contract liabilities, additions 0
Deferred revenue, deductions (2,730)
Contract liabilities, deductions (2,730)
Deferred revenue, end of period 108,066
Contract liabilities, end of period $ 108,066
XML 80 R68.htm IDEA: XBRL DOCUMENT v3.21.1
Related-Party Transactions - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Founders    
Related Party Transaction [Line Items]    
Consulting services expenses (less than) $ 0.1 $ 0.1
XML 81 R69.htm IDEA: XBRL DOCUMENT v3.21.1
Collaboration Agreements - AskBio (Narrative) (Details) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Operating expenses $ 18,208 $ 18,822
AskBio License    
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]    
Operating expenses   $ 1,200
Cost share percentage 50.00%  
XML 82 R70.htm IDEA: XBRL DOCUMENT v3.21.1
Collaboration Agreements - MIT (Narrative) (Details) - Spark License Agreement
3 Months Ended
Mar. 31, 2021
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Contractual payments defined in the Exclusive Patent License agreement $ 0
MIT  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Contractual payments defined in the Exclusive Patent License agreement 2,200,000
License and option agreement, payments made relative to calculated premium paid for initial equity investment made under the purchase agreement $ 400,000
XML 83 R71.htm IDEA: XBRL DOCUMENT v3.21.1
Collaboration Agreements - Shenyang Sunshine Pharmaceutical Co., Ltd (Narrative) (Details) - 3SBio License
$ in Millions
3 Months Ended
Mar. 31, 2021
USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]  
Aggregate amount of upfront and milestone-based payments $ 7.0
Aggregate amount for future payments upon achievement of clinical and regulatory approval milestones for products containing ImmTOR platform $ 15.0
XML 84 R72.htm IDEA: XBRL DOCUMENT v3.21.1
Income Taxes - Narrative (Details) - USD ($)
Mar. 31, 2021
Dec. 31, 2020
Income Tax Disclosure [Abstract]    
Operating loss carryforwards, carried forward indefinitely $ 234,500,000  
Net operating losses available for use through 2028 36,500,000  
Unrecognized tax benefits $ 0 $ 0
XML 85 R73.htm IDEA: XBRL DOCUMENT v3.21.1
Defined Contribution Plan - Narrative (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Retirement Benefits [Abstract]    
Vesting period 4 years  
Employer contribution made $ 0.1 $ 0.1
XML 86 R74.htm IDEA: XBRL DOCUMENT v3.21.1
Subsequent Events (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended
Apr. 13, 2021
May 13, 2021
Aug. 31, 2017
Sarepta Therapeutics, Inc. | Forecast      
Subsequent Event [Line Items]      
Milestone payment $ 3.0    
2020 Sale Agreement - At-the-Market Offering      
Subsequent Event [Line Items]      
Sale common stock     $ 50.0
Subsequent Event | 2020 Sale Agreement - At-the-Market Offering      
Subsequent Event [Line Items]      
Sale of stock, number of shares issued in transaction (in shares)   206,593  
Share price (in dollars per share)   $ 4.51  
Sale common stock   $ 0.9  
EXCEL 87 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 89 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 90 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 195 392 1 false 72 0 false 7 false false R1.htm 0001001 - Document - Cover page Sheet http://www.selectabio.com/role/Coverpage Cover page Cover 1 false false R2.htm 1001002 - Statement - Consolidated Balance Sheets Sheet http://www.selectabio.com/role/ConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 1002003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss Sheet http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss Consolidated Statements of Operations and Comprehensive Loss Statements 4 false false R5.htm 1004005 - Statement - Consolidated Statements of Changes in Stockholders??? (Deficit) Equity Sheet http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity Consolidated Statements of Changes in Stockholders??? (Deficit) Equity Statements 5 false false R6.htm 1005006 - Statement - Consolidated Statements of Cash Flows Sheet http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 2101101 - Disclosure - Nature of the Business and Basis of Presentation Sheet http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentation Nature of the Business and Basis of Presentation Notes 7 false false R8.htm 2103102 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.selectabio.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 2105103 - Disclosure - Marketable Securities Sheet http://www.selectabio.com/role/MarketableSecurities Marketable Securities Notes 9 false false R10.htm 2109104 - Disclosure - Net Loss Per Share Sheet http://www.selectabio.com/role/NetLossPerShare Net Loss Per Share Notes 10 false false R11.htm 2113105 - Disclosure - Fair Value Measurements Sheet http://www.selectabio.com/role/FairValueMeasurements Fair Value Measurements Notes 11 false false R12.htm 2120106 - Disclosure - Property and Equipment Sheet http://www.selectabio.com/role/PropertyandEquipment Property and Equipment Notes 12 false false R13.htm 2124107 - Disclosure - Accrued Expenses Sheet http://www.selectabio.com/role/AccruedExpenses Accrued Expenses Notes 13 false false R14.htm 2127108 - Disclosure - Leases Sheet http://www.selectabio.com/role/Leases Leases Notes 14 false false R15.htm 2135109 - Disclosure - Debt Sheet http://www.selectabio.com/role/Debt Debt Notes 15 false false R16.htm 2139110 - Disclosure - Equity Sheet http://www.selectabio.com/role/Equity Equity Notes 16 false false R17.htm 2144111 - Disclosure - Stock Incentive Plans Sheet http://www.selectabio.com/role/StockIncentivePlans Stock Incentive Plans Notes 17 false false R18.htm 2152112 - Disclosure - Revenue Arrangements Sheet http://www.selectabio.com/role/RevenueArrangements Revenue Arrangements Notes 18 false false R19.htm 2156113 - Disclosure - Related-Party Transactions Sheet http://www.selectabio.com/role/RelatedPartyTransactions Related-Party Transactions Notes 19 false false R20.htm 2158114 - Disclosure - Collaboration Agreements Sheet http://www.selectabio.com/role/CollaborationAgreements Collaboration Agreements Notes 20 false false R21.htm 2162115 - Disclosure - Income Taxes Sheet http://www.selectabio.com/role/IncomeTaxes Income Taxes Notes 21 false false R22.htm 2164116 - Disclosure - Defined Contribution Plan Sheet http://www.selectabio.com/role/DefinedContributionPlan Defined Contribution Plan Notes 22 false false R23.htm 2166117 - Disclosure - Commitments and Contingencies Sheet http://www.selectabio.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 23 false false R24.htm 2167118 - Disclosure - Subsequent Events Sheet http://www.selectabio.com/role/SubsequentEvents Subsequent Events Notes 24 false false R25.htm 2204201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.selectabio.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.selectabio.com/role/SummaryofSignificantAccountingPolicies 25 false false R26.htm 2306301 - Disclosure - Marketable Securities (Tables) Sheet http://www.selectabio.com/role/MarketableSecuritiesTables Marketable Securities (Tables) Tables http://www.selectabio.com/role/MarketableSecurities 26 false false R27.htm 2310302 - Disclosure - Net Loss Per Share (Tables) Sheet http://www.selectabio.com/role/NetLossPerShareTables Net Loss Per Share (Tables) Tables http://www.selectabio.com/role/NetLossPerShare 27 false false R28.htm 2314303 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.selectabio.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.selectabio.com/role/FairValueMeasurements 28 false false R29.htm 2321304 - Disclosure - Property and Equipment (Tables) Sheet http://www.selectabio.com/role/PropertyandEquipmentTables Property and Equipment (Tables) Tables http://www.selectabio.com/role/PropertyandEquipment 29 false false R30.htm 2325305 - Disclosure - Accrued Expenses (Tables) Sheet http://www.selectabio.com/role/AccruedExpensesTables Accrued Expenses (Tables) Tables http://www.selectabio.com/role/AccruedExpenses 30 false false R31.htm 2328306 - Disclosure - Leases (Tables) Sheet http://www.selectabio.com/role/LeasesTables Leases (Tables) Tables http://www.selectabio.com/role/Leases 31 false false R32.htm 2336307 - Disclosure - Debt (Tables) Sheet http://www.selectabio.com/role/DebtTables Debt (Tables) Tables http://www.selectabio.com/role/Debt 32 false false R33.htm 2340308 - Disclosure - Equity (Tables) Sheet http://www.selectabio.com/role/EquityTables Equity (Tables) Tables http://www.selectabio.com/role/Equity 33 false false R34.htm 2345309 - Disclosure - Stock Incentive Plans (Tables) Sheet http://www.selectabio.com/role/StockIncentivePlansTables Stock Incentive Plans (Tables) Tables http://www.selectabio.com/role/StockIncentivePlans 34 false false R35.htm 2353310 - Disclosure - Revenue Arrangements (Tables) Sheet http://www.selectabio.com/role/RevenueArrangementsTables Revenue Arrangements (Tables) Tables http://www.selectabio.com/role/RevenueArrangements 35 false false R36.htm 2402401 - Disclosure - Nature of the Business and Basis of Presentation - Liquidity (Details) Sheet http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails Nature of the Business and Basis of Presentation - Liquidity (Details) Details http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentation 36 false false R37.htm 2407402 - Disclosure - Marketable Securities - Summary of Available-for-Sale Marketable Securities (Details) Sheet http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails Marketable Securities - Summary of Available-for-Sale Marketable Securities (Details) Details 37 false false R38.htm 2408403 - Disclosure - Marketable Securities - Narrative (Details) Sheet http://www.selectabio.com/role/MarketableSecuritiesNarrativeDetails Marketable Securities - Narrative (Details) Details 38 false false R39.htm 2411404 - Disclosure - Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) Sheet http://www.selectabio.com/role/NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details) Details 39 false false R40.htm 2412405 - Disclosure - Net Loss Per Share - Schedule of Potential Common Shares Issuable Upon Conversion of Warrants (Details) Sheet http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails Net Loss Per Share - Schedule of Potential Common Shares Issuable Upon Conversion of Warrants (Details) Details 40 false false R41.htm 2415406 - Disclosure - Fair Value Measurements - Summary of Assets Measured at Fair Value on a Recurring Basis (Details) Sheet http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails Fair Value Measurements - Summary of Assets Measured at Fair Value on a Recurring Basis (Details) Details 41 false false R42.htm 2416407 - Disclosure - Fair Value Measurements - Assumptions used to record the fair value of the warrants (Details) Sheet http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails Fair Value Measurements - Assumptions used to record the fair value of the warrants (Details) Details 42 false false R43.htm 2417408 - Disclosure - Fair Value Measurements - Change in the warrant liabilities (Details) Sheet http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails Fair Value Measurements - Change in the warrant liabilities (Details) Details 43 false false R44.htm 2418409 - Disclosure - Fair Value Measurements - Narrative (Details) Sheet http://www.selectabio.com/role/FairValueMeasurementsNarrativeDetails Fair Value Measurements - Narrative (Details) Details 44 false false R45.htm 2419410 - Disclosure - Fair Value Measurements - Schedule of Cash and Cash Equivalents (Details) Sheet http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails Fair Value Measurements - Schedule of Cash and Cash Equivalents (Details) Details 45 false false R46.htm 2422411 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details) Sheet http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails Property and Equipment - Schedule of Property and Equipment (Details) Details 46 false false R47.htm 2423412 - Disclosure - Property and Equipment - Narrative (Details) Sheet http://www.selectabio.com/role/PropertyandEquipmentNarrativeDetails Property and Equipment - Narrative (Details) Details 47 false false R48.htm 2426413 - Disclosure - Accrued Expenses (Details) Sheet http://www.selectabio.com/role/AccruedExpensesDetails Accrued Expenses (Details) Details http://www.selectabio.com/role/AccruedExpensesTables 48 false false R49.htm 2429414 - Disclosure - Leases - Narrative (Details) Sheet http://www.selectabio.com/role/LeasesNarrativeDetails Leases - Narrative (Details) Details 49 false false R50.htm 2430415 - Disclosure - Leases - Components of Operating Leases (Details) Sheet http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails Leases - Components of Operating Leases (Details) Details 50 false false R51.htm 2431416 - Disclosure - Leases - Components of lease costs (Details) Sheet http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails Leases - Components of lease costs (Details) Details 51 false false R52.htm 2432417 - Disclosure - Leases - Operating Lease, Liability, Maturity (Details) Sheet http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails Leases - Operating Lease, Liability, Maturity (Details) Details 52 false false R53.htm 2433418 - Disclosure - Leases - Other Information (Details) Sheet http://www.selectabio.com/role/LeasesOtherInformationDetails Leases - Other Information (Details) Details 53 false false R54.htm 2434419 - Disclosure - Leases - Lease Term and Discount Rate (Details) Sheet http://www.selectabio.com/role/LeasesLeaseTermandDiscountRateDetails Leases - Lease Term and Discount Rate (Details) Details 54 false false R55.htm 2437420 - Disclosure - Debt - Term Loans (Narrative) (Details) Sheet http://www.selectabio.com/role/DebtTermLoansNarrativeDetails Debt - Term Loans (Narrative) (Details) Details 55 false false R56.htm 2438421 - Disclosure - Debt - Schedule of Future Minimum Payments on the Term Loans (Details) Sheet http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails Debt - Schedule of Future Minimum Payments on the Term Loans (Details) Details 56 false false R57.htm 2441422 - Disclosure - Equity - Narrative (Details) Sheet http://www.selectabio.com/role/EquityNarrativeDetails Equity - Narrative (Details) Details 57 false false R58.htm 2442423 - Disclosure - Equity - Warranty Activity (Details) Sheet http://www.selectabio.com/role/EquityWarrantyActivityDetails Equity - Warranty Activity (Details) Details 58 false false R59.htm 2443424 - Disclosure - Equity - Schedule of Authorized Shares of Common Stock for Future Issuance (Details) Sheet http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails Equity - Schedule of Authorized Shares of Common Stock for Future Issuance (Details) Details 59 false false R60.htm 2446425 - Disclosure - Stock Incentive Plans - Narrative (Details) Sheet http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails Stock Incentive Plans - Narrative (Details) Details 60 false false R61.htm 2447426 - Disclosure - Stock Incentive Plans - Schedule of Stock-Based Compensation Expense Related to Stock Options and Restricted Common Stock (Details) Sheet http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails Stock Incentive Plans - Schedule of Stock-Based Compensation Expense Related to Stock Options and Restricted Common Stock (Details) Details 61 false false R62.htm 2448427 - Disclosure - Stock Incentive Plans - Schedule of Assumptions (Details) Sheet http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails Stock Incentive Plans - Schedule of Assumptions (Details) Details 62 false false R63.htm 2449428 - Disclosure - Stock Incentive Plans - Summary of Options Activity (Details) Sheet http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails Stock Incentive Plans - Summary of Options Activity (Details) Details 63 false false R64.htm 2450429 - Disclosure - Stock Incentive Plans - Restricted Stock Units (Details) Sheet http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails Stock Incentive Plans - Restricted Stock Units (Details) Details 64 false false R65.htm 2451430 - Disclosure - Stock Incentive Plans - Employee Stock Purchase Plan (Narrative) (Details) Sheet http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails Stock Incentive Plans - Employee Stock Purchase Plan (Narrative) (Details) Details 65 false false R66.htm 2454431 - Disclosure - Revenue Arrangements - Narrative (Details) Sheet http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails Revenue Arrangements - Narrative (Details) Details 66 false false R67.htm 2455432 - Disclosure - Revenue Arrangements - Schedule of Changes in Contract Liabilities (Details) Sheet http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails Revenue Arrangements - Schedule of Changes in Contract Liabilities (Details) Details 67 false false R68.htm 2457433 - Disclosure - Related-Party Transactions - Narrative (Details) Sheet http://www.selectabio.com/role/RelatedPartyTransactionsNarrativeDetails Related-Party Transactions - Narrative (Details) Details 68 false false R69.htm 2459434 - Disclosure - Collaboration Agreements - AskBio (Narrative) (Details) Sheet http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails Collaboration Agreements - AskBio (Narrative) (Details) Details 69 false false R70.htm 2460435 - Disclosure - Collaboration Agreements - MIT (Narrative) (Details) Sheet http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails Collaboration Agreements - MIT (Narrative) (Details) Details http://www.selectabio.com/role/CollaborationAgreements 70 false false R71.htm 2461436 - Disclosure - Collaboration Agreements - Shenyang Sunshine Pharmaceutical Co., Ltd (Narrative) (Details) Sheet http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails Collaboration Agreements - Shenyang Sunshine Pharmaceutical Co., Ltd (Narrative) (Details) Details 71 false false R72.htm 2463437 - Disclosure - Income Taxes - Narrative (Details) Sheet http://www.selectabio.com/role/IncomeTaxesNarrativeDetails Income Taxes - Narrative (Details) Details 72 false false R73.htm 2465438 - Disclosure - Defined Contribution Plan - Narrative (Details) Sheet http://www.selectabio.com/role/DefinedContributionPlanNarrativeDetails Defined Contribution Plan - Narrative (Details) Details 73 false false R74.htm 2468439 - Disclosure - Subsequent Events (Details) Sheet http://www.selectabio.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.selectabio.com/role/SubsequentEvents 74 false false All Reports Book All Reports selb-20210331.htm exhibit101_dircompprogram.htm exhibit311_03312021.htm exhibit312_03312021.htm exhibit321_03312021.htm exhibit322_03312021.htm selb-20210331.xsd selb-20210331_cal.xml selb-20210331_def.xml selb-20210331_lab.xml selb-20210331_pre.xml http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/country/2020-01-31 true true JSON 92 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "selb-20210331.htm": { "axisCustom": 1, "axisStandard": 23, "contextCount": 195, "dts": { "calculationLink": { "local": [ "selb-20210331_cal.xml" ] }, "definitionLink": { "local": [ "selb-20210331_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "selb-20210331.htm" ] }, "labelLink": { "local": [ "selb-20210331_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "selb-20210331_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "selb-20210331.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 535, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 5, "total": 5 }, "keyCustom": 50, "keyStandard": 342, "memberCustom": 28, "memberStandard": 39, "nsprefix": "selb", "nsuri": "http://www.selectabio.com/20210331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover page", "role": "http://www.selectabio.com/role/Coverpage", "shortName": "Cover page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2109104 - Disclosure - Net Loss Per Share", "role": "http://www.selectabio.com/role/NetLossPerShare", "shortName": "Net Loss Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2113105 - Disclosure - Fair Value Measurements", "role": "http://www.selectabio.com/role/FairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2120106 - Disclosure - Property and Equipment", "role": "http://www.selectabio.com/role/PropertyandEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2124107 - Disclosure - Accrued Expenses", "role": "http://www.selectabio.com/role/AccruedExpenses", "shortName": "Accrued Expenses", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2127108 - Disclosure - Leases", "role": "http://www.selectabio.com/role/Leases", "shortName": "Leases", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2135109 - Disclosure - Debt", "role": "http://www.selectabio.com/role/Debt", "shortName": "Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2139110 - Disclosure - Equity", "role": "http://www.selectabio.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2144111 - Disclosure - Stock Incentive Plans", "role": "http://www.selectabio.com/role/StockIncentivePlans", "shortName": "Stock Incentive Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2152112 - Disclosure - Revenue Arrangements", "role": "http://www.selectabio.com/role/RevenueArrangements", "shortName": "Revenue Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2156113 - Disclosure - Related-Party Transactions", "role": "http://www.selectabio.com/role/RelatedPartyTransactions", "shortName": "Related-Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - Consolidated Balance Sheets", "role": "http://www.selectabio.com/role/ConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "selb:CollaborationAndLicenseAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2158114 - Disclosure - Collaboration Agreements", "role": "http://www.selectabio.com/role/CollaborationAgreements", "shortName": "Collaboration Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "selb:CollaborationAndLicenseAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2162115 - Disclosure - Income Taxes", "role": "http://www.selectabio.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2164116 - Disclosure - Defined Contribution Plan", "role": "http://www.selectabio.com/role/DefinedContributionPlan", "shortName": "Defined Contribution Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2166117 - Disclosure - Commitments and Contingencies", "role": "http://www.selectabio.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2167118 - Disclosure - Subsequent Events", "role": "http://www.selectabio.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)", "role": "http://www.selectabio.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2306301 - Disclosure - Marketable Securities (Tables)", "role": "http://www.selectabio.com/role/MarketableSecuritiesTables", "shortName": "Marketable Securities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2310302 - Disclosure - Net Loss Per Share (Tables)", "role": "http://www.selectabio.com/role/NetLossPerShareTables", "shortName": "Net Loss Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2314303 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.selectabio.com/role/FairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2321304 - Disclosure - Property and Equipment (Tables)", "role": "http://www.selectabio.com/role/PropertyandEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2325305 - Disclosure - Accrued Expenses (Tables)", "role": "http://www.selectabio.com/role/AccruedExpensesTables", "shortName": "Accrued Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "selb:LesseeComponentsOfOperatingLeaseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2328306 - Disclosure - Leases (Tables)", "role": "http://www.selectabio.com/role/LeasesTables", "shortName": "Leases (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "selb:LesseeComponentsOfOperatingLeaseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2336307 - Disclosure - Debt (Tables)", "role": "http://www.selectabio.com/role/DebtTables", "shortName": "Debt (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2340308 - Disclosure - Equity (Tables)", "role": "http://www.selectabio.com/role/EquityTables", "shortName": "Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2345309 - Disclosure - Stock Incentive Plans (Tables)", "role": "http://www.selectabio.com/role/StockIncentivePlansTables", "shortName": "Stock Incentive Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2353310 - Disclosure - Revenue Arrangements (Tables)", "role": "http://www.selectabio.com/role/RevenueArrangementsTables", "shortName": "Revenue Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "selb:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2402401 - Disclosure - Nature of the Business and Basis of Presentation - Liquidity (Details)", "role": "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails", "shortName": "Nature of the Business and Basis of Presentation - Liquidity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "selb:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2407402 - Disclosure - Marketable Securities - Summary of Available-for-Sale Marketable Securities (Details)", "role": "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails", "shortName": "Marketable Securities - Summary of Available-for-Sale Marketable Securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2408403 - Disclosure - Marketable Securities - Narrative (Details)", "role": "http://www.selectabio.com/role/MarketableSecuritiesNarrativeDetails", "shortName": "Marketable Securities - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2411404 - Disclosure - Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details)", "role": "http://www.selectabio.com/role/NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails", "shortName": "Net Loss Per Share - Computation of Basic and Diluted Net Loss Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "role": "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2412405 - Disclosure - Net Loss Per Share - Schedule of Potential Common Shares Issuable Upon Conversion of Warrants (Details)", "role": "http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails", "shortName": "Net Loss Per Share - Schedule of Potential Common Shares Issuable Upon Conversion of Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415406 - Disclosure - Fair Value Measurements - Summary of Assets Measured at Fair Value on a Recurring Basis (Details)", "role": "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails", "shortName": "Fair Value Measurements - Summary of Assets Measured at Fair Value on a Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ief7e41d172914136a4d75381f191624f_I20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i09c393762b464d30a19a24b55c2f5d20_I20210331", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2416407 - Disclosure - Fair Value Measurements - Assumptions used to record the fair value of the warrants (Details)", "role": "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails", "shortName": "Fair Value Measurements - Assumptions used to record the fair value of the warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i09c393762b464d30a19a24b55c2f5d20_I20210331", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i118f57dc685b47c8b1b5f190c4eed731_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2417408 - Disclosure - Fair Value Measurements - Change in the warrant liabilities (Details)", "role": "http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails", "shortName": "Fair Value Measurements - Change in the warrant liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i118f57dc685b47c8b1b5f190c4eed731_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418409 - Disclosure - Fair Value Measurements - Narrative (Details)", "role": "http://www.selectabio.com/role/FairValueMeasurementsNarrativeDetails", "shortName": "Fair Value Measurements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419410 - Disclosure - Fair Value Measurements - Schedule of Cash and Cash Equivalents (Details)", "role": "http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails", "shortName": "Fair Value Measurements - Schedule of Cash and Cash Equivalents (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "iff7e2530342c41bca8c84fce55f0cc6f_I20200331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422411 - Disclosure - Property and Equipment - Schedule of Property and Equipment (Details)", "role": "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails", "shortName": "Property and Equipment - Schedule of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423412 - Disclosure - Property and Equipment - Narrative (Details)", "role": "http://www.selectabio.com/role/PropertyandEquipmentNarrativeDetails", "shortName": "Property and Equipment - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426413 - Disclosure - Accrued Expenses (Details)", "role": "http://www.selectabio.com/role/AccruedExpensesDetails", "shortName": "Accrued Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LeaseCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2429414 - Disclosure - Leases - Narrative (Details)", "role": "http://www.selectabio.com/role/LeasesNarrativeDetails", "shortName": "Leases - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i8a6242358159403bbb0d1d272fafb3bc_I20190731", "decimals": "0", "lang": "en-US", "name": "us-gaap:AreaOfRealEstateProperty", "reportCount": 1, "unique": true, "unitRef": "sqft", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i8f5d5586be294d54be1415ab00417669_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - Consolidated Statements of Changes in Stockholders\u2019 (Deficit) Equity", "role": "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity", "shortName": "Consolidated Statements of Changes in Stockholders\u2019 (Deficit) Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i8f5d5586be294d54be1415ab00417669_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2430415 - Disclosure - Leases - Components of Operating Leases (Details)", "role": "http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails", "shortName": "Leases - Components of Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431416 - Disclosure - Leases - Components of lease costs (Details)", "role": "http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails", "shortName": "Leases - Components of lease costs (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432417 - Disclosure - Leases - Operating Lease, Liability, Maturity (Details)", "role": "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails", "shortName": "Leases - Operating Lease, Liability, Maturity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2433418 - Disclosure - Leases - Other Information (Details)", "role": "http://www.selectabio.com/role/LeasesOtherInformationDetails", "shortName": "Leases - Other Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434419 - Disclosure - Leases - Lease Term and Discount Rate (Details)", "role": "http://www.selectabio.com/role/LeasesLeaseTermandDiscountRateDetails", "shortName": "Leases - Lease Term and Discount Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2437420 - Disclosure - Debt - Term Loans (Narrative) (Details)", "role": "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails", "shortName": "Debt - Term Loans (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438421 - Disclosure - Debt - Schedule of Future Minimum Payments on the Term Loans (Details)", "role": "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails", "shortName": "Debt - Schedule of Future Minimum Payments on the Term Loans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i867f4cd50cdf4945bf8a2b4c13258dfd_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441422 - Disclosure - Equity - Narrative (Details)", "role": "http://www.selectabio.com/role/EquityNarrativeDetails", "shortName": "Equity - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "INF", "lang": "en-US", "name": "selb:VotesPerShareofCommonStock", "reportCount": 1, "unique": true, "unitRef": "vote", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2442423 - Disclosure - Equity - Warranty Activity (Details)", "role": "http://www.selectabio.com/role/EquityWarrantyActivityDetails", "shortName": "Equity - Warranty Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "id99ce4003b574f658d3b62852041d661_I20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2443424 - Disclosure - Equity - Schedule of Authorized Shares of Common Stock for Future Issuance (Details)", "role": "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails", "shortName": "Equity - Schedule of Authorized Shares of Common Stock for Future Issuance (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "icaed7df33b254fc68b5b0e15b600935f_I20210331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:OtherDepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446425 - Disclosure - Stock Incentive Plans - Narrative (Details)", "role": "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails", "shortName": "Stock Incentive Plans - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "INF", "lang": "en-US", "name": "selb:ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2447426 - Disclosure - Stock Incentive Plans - Schedule of Stock-Based Compensation Expense Related to Stock Options and Restricted Common Stock (Details)", "role": "http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails", "shortName": "Stock Incentive Plans - Schedule of Stock-Based Compensation Expense Related to Stock Options and Restricted Common Stock (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i16033c04e5ea4cc5bbfdba5f3c1bd666_D20210101-20210331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i0a83cea2026d4acd853ecd648a6ff3cf_D20210101-20210331", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2448427 - Disclosure - Stock Incentive Plans - Schedule of Assumptions (Details)", "role": "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails", "shortName": "Stock Incentive Plans - Schedule of Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i0a83cea2026d4acd853ecd648a6ff3cf_D20210101-20210331", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i9b0d673a9945438a9e404b6c6b57eba2_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449428 - Disclosure - Stock Incentive Plans - Summary of Options Activity (Details)", "role": "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails", "shortName": "Stock Incentive Plans - Summary of Options Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ia87a6b98f0714c88b1aa992fc475f7a1_D20210101-20210331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i23dc483d5e024cd3ab41d280f32cf960_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450429 - Disclosure - Stock Incentive Plans - Restricted Stock Units (Details)", "role": "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails", "shortName": "Stock Incentive Plans - Restricted Stock Units (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i23dc483d5e024cd3ab41d280f32cf960_I20201231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfStockByClassTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2451430 - Disclosure - Stock Incentive Plans - Employee Stock Purchase Plan (Narrative) (Details)", "role": "http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails", "shortName": "Stock Incentive Plans - Employee Stock Purchase Plan (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i3a0400d76b2a4414a1b0b75fa0e22620_D20210101-20210331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454431 - Disclosure - Revenue Arrangements - Narrative (Details)", "role": "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails", "shortName": "Revenue Arrangements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:CapitalizedContractCostAmortization", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ib56f1adc867e406ca7face50c5da1c9c_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "selb:ContractwithCustomerLiabilityDeferredRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2455432 - Disclosure - Revenue Arrangements - Schedule of Changes in Contract Liabilities (Details)", "role": "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails", "shortName": "Revenue Arrangements - Schedule of Changes in Contract Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ib56f1adc867e406ca7face50c5da1c9c_I20201231", "decimals": "-3", "first": true, "lang": "en-US", "name": "selb:ContractwithCustomerLiabilityDeferredRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i961e2381798844178d4558010699b490_D20210101-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2457433 - Disclosure - Related-Party Transactions - Narrative (Details)", "role": "http://www.selectabio.com/role/RelatedPartyTransactionsNarrativeDetails", "shortName": "Related-Party Transactions - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i961e2381798844178d4558010699b490_D20210101-20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:OperatingExpenses", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2459434 - Disclosure - Collaboration Agreements - AskBio (Narrative) (Details)", "role": "http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails", "shortName": "Collaboration Agreements - AskBio (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i2d6aabf5381c4d8eafad236940060193_D20200101-20200331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:OperatingExpenses", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Nature of the Business and Basis of Presentation", "role": "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentation", "shortName": "Nature of the Business and Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "iec431b313cb846b2aa7358a0b7afcf53_D20210101-20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "selb:LicenseAndOptionAgreementContractualPaymentsMade", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2460435 - Disclosure - Collaboration Agreements - MIT (Narrative) (Details)", "role": "http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails", "shortName": "Collaboration Agreements - MIT (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "iec431b313cb846b2aa7358a0b7afcf53_D20210101-20210331", "decimals": "INF", "first": true, "lang": "en-US", "name": "selb:LicenseAndOptionAgreementContractualPaymentsMade", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ibb68c9bff506451eb919c2f81711b851_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "selb:AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2461436 - Disclosure - Collaboration Agreements - Shenyang Sunshine Pharmaceutical Co., Ltd (Narrative) (Details)", "role": "http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails", "shortName": "Collaboration Agreements - Shenyang Sunshine Pharmaceutical Co., Ltd (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ibb68c9bff506451eb919c2f81711b851_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "selb:AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2463437 - Disclosure - Income Taxes - Narrative (Details)", "role": "http://www.selectabio.com/role/IncomeTaxesNarrativeDetails", "shortName": "Income Taxes - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "ied8d945ebce54ed8a4badfed477a64e8_I20210331", "decimals": "-5", "first": true, "lang": "en-US", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "selb:DefinedContributionPlanEmployersMatchingContributionVestingPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2465438 - Disclosure - Defined Contribution Plan - Narrative (Details)", "role": "http://www.selectabio.com/role/DefinedContributionPlanNarrativeDetails", "shortName": "Defined Contribution Plan - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "selb:DefinedContributionPlanEmployersMatchingContributionVestingPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "iebf9f6ef11cf4e6e8cfcb2c64010f2ad_D20210413-20210413", "decimals": "-5", "first": true, "lang": "en-US", "name": "selb:LicenseAndOptionAgreementMilestonePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2468439 - Disclosure - Subsequent Events (Details)", "role": "http://www.selectabio.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "iebf9f6ef11cf4e6e8cfcb2c64010f2ad_D20210413-20210413", "decimals": "-5", "first": true, "lang": "en-US", "name": "selb:LicenseAndOptionAgreementMilestonePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.selectabio.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2105103 - Disclosure - Marketable Securities", "role": "http://www.selectabio.com/role/MarketableSecurities", "shortName": "Marketable Securities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "selb-20210331.htm", "contextRef": "i93f17f89c13f486486776019ba38a82f_D20210101-20210331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 72, "tag": { "country_RU": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "RUSSIAN FEDERATION", "terseLabel": "Russian subsidiary" } } }, "localname": "RU", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r469" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r470" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r473" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r472" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Smaller Reporting Company" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r471" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r467" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r468" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Coverpage" ], "xbrltype": "tradingSymbolItemType" }, "selb_A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan", "label": "2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan [Member]", "terseLabel": "2008 Plan, 2016 Plan, and 2018 Inducement Incentive Award Plan" } } }, "localname": "A2008Plan2016PlanAnd2018InducementIncentiveAwardPlanMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "domainItemType" }, "selb_A2017PIPEMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2017 PIPE [Member]", "label": "2017 PIPE [Member]", "terseLabel": "2017 PIPE" } } }, "localname": "A2017PIPEMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "selb_A2017TermLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2017 Term Loans [Member]", "label": "2017 Term Loans [Member]", "terseLabel": "2017 Term Loans" } } }, "localname": "A2017TermLoansMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails", "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "domainItemType" }, "selb_A2020SaleAgreementAtTheMarketOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Sale Agreement - At-The-Market Offering", "label": "2020 Sale Agreement - At-The-Market Offering [Member]", "terseLabel": "2020 Sale Agreement - At-the-Market Offering" } } }, "localname": "A2020SaleAgreementAtTheMarketOfferingMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/EquityNarrativeDetails", "http://www.selectabio.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "selb_A2020TermLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Term Loans", "label": "2020 Term Loans [Member]", "terseLabel": "2020 Term Loans" } } }, "localname": "A2020TermLoansMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "domainItemType" }, "selb_A65GroveStreetWatertownMAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "65 Grove Street, Watertown,MA [Member]", "label": "65 Grove Street, Watertown,MA [Member]", "terseLabel": "65 Grove Street, Watertown,MA" } } }, "localname": "A65GroveStreetWatertownMAMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "selb_AccruedAuditFeesCurrent": { "auth_ref": [], "calculation": { "http://www.selectabio.com/role/AccruedExpensesDetails": { "order": 5.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Audit Fees, Current", "label": "Accrued Audit Fees, Current", "terseLabel": "Accrued professional and consulting services" } } }, "localname": "AccruedAuditFeesCurrent", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "selb_AccruedCollaborationandLicensing": { "auth_ref": [], "calculation": { "http://www.selectabio.com/role/AccruedExpensesDetails": { "order": 2.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Collaboration and Licensing", "label": "Accrued Collaboration and Licensing", "terseLabel": "Collaboration and licensing" } } }, "localname": "AccruedCollaborationandLicensing", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "selb_AccruedInterestCurrent": { "auth_ref": [], "calculation": { "http://www.selectabio.com/role/AccruedExpensesDetails": { "order": 6.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Interest, Current", "label": "Accrued Interest, Current", "terseLabel": "Accrued interest" } } }, "localname": "AccruedInterestCurrent", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "selb_AccruedPatentFeesCurrent": { "auth_ref": [], "calculation": { "http://www.selectabio.com/role/AccruedExpensesDetails": { "order": 3.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of patent fees.", "label": "Accrued Patent Fees Current", "terseLabel": "Accrued patent fees" } } }, "localname": "AccruedPatentFeesCurrent", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "selb_AccruedResearchAndDevelopmentCostsCurrent": { "auth_ref": [], "calculation": { "http://www.selectabio.com/role/AccruedExpensesDetails": { "order": 4.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of research and development costs.", "label": "Accrued Research And Development Costs Current", "terseLabel": "Accrued external research and development costs" } } }, "localname": "AccruedResearchAndDevelopmentCostsCurrent", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "selb_AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Aggregate Amount For Future Payments Upon Achievement Of Clinical And Regulatory Approval Milestones For Products Containing ImmTOR Platform", "label": "Aggregate Amount For Future Payments Upon Achievement Of Clinical And Regulatory Approval Milestones For Products Containing ImmTOR Platform", "terseLabel": "Aggregate amount for future payments upon achievement of clinical and regulatory approval milestones for products containing ImmTOR platform" } } }, "localname": "AggregateAmountForFuturePaymentsUponAchievementOfClinicalAndRegulatoryApprovalMilestonesForProductsContainingImmTORPlatform", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "selb_AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate Amount Of Upfront And Milestone Based Payments Paid", "label": "Aggregate Amount Of Upfront And Milestone Based Payments Paid", "terseLabel": "Aggregate amount of upfront and milestone-based payments" } } }, "localname": "AggregateAmountOfUpfrontAndMilestoneBasedPaymentsPaid", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "selb_AskBioLicenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AskBio License [Member]", "label": "AskBio License [Member]", "terseLabel": "AskBio License" } } }, "localname": "AskBioLicenseMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails" ], "xbrltype": "domainItemType" }, "selb_AtTheMarketOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "At-The-Market Offering [Member]", "label": "At-The-Market Offering [Member]", "terseLabel": "At-The-Market Offering" } } }, "localname": "AtTheMarketOfferingMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "selb_August2020ShelfRegistrationStatementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "August 2020 Shelf Registration Statement", "label": "August 2020 Shelf Registration Statement [Member]", "terseLabel": "August 2020 Shelf Registration Statement" } } }, "localname": "August2020ShelfRegistrationStatementMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "selb_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Debt Securities, Available-For-Sale", "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Debt Securities, Available-For-Sale", "terseLabel": "Cash, cash equivalents, restricted cash and marketable securities" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndDebtSecuritiesAvailableForSale", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails" ], "xbrltype": "monetaryItemType" }, "selb_ChangeInContractWithCustomerLiabilityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Change In Contract With Customer, Liability [Roll Forward]", "label": "Change In Contract With Customer, Liability [Roll Forward]", "terseLabel": "Contract liabilities:" } } }, "localname": "ChangeInContractWithCustomerLiabilityRollForward", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "selb_ClassOfWarrantOrRightExpirationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Expiration Period", "label": "Class Of Warrant Or Right, Expiration Period", "terseLabel": "Class of warrant or right, expiration period" } } }, "localname": "ClassOfWarrantOrRightExpirationPeriod", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "durationItemType" }, "selb_ClassOfWarrantOrRightNumberOfWarrantsExercised": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class of Warrant or Right, Number Of Warrants Exercised", "label": "Class Of Warrant Or Right, Number Of Warrants Exercised", "terseLabel": "Class of warrant or right, number of warrants exercised (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfWarrantsExercised", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "selb_CollaborationAndLicenseAgreementsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration And License Agreements", "label": "Collaboration And License Agreements [Text Block]", "terseLabel": "Collaboration Agreements" } } }, "localname": "CollaborationAndLicenseAgreementsTextBlock", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/CollaborationAgreements" ], "xbrltype": "textBlockItemType" }, "selb_CollaborativeArrangementCostSharePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative Arrangement, Cost Share Percentage", "label": "Collaborative Arrangement, Cost Share Percentage", "terseLabel": "Cost share percentage" } } }, "localname": "CollaborativeArrangementCostSharePercentage", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails" ], "xbrltype": "percentItemType" }, "selb_CommonWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Warrant [Member]", "label": "Common Warrant [Member]", "terseLabel": "Common Warrant" } } }, "localname": "CommonWarrantMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "selb_ContractwithCustomerLiabilityDeferredRevenue": { "auth_ref": [], "calculation": { "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_ContractWithCustomerLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract with Customer, Liability, Deferred Revenue", "label": "Contract with Customer, Liability, Deferred Revenue", "periodEndLabel": "Deferred revenue, end of period", "periodStartLabel": "Deferred revenue, beginning of period" } } }, "localname": "ContractwithCustomerLiabilityDeferredRevenue", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "selb_ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts": { "auth_ref": [], "calculation": { "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails": { "order": 1.0, "parentTag": "selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract with Customer, Liability, Deferred Revenue, Increase From Cash Receipts", "label": "Contract with Customer, Liability, Deferred Revenue, Increase From Cash Receipts", "terseLabel": "Deferred revenue, additions" } } }, "localname": "ContractwithCustomerLiabilityDeferredRevenueIncreaseFromCashReceipts", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "selb_ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized": { "auth_ref": [], "calculation": { "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_ContractWithCustomerLiabilityRevenueRecognized", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract with Customer, Liability, Deferred Revenue, Revenue Recognized", "label": "Contract with Customer, Liability, Deferred Revenue, Revenue Recognized", "negatedLabel": "Deferred revenue, deductions" } } }, "localname": "ContractwithCustomerLiabilityDeferredRevenueRevenueRecognized", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "selb_ContractwithCustomerLiabilityIncreaseFromCashReceipts": { "auth_ref": [], "calculation": { "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contract with Customer, Liability, Increase From Cash Receipts", "label": "Contract with Customer, Liability, Increase From Cash Receipts", "totalLabel": "Contract liabilities, additions" } } }, "localname": "ContractwithCustomerLiabilityIncreaseFromCashReceipts", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "selb_DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Additional Accrued Interest In the Event Of Default", "label": "Debt Instrument, Additional Accrued Interest In the Event Of Default", "terseLabel": "Debt instrument, additional accrued interest in the event of default" } } }, "localname": "DebtInstrumentAdditionalAccruedInterestInTheEventOfDefault", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "pureItemType" }, "selb_DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Default, Bankruptcy, Or Insolvency Value Of Triggering Accelerated Redemption", "label": "Debt Instrument, Default, Bankruptcy, Or Insolvency Value Of Triggering Accelerated Redemption", "terseLabel": "Debt instrument, default, bankruptcy, or insolvency value of triggering accelerated redemption" } } }, "localname": "DebtInstrumentDefaultBankruptcyOrInsolvencyValueOfTriggeringAcceleratedRedemption", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "selb_DebtInstrumentInterestPortion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The interest portion of gross outstanding debt.", "label": "Debt Instrument Interest Portion", "negatedTerseLabel": "Less: Amount representing interest" } } }, "localname": "DebtInstrumentInterestPortion", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails" ], "xbrltype": "monetaryItemType" }, "selb_DebtInstrumentPrepaymentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Prepayment Fee, Percentage", "label": "Debt Instrument, Prepayment Fee, Percentage", "terseLabel": "Debt instrument, prepayment fee, percentage" } } }, "localname": "DebtInstrumentPrepaymentFeePercentage", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "pureItemType" }, "selb_DecemberTwoThousandNineteenFinancingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "December Two Thousand Nineteen Financing [Member]", "label": "December Two Thousand Nineteen Financing [Member]", "terseLabel": "December 2019 Financing" } } }, "localname": "DecemberTwoThousandNineteenFinancingMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "selb_DefinedContributionPlanEmployersMatchingContributionVestingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period which an employee's right to exercise a plan is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Defined Contribution Plan Employers Matching Contribution Vesting Period", "terseLabel": "Vesting period" } } }, "localname": "DefinedContributionPlanEmployersMatchingContributionVestingPeriod", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/DefinedContributionPlanNarrativeDetails" ], "xbrltype": "durationItemType" }, "selb_EligiblePeriodToReceiveRoyalties": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eligible Period To Receive Royalties", "label": "Eligible Period To Receive Royalties", "terseLabel": "Period after first commercial sale when the Company is eligible to receive royalties" } } }, "localname": "EligiblePeriodToReceiveRoyalties", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "durationItemType" }, "selb_EmployeeStockPurchasePlan2016Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represent information pertaining to the 2016 Employee Stock Purchase Plan.", "label": "Employee Stock Purchase Plan2016 [Member]", "terseLabel": "ESPP" } } }, "localname": "EmployeeStockPurchasePlan2016Member", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "selb_EmploymentInducementIncentiveAwardPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employment Inducement Incentive Award Plan [Member]", "label": "Employment Inducement Incentive Award Plan [Member]", "terseLabel": "Employment Inducement Incentive Award Plan" } } }, "localname": "EmploymentInducementIncentiveAwardPlanMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "selb_EquityOfferingCostsInAccruedLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity Offering Costs In Accrued Liabilities", "label": "Equity Offering Costs In Accrued Liabilities", "terseLabel": "Equity offering costs in accrued liabilities" } } }, "localname": "EquityOfferingCostsInAccruedLiabilities", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "selb_ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Exclusive patent license agreement with Massachusetts Institute of Technology. \"", "label": "Exclusive Patent License Agreement With Massachusetts Institute Of Technology [Member]", "terseLabel": "MIT" } } }, "localname": "ExclusivePatentLicenseAgreementWithMassachusettsInstituteOfTechnologyMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails" ], "xbrltype": "domainItemType" }, "selb_FounderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to founder member.", "label": "Founder [Member]", "terseLabel": "Founders" } } }, "localname": "FounderMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "selb_LaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to laboratory equipment.", "label": "Laboratory Equipment [Member]", "terseLabel": "Laboratory equipment" } } }, "localname": "LaboratoryEquipmentMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "selb_LeaseArrangementAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease Arrangement [Axis]", "label": "Lease Arrangement [Axis]", "terseLabel": "Lease Arrangement [Axis]" } } }, "localname": "LeaseArrangementAxis", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "selb_LeaseArrangementDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "[Domain] for Lease Arrangement [Axis]", "label": "Lease Arrangement [Domain]", "terseLabel": "Lease Arrangement [Domain]" } } }, "localname": "LeaseArrangementDomain", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "selb_LesseeComponentsOfOperatingLeaseTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lessee, Components Of Operating Lease", "label": "Lessee, Components Of Operating Lease [Table Text Block]", "terseLabel": "Schedule of Lessee, Components Of Operating Lease" } } }, "localname": "LesseeComponentsOfOperatingLeaseTableTextBlock", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "selb_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "auth_ref": [], "calculation": { "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four", "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "selb_LicenseAgreementForPompeDiseaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreement For Pompe Disease [Member]", "label": "License Agreement For Pompe Disease [Member]", "terseLabel": "License Agreement For Pompe Disease" } } }, "localname": "LicenseAgreementForPompeDiseaseMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "selb_LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to License agreement with Shenyang Sunshine Pharmaceutical co., ltd.", "label": "License Agreement With Shenyang Sunshine Pharmaceutical Company Limited [Member]", "terseLabel": "3SBio License" } } }, "localname": "LicenseAgreementWithShenyangSunshinePharmaceuticalCompanyLimitedMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails" ], "xbrltype": "domainItemType" }, "selb_LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License And Option Agreement, Calculated Premium Paid For Equity Investment Under Purchase Agreement", "label": "License And Option Agreement, Calculated Premium Paid For Equity Investment Under Purchase Agreement", "terseLabel": "License and option agreement, payments made relative to calculated premium paid for initial equity investment made under the purchase agreement" } } }, "localname": "LicenseAndOptionAgreementCalculatedPremiumPaidForEquityInvestmentUnderPurchaseAgreement", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "selb_LicenseAndOptionAgreementContractualPaymentsMade": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License And Option Agreement, Contractual Payments Made", "label": "License And Option Agreement, Contractual Payments Made", "verboseLabel": "Contractual payments defined in the Exclusive Patent License agreement" } } }, "localname": "LicenseAndOptionAgreementContractualPaymentsMade", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "selb_LicenseAndOptionAgreementDevelopmentMilestone": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License And Option Agreement, Development Milestone", "label": "License And Option Agreement, Development Milestone", "terseLabel": "Development milestone" } } }, "localname": "LicenseAndOptionAgreementDevelopmentMilestone", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "selb_LicenseAndOptionAgreementExecutionFeePayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License And Option Agreement, Execution Fee Payment", "label": "License And Option Agreement, Execution Fee Payment", "terseLabel": "Initial upfront execution fee payment" } } }, "localname": "LicenseAndOptionAgreementExecutionFeePayment", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "selb_LicenseAndOptionAgreementInitialUpFrontCashPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License And Option Agreement, Initial Up-Front Cash Payment", "label": "License And Option Agreement, Initial Up-Front Cash Payment", "terseLabel": "Initial up-front cash payment" } } }, "localname": "LicenseAndOptionAgreementInitialUpFrontCashPayment", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "selb_LicenseAndOptionAgreementMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License And Option Agreement, Milestone Payments", "label": "License And Option Agreement, Milestone Payments", "terseLabel": "Milestone payment" } } }, "localname": "LicenseAndOptionAgreementMilestonePayments", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "selb_LicenseAndOptionAgreementOptionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License And Option Agreement, Option Term", "label": "License And Option Agreement, Option Term", "terseLabel": "Option term" } } }, "localname": "LicenseAndOptionAgreementOptionTerm", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "durationItemType" }, "selb_LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License And Option Agreement, Sales Milestone Payments That May Be Received", "label": "License And Option Agreement, Sales Milestone Payments That May Be Received", "terseLabel": "Sales milestone payments" } } }, "localname": "LicenseAndOptionAgreementSalesMilestonePaymentsThatMayBeReceived", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "selb_LicenseAndOptionAgreementUpfrontCashPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "License And Option Agreement, Upfront Cash Payment", "label": "License And Option Agreement, Upfront Cash Payment", "terseLabel": "Upfront cash payment" } } }, "localname": "LicenseAndOptionAgreementUpfrontCashPayment", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "selb_LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License And Option Agreement, Written Day Notice Period Before Cancellation", "label": "License And Option Agreement, Written Day Notice Period Before Cancellation", "terseLabel": "License and option agreement, written day notice period before cancellation" } } }, "localname": "LicenseAndOptionAgreementWrittenDayNoticePeriodBeforeCancellation", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "durationItemType" }, "selb_LockUpFromClosingTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lock-up From Closing, Term", "label": "Lock-up From Closing, Term", "terseLabel": "Lock-up from closing, term" } } }, "localname": "LockUpFromClosingTerm", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/EquityNarrativeDetails" ], "xbrltype": "durationItemType" }, "selb_NonEmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An arrangement whereby a non-employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement.", "label": "Non Employee Stock Option [Member]", "terseLabel": "Non-employee stock options", "verboseLabel": "Non-employee consultants" } } }, "localname": "NonEmployeeStockOptionMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails", "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "domainItemType" }, "selb_PreFundedWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pre-Funded Warrant [Member]", "label": "Pre-Funded Warrant [Member]", "terseLabel": "Pre-Funded Warrant" } } }, "localname": "PreFundedWarrantMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/EquityNarrativeDetails" ], "xbrltype": "domainItemType" }, "selb_ResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to research and development expenses included in the income statement.", "label": "Research And Development [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails" ], "xbrltype": "domainItemType" }, "selb_RestrictedStockUnitsRSUsReservedForIssuanceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Units (RSUs) Reserved For Issuance", "label": "Restricted Stock Units (RSUs) Reserved For Issuance [Member]", "terseLabel": "RSUs reserved for issuance" } } }, "localname": "RestrictedStockUnitsRSUsReservedForIssuanceMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "selb_RestrictedStockUnitsUnvestedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted Stock Units, Unvested", "label": "Restricted Stock Units, Unvested [Member]", "terseLabel": "Unvested restricted stock units" } } }, "localname": "RestrictedStockUnitsUnvestedMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails" ], "xbrltype": "domainItemType" }, "selb_RevenueNumberOfPerformanceObligations": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue, Number Of Performance Obligations", "label": "Revenue, Number Of Performance Obligations", "terseLabel": "Number of obligations" } } }, "localname": "RevenueNumberOfPerformanceObligations", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "integerItemType" }, "selb_SOBIPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SOBI Purchase Agreement [Member]", "label": "SOBI Purchase Agreement [Member]", "terseLabel": "SOBI Purchase Agreement" } } }, "localname": "SOBIPurchaseAgreementMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/EquityNarrativeDetails", "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "selb_SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of Stock, Percentage Of Ten-Day Volume Weighted Average Price Of Common Stock", "label": "Sale of Stock, Percentage Of Ten-Day Volume Weighted Average Price Of Common Stock", "terseLabel": "Sale of stock, percentage of ten-day volume weighted average price of common stock" } } }, "localname": "SaleofStockPercentageOfTenDayVolumeWeightedAveragePriceOfCommonStock", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/EquityNarrativeDetails" ], "xbrltype": "percentItemType" }, "selb_SareptaTherapeuticsInc.Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sarepta Therapeutics, Inc. [Member]", "label": "Sarepta Therapeutics, Inc. [Member]", "terseLabel": "Sarepta Therapeutics, Inc." } } }, "localname": "SareptaTherapeuticsInc.Member", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails", "http://www.selectabio.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Awarded in Period", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Awarded in Period", "terseLabel": "Awarded in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAwardedInPeriod", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "sharesItemType" }, "selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reserved For Issuance", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reserved For Issuance", "terseLabel": "Reserved for issuance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuance", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reserved For Issuance, Weighted Average Grant Date Fair Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reserved For Issuance, Weighted Average Grant Date Fair Value", "terseLabel": "Reserved for issuance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReservedForIssuanceWeightedAverageGrantDateFairValue", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighed-average fair value relating to the share-based payment award.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Fair Value", "terseLabel": "Weighted-average fair value of common stock (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageFairValue", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails" ], "xbrltype": "perShareItemType" }, "selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of forfeitures rate of the stock options based on the historical trends.", "label": "Share-based Compensation Arrangement By Share-based Payment Award Forfeitures Rate", "terseLabel": "Estimated forfeitures rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeituresRate", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "percentItemType" }, "selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant, Increase (Decrease)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Number Of Shares Available For Grant, Increase (Decrease)", "terseLabel": "Number of shares authorized, increase (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantIncreaseDecrease", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "sharesItemType" }, "selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value [Abstract]", "terseLabel": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValueAbstract", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "selb_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "n/a", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]", "terseLabel": "Weighted-average remaining contractual term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "selb_ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-Based Goods And Non Employee Services Transaction, Compensation Not Yet Recognized, Stock Options", "label": "Share-Based Goods And Non Employee Services Transaction, Compensation Not Yet Recognized, Stock Options", "terseLabel": "Unrecognized compensation expense related to unvested non-employee stock options" } } }, "localname": "ShareBasedGoodsAndNonEmployeeServicesTransactionCompensationNotYetRecognizedStockOptions", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Intrinsic Value", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Intrinsic Value", "terseLabel": "Vested" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingIntrinsicValue", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "selb_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Remaining Contractual Term", "label": "Share-based Compensation Arrangement By Share-based Payment Award, Options, Vested, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Vested, term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedOutstandingWeightedAverageRemainingContractualTerm", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "selb_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Exercise Price", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Exercise Price", "verboseLabel": "Vested (in dollars per share)" } } }, "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsVestedWeightedAverageExercisePrice", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "selb_StockIncentivePlan2016Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to the 2016 stock incentive plan, which provides for the granting of stock based awards to employees, directors, and consultants under terms and provisions established by the board of directors.", "label": "Stock Incentive Plan2016 [Member]", "terseLabel": "2016 Plan" } } }, "localname": "StockIncentivePlan2016Member", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "selb_TermALoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term A Loans", "label": "Term A Loans [Member]", "terseLabel": "Term A Loans" } } }, "localname": "TermALoansMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "domainItemType" }, "selb_TermBLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term B Loans", "label": "Term B Loans [Member]", "terseLabel": "Term B Loans" } } }, "localname": "TermBLoansMember", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "domainItemType" }, "selb_VotesPerShareofCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Votes Per Share of Common Stock", "label": "Votes Per Share of Common Stock", "terseLabel": "Number of votes per share that common stockholders are entitled to" } } }, "localname": "VotesPerShareofCommonStock", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/EquityNarrativeDetails" ], "xbrltype": "integerItemType" }, "selb_WarrantIssued": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant Issued", "label": "Warrant Issued", "terseLabel": "Warrant Issued" } } }, "localname": "WarrantIssued", "nsuri": "http://www.selectabio.com/20210331", "presentation": [ "http://www.selectabio.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "srt_MaximumMember": { "auth_ref": [ "r246", "r248", "r376", "r377", "r378", "r379", "r380", "r381", "r400", "r440", "r442" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r246", "r248", "r376", "r377", "r378", "r379", "r380", "r381", "r400", "r440", "r442" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r226", "r246", "r248", "r376", "r377", "r378", "r379", "r380", "r381", "r400", "r440", "r442" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r226", "r246", "r248", "r376", "r377", "r378", "r379", "r380", "r381", "r400", "r440", "r442" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.selectabio.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.selectabio.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r135", "r136", "r214", "r219", "r441", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r135", "r136", "r214", "r219", "r441", "r452", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r175", "r247", "r368" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.selectabio.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]", "terseLabel": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.", "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accrued Expenses" } } }, "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/AccruedExpenses" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r30" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r3", "r18", "r138", "r139" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets", "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r77" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedTerseLabel": "Amortization of premiums and discounts on marketable securities" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.selectabio.com/role/AccruedExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "totalLabel": "Accrued expenses", "verboseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/AccruedExpensesDetails", "http://www.selectabio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r29", "r167" ], "calculation": { "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r21", "r45", "r46", "r47", "r433", "r447", "r448" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r44", "r47", "r48", "r93", "r94", "r95", "r308", "r443", "r444" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "verboseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r19", "r284" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r93", "r94", "r95", "r281", "r282", "r283" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Adjustments to Additional Paid in Capital, Other", "terseLabel": "Other financing fees" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r250", "r252", "r287", "r288" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r179", "r190", "r198" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Adjustments to additional paid in capital, warrant issued" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r252", "r277", "r286" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-based Payment Arrangement, Expense", "netLabel": "Stock-based compensation expense", "terseLabel": "Stock\u2011based compensation expense", "verboseLabel": "Total stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "verboseLabel": "Potential common shares" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfRealEstateProperty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of a real estate property.", "label": "Area of Real Estate Property", "terseLabel": "Area of additional office space leased" } } }, "localname": "AreaOfRealEstateProperty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesNarrativeDetails" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails", "http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails", "http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails", "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r86", "r123", "r126", "r132", "r152", "r306", "r309", "r325", "r417", "r430" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets", "verboseLabel": "Assets:" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets", "http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r5", "r41", "r86", "r152", "r306", "r309", "r325" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r314" ], "calculation": { "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r147" ], "calculation": { "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r148" ], "calculation": { "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r145", "r159" ], "calculation": { "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r141", "r146", "r159", "r420" ], "calculation": { "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Fair value", "verboseLabel": "Marketable securities:" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails", "http://www.selectabio.com/role/MarketableSecuritiesNarrativeDetails", "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r143", "r159" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-sale, Current", "terseLabel": "Marketable securities" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r253", "r279" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails", "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails", "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails", "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r80", "r81", "r82" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Purchase of property and equipment not yet paid" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalizedContractCostAmortization": { "auth_ref": [ "r164" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.", "label": "Capitalized Contract Cost, Amortization", "terseLabel": "Contract assets amortization (less than)" } } }, "localname": "CapitalizedContractCostAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Cash": { "auth_ref": [ "r27", "r449", "r450" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash maintained in Russian bank accounts" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r27", "r78" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets", "http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Money market funds" } } }, "localname": "CashAndCashEquivalentsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Cash and Cash Equivalents [Line Items]", "terseLabel": "Cash and Cash Equivalents [Line Items]" } } }, "localname": "CashAndCashEquivalentsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r72", "r78", "r83" ], "calculation": { "http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period", "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the consolidated statement of cash flows" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows", "http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r72", "r330" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash, cash equivalents, and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Stock [Line Items]", "terseLabel": "Class of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails", "http://www.selectabio.com/role/EquityNarrativeDetails", "http://www.selectabio.com/role/EquityWarrantyActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/EquityWarrantyActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Class of warrant or right, number of securities called by warrants or rights (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Class of warrant or right, outstanding (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/EquityNarrativeDetails", "http://www.selectabio.com/role/EquityWarrantyActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r199", "r251" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]", "terseLabel": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/EquityWarrantyActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails", "http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails", "http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r177" ], "lang": { "en-us": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails", "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r37", "r174", "r421", "r437" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note\u00a017)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r171", "r172", "r173", "r176" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r39" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Total (in shares)", "verboseLabel": "Common stock authorized and reserved for future issuance (in shares)" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails", "http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r93", "r94" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common\u00a0stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.selectabio.com/role/EquityNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.selectabio.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.selectabio.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r17", "r190" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical", "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity", "http://www.selectabio.com/role/EquityNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r17" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value; 200,000,000 shares authorized; 112,977,004 and 108,071,249 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r50", "r52", "r53", "r56", "r423", "r439" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment and software" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConstructionInProgressMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.", "label": "Construction in Progress [Member]", "terseLabel": "Construction in process" } } }, "localname": "ConstructionInProgressMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r204" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "terseLabel": "Schedule of Changes in Contract Liabilities" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "auth_ref": [ "r201", "r203", "r215" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "terseLabel": "Contract assets" } } }, "localname": "ContractWithCustomerAssetNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r201", "r202", "r215" ], "calculation": { "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract with Customer, Liability", "periodEndLabel": "Contract liabilities, end of period", "periodStartLabel": "Contract liabilities, beginning of period" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r201", "r202", "r215" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue", "verboseLabel": "Short-term contract liability" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets", "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "auth_ref": [ "r201", "r202", "r215" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue", "verboseLabel": "Long-term contract liability" } } }, "localname": "ContractWithCustomerLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets", "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r216" ], "calculation": { "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract with Customer, Liability, Revenue Recognized", "negatedTotalLabel": "Contract liabilities, deductions", "terseLabel": "Revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails", "http://www.selectabio.com/role/RevenueArrangementsScheduleofChangesinContractLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CorporateBondSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).", "label": "Corporate Bond Securities [Member]", "terseLabel": "Corporate bonds" } } }, "localname": "CorporateBondSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails", "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost of Revenue [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails", "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails", "http://www.selectabio.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails", "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails", "http://www.selectabio.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r184" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Debt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.", "label": "Debt Instrument, Periodic Payment Terms, Balloon Payment to be Paid", "terseLabel": "Final payment fee" } } }, "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Information about timing of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period [Axis]", "terseLabel": "Debt Instrument, Redemption, Period [Axis]" } } }, "localname": "DebtInstrumentRedemptionPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Period as defined under terms of the debt agreement for debt redemption features.", "label": "Debt Instrument, Redemption, Period [Domain]", "terseLabel": "Debt Instrument, Redemption, Period [Domain]" } } }, "localname": "DebtInstrumentRedemptionPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodOneMember": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period One [Member]", "terseLabel": "Debt Instrument, Redemption, Period One" } } }, "localname": "DebtInstrumentRedemptionPeriodOneMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodThreeMember": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Period three representing third most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Three [Member]", "terseLabel": "Debt Instrument, Redemption, Period Three" } } }, "localname": "DebtInstrumentRedemptionPeriodThreeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.", "label": "Debt Instrument, Redemption, Period Two [Member]", "terseLabel": "Debt Instrument, Redemption, Period Two" } } }, "localname": "DebtInstrumentRedemptionPeriodTwoMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of principal amount of debt redeemed.", "label": "Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed", "terseLabel": "Debt instrument, redemption price, percentage of principal amount redeemed" } } }, "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": { "auth_ref": [ "r180", "r339" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.", "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net", "negatedTerseLabel": "Less: Debt discount and deferred charges" } } }, "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": { "auth_ref": [ "r340" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.", "label": "Debt Issuance Costs, Line of Credit Arrangements, Net", "terseLabel": "Debt issuance costs, line of credit arrangements (less than)" } } }, "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r151" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table Text Block]", "terseLabel": "Summary of Available-for-Sale Marketable Securities" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/MarketableSecuritiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration", "terseLabel": "Operating loss carryforwards, carried forward indefinitely" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration", "terseLabel": "Net operating losses available for use through 2028" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r245" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Employer contribution made" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DefinedContributionPlanNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r76", "r165" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/PropertyandEquipmentNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r214", "r218", "r219", "r220", "r221", "r222", "r223", "r224" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r289" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock Incentive Plans" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": { "auth_ref": [ "r253", "r279" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of share-based payment arrangement.", "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]", "terseLabel": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award" } } }, "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsCommonStock": { "auth_ref": [ "r198", "r426" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Common Stock", "terseLabel": "Dividends declared or paid on common stock" } } }, "localname": "DividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Basic and Diluted", "terseLabel": "Net loss per share attributable to common stockholders\u2014basic and diluted (in dollars per share)", "verboseLabel": "Basic and diluted (in dollars per share)" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.selectabio.com/role/NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAndDilutedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Net loss per share:" } } }, "localname": "EarningsPerShareBasicAndDilutedAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r112", "r113", "r114", "r115" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/NetLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": { "auth_ref": [ "r330" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.", "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.selectabio.com/role/AccruedExpensesDetails": { "order": 1.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and employee related expenses" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r278" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "verboseLabel": "Weighted average period for recognition" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r278" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r278" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation expense related to unvested employee stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r275" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-based Payment Arrangement, Option [Member]", "terseLabel": "Stock options to purchase common stock", "verboseLabel": "Outstanding common stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails", "http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r93", "r94", "r95", "r97", "r102", "r104", "r117", "r153", "r190", "r198", "r281", "r282", "r283", "r298", "r299", "r331", "r332", "r333", "r334", "r335", "r336", "r443", "r444", "r445" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity", "http://www.selectabio.com/role/EquityNarrativeDetails", "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails", "http://www.selectabio.com/role/EquityWarrantyActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r76", "r185" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 5.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Fair Value Adjustment of Warrants", "negatedTerseLabel": "Change in fair value of warrant liabilities", "terseLabel": "Warrant liabilities revaluation" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows", "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r314", "r315", "r316", "r323" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of Fair Value Measurement Inputs and Valuation Techniques" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r227", "r229", "r230", "r231", "r232", "r233", "r234", "r242", "r315", "r373", "r374", "r375" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r322", "r323" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]", "terseLabel": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/EquityWarrantyActivityDetails", "http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r314", "r315", "r318", "r319", "r324" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]", "terseLabel": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r227", "r229", "r234", "r242", "r315", "r373" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "(Level\u00a01)" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r227", "r229", "r234", "r242", "r315", "r374" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "(Level\u00a02)" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r227", "r229", "r230", "r231", "r232", "r233", "r234", "r242", "r315", "r375" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "(Level\u00a03)" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]", "terseLabel": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/EquityWarrantyActivityDetails", "http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r320", "r323" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r320", "r323" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Schedule Of Changes In The Warrant Liabilities" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into (out of) level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net", "terseLabel": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, transfers, net" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r321" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net", "terseLabel": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, transfers, net" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r320" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Fair value as of March 31, 2021", "periodStartLabel": "Fair value as of December 31, 2020" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r227", "r229", "r230", "r231", "r232", "r233", "r234", "r242", "r373", "r374", "r375" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r322", "r324" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FinanceLeaseRightOfUseAssetAmortization": { "auth_ref": [ "r343", "r346", "r355" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.", "label": "Finance Lease, Right-of-Use Asset, Amortization", "terseLabel": "Non-cash lease expense" } } }, "localname": "FinanceLeaseRightOfUseAssetAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r149", "r150", "r154", "r155", "r156", "r157", "r158", "r160", "r161", "r162", "r163", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails", "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r326", "r327", "r328", "r329" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "terseLabel": "Foreign currency transaction gain, net" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r76" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on disposal of property and equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "auth_ref": [ "r76", "r182", "r183" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.", "label": "Gain (Loss) on Extinguishment of Debt", "negatedTerseLabel": "Loss on extinguishment of debt" } } }, "localname": "GainsLossesOnExtinguishmentOfDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r60" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r57" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r169" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r294", "r296", "r297", "r300", "r301", "r302", "r303", "r304" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r75" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r75" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "auth_ref": [ "r75" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r75" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r75" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses, deposits and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity" ], "xbrltype": "stringItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r54", "r122", "r338", "r339", "r424" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 4.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r71", "r73", "r79" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r61", "r62" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment Income, Net", "terseLabel": "Investment income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]", "terseLabel": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r151", "r414", "r425", "r451" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Marketable Securities" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/MarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r353", "r355" ], "calculation": { "http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "terseLabel": "Lessee-paid construction costs", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails", "http://www.selectabio.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of Lease, Cost" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]", "terseLabel": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of Lessee, Operating Lease, Liability, Maturity" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r354" ], "calculation": { "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r354" ], "calculation": { "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r354" ], "calculation": { "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r354" ], "calculation": { "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r354" ], "calculation": { "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r354" ], "calculation": { "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "2021 (remainder)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r354" ], "calculation": { "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "auth_ref": [ "r345" ], "lang": { "en-us": { "role": { "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Term of contract" } } }, "localname": "LesseeOperatingLeaseTermOfContract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r356" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Leases" ], "xbrltype": "textBlockItemType" }, "us-gaap_LetterOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).", "label": "Letter of Credit [Member]", "terseLabel": "Letter of credit" } } }, "localname": "LetterOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r33", "r86", "r127", "r152", "r307", "r309", "r310", "r325" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r24", "r86", "r152", "r325", "r419", "r435" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 (deficit) equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and stockholders\u2019 (deficit) equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r35", "r86", "r152", "r307", "r309", "r310", "r325" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r314" ], "calculation": { "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LicenseAgreementTermsMember": { "auth_ref": [ "r291", "r292" ], "lang": { "en-us": { "role": { "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "License Agreement Terms [Member]", "terseLabel": "Spark License Agreement" } } }, "localname": "LicenseAgreementTermsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCredit": { "auth_ref": [ "r14", "r418", "r428" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.", "label": "Long-term Line of Credit", "terseLabel": "Term loan facility" } } }, "localname": "LineOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Line of Credit Facility [Line Items]", "terseLabel": "Line of Credit Facility [Line Items]" } } }, "localname": "LineOfCreditFacilityLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails", "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "auth_ref": [ "r31" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity" } } }, "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityTable": { "auth_ref": [ "r31", "r88" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.", "label": "Line of Credit Facility [Table]", "terseLabel": "Line of Credit Facility [Table]" } } }, "localname": "LineOfCreditFacilityTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails", "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LoansPayableCurrent": { "auth_ref": [ "r34" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.", "label": "Loans Payable, Current", "terseLabel": "Loan payable" } } }, "localname": "LoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebt": { "auth_ref": [ "r14", "r181", "r418", "r431" ], "calculation": { "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt", "totalLabel": "Total minimum debt payments" } } }, "localname": "LongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtByMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long-term Debt, Fiscal Year Maturity [Abstract]", "terseLabel": "Long-term Debt, Fiscal Year Maturity [Abstract]" } } }, "localname": "LongTermDebtByMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongTermDebtCurrent": { "auth_ref": [ "r32" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Current Maturities", "negatedLabel": "Less: Current portion of loan payable" } } }, "localname": "LongTermDebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "auth_ref": [ "r91", "r178" ], "calculation": { "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails": { "order": 2.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year One", "terseLabel": "2022" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "auth_ref": [ "r91", "r178" ], "calculation": { "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails": { "order": 5.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Four", "terseLabel": "2025" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "auth_ref": [ "r91", "r178" ], "calculation": { "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails": { "order": 4.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Three", "terseLabel": "2024" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "auth_ref": [ "r91", "r178" ], "calculation": { "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails": { "order": 3.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Long-Term Debt, Maturity, Year Two", "terseLabel": "2023" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": { "auth_ref": [ "r91" ], "calculation": { "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails": { "order": 1.0, "parentTag": "us-gaap_LongTermDebt", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.", "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year", "terseLabel": "2021 (remainder)" } } }, "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r36" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Loan payable, net of current portion" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtScheduleofFutureMinimumPaymentsontheTermLoansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermLoansPayable": { "auth_ref": [ "r36" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.", "label": "Loans Payable, Noncurrent", "terseLabel": "Loan payable, net of current portion" } } }, "localname": "LongTermLoansPayable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "auth_ref": [ "r58" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security.", "label": "Marketable Securities, Unrealized Gain (Loss)", "terseLabel": "Unrealized (losses) on marketable securities" } } }, "localname": "MarketableSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]", "terseLabel": "Dividend yield" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Expected life (in years)" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Expected volatility" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk-free interest rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money market funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r72" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r72" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r72", "r74", "r77" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash (used in) operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r0", "r49", "r51", "r55", "r77", "r86", "r96", "r98", "r99", "r100", "r101", "r103", "r104", "r108", "r123", "r125", "r128", "r131", "r133", "r152", "r325", "r422", "r438" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows", "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity", "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r98", "r99", "r100", "r101", "r105", "r106", "r109", "r111", "r123", "r125", "r128", "r131", "r133" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "netLabel": "Net loss attributable to common stockholders" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncash Investing and Financing Items [Abstract]", "terseLabel": "Noncash investing and financing activities" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_OfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.", "label": "Office Equipment [Member]", "terseLabel": "Office equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "terseLabel": "Operating expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails", "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r123", "r125", "r128", "r131", "r133" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r347", "r355" ], "calculation": { "http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "auth_ref": [ "r116", "r357" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of components of income from operating lease.", "label": "Operating Lease, Lease Income [Table Text Block]", "terseLabel": "Schedule of Operating Lease, Lease Income" } } }, "localname": "OperatingLeaseLeaseIncomeTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r342" ], "calculation": { "http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Lease liabilities", "totalLabel": "Total operating lease liabilities" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails", "http://www.selectabio.com/role/LeasesOperatingLeaseLiabilityMaturityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r342" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Current operating lease liabilities", "verboseLabel": "Lease liability" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets", "http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r342" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Non-current operating lease liabilities", "verboseLabel": "Lease liability" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets", "http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r344", "r350" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesOtherInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r341" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Right-of-use asset, net" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets", "http://www.selectabio.com/role/LeasesComponentsofOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r352", "r355" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Operating lease, weighted average discount rate, percent" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesLeaseTermandDiscountRateDetails", "http://www.selectabio.com/role/LeasesNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r351", "r355" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Operating lease, weighted average remaining lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesLeaseTermandDiscountRateDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingLeasedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Leased Assets [Line Items]", "terseLabel": "Operating Leased Assets [Line Items]" } } }, "localname": "OperatingLeasedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r1", "r311" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Nature of the Business and Basis of Presentation" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r7", "r8", "r9", "r34" ], "calculation": { "http://www.selectabio.com/role/AccruedExpensesDetails": { "order": 7.0, "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/AccruedExpensesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r13", "r416", "r429" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "terseLabel": "Other assets" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r42" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "terseLabel": "Currency translation adjustment", "verboseLabel": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity", "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Tax [Abstract]", "terseLabel": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r43", "r45" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 3.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "terseLabel": "Unrealized (losses) on marketable securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity", "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r312", "r313" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other Current Assets" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherDepreciationAndAmortization": { "auth_ref": [ "r59", "r76", "r165" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense charged against earnings to allocate the cost of tangible and intangible assets over their remaining economic lives, classified as other.", "label": "Other Depreciation and Amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "OtherDepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent [Abstract]", "terseLabel": "Non-current liabilities:" } } }, "localname": "OtherLiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r63" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 6.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense), net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": { "auth_ref": [ "r144" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).", "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale", "terseLabel": "Marketable securities adjusted for other than temporary declines in fair value" } } }, "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/MarketableSecuritiesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaidInKindInterest": { "auth_ref": [ "r76" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Paid-in-Kind Interest", "terseLabel": "Non-cash interest expense" } } }, "localname": "PaidInKindInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]", "terseLabel": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r70" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments of Financing Costs", "negatedTerseLabel": "Issuance costs paid for December 2019 financing" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r70" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments of Stock Issuance Costs", "terseLabel": "Issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r64", "r65", "r142" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedTerseLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r66" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r226", "r228", "r234", "r235", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r249" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "Defined Contribution Plan" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DefinedContributionPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r253", "r279" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "verboseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r16" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2021 and December 31, 2020" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r4", "r25", "r26" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.", "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r67" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Net proceeds from issuance of common stock", "verboseLabel": "Shares issued, value" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows", "http://www.selectabio.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r68", "r70", "r90" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other financing fees" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r67", "r280" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r67" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from issuance of common stock under Employee Stock Purchase Plan" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]", "terseLabel": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r29", "r168" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r170", "r454", "r455", "r456" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/PropertyandEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r28", "r166" ], "calculation": { "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Total property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r11", "r12", "r168", "r436" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets", "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r11", "r168" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/PropertyandEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r11", "r166" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RedemptionPremium": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The excess of the (1) fair value of consideration transferred to the holders of a security in excess of (2) the carrying amount of the security reported on the registrant's balance sheet, which will be deducted from net earnings to derive net earnings available to common shareholders. This amount is generally an adjustment considered in the computation of earnings per share.", "label": "Redemption Premium", "terseLabel": "Redemption premium" } } }, "localname": "RedemptionPremium", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/EquityNarrativeDetails", "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r236", "r360", "r361" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": { "auth_ref": [ "r360" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.", "label": "Related Party Transaction, Expenses from Transactions with Related Party", "terseLabel": "Consulting services expenses (less than)" } } }, "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]", "terseLabel": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r236", "r360", "r363", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]", "terseLabel": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r358", "r359", "r361", "r364", "r365" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related-Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLinesOfCredit": { "auth_ref": [ "r69", "r89" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.", "label": "Repayments of Lines of Credit", "terseLabel": "Repayments of lines of credit" } } }, "localname": "RepaymentsOfLinesOfCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r69" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedTerseLabel": "Repayments of principal on outstanding debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "auth_ref": [ "r291", "r292" ], "lang": { "en-us": { "role": { "documentation": "Information by form of arrangement related to research and development.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails", "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails", "http://www.selectabio.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "auth_ref": [ "r291", "r292" ], "lang": { "en-us": { "role": { "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]" } } }, "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails", "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails", "http://www.selectabio.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r290", "r466" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r10", "r78", "r83", "r415", "r432" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash and cash equivalents" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r10", "r78", "r83" ], "calculation": { "http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Current", "terseLabel": "Short-term restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": { "auth_ref": [ "r6", "r13", "r78", "r83", "r453" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents, Noncurrent", "terseLabel": "Long-term restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalentsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets", "http://www.selectabio.com/role/FairValueMeasurementsScheduleofCashandCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashNoncurrent": { "auth_ref": [ "r6", "r13", "r83", "r453" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash, Noncurrent", "terseLabel": "Long-term restricted cash" } } }, "localname": "RestrictedCashNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Unvested restricted stock units" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails", "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r20", "r198", "r284", "r434", "r446", "r448" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets", "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r93", "r94", "r95", "r97", "r102", "r104", "r153", "r281", "r282", "r283", "r298", "r299", "r443", "r445" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]", "terseLabel": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r120", "r121", "r124", "r129", "r130", "r134", "r135", "r137", "r213", "r214", "r401" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Grant and collaboration revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r204", "r205", "r206", "r207", "r208", "r209", "r211", "r212", "r217", "r225" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue Arrangements" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/RevenueArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r210" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Remaining performance obligation" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received on stock transaction after deduction of issuance costs.", "label": "Sale of Stock, Consideration Received on Transaction", "verboseLabel": "Sale common stock" } } }, "localname": "SaleOfStockConsiderationReceivedOnTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails", "http://www.selectabio.com/role/EquityNarrativeDetails", "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails", "http://www.selectabio.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]", "terseLabel": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails", "http://www.selectabio.com/role/EquityNarrativeDetails", "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails", "http://www.selectabio.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)" } } }, "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/EquityNarrativeDetails", "http://www.selectabio.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "verboseLabel": "Share price (in dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/EquityNarrativeDetails", "http://www.selectabio.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of Accrued Expenses" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/AccruedExpensesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of Potential Common Shares Issuable Upon Conversion of Warrants" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.", "label": "Schedule of Cash and Cash Equivalents [Table]", "terseLabel": "Schedule of Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/NatureoftheBusinessandBasisofPresentationLiquidityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Cash and Cash Equivalents" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails", "http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails", "http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": { "auth_ref": [ "r276" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.", "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]", "terseLabel": "Schedule of Stock-Based Compensation" } } }, "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Computation of Basic and Diluted Net Loss Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/NetLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r252", "r276", "r286" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansScheduleofStockBasedCompensationExpenseRelatedtoStockOptionsandRestrictedCommonStockDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r314", "r315" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of Assets Measured at Fair Value on a Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.", "label": "Schedule of Maturities of Long-term Debt [Table Text Block]", "terseLabel": "Schedule of Future Minimum Payments on the Term Loans" } } }, "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Schedule of Operating Leased Assets [Table]", "terseLabel": "Schedule of Operating Leased Assets [Table]" } } }, "localname": "ScheduleOfOperatingLeasedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r29", "r168" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/PropertyandEquipmentScheduleofPropertyandEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r87", "r362", "r363" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/RelatedPartyTransactionsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "auth_ref": [ "r10", "r83", "r415", "r432" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Restricted Cash and Cash Equivalents" } } }, "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r253", "r279" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails", "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails", "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r256", "r265", "r268" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of Options Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r270" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of Weighted Average Assumptions Used" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r38", "r84", "r118", "r119", "r186", "r188", "r189", "r191", "r193", "r194", "r195", "r196", "r197", "r198" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule of Stock by Class [Table]", "terseLabel": "Schedule of Stock by Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfStockByClassTextBlock": { "auth_ref": [ "r15", "r16", "r17", "r187", "r188", "r189", "r191", "r193", "r194", "r195", "r196", "r197", "r198" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.", "label": "Schedule of Stock by Class [Table Text Block]", "terseLabel": "Schedule of Authorized Shares of Common Stock for Future Issuance" } } }, "localname": "ScheduleOfStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r199", "r251" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Schedule of Stockholders' Equity Note, Warrants or Rights" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r75" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r254" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Award vesting term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r264" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited in period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Grants in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r262" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Grants in period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Unvested at end of period (in shares)", "periodStartLabel": "Unvested at beginning of period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r261" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Unvested at end of period (in dollars per share)", "periodStartLabel": "Unvested at beginning of period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Vested in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "auth_ref": [ "r267" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "terseLabel": "Vested in period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r263" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested in period (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r273" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "verboseLabel": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r272" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "verboseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r274" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "verboseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails", "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails", "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares authorized for grants (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value of stock options (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r279" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r258", "r279" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Options" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Ending balance (in dollars per share)", "periodStartLabel": "Beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r268" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "verboseLabel": "Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "verboseLabel": "Vested and expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "verboseLabel": "Vested and expected to vest (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period", "terseLabel": "Shares of common stock issued to employees under the ESPP (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansEmployeeStockPurchasePlanNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r251", "r255" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails", "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansRestrictedStockUnitsDetails", "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails", "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r271", "r285" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "verboseLabel": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding, term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r269" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Vested and expected to vest, term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares", "terseLabel": "Vested (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermLeaseCost": { "auth_ref": [ "r348", "r355" ], "calculation": { "http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails": { "order": 3.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.", "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease cost" } } }, "localname": "ShortTermLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r92" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r40", "r93", "r94", "r95", "r97", "r102", "r104", "r117", "r153", "r190", "r198", "r281", "r282", "r283", "r298", "r299", "r331", "r332", "r333", "r334", "r335", "r336", "r443", "r444", "r445" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity", "http://www.selectabio.com/role/EquityNarrativeDetails", "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails", "http://www.selectabio.com/role/EquityWarrantyActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]", "terseLabel": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r93", "r94", "r95", "r117", "r401" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity" ], "xbrltype": "stringItemType" }, "us-gaap_StockCompensationPlanMember": { "auth_ref": [ "r112" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.", "label": "Share-based Payment Arrangement [Member]", "netLabel": "Employees", "terseLabel": "Shares available for future stock incentive awards", "verboseLabel": "Employee stock option grants" } } }, "localname": "StockCompensationPlanMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails", "http://www.selectabio.com/role/StockIncentivePlansNarrativeDetails", "http://www.selectabio.com/role/StockIncentivePlansScheduleofAssumptionsDetails", "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r16", "r17", "r190", "r198" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "verboseLabel": "Issuance of common stock under Employee Stock Purchase Plan (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Shares, Other", "terseLabel": "Issuance of common stock through at-the-market offering, net (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "auth_ref": [ "r190", "r198" ], "lang": { "en-us": { "role": { "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "terseLabel": "Issuance of vested restricted stock units (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r16", "r17", "r190", "r198", "r259" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Issuance of common stock upon exercise of options (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity", "http://www.selectabio.com/role/StockIncentivePlansSummaryofOptionsActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "auth_ref": [ "r16", "r17", "r190", "r198" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.", "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under Employee Stock Purchase Plan" } } }, "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of shares of stock issued attributable to transactions classified as other.", "label": "Stock Issued During Period, Value, Other", "terseLabel": "Issuance of common stock through at-the-market offering, net" } } }, "localname": "StockIssuedDuringPeriodValueOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "auth_ref": [ "r16", "r17", "r190", "r198" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "terseLabel": "Issuance of vested restricted stock units" } } }, "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r40", "r190", "r198" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of options" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r17", "r22", "r23", "r86", "r140", "r152", "r325" ], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 (deficit) equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets", "http://www.selectabio.com/role/ConsolidatedStatementsofChangesinStockholdersDeficitEquity" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 (deficit) equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r85", "r198", "r200" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r337", "r367" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r337", "r367" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r337", "r367" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r337", "r367" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]", "terseLabel": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r366", "r369" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Different names of stock transactions and the different attributes of each transaction.", "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]", "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]" } } }, "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]", "terseLabel": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails", "http://www.selectabio.com/role/EquityNarrativeDetails", "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails", "http://www.selectabio.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsidiarySaleOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary, Sale of Stock [Line Items]", "terseLabel": "Subsidiary, Sale of Stock [Line Items]" } } }, "localname": "SubsidiarySaleOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/EquityNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplement cash flow information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r149", "r150", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails", "http://www.selectabio.com/role/MarketableSecuritiesSummaryofAvailableforSaleMarketableSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/CollaborationAgreementsAskBioNarrativeDetails", "http://www.selectabio.com/role/CollaborationAgreementsMITNarrativeDetails", "http://www.selectabio.com/role/CollaborationAgreementsShenyangSunshinePharmaceuticalCoLtdNarrativeDetails", "http://www.selectabio.com/role/RevenueArrangementsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r293", "r295" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "terseLabel": "Unrecognized tax benefits" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/IncomeTaxesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]", "terseLabel": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique.", "label": "Valuation Approach and Technique [Domain]", "terseLabel": "Valuation Approach and Technique [Domain]" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationTechniqueOptionPricingModelMember": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Valuation technique calculating price of option.", "label": "Valuation Technique, Option Pricing Model [Member]", "terseLabel": "Valuation Technique, Option Pricing Model" } } }, "localname": "ValuationTechniqueOptionPricingModelMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r349", "r355" ], "calculation": { "http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/LeasesComponentsofleasecostsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount": { "auth_ref": [ "r107", "r111", "r192" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of (increase) decrease in equity for down round feature triggered for warrant classified as equity.", "label": "Warrant, Down Round Feature, (Increase) Decrease in Equity, Amount", "terseLabel": "Warrant, increase (decrease) in equity, amount" } } }, "localname": "WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/EquityNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "netLabel": "Warrant liabilities", "terseLabel": "Warrants to purchase common stock", "verboseLabel": "Exercise of common warrants" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/DebtTermLoansNarrativeDetails", "http://www.selectabio.com/role/EquityNarrativeDetails", "http://www.selectabio.com/role/EquityScheduleofAuthorizedSharesofCommonStockforFutureIssuanceDetails", "http://www.selectabio.com/role/EquityWarrantyActivityDetails", "http://www.selectabio.com/role/FairValueMeasurementsChangeinthewarrantliabilitiesDetails", "http://www.selectabio.com/role/NetLossPerShareScheduleofPotentialCommonSharesIssuableUponConversionofWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "calculation": { "http://www.selectabio.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Warrant liabilities", "verboseLabel": "Warrant liabilities" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedBalanceSheets", "http://www.selectabio.com/role/EquityNarrativeDetails", "http://www.selectabio.com/role/FairValueMeasurementsSummaryofAssetsMeasuredatFairValueonaRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Warrants and rights outstanding, measurement input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r319" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrants and rights outstanding, term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/FairValueMeasurementsAssumptionsusedtorecordthefairvalueofthewarrantsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted", "terseLabel": "Weighted\u2011average common shares outstanding\u2014basic and diluted (in shares)", "verboseLabel": "Basic and diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.selectabio.com/role/NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted average common shares outstanding:", "verboseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.selectabio.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "http://www.selectabio.com/role/NetLossPerShareComputationofBasicandDilutedNetLossPerShareDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "12B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL109261756-109256" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r115": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "270", "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=SL77927221-108306" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "8A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=SL6284422-111562" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r151": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=68051541&loc=SL49131252-203054" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r173": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r176": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=109126253&loc=d3e4724-112606" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "40", "SubTopic": "50", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=SL109261905-112644" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r225": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r249": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(8))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907" }, "r289": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r304": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r311": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971" }, "r356": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/subtopic&trid=77888251" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=121576215&loc=SL77919372-209981" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r365": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r369": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447" }, "r414": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "http://asc.fasb.org/subtopic&trid=2176304" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r425": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "http://asc.fasb.org/subtopic&trid=2209399" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "e", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r451": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "http://asc.fasb.org/subtopic&trid=2324412" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r467": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r468": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r469": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r470": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r471": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r472": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r473": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3151-108585" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04.(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r92": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" } }, "version": "2.1" } ZIP 93 0001453687-21-000069-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001453687-21-000069-xbrl.zip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�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end

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